CN1726395A - Specific markers for pancreatic cancer - Google Patents
Specific markers for pancreatic cancer Download PDFInfo
- Publication number
- CN1726395A CN1726395A CN 200380106539 CN200380106539A CN1726395A CN 1726395 A CN1726395 A CN 1726395A CN 200380106539 CN200380106539 CN 200380106539 CN 200380106539 A CN200380106539 A CN 200380106539A CN 1726395 A CN1726395 A CN 1726395A
- Authority
- CN
- China
- Prior art keywords
- leu
- glu
- ala
- gly
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention provides polypeptides which are up- or down-regulated in pancreatic cancer and which can be used as markers for diagnosis of pancreatic cancer. The invention also provides an in vitro method for the diagnosis of pancreatic cancer and/or the susceptibility to pancreatic cancer comprising the steps of a) obtaining a biological sample; and b) detecting and/or measuring the increase of one or more polypeptides as disclosed herein. Furthermore, screening methods relating to inhibitors and antagonists of the specific polypeptides disclosed herein are provided.
Description
Technical field
The present invention relates to be used to diagnose cancer of pancreas (pancreaticcarcinoma, PC) mark, this mark comprises at least a being accredited as by protein science and express the polypeptide that increases in cancer of pancreas, the invention still further relates to a kind of in-vitro diagnosis cancer of pancreas and/or to the method for cancer of pancreas neurological susceptibility, this method may further comprise the steps: a) obtain biological specimen; B) detect and/or measure disclosed specific mark among the present invention.In addition, the present invention also provides the screening technique of the antagonist of relevant disclosed specific mark with the treatment cancer of pancreas.
Background technology
In the west, cancer of pancreas is to cause dead Chang Yin.It is one of malignant tumour of tool harmfulness, and general 5 annual survival rates are 0.4%, in a lot of cancer of pancreas patients, diagnoses before being difficult to reach operation accurately with conventional image check.Be late period when most patient is made a definite diagnosis, and with local diffusion or transfer.20% selected excision of patient's energy only arranged usually, thereby might adopt operative treatment.This found reason of ability that reaches an advanced stage is the diagnostic method that lacks this disease of early detection.Except the shortage of diagnostic method, the another one reason that causes cancer of pancreas patient high mortality is to lack effective methods of treatment.Therefore, being used for early diagnosis pancreatic neoplasm and being used to, to develop the preparation (biological therapy target) of treatment cancer of pancreas be the challenge that has importance.
Summary of the invention
The present invention has identified the polypeptide of expressing change in cancer of pancreas by using new protein science technology, can be as the mark of cancer of pancreas early diagnosis.By using the protein science scientific discovery, with the pancreas tissue of health relatively, one group of special polypeptide is being taken from the middle difference ground expression of suffering from HR/03.11.2003 cancer of pancreas individuality.The polypeptide of the differential expression of indication is listed in attached table 2 and 3.List in the table 3 polypeptide by before confirmed in cancer of pancreas, to increase on the transcriptional level (people such as Iacobuzio-Donahue, (2002), Am.J.Pathol.160,1239-1249).Yet well-known, the adjusting on the transcriptional level might not represent that corresponding expression of gene has similar change on translation skill.Therefore, the polypeptide that has only proof to list in table 3 is expressed in cancer of pancreas and is increased, and just may utilize them to carry out being used to detect cancer of pancreas based on the diagnostic analysis of polypeptide.
According to table 2 and the listed polypeptide of table 3, the invention provides a kind of mark that is used to diagnose cancer of pancreas, it comprises at least a polypeptide (the Seq ID No.1-24, and 26-49 that lists in table 2 and/or the table 3 that be selected from; And/or Seq ID No.25 and 50-55).Therefore, terminology used here " mark " is meant the polypeptide of one or more differential expressions in cancer, and can be independent, or as known in cancer of pancreas the potpourri of the multiple polypeptides of differential expression, be used to diagnose cancer of pancreas or to the neurological susceptibility of cancer of pancreas.The polypeptide of the preferred indication of level Four is selected from Seq ID No.2-10,12-15,17,19,20,23,24,27,28,31-40,42-45,47 and 48; And/or SeqID No.25 and 50-54.The polypeptide of three grades of preferred indications is selected from Seq IDNo.3,4,6,9,14,15,27,31-35,37,39,40; And/or Seq ID No.50-52.The polypeptide of the preferred indication of secondary is selected from SeqID No.4, and 6,9,14,15,31,33-35, and/or Seq IDNo.51 and 52.The polypeptide of the preferred indication of one-level is selected from Seq ID No.4,6,14,15 and 31; And/or Seq ID No.52.
Terminology used here " polypeptide " is meant polymer of amino acid, rather than refers to the length of indication.Therefore, peptide, oligopeptides and albumen all are included in the definition of polypeptide.
Preferred mark of the present invention is a kind of or comprises at least a mark that is selected from the listed polypeptide of table 2.
In addition, be selected from that a part that table 2 and/or 3 listed polypeptide are used as mark or mark is used to diagnose cancer of pancreas and/or to the neurological susceptibility of cancer of pancreas.The polypeptide of the preferred indication of level Four is selected from the Seq ID No.2-10 of table 2,12-15, and 17,19,20,23,24,27,28,31-40,42-45,47 and 48, and/or the Seq ID No.25 and the 50-54 of table 3.By table 2 and table 3 as seen, at least 2 times of these polypeptide differential expressions.The polypeptide of three grades of preferred indications is selected from the Seq IDNo.3 of table 2, and 4,6,9,14,15,27,31-35,37,39,40, and/or the Seq ID N of table 3 is o.50-52.By table 2 and table 3 as seen, these polypeptide are induced 3 times at least.The polypeptide of the preferred indication of secondary is selected from the SeqID No.4 of table 2, and 6,9,14,15,31,33-35, and/or the Seq ID No.51-52 of table 3.By table 2 and table 3 as seen, these polypeptide are induced 4 times at least, and the polypeptide of the preferred indication of one-level is selected from the Seq IDNo.4 of table 2, and 6,14,15 and 31, and/or the Seq ID No.52 of table 3.Shown in table 2 and table 3, these polypeptide are induced 5 times.
The present invention relates to be used to diagnose the mark of cancer of pancreas, this mark comprises at least a polypeptide of listing in table 6 that is selected from.At least a polypeptide of preferred indication does not comprise Seq ID No.25 and 50-55 in addition.
In a preferred embodiment, mark mentioned above comprises at least a polypeptide of listing in table 5 in addition.
Several groups of polypeptide are accredited as the mark of cancer of pancreas:
Enzyme
Cause that one of enzyme that we note is glutamine gamma-glutamyl based transferase/tTG (TGLC, Seq ID No.54).It is the member of transglutamin-ase 9 enzyme family, and this enzymatic relies on Ca
2+Reaction, cause posttranslational modification (with the polyamines crosslinked) (Greenberg of albumen on the level of glutamine and lysine residue, C.S., Birckbichler, P.J., and Rice, R.H.Transglutaminases:multifunctional cross-linking enzymes thatstabilize tissues.FASEBJ., 5:3071-3077,1991).Describe the multiple effect of this albumen is existing, Apoptosis is wherein arranged, adhesion and differentiation (Amendola, A., Fesus, L., Piacentini, M., and Szondy, Z. " Tissue " transglutaminase in AIDS.J.Immunol.Methods, 265:145-159,2002).Some dispute of the effect of TGLC aspect Apoptosis.Although having several evidences to propose TGLC is a kind of proapoptosis albumen (Melino, G., Deng the people, Mol.CellBiol., 14:6584-6596,1994), but discovery TGLC such as Jason are with the mode of the anti-apoptotic (Boehm that works, J.E. wait people .J.Biol.Chem., 277:20127-20130,2002).A lot of substrates of TGLC are key components of extracellular matrix (ECM), fibronectin for example, osteonectin, collagen, this make TGLC become ECM form in important enzyme (Raghunath, M. wait the people, J.Clin.Invest, 98:1174-1184,1996., Nemes, Z., people such as Jr., J.Biol.Chem., 272:20577-20583,1997), it is relevant with a lot of pathological conditions that unusual ECM forms, for example fiberization, and may in the hyperplasia of the viewed fibr tissue of PC, work, people such as Haroon describe TGLC and promote that the ability of EMC is pith (Haroon, people such as Z.A., the Lab Invest of host's neoplasm growth acknowledgement mechanism, 79:1679-1686,1999).What is interesting is that the forfeiture of TGLC is the biomarker of adenocarcinoma of the prostate (Birckbichler, P.J., et al., Cancer, 89:412-423,2000), propose following problems thus: whether measured TGLC is produced by the vessel cell and/or the stroma cell of tumorigenesis.The mensuration of mRNA level shows in PC, normal structure and PC clone, TGLC high expressed (Iacobuzio-Donahue all in two kinds of cell types, C.A. wait the people, Am.J.Pathol., 160:1239-1249,2002), therefore, a preferred version of the present invention is the mark that comprises Seq ID No.54.
Cytoskeletal protein
Detect several expression and be higher than its cytoskeletal protein of normal pancreatic tissue on every side in PC, wherein a kind of is gelsolin, and it is a kind of Ca
2+And PIP2 (polyphosphoinositide 4, the 5-bisphosphate) capping protein of Tiao Jieing, this albumen is the albumen that a kind of multi-functional actin is regulated, and reinvent at actin, (Maruta works aspect migration, signal transduction, Apoptosis and the carcinogenesis, H.G proteins cytoskeleton andcancer.Austin, Tex.:R.G.Landes, 1998).In the research of several cancers, when the generation of cancer (breast, colon, stomach, bladder, prostate and lung), the expression of gelsolin is described to express descend (Asch, people such as H.L., Cancer Res., 56:4841-4845,1996; Dosaka-Akita, people such as H., Cancer Res., 58:322-327,1998, Prasad, people such as S.C., Electrophoresis, 18:629-637,1997).Another kind of example of expressing the cytoskeletal protein that increases is the flesh fasciclin, (Seq ID No.58), and it is a kind of actin binding protein, works in cytostromatic adhesion, cell interaction and migration.Existing report, bundle protein is high expressed in several cancers, for example mammary gland, colon and carcinoma of mouth (29).
The present invention also is that to increase polypeptide with bundle protein 2 as the expression in the cancer of pancreas be feature (Seq ID No.56).Therefore, a preferred embodiment of the present invention is the mark that comprises Seq ID No.3.In another preferred embodiment, this mark comprises Seq ID No.56.
In our research, cytokeratin 7 (Seq ID NO.52) and cytokeratin 19 (Seq ID NO.33) show than high expressed in PC.These two kinds of albumen are existing the description in other cancers, and relevant with metastasis of cancer (Moll, R., Int.J.Biol.Markers, 9:63-69,1994).
In PC, detect the actinine 4 (Seq IDNo.5) of high protein level.There is the researcher to think this albumen relevant (Honda, K., Yamada, T., Endo, R., Ino with the aggressive of cell migration and cancer, Y., Gotoh, M., Tsuda, H., Yamada, Y., Chiba, H., and Hirohashi, S.J.Cell Biol., 140:1383-1393,1998.).In a word, the high expressed that presents of cytoskeletal protein may be the high invasiveness of PC and the key factor that might form transfer.Therefore, a preferred embodiment of the present invention is the mark that comprises Seq IDNo.52.In a further preferred embodiment, this mark comprises Seq ID No.5.
Shift
The feature of exocrine pancreas cancer is local widely the infringement, the transfer in early stage lymph and blood road.The transfer of PC is found in bone, eye, bladder etc.The scope of angiogenesis depends on the balance by the factor of the preceding angiogenesis factor of cancer and host cell release and angiogenesis inhibitor.At present, it seems it is the reliable parameter of judging angiogenic activity with microvessel density (IMD) in the knurl of immunocytochemical determination.In various cancers, its survival rate of patient that IMD is high low (Fujioka, people such as S., Cancer, 92:1788-1797,2001).Thymidine phosphorylase (TYPH or the TP.Seq ID No.31) strongly expressed in PC that is equal to blood platelet source property growth factor, and the chemotaxis of the TP catabolite 2-deoxy-D-ribose stimulating endothelial cell by thymidine, indirect induction angiogenesis (Haraguchi thus, M. wait the people, Nature, 368:198,1994.).People such as Shuichi Fujioka find PC survivor general and that do not have recurrence, and the state of IMD and TP is a prediction index (Fujioka, S., et al., Cancer, 92:1788-1797,2001) independently in PC.Also having a kind of albumen that may participate in forming transfer is Gegenbaur's cell atopen 2 (Seq ID No.53), and this albumen detected level in PC is higher than the level in its surrounding tissue, infers that it is a kind of bone adhesion protein.Breast cancer is transferred to bone (Guise, T.A.Cancer, 88:2892-2898,2000) usually.Though the effect of this albumen in PC is not clear and definite as yet, our discovery has proposed Gegenbaur's cell similarly effect in PC.Therefore, a preferred embodiment of the present invention is the mark that comprises Seq ID No.31.In a further preferred embodiment, this mark comprises Seq ID No.53.
The micromolecule gtp binding protein
4 kinds of micromolecule gtp binding proteins and the expression of interaction protein in PC are higher than its expression in normal pancreatic tissue.These albumen comprise RAN (Seq ID No.27), GBLP (similar guanine-nucleotide-binding protein β protein subunit RACK1, Seq ID No.47), GDIR (the Rho GDP inhibitor 1 that dissociates, Seq ID No.55), with IQG1 or IQGAP1 (similar Ras gtpase activating protein, Seq ID No.25).The micromolecule gtp binding protein is formed a superfamily, this family can be divided at least 5 families: Ras, Rho, Rab, Sarl/Arf on structure, and Ran family, and participation gene expression adjusting, cytoskeletal organization regeneration and nucleo-cytoplasmic transport (Takai, Y. wait the people, Physiol Rev., 81:153-208,2001).Known RAN promotes the trans-activation of androgen receptor mediation, and has shown its high expressed (Sampson, people such as E.R., J.Biol.Regul.Homeost.Agents, 15:123-129,2001) in prostate cancer.RAN is expressed in up-regulated in 81% the tumor of prostate case, and this rise has the hyper-proliferative (Li, people such as P., Am J Pathol., 161:1467-1474,2002) that helps prostate tumor cells.GBLP is a kind of anchorin of activated protein kinase C β and various other albumen.Protein kinase C plays an important role in the growth of angiogenesis and cancer.Bern etc. find that GBLP expresses increase in the extracorporeal blood vessel generative process, and also relevant with the non-endothelial cell in the angiogenic activity tissue (Berns, people such as H., FASEB J., 14:2549-2558,2000).In addition, in the propagation epithelial cell of the epithelial cell of people's colon cancer and normal colonic tissue, the mRNA that detects GBLP expresses.
Therefore, high GBLP express and tumor growth between may exist and get in touch.Having found that GDIR (Rho GDP dissociate inhibitor) expresses in drug resistance fibrosarcoma cell system increases (Sinha, P. wait the people, Electrophoresis, 20:2961-2969,1999), and may block Ras and the kinase mediated Apoptosis signal pathway of c-jun, cause increase to the environmental stress resistance.IQG1 (similar Ras gtpase activating protein) is Cdc42-, Racl-and the caldesmon of a kind of 190Kda of wide expression, and it and F-actin interact in vivo, and can with the F actin filament external crosslinked.IQG1 is by the α-catenin that dissociates, to bearing adjusting based on the cell-cell adhesion of Ecc (E-cadherin/calmodulin compound).The expression increase of IQGAP1 relevant with the malignant phenotype of cancer of the stomach (Sugimoto, people such as N., J.Hum.Genet., 46:21-25,2001).
By immunohistochemical analysis, find IQGAP1 high expressed and relevant with the invasion and attack of cancer (Nabeshima, K. waits the people, Cancer Lett., 176:101-109,2002) in colorectal cancer.Because the invasiveness of cancer is relevant with the local failure of cell-cell adhesion, the data of our result and Iacabuzio-Donahue etc. all proposes the destruction that IQGAP1 may participate in local adhesion, and participates in the invasion and attack of PC to surrounding tissue.Therefore, a preferred embodiment of the present invention is the mark that comprises Seq ID No.27.In another preferred scheme, this mark comprises Seq IDNo.47.Also have in another embodiment preferred, this mark comprises SeqID No.55.Also have in addition that this mark comprises Seq ID No.25 in the embodiment preferred.
The S100 protein family
Another kind albumen of high level expression in PC is S109 (S100A9, MRP-14, calgranulin B, Seq ID No.49), and it is the member of the low-molecular-weight calbindin S100 of high homology protein family.The feature of calgranulin is that its cell type specificity in epithelium, marrow and endothelium derived cell is expressed, and be accumulated in position (for example rheumatoid arthritis, cystic fibrosis, psoriasis, allergic dermatitis, the inflammatory bowel disease) (Donato of acute or chronic inflammation, R.Int.J.Biochem.Cell Biol., 33637-668,2001).S100A8 and S100A9 can form the non-covalent heterodimer albumen composition that is called the calcium sozin.Can think that according to present report S100A9 and S100A8 have in the born of the same parents widely or the outer function (Schafer, B.W.and Heizmann, C.W.Trends Biochem.Sci., 21:134-140,1996) of born of the same parents.S100A8 and S100A9 are subjected in the mode that depends on c-Fos that glucocorticoid is negative to be regulated, and at the generating process high expressed (Gebhardt, C. wait the people, Oncogene, 21:4266-4276,2002) of cutaneum carcinoma.Shown in protein science was analyzed, the expression of these albumen in colon cancer also was more to be better than its expression (Stulik, people such as J., Electrophoresis, 20:1047-1054,1999) in corresponding normal mucous membrane of colon.In gland cancer (AC) cell culture of the various organs that derive from the people, detected S100A9, its relevant with the differentiation of tumour in the adenocarcinoma of lung (Arai, people such as K., Oncol.Rep., 8:591-596,2001).The research work of Iacobuzio-Donahue etc. shows the high expressed of S100A9 in PC relevant with the hypomethylation degree of its poorly differentiated and DNA (Rosty, people such as C., Am.J.Pathol., 160:45-50,2002).Therefore, a preferred embodiment of the present invention is the mark that comprises Seq ID No.49.
We find, annexin 1 (Seq ID No.51) and annexin 2 (Seq ID No.19) high expressed in PC.The both is the embrane-associated protein family member who depends on Ca2+.Especially, described function is included in vital role (Masaki, the people such as T. in the vicious transformation, Hepatology, 24:72-81,1996), the control (Solito of epithelial cell line propagation, E. wait the people, Cell Growth Differ., 9:327-336,1998) and apoptotic mediation (Canaider, S., et al., .Life Sci., 66:L265-L270,2000).Remain indirect for the evidence of supporting any annexin in the generation of cancer, to become reason.In the MCF-7 breast cancer cell, the high expressed of annexin 1 causes Ca behind purine source acceptor or bradykinin receptor activation
+Retardance (the Frey that discharges, B.M. wait the people, FASEB J., 13:2235-2245,1999), and the high expressed of annexin 1 in mouse fibroblast cell causes directly suppressing kytoplasm PLA2, the serum response element (Oh, people such as J., the FEBS Lett. that suppress c-fos subsequently again, 477:244-248,2000).
In sum, these researchs mean a kind of growth-inhibiting effect to annexin.These results of study can not be supported that promptly annexin 1 is at prostate cancer cell line (Vaarala, M.H. by following discovery, LabInvest, SO:1259-1268,2000), the cancer of the esophagus (Emmert-Buck, M.R., et al., Mol.Carcinog., 27:158-165,2000), stomach cancer cell system (Sinha, P., Deng the people, J.Biochem.Biophys.Methods, 37:105-116,1998), mammal gland cancer (Pencil, S.D.and Toth, M.Clin.Exp.Metastasis, 16:113-121,1998) and liver cancer (de Coupade, C. wait the people, Hepatology, 31:371-380,2000) in strong expression increase.The research of liver cancer shows that also by the antisense strategy to annexin 1, normal and pernicious hepatocellular multiplication rate all reduces.
Above-mentioned these results and our data are as can be seen, the growth of cell is relevant with annexin 1 increase, rather than relevant with its minimizing, and this argument is also by (Am.J.Pathol. such as Iacobuzio-Donabue, 160:1239-1249,2002) research institute supports.Therefore, a preferred embodiment of the present invention is the mark that comprises Seq ID No.51.In another preferred embodiment, this mark comprises Seq ID No.19.
Some other in PC the albumen of high expressed clear and definite effect can be arranged in PC, perhaps indirect getting in touch arranged with PC, BGH3 (the albumen that TGF β 1 induces for example, Seq ID No.6), it is a kind of secretory protein and can be used as bioactive TGF-β 1 (Langham, R.G. are arranged, et al., Transplantation, 72:1826-1829,2001) mark.Therefore, a preferred embodiment of the present invention is the mark that comprises Seq ID No.6.
Utilize to identify the polypeptide of differential expression in cancer of pancreas, the invention provides a kind ofly that this method may further comprise the steps: obtain biological specimen in the in-vitro diagnosis cancer of pancreas and/or to the method for cancer of pancreas neurological susceptibility; Detect and/or measure the mark that expression mentioned above increases.Terminology used here " detection " is meant not existing of qualitative determination polypeptide or exists.Terminology used here " measurement " is meant the expression of quantitative measurement polypeptide in cancer of pancreas patient's biological specimen and the expression difference in the biological specimen of healthy individual.The method that detects and measure the polypeptide in the biological specimen is well known in the art, and includes, but are not limited to Western trace, ELISA or RIA.The antibody of energy Identification Lists 2,3,5 and/or 6 listed polypeptide can be the antibody that produces in order to be used for detecting the polypeptide of indication, for example produces by the protein immunization rabbit by purifying, perhaps can use the antibody of known identification indication polypeptide.For example, a kind of can be in conjunction with the antibody of metaprotein, as polyclonal antibody, can be used in the Western trace, detecting polypeptide of the present invention.An example measuring the method for certain mark is ELISA.Such protein quantification is based on a kind of antibody that can catch specific antigen, and the second antibody that can detect the antigen of this seizure.Also have a kind of method that detects the mark of diagnosis cancer of pancreas is to detect whether there is mark of the present invention by analyzing biopsy sample.Whether the method that detects these marks is well known in the art, include, but not limited to the polypeptide that immunohistochemistry or immunofluorescence detect mark of the present invention and exist.The Harlow that the preparation of antibody mentioned above and using method and analytical approach are published at Cold SpringHarbor Laboratorg, E and Lane, D.Antibodies:A Laboratory Manaal states in (1988).By analyzing the potpourri of multiple table 2,3,5 and/or 6 listed polypeptide, can improve the accuracy of diagnosis of pancreatic cancer.Therefore, in-vitro method mentioned above comprises a kind of mark, and this mark contains at least 2 kinds, preferably at least 3 kinds of level Four, three grades preferably at least 4 kinds, preferably at least 5 kinds of secondarys, and the preferred at least 6 kinds of tables 2 of one-level, 3,5 and/or 6 listed polypeptide.
For the diagnosis of cancer of pancreas, need be whether to the existence of suitable its certain mark of biological sample analysis.The biological specimen of indication can be the cell of serum, blood plasma, pancreatic secretion or pancreatic tissue.The cell in pancreatic tissue source can obtain by ERCP, secretin stimulation, fine needle imbibition, cell interference and big vent needle biopsy.
By detecting and/or measure the nucleic acid molecules of coding mark mentioned above, also can diagnose cancer of pancreas, preferred nucleic acid molecules is RNA or DNA.In another embodiment, the DNA of indication is cDNA.
In one embodiment of the invention, in-vitro method mentioned above comprises: the nucleic acid of more at least 2 kinds of coding indication polypeptide is being doubted the trouble cancer of pancreas and/or the expression in healthy individual to expression in the individuality of cancer of pancreas susceptible and identical nucleic acid.
In another embodiment of the invention, in-vitro method mentioned above comprises: relatively indication is marked to doubt and suffers from cancer of pancreas and/or to expression in the individuality of cancer of pancreas susceptible and the expression that is marked at equally in the healthy individual.In three grades of embodiment preferred of in-vitro method, the raising of the expression of institute's digit synbol or minimizing are the signs of cancer of pancreas and/or cancer of pancreas neurological susceptibility.
The present invention also provides the screening technique of a kind of evaluation and/or acquisition and table 2 and/or 3 listed interactional compounds of polypeptide, wherein said table 2 and/or 3 expression of listed polypeptide in cancer of pancreas are express to increase, and the polypeptide that this method comprises the steps: to make indication and one or more chemicals contact can making under its interactional condition; Detect the interaction between this compound or multiple compound and the indication polypeptide then.
" interaction " in the screening technique described here can be measured by conventional method, membrane-bound polypeptide is opposite with detecting, the type of the interactional conventional method of detection compound and solvable polypeptide, can be to use the recombinant polypeptide of purifying, or by a kind of in-vitro method of the natural polypeptides of the cell purification of endogenous this polypeptide of expression.As a kind of nonrestrictive example, polypeptide of the present invention can be incorporated on the bead be fixed on plastics or other surfaces on, the mark that the interaction of compound and polypeptide can be attached on the polypeptide by the compound and the measurement of usage flag is measured, or measures by the known ligand of mark on the displacement polypeptide.
For with cell surface on the membrane-bound polypeptide of cell, or to stride the polypeptide of the formal representation of polypeptide in film or the film, the available diverse ways of the interaction of the polypeptide of compound and indication detects, these methods comprise, but be not limited to, use normal expression polypeptide or the polypeptide method of the cell of high expressed therein, for example, by detecting known ligand replacement rate with compound mark to be screened.
Perhaps, can check the interaction of compound and this peptide species with film preparation.The transactional analysis method that is adopted in the method disclosed herein can comprise: FRET analytic approach (FRET (fluorescence resonance energy transfer) (fluorescenceresonance energy tranfer); Especially, as at Ng, Science 283 (1999), and 2085-2089 or Ubarretxena-Belandia, Biochem.38 (1999) is described in the 7398-7405), TR-FRET, and biochemical analysis disclosed herein.In addition, also can use commercially available analytic product, as " Amplified Luminescent ProximityHomogenous Assay
TM" (BioSignal Packard).Also have method well-known in the art in addition, especially, as at Fernandez, Curr.Opin.Chem.Biol.2 (1998), the method described in the 547-603.
" interactional mensuration " also can be learned and/or biochemical analysis method carry out by specific immune well-known in the art, and these methods comprise, as described homogeneous phase and heterogeneous analytic approach hereinafter.The interaction analyzing method of the employing read-out system of indication is well-known in the art, and (especially, as at EP-0 963 376, WO 98/25947, described in the WO 00/02911 especially to comprise double heterozygote screening; And as in appended embodiment illustrated), especially, as at Kasus-Jacobi, Oncogene 19 (2000), and the GST-described in the 2052-2059 forces down post, cell extract co-precipitation analytic approach, " interaction-seizure " system (especially, as at US 6, described in 004,746) expression cloning (as λ gt11), phage display be (especially, as at US 5, described in 541,109), external binding analysis method etc.More transactional analysis method and corresponding read-out system thereof especially are described in US 5,525,490, among WO 99/51741, WO 00/17221, WO 00/14271 or the WO 00/05410, Vidal and Legrain (1999) are at Nucleic Acids Research 27, describe among the 919-929, summarize and summed up other in transactional analysis method known in the art, these methods can adopt according to the present invention.
(interaction) analytical approach of homogeneous phase comprises a pair of analytical approach of staying in the solution of wherein combination, and comprises the analytical approach as aggegation analysis and so on.Heterogeneous analytical approach especially comprises immunoassay, for example, enzyme linked immunosorbent assay (ELISA) (ELISA), radiommunoassay (RIA), immunoradiometric assay (IRMA), Flow Injection Analysis (FIA), flow activation cell sorting (FACS), chemiluminescence immune assay (CLIA) or living electrochemiluminescence analytical approachs such as (ECL).
The present invention also provides a kind of screening technique that is used to identify and/or obtain certain compound, and this compound is the inhibitor or the antagonist of table 2 and/or 3 listed polypeptide, and indication polypeptide being expressed as in cancer of pancreas expressed and increased.This screening technique comprises the following steps: a) to make the polypeptide of indication, contacts can making under this compound and the interactional condition of indication polypeptide with the compound of identifying by above-mentioned screening technique and/or obtaining; B) activity of mensuration indication polypeptide; C) by the definition of (a), be determined at the activity of the indication polypeptide of expressing among the host, this polypeptide does not contact with the compound of indication; D) will be in (b) and the active level that (c) records contact, wherein, it is low that the specific activity that records in (b) records in (c), shows that then this compound is inhibitor or antagonist.Terminology used here inhibitor and antagonist are used interchangeably.This screening analysis can be carried out by external test or by the mensuration based on the host.Adopted in the screening technique of the present invention, comprise and/or the host of expression table 2,3,5 and/or 6 listed polypeptide, can comprise protokaryon and eukaryotic, the cell of indication can comprise bacterial cell, yeast cells and cultivate (tissue) clone, especially derive from mammiferous cultivation (tissue) clone.In addition, animal also can be used as the host, for example, and inhuman, genetically modified animal.Therefore, the host of indication (cell) can carry out transfection or conversion with the carrier that comprises the nucleic acid encoding molecule, and as disclosed in this, this polypeptide is regulated for difference in cancer of pancreas.Therefore, the host cell of indication or host can carry out genetic modification with the nucleic acid molecules of this peptide species of coding or with the carrier that comprises this nucleic acid molecules.The connotation of term " genetic modification " be this host cell or host except that comprising its natural gene group, also comprise the listed polypeptide of coding schedule 2,3,5 and/or 6 or the nucleic acid molecules or the carrier of its at least one fragment.The other genetic material of indication can be imported into host's (cell) or import among one of its former generation/parent.This nucleic acid molecules or carrier can be used as genome molecule independently outward, preferably as the molecule that can duplicate, perhaps can stably be incorporated in host cell or host's the genome and are present in the host cell or host of genetic modification.
As mentioned above, host cell of the present invention can be any protokaryon or eukaryotic.The prokaryotic that is generally used for the clone of Escherichia coli or bacillus etc. is the prokaryotic that is suitable for.And in the screening technique disclosed herein, also consider and use these prokaryotic host cells.In addition, eukaryotic comprises, for example fungi or zooblast.Suitable fungal cell's example has yeast cells, the yeast cells that preferred yeast belongs to, the yeast cells of preferably saccharomyces cerevisiae kind.Suitable zooblast is, for example insect cell, vertebrate cells, and the preferred mammal cell, for example, CHO, Hela, NIH3T3 or MOLT-4.Other suitable clone known in the art can obtain from clone depository, for example (ATCC) obtains from American Type Culture Collection (American Type CuleareCollection).
The host also can be selected from inhuman mammal, preferred mouse, rat, sheep, calf, dog, monkey or ape.As indicated above, the animal/mammal of indication also comprises inhuman transgenic animals, and preferably it expresses the polypeptide that at least a difference in cancer of pancreas disclosed herein is regulated.The polypeptide of preferred indication is to express the polypeptide that increases in the cancer of pancreas tissue of patient.But, also consider to select the following transgenic animals that produced for use: promptly do not express marker gene disclosed herein, or express the transgenic animals of limited amount indication marker gene product.The animal of preferred indication is relevant with the negative polypeptide of regulating in cancer of pancreas.Comprise and/or express expression of the present invention and increase polypeptide, perhaps, the genetically modified non-human animal who comprises the negative adjusting polypeptide of silence or inefficient form, for the research cancer of pancreas is useful model, and the medicine and the therapy that are used for the treatment of with prevention of pancreatic cancer for test provide useful model.
A kind of and table 2,3,5 and/or 6 listed polypeptide interact, and suppress or the compound of the polypeptide of antagonism indication is identified by following method, are determined at the activity of indication polypeptide under this compound existence that is:.Terminology used here " activity " is relevant with these one or more functional characteristics of the polypeptide of indication.For table 2,3,5 and/or 6 listed enzymes, term " activity " relates to the enzymatic activity of specific polypeptides.For table 2,3,5 and/or 6 listed enzymes, its active analytical approach is well-known.
The adhesion molecule that his-and-hers watches 2,3,5 and/or 6 are listed, term " activity " refers to the adhesive property of relevant polypeptide, and available following analysis method is measured, for example, but be not limited to the adhesion Analysis method, cellular invasion analytic approach, or the external interaction of adhesion molecule and known part.These analytical approachs are well known in the art.
For cytoskeletal protein, term " activity " is subjected to the adjusting of this type of polypeptide relevant with cytoskeleton, and perhaps to mix cytoskeleton relevant with it.As a nonrestrictive example, gelsolin is to the regulating power of actin polymerization effect, or microfilament protein A promotes the crosslinked ability of actin fiber can adopt external actin polymerization function analysis method to measure.As nonrestrictive example, regulate relevant activity with cytoskeletal structure and can further pass through cellular invasion analytic approach, cell migration analytic approach, analysis of cell proliferation method or fluoroimmunoassay, or with fluorescently-labeled phalloidine to actin stock-dye measure.All these analytical approachs are all known for those skilled in the art.
For ion channel (chloride cell passage albumen), term " activity " is relevant with the ionic flux of striding film (chloride flux).The method that mensuration is striden the film ionic flux is well-known to those skilled in the art.
For transcription factor, for example, KIAA1034, term " activity " is relevant with the ability that its regulatory gene is transcribed.The transcriptional activity of polypeptide can adopt normally used analytical approach to measure, and for example uses the reporter analytic approach.
For growth factor and hormone or their acceptor, term " activity " is relevant in conjunction with the ability of its acceptor or part respectively with them, and induce the ability of receptor activation, signal series connection subsequently relevant with it, and/or it is finally relevant by the ability of growth factor or hormone-mediated caused these one or more cell functions of receptor activation with the mediation factor or acceptor.Can measure by common known part binding analysis method with the growth factor or the hormone of receptors bind.The activation of acceptor can be by detecting the receptor autophosphorylation phosphorylation, or the modification or the collection (by the immunoprecipitation and the Western trace of signal compound) of the downstream signal amboceptor by the analysis this receptor are measured.The cell function of being regulated by growth factor or hormone and acceptor thereof can be measured by cell proliferation (for example mix with thymidine or cell count is measured), cell migration analysis (for example measuring with the Boyden chamber of improvement), cell survival or Apoptosis analysis (for example measuring with DAPI dyeing), angiogenesis analysis (for example analyzed in vitro is measured forming of interior leather hose, and market is on sale).Except these analytical approachs, other analytical approachs also can be used for measuring these and other cell functions.
The inhibitor of table 2 and/or 3 listed polypeptide or antagonist can identify by above-mentioned screening technique, and when this compound existed, low when recording this compound of specific activity not existing in this screening technique showed that then this compound is inhibitor or antagonist.
At above disclosed screening technique, the present invention further provides a kind of screening technique of differentiating and/or obtaining certain compound, this compound is the listed polypeptide expression inhibitor of table 2 and/or table 3, the indication polypeptide expression increases for expressing in cancer of pancreas.This method may further comprise the steps: the host who expresses the indication polypeptide is contacted with compound; B) measure the polypeptide expression level and/or the activity of indication: c) press a) and define, expression and/or the activity of polypeptide in the host of mensuration indication, this host does not contact with the compound of indication; D) will be at b) and c) in the indication polypeptide expression level measured quantitatively get in touch, it is lower than what record in (c) wherein to record expression in (b), shows that then this compound is an indication polypeptide expression inhibitor.
Table 2,3,5 and/or 6 listed polypeptide expression inhibitor are identified by screening technique mentioned above, in this screening technique, do not reduce when this compound of expression ratio that records albumen when compound exists or not, show that then this compound is the polypeptide expression inhibitor.
Terminology used here " expression " and table 2,3 and/or 6 listed polypeptide expression levels are relevant, this polypeptide is in cancer of pancreas, in cell, preferably in pancreatic cancer cell system, increase for expressing, its expression is higher than the expression of same polypeptide in healthy pancreatic cell, and preferred its expression of level Four is higher at least 2 times than the expression in healthy pancreatic cell, three grades preferably high at least 3 times, preferably high at least 4 times of secondary, preferably high at least 5 times of one-level.
In addition, the invention provides the compound that a kind of any screening technique is by mentioned earlier identified and/or obtained.The compound of indication further is included in the pharmaceutical composition.The also claimed a kind of method for preparing the pharmaceutical composition of indication of the present invention, it comprises by prescription prepares the compound of indication with pharmaceutically useful carrier or thinning agent.The carrier material of any routine can adopt.This carrier material can be organic or inorganic be suitable in the intestines, through the material of skin or parenteral.Suitable carriers comprises water, gelatin, gum arabic, lactose, starch, dolomol, talcum, vegetable oil, poly alkylene glycol, vaseline etc.In addition, this pharmaceutical preparation can comprise other reagent that pharmaceutically active is arranged.Other adjuvant such as flavoring additives, stabilizing agent, emulsifying agent, buffering agent etc. can add according to the convention that the medicine of generally acknowledging cooperates.
The compound of indication can be used to prepare the medicament of treatment or prevention of pancreatic cancer.In addition, the compound of indication also can be used to prepare the diagnosis cancer of pancreas or suffer from the diagnosis composition that cancer of pancreas is inclined to.The compound of preferred indication comprises antibody, antibody derivatives, antibody fragment, peptide or antisense and constitutes thing.
Within the scope of the invention, list in the antibody of albumen of table 2 and/or table 3 or the method that its Fab can be used for the in-vitro diagnosis cancer of pancreas.
In order to diagnose screening effectively, the invention provides a kind of kit that is used to diagnose cancer of pancreas, it comprises one or more above-mentioned antibody or its Fab.It is the kit that comprises the nucleic acid of one or more marks mentioned above of encoding that another kind provided by the invention is used to diagnose the kit of cancer of pancreas.Provided by the invention to also have a kind of kit be the kit that is used for screening compounds, and any polypeptide of table 2 and/or table 3 is listed in this compound antagonism, or suppresses any indication polypeptide expression.
The present invention relates to be used to diagnose the mark of cancer of pancreas, this mark comprises at least a listed polypeptide of table 6 that is selected from.The mark of preferred indication does not comprise Seq IDNo.25 and 50-55.In three grades of embodiment preferred, the mark of indication comprises the listed polypeptide of at least a table 5.
A kind of in-vitro diagnosis cancer of pancreas also is provided in the present invention and/or to the method for cancer of pancreas neurological susceptibility, this method may further comprise the steps:
A) obtain biological specimen
B) detect and/or measure the increase of the listed polypeptide of at least a table 6.
The in-vitro method of the preferred indication of level Four comprises the step that detects and/or measure the minimizing of the listed polypeptide of at least a table 5 in addition.Three grades preferred in the in-vitro method of indication, and at least a polypeptide of indication does not comprise Seq ID No.25 and 50-55.Secondary is preferred, and in the in-vitro method of indication, the biological specimen of indication derives from serum, blood plasma, pancreatic secretion and pancreatic tissue cell.
The present invention further provides a kind of method that is used to diagnose cancer of pancreas and/or cancer of pancreas neurological susceptibility, this method may further comprise the steps:
A) obtain biological specimen; And
B) detect and/or measure the above increase of the nucleic acid of institute's digit synbol of at least a coding.
Preferably in the in-vitro method of indication, the nucleic acid molecules of indication is RNA or DNA, and three grades preferred in the in-vitro method of indication, and the DNA of indication is cDNA.
In another three grades of embodiment preferred of any in-vitro method mentioned above, the nucleic acid of at least one indication is suffered from cancer of pancreas and/or expression in the individuality of cancer of pancreas susceptible and the same expression of nucleic acid in healthy individual are compared doubting.In the one-level embodiment preferred of any in-vitro method mentioned above, indication is marked at doubt suffers from cancer of pancreas and/or expression in the individuality of cancer of pancreas susceptible and the same expression that is marked in the healthy individual are compared.
In three grades of embodiment preferred of in-vitro method mentioned above, the increase of indication marker expression level is the sign of cancer of pancreas and/or cancer of pancreas neurological susceptibility.
The invention still further relates to the screening technique of identifying and/or obtaining certain compound, this compound polypeptide listed with being selected from table 6 interacts, and the polypeptide expression of indication increases for expressing in cancer of pancreas, and this method comprises the following steps:
A) polypeptide that makes indication and one or more compounds contact can making under this compound and the interactional condition of the polypeptide of indication; And
B) detect one or more compounds of indication and the interaction between the indication polypeptide.
In addition, the invention provides a kind of screening technique that is used to identify and/or obtain certain compound, this compound is the inhibitor or the antagonist of the listed polypeptide of table 6, and the indication polypeptide expression increases for expressing in cancer of pancreas, and this method may further comprise the steps:
A) polypeptide of indication can be contacted under the interactional condition with the polypeptide of indication at the compound of indication with the compound that the described screening technique of claim 39 is identified and/or obtained;
B) activity of mensuration indication polypeptide;
C) press a) and define, be determined at the activity of the indication polypeptide of expressing among the host, this polypeptide does not contact with described compound; And
D) will be at b) and c) in the active level contact that records, wherein at b) in the specific activity that records at c) in record low, show that then this compound is inhibitor or antagonist.
The present invention also provides a kind of screening technique of identifying and/or obtaining certain compound, and this compound is to be selected from the listed polypeptide expression inhibitor of table 6, and the polypeptide expression of indication increases for expressing in cancer of pancreas, and this method may further comprise the steps:
A) host who expresses the indication polypeptide is contacted with certain compound;
B) measure indication polypeptide expression level and/or activity;
C) press a) defined, measure the expression and/or the activity of polypeptide in the host of indication, this host does not contact with described compound; And
D) will be at b) and c) in the indication polypeptide expression level measured quantitatively get in touch, wherein at b) in the expression that records than at c) in record low, show that then this compound is an indication polypeptide expression inhibitor.
The invention provides a kind of compound of identifying and/or obtaining by screening technique mentioned above.
In addition, the invention provides a kind of pharmaceutical composition that comprises compound mentioned above.A kind of method for preparing pharmaceutical composition mentioned above also is provided, and this method comprises by prescription to be prepared compound mentioned above with pharmaceutically useful carrier or thinning agent.
The invention provides compound mentioned above purposes in the medicament of preparation treatment or prevention of pancreatic cancer.The present invention also provides the purposes of compound in the diagnosis composition of preparation diagnosis cancer of pancreas or trouble cancer of pancreas tendency mentioned above.In a preferred embodiment, purposes mentioned above relates to the compound that comprises antibody, antibody derivatives, antibody fragment, peptide or antisense formation thing.
Within the scope of the invention, the antibody of table 5 and/or 6 listed albumen or its Fab can be used for the method for in-vitro diagnosis cancer of pancreas.
In order to diagnose screening effectively, the invention provides a kind of kit that is used for diagnosis of pancreatic cancer, it comprises one or more above-mentioned antibody or its Fab.It is the kit that comprises the nucleic acid of one or more marks mentioned above of encoding that another kind provided by the invention is used to diagnose the kit of cancer of pancreas.Provided by the invention to also have a kind of kit be the kit that is used for screening compounds, and any polypeptide of table 5 and/or table 6 is listed in this compound antagonism, or suppresses any indication polypeptide expression.
In the present invention, described hereinbefore basically albumen, compound, kit, method and purposes, especially relevant above-mentioned example is all claimed.
Embodiment
The collection of tissue samples
Gather cancer of pancreas and contiguous normal pancreatic tissue from the listed patient of table 1.Sample (is shorter than 30 minutes) immediately and gathers after excision, and in liquid nitrogen about 1 minute of snap frozen, be stored in temperature then in-80 ℃ the refrigerator.
The sample of formalin fixed
After cutting into slices with hematoxylin eosin stain through formalin fixed and with paraffin-embedded sample, be used to identify its histopathology feature.With the WHO system tumour is classified, the cancer of pancreas type that comprises in this research is as shown in table 1.
The 12 strain cancer of pancreas samples that are used for this research are to constitute the preponderate duct carcinoma of part of cancer of pancreas.The pairing sample of taking from normal structure on patient's cancer of pancreas pathology on every side is with comparing.
We have carried out the mensuration of 12 pairs of dielectrophoresis collection of illustrative plates, in order to the protein expression between comparison of tumor tissue and the normal control tissue.In order to carry out the evaluation of albumen, can produce total cancer extract and total normal protein extract thus with in the sample sets.Undertaken quantitatively by following 2 steps then: (I) compare with the gel of PDQuest imaging analysis software to each concentrated sample.(II), intersect and determine the change identified on the sample levels concentrating by to the analysis of each sample.Change multiple shown in the table 2,3,5 and 6 is to use concentrated sample determination.
The preparation of electrophoresis sample
Freezing in liquid nitrogen with having removed clot and having polluted the sample of organizing, wear into powder then.Sample is suspended in the lysis buffer (8M urea, 4%CHAPS, 40m Mol/L Tris-Cl, 0.5% carrier ampholyte, 100mM/LDTT and 0.1ig/il PMSF), and at 1200rpm centrifugal 30 minutes, supernatant stores down at-80 ℃.With the protein concentration in Bradford method (Bradford, M.Anal.Biochem.72,248,1976) the mensuration extract.
Two dimensional gel electrophore-sis
(18cm pH3-10) goes up application of sample at the ipg strip of rehydration to adopt cup application of sample method will contain the sample of 1mg albumen.Carry out isoelectric focusing electrophoresis (IEF) under the following conditions with the PharmaciaMultiphor device: at first through 24 hours with the voltage 200-5000V that raises, applying weighing apparatus then and pressing 5000V to reach 24 hours, electrophoresis temperature is 20 ℃.After the IEF, band 10ml balance solution I (6M urea, 50mM Tris pH8.8,30% glycerine, 2.0%SDS, 30mM dithiothreitol (DTT)) balance is 15 minutes, uses balance solution II (6M urea, 50mM Tris pH8.8 then, 30% glycerine, 2.0%SDS, 0.23M iodoacetamide) balance 15 minutes again.
The sds polyacrylamide gel electrophoresis of second direction (SDS-PAGE) adopt Hoefer ISO-DALT device carry out (10 clotting glue/time, 24 * 20cm), the IEF bar places the polyacrylamide gel of 12% homogeneous (on 1.5mm * 24cm * 20cm).Gel electrophoresis is carried out under constant voltage (80V, 20 ℃) in TGS-damping fluid (250mm Tris, 1.92M glycocoll, 1% (w/v) SDS, pH=8.3, Bio Rad).
Gel sets and dyeing
Make gel in 50% methyl alcohol/20% acetic acid, fix 30 minutes, in ultrapure water, washed 30 minutes then, use NOVEX Colloidal Blue staining kit (Invitrogen) to dye again according to manufacturer's recommendation.
Identification of Fusion Protein
The evaluation of albumen adopts two step method to carry out.
Digestion in the gel
With getting point apparatus picking gel point automatically and being transferred on 96 orifice plates.600-800 point of every clotting glue picking, gel point washs with ultrapure water, then drying in the fast evaporation under vacuum device with the 30% acetonitrile solution decolouring that 100 μ l are dissolved in 50mM ammonium bicarbonate.Wafer is dissolved in the trypsase of 50mM ammonium bicarbonate with 10ng/ μ l, and (USA) solution at room temperature digested maximum 16 hours for Promega, Madison.0.1% trifluoroacetic acid (TFA) that is dissolved in 50% acetonitrile with 20 μ l extracts the peptide of each gel point.Matrix solution comprises 0.025% (w/v) alpha-cyano-4-hydroxycinnamic acid (Sigma) that is dissolved in 50% acetonitrile/0.1%TFA, and contain the internal standard peptide and take off arginine bradykinin (Sigma, MW904.4681Da) and corticotropin fragment 18-39 (Sigma, MW2465.1989Da).
MALDI-TOF analyzes
1.5 μ l peptide extracts and 1.0 μ l matrix solutions are added on the point of MS target simultaneously.Recrystallization is carried out in explanation by manufacturer's indication.Flight mass spectrometer (Autoflex, Bruker, Analytics, Bremen, MALDI Germany) analyzed sample in the time.The note at the peak that is undertaken by the coupling of peptide and database search all adopt the software of inner exploitation to carry out.Compare the quality of peptide and the peptide quality in theory of available all albumen of each species.Adopt monoisotopic quality, the mass deviation of permission is 0.0025%.The mensuration of identity property needs 4 kinds of peptides that are complementary at least.Mispairing or mistake are cut the site and are not taken into account.
Table 1: the clinical and histopathology feature of sample
| Catalogue number(Cat.No.) | Sex | Age | Tumor locus | Histology | Lymphatic metastasis |
| Pc-01 | The man | 48 | Head of pancreas | The duct adenocarcinoma of moderate differentiation | Be |
| Pc-02 | The man | 68 | Head of pancreas | The gland cancer of differentiation difference | Be |
| Pc-03 | The man | 44 | Head of pancreas | The duct adenocarcinoma of differentiation difference, the hyaline cell type | Be |
| Pc-04 | The man | 66 | Head of pancreas | The duct adenocarcinoma that differentiation is good | Be |
| Pc-05 | The woman | 45 | Head of pancreas | The duct adenocarcinoma that differentiation is good | Not |
| Pc-06 | The woman | 65 | Head of pancreas | The duct adenocarcinoma that differentiation is good | Be |
| Pc-07 | The man | 59 | Head of pancreas | The duct adenocarcinoma of moderate differentiation | Be |
| Pc-08 | The woman | 62 | Body of pancreas | The duct adenocarcinoma that differentiation is good | Be |
| Pc-09 | The man | 54 | Head of pancreas | The pipe gland cancer that the moderate differentiation is led | Not |
| Pc-10 | The woman | 53 | Head of pancreas | The duct adenocarcinoma that differentiation is good | Not |
| Pc-11 | The woman | 54 | Head of pancreas | The duct adenocarcinoma of moderate differentiation | Be |
| Pc-12 | The woman | 69 | Head of pancreas | The duct adenocarcinoma of moderate differentiation | Be |
Table 2 is up-regulated protein I in cancer of pancreas
| Albumen | Acc No | Explanation | Seq ID No | Change multiple |
| Sw:CATD_ people | P07339 | Cathepsin D's precursor (ec 3.4.23.5) | 1 | ＜2 |
| Sw:IDHC_ people | O75874 | Tenuigenin isocitric dehydrogenase [NADP] (ec 1.1.1.42) | 2 | 2 |
| Sw:GELS_ people | P06396 | The pGSN precursor | 3 | 3 |
| Sw:CFAB_ people | P00751 | Complement factor B precursor (ec 3.4.21.47) | 4 | 5 |
| Sw:AAC4_ people | O43707 | α-actinine 4 (non-muscle α-actinine 4) | 5 | 2 |
| Sw:AAC1_ people | P12814 | α-actinine 1 (α-actinine cytoskeleton isotype) | 7 | 2 |
| Sw:TBA4_ people | P05215 | Tubulin α-4 chain | 8 | 2 |
| Sw:ABP2_ people | P21333 | Tenuin A (endothelium actin binding protein) | 9 | 4 |
| Sw:TAGL_ people | P37802 | Transgelin 2 (the smooth muscle 4 protein 22-α) | 10 | 2 |
| Sw:TPM4_ people | P07226 | Tropomyosin α 4 chains | 11 | ＜2 |
| Sw:BGH3_ people | Q15582 | The protein I G-H3 precursor that transforming growth factor-beta is induced | 6 | 5 |
| Sw:CALD_ people | Q05682 | Caldesmon (cdm) | 12 | 2 |
| Sw:ENOL_ people | Q05524 | α-enolase | 13 | 2 |
| Sw:ACY1_ people | Q03154 | Amino-acylase-I | 14 | 5 |
| Sw:CAPB_ people | P47756 | F-capping protein β subunit (capz β) | 15 | 5 |
| Sw:IPYR_ people | Q15181 | Inorganic pyrophosphatase | 16 | ＜2 |
| Sw:LEG3_ people | P17931 | Galectins 3 (agglutinin 3 that galactose is special) | 17 | 2 |
| Sw:POR2_ people | P45880 | Rely on the negative ion selector channel albumen 2 of voltage | 18 | ＜2 |
| Sw:ANX2_ people | P07355 | Annexin II | 19 | 2 |
| Sw:CBP2_ people | P50454 | Collagen is in conjunction with albumen 2 precursors | 20 | 2 |
| Sw:COF1_ people | P23528 | Non-muscle isotype Cofilin | 21 | ＜2 |
| Sw:DYPH_ people | P05092 | Peptidyl-prolyl cis-trans isomerase A | 22 | ＜2 |
| Sw:DYI2_ people | Q13409 | Kytoplasm dynein intermediate chain 2 | 23 | 2 |
| Sw:ECH1_ people | Q13011 | Mitochondria δ 3,5-δ 2,4-dienol coacetylase isomerase precursor | 24 | 2 |
| Sw:MLRN_ people | P24844 | The light chain 2 that myosin is regulated | 48 | 2 |
| Sw:PLSL_ people | P13796 | The L-fimbrin | 26 | ＜2 |
| Sw:RAN_ people | P17080 | The nuclear protein ran of GTP combination | 27 | 3 |
| Sw:ROK_ people | Q07244 | Heterogeneous nuclear ribonucleoprotein K | 28 | 2 |
| Sw:TCTP_ people | P13693 | The tumour of translational control | 29 | ＜2 |
| Sw:TPM1_ people | P09493 | Tropomyosin 1 α chain | 30 | ＜2 |
| Sw:TYPH_ people | P19971 | The thymidine phosphorylase precursor | 31 | 5 |
| Sw:AMPL_ people | P28838 | The amino phthalein enzyme of cytosol | 32 | 3 |
| Sw:KICS_ people | P08727 | I type cytoskeleton 19 keratin (cytokeratin 19) | 33 | 4 |
| Sw:ALDX_ people | P14550 | Alcohol dehydrogenase [NADP+] | 34 | 4 |
| Sw:EL3A_ people | P09093 | Elastoser IIIa precursor | 35 | 4 |
| : DLDH_ people | P09622 | Mitochondria dihydrolipoamide dehydrogenase precursor | 36 | 2 |
| Sw:ECHM_ people | P30084 | Mitochondria enoyl-CoA hydratase precursor | 37 | 3 |
| Sw:HSBX_ people | O14558 | Class heat shock 20kda albumen p20 | 38 | 2 |
| Sw:MLEN-people | P16475 | Non-muscle isotype alkalescence myosin light chain | 39 | 3 |
| Sw:CALX-people | P27824 | Calcium connects amyloid protein precursor | 40 | 3 |
| Sw:MA32-people | P07021 | Complement component 1 | 41 | ＜2 |
| Sw:NUAM-people | P28331 | Mitochondria NADH CoQ oxide-reductase 75kda subunit precursor | 42 | 2 |
| Sw:PBEF-people | P43490 | Pre B cell enhancer precursor | 43 | 2 |
| Sw:RET1-people | P09455 | The RBP ELISA I of cell | 44 | 2 |
| Sw:TCPG-people | P49368 | T-compound protein 1, the γ subunit | 45 | 2 |
| Sw:RINI-people | P13489 | Placental ribonuclease inhibitor | 46 | ＜2 |
| Sw:GBLP-people | P25388 | Class guanine-nucleotide-binding protein β protein subunit 12.3 | 47 | 2 |
| Sw:S109-people | P06702 | Calgranulin B | 49 | ＜2 |
Table 3: up-regulated protein I I in cancer of pancreas
| Albumen | Acc No | Explanation | Seq ID No | The multiple that changes |
| Sw:CAPG_ people | P40121 | The macrophage capping protein | 50 | 3 |
| Sw:ANX1_ people | P04083 | Annexin I (lipocortin I) (calcium-dependent protein II) | 51 | 4 |
| Sw:K2C7_ people | P08729 | II type cytoskeleton 7 keratin | 52 | 5 |
| Humangp：CH R13_Q15063 | Q15063 | Gegenbaur's cell specific factor 2 precursors | 53 | 2 |
| Sw:TGLC_ people | P21980 | Albumen-glutamine gamma-glutamyl based transferase | 54 | 2 |
| Sw:GDIR_ people | P52565 | The Rho GDP inhibitor 1 that dissociates | 55 | ＜2 |
| Sw:IQG1_ people | P46940 | Class Ras gtpase activating protein | 25 | 2 |
Table 4 albumen is according to the biological process of its participation or the rough classification of basic function
| Protein function a | Albumen kind number b | Number percent (%) c |
| The structure of cytoskeleton is formed and is regulated | 61 | 20.8 |
| Cell cycle and metabolism | 74 | 25.3 |
| Stimulate to external world or stress reply | 61 | 20.8 |
| The signal conduction | 13 | 4.4 |
| Kernel function | 18 | 6.1 |
| Transhipment processing | 19 | 6.5 |
| Hemostasis | 12 | 4.1 |
| Cell adhesion | 7 | 2.4 |
| Chaperone | 7 | 2.4 |
| Apoptosis | 3 | 1 |
| Unknown function | 11 | 3.7 |
| Other | 7 | 2.4 |
| Amount to | 293 | 100 |
The level of table 5 in normal pancreas tissue is higher than the albumen in cancerous tissue
| Albumen a | Acc No b | Explanation c | Multiple d | Seq ID No |
| Cytoskeleton is regulated | ||||
| Sw:DESM_ people | P17661 | Desmin | 3 | 70 |
| Proteolysis and peptide cracking | ||||
| Sw:CBPB_ people | P15086 | Carboxypeptidase b precursor | 2 | 71 |
| Sw:CBP1_ people | P15085 | Carboxypeptidase a1 precursor | Do not calculate | 72 |
| Sw:CPB2_ people | P50454 | Carboxypeptidase a2 precursor | Do not calculate | 73 |
| Sw:CTRB_ people | P17538 | Chymotrypsinogen b precursor | Do not calculate | 74 |
| Sw:TRY1_ people | P07477 | Trypsase i precursor (ec 3.4.21.4) (cationic trypsinogen pepsinogen) | Do not calculate | 75 |
| Sw:TRY2_ people | P07478 | Trypsase ii precursor (negative ion trypsinogen) | 3 | 76 |
| Sw:ILEU_ people | P30740 | Inhibitors of neutrophil elastase | 4 | 77 |
| Chaperone | ||||
| Sw:CH60_ people | P10809 | The people, mitochondrial matrix albumen p1 precursor | 2 | 78 |
| Sw:ENPL_ people | P14625 | The glycoregulatory albumen of 94kda grape | 3 | 79 |
| Sw:ER29_ people | P30040 | Endoplasmic reticulum albumen erp 29 precursors | 2 | 80 |
| Sw:PDA2_ people | Q13087 | Protein disulphideisomerase a2 precursor | 2 | 81 |
| Sw:PDA3_ people | P30101 | Protein disulphideisomerase a3 precursor | 2 | 82 |
| Oxidoreducing enzyme | ||||
| Sw:ADHB_ people | P00325 | Alcohol dehydrogenase β chain | 2 | 83 |
| Sw:GTO1_ people | P78417 | Glutathione transferase ω 1 | Do not calculate | 84 |
| Sw:OXRP_ people | Q9Y4L1 | The amyloid protein precursor that 150kda oxygen is regulated | Do not calculate | 85 |
| Sw:PDX4_ people | Q13162 | Peroxidating reduction albumen 4 | ＜2 | 86 |
| Sw:ULA4_ people | P30039 | Mawd is in conjunction with albumen | ＜2 | 87 |
| The metabolism of bioprocess | ||||
| sw：AMYC_ | P19961 | AMS 2b precursor | 3 | 88 |
| The people | ||||
| Sw:AMYP_ people | P04746 | The pancreatic precursor | Do not calculate | 89 |
| Sw:ATPA_ people | P25705 | Mitochondrial ATP synthetase alpha chain precursor | ＜2 | 90 |
| Sw:BAL_ people | P19835 | The lipase precursor that bile salt activates | 3 | 91 |
| Sw:L1P1_ people | P54315 | Albumen 1 precursor that pancreatic lipase is relevant | ＜2 | 92 |
| Sw:LIP2_ people | P54317 | Albumen 2 precursors that pancreatic lipase is relevant | Do not calculate | 93 |
| Sw:LIPP_ people | P16233 | Pancreas triacylglycerol lipase precursor | Do not calculate | 94 |
| Sw:DPY2_ people | Q16555 | The albumen 2 that dihydropyrimidinase is relevant | 95 | |
| Sw:GABT_ people | P80404 | 4-aminobutyric acid ester aminopherase | 2 | 96 |
| Sw:GATM_ people | P50440 | Mitochondria glycine amidinotransferase precursor | Do not calculate | 97 |
| Sw:GR78_ people | P11021 | The glycoregulatory amyloid protein precursor of 78kda grape (GRP 78) | 3 | 98 |
| Sw:IF32_ people | Q13347 | Eukaryotic translation initiation factor 3 subunits 2 | ＜2 | 99 |
| Sw:DPY2_ people | Q16555 | The albumen 2 that dihydropyrimidinase is relevant | 100 | |
| Sw:PGMU_ people | P36871 | Phosphoglucomutase | 2 | 101 |
| Sw:PSA1_ people | P25786 | Proteasome subunit α 1 type | 2 | 102 |
| Heat shock protein | ||||
| sw：HS27 | P04792 | Heat shock 27kda albumen | Do not calculate | 103 |
| Signal | ||||
| sw：PD6I | Q8WUM4 | Apoptosis 6 interaction proteins | 5 | 104 |
| Muscle development | ||||
| Hsugp：05268 7-10-0 | Q9bva2 | 4.5lim domain 3 | ＜2 | 105 |
| sw：sli2 | Q13643 | Skeleton muscle LIM albumen 2 (SLIM2) (4.5li m domain protein 3) (PHL3) | ＜2 | 106 |
| The transhipment of bioprocess | ||||
| Sw:CYB5_ people | P00167 | Cytochrome b5 | 2 | 107 |
| Cell adhesion | ||||
| Sw:PAP1_ people | Q06141 | Pancreatitis associated protein 1 precursor | Do not calculate | 108 |
| Other | ||||
| Sw:CA16_ people | P12109 | Collagen α 1 (vi) chain precursor | 5 | 109 |
| Sw:LUM_ people | P51884 | Basement membrane glycan precursor | 3 | 110 |
Table 6: the level in cancer of pancreas is higher than the albumen in normal structure
| Albumen a | Acc No b | Explanation c | Multiple d | Seq ID No |
| Cytoskeleton is regulated | ||||
| Sw:FSC2_ people | O14926 | Flesh fasciclin (retina flesh fasciclin) | 2 | 56 |
| Sw:AAC1_ people | P12814 | α-actinine 1 | 2 | 7 |
| Sw:AAC4_ people | O43707 | α-actinine 4 | 2 | 5 |
| Sw:ABP2_ people | P21333 | Endothelium actin binding protein (α-tenuin) | 4 | 9 |
| Sw:ANX2_ people | P07355 | (lipocortin ii) for people's annexin ii | 2 | 19 |
| Sw:CALD_ people | Q05682 | Caldesmon (cdm) | 2 | 12 |
| W:CAPB_ people | P47756 | F-capping protein β subunit | 5 | 15 |
| Sw:CAPG_ people | P40121 | The macrophage capping protein | 3 | 50 |
| Sw:CPF1_ people | P23528 | Non-muscle isotype (p18) Cofilin | ＜2 | 21 |
| Sw:DEST_ people | P18282 | Destrin (actin depolymerizing factor) (adf) | 2 | 57 |
| Sw:DYI2_ people | Q13409 | Dynein intermediate chain 2 (fragment) | 2 | 23 |
| Sw:GELS_ people | P06396 | AGEL | 3 | 3 |
| Sw:K1CS_ people | P08727 | I type cytoskeleton 19 keratin | 4 | 33 |
| Sw:K2C7_ people | P08729 | Ii type cytoskeleton 7 keratin | 5 | 52 |
| Sw:MLEN_ people | P16475 | The alkalescence myosin light chain | 3 | 39 |
| Sw:PLSL_ people | P13796 | 1-fimbrin (lymphocyte cytoplasmic protein 1) | ＜2 | 26 |
| Sw:TAGL_ people | P37802 | Transgelin (2 2kda actin binding protein) | 2 | 10 |
| Sw:TBA4_ people | P05215 | Tubulin α chain | 2 | 8 |
| Proteolysis and peptide cracking | ||||
| sw：ACY1 | Q03154 | ACY1 | 5 | 14 |
| sw：AMPL | P28838 | Kytoplasm ammonia phthalein enzyme | 3 | 32 |
| sw：CATD | P07339 | Cathepsin d precursor | ＜2 | 1 |
| Sw:CFAB_ people | P00751 | Complement factor b precursor | 5 | 4 |
| Sw:EL3A_ people | P09093 | Elastoser iiia precursor | 4 | 35 |
| Chaperone | ||||
| Sw:APE_ people | P02649 | Apo e precursor (apo-e) | ＜2 | 59 |
| Sw:CALX_ people | P27824 | Calnexin (p90) precursor | 3 | 40 |
| Sw:CYPH_ people | P05092 | Peptidyl-propyl cis-trans isomerase a | ＜2 | 22 |
| Sw:TCPG_ people | P49368 | T-compound protein 1, the γ subunit | 2 | 45 |
| Sw:CBP2_ people | P50454 | People's collagen is in conjunction with albumen 2 precursors | 2 | 20 |
| Tr_ people Q96C61 | Q96C61 | The false 88.6kda albumen of intending | 5 | 60 |
| Oxidoreducing enzyme | ||||
| Sw:DLDH_ people | P09622 | Dihydrolipoamide dehydrogenase | 2 | 36 |
| Sw:IDHC_ people | O75874 | Kytoplasm isocitric dehydrogenase (NADP) | 2 | 2 |
| Sw:NUAM_ people | P28331 | NADH ubiquinone oxidoreducing enzyme 75kda subunit | 2 | 42 |
| The metabolism of bioprocess | ||||
| Sw:ALDX_ people | P14550 | Alcohol dehydrogenase [NADP+] | 4 | 34 |
| Sw:ECH1_ people | Q13011 | δ 3,5-. δ 2,4-diene acyl coenzyme A isomerase | 2 | 24 |
| Sw:ECHM_ people | P30084 | Mitochondria enoyl-CoA hydratase precursor | 3 | 37 |
| Sw:IPYR_ people | Q15181 | Inorganic pyrophosphatase | ＜2 | 16 |
| sw：TYPH_ | P19971 | Thymidine phosphatase precursor | 5 | 31 |
| The people | ||||
| Sw:ENOA_ people | P06733 | People α enolase | 2 | 61 |
| Sw:ENOL_ people | Q05524 | Lung specificity α enolase | 2 | 13 |
| Sw:SYW_ people | P23381 | Tryptophane tRNA synzyme | 2 | 62 |
| Heat shock protein | ||||
| Sw:HSBX_ people | O14558 | Class heat shock 20kda albumen p20 | 2 | 38 |
| Signal | ||||
| Sw:GBLPP _ people | P25388 | Class guanine-nucleotide-binding protein β protein subunit 12.3 | 2 | 47 |
| Sw:GDIR_ people | P52565 | The Rho GDP inhibitor 1 that dissociates | ＜2 | 55 |
| W:IQG1_ people | P46940 | Class Ras gtpase activating protein IQGAP1 | 2 | 25 |
| Sw:PBEF_ people | P43490 | Pre B cell enhancer precursor | 2 | 43 |
| Sw:RAN_ people | P17080 | GTP syncaryon albumen ran | 3 | 27 |
| Immune response | ||||
| Sw:KAC_ people | P01834 | Ig kappa chain c zone | 2 | 63 |
| Sw:MA32_ people | Q07021 | Preceding mRAN splicing factor sf2, the p32 subunit | ＜2 | 41 |
| Inflammatory response | ||||
| Sw:ANX1_ people | P04083 | Annexin (lipocortin 1) | 4 | 51 |
| Sw:LEG3_ people | P17931 | Galectins 3 | 2 | 17 |
| Sw:S109_ people | P06702 | Calgranulin b (mrp14) | ＜2 | 49 |
| Muscle development | ||||
| Sw:TPM1_ people | P09493 | Tropomyosin 1 α chain | ＜2 | 30 |
| W:TPM4_ people | P07226 | Tropomyosin α 4 chains | ＜2 | 11 |
| Sw:MLRN_ people | P24844 | The light chain 2 that myosin is regulated | 2 | 48 |
| The transhipment of bioprocess | ||||
| Humangp： CHR2-Q15 092 | Q15092 | Transmembrane protein | 2 | 64 |
| Sw:POR2_ people | P45880 | The voltage-dependent sun from | ＜2 | 18 |
| Sub-selectivity channel protein 2 | ||||
| Sw:RET1_ people | P09455 | RBP ELISA I | 2 | 44 |
| RNA processing | ||||
| Humangp： CHR20-Q9 P2E9 | O75300 | Ribophorin I (KIAA1398 albumen) | ＜2 | 65 |
| Sw:RIN1_ people | P13489 | Placental ribonuclease inhibitor | ＜2 | 46 |
| Sw:ROK_ people | Q07244 | Heterogeneous nuclear ribonucleoprotein k | 2 | 28 |
| Blood clotting is poly- | ||||
| Sw:FIBG_ people | P02679 | Fibrinogen γ chain precursor | 3 | 66 |
| Sw:THRB_ people | P00734 | The factor precursor | ＜2 | 67 |
| Anti-apoptotic | ||||
| Sw:TCTP_ people | P13693 | The oncoprotein of translational control (p23) | ＜2 | 29 |
| Cell adhesion | ||||
| Humangp： CHR13-Q1 5063 | Q15063 | Gegenbaur's cell specific factor 2 precursors | 2 | 53 |
| Sw:BGH3_ people | Q15582 | The albumen that transforming growth factor-beta is induced | 5 | 6 |
| Other | ||||
| Sw:TGLC_ people | P21980 | TTG | 2 | 54 |
| Sw:KPY1_ people | P14618 | People's pyruvate kinase, the kytoplasm thyroxine-binding globulin | 3 | 68 |
| Humangp： CHR19-Q9 6D15 | Q96D15 | Net is knitted calbindin 3 precursors | 2 | 69 |
Sequence table
＜110〉Sinogenomax Co., Ltd.
＜120〉specific mark of cancer of pancreas
<130>SGF-01-1117
<160>110
<170>PatentIn version 3.2
<210>1
<211>412
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉histone D precursor
<222>(1)..(412)
＜223〉on Dec 6th, 2002 registration number: P07339
<400>1
Met Gln Pro Ser Ser Leu Leu Pro Leu Ala Leu Cys Leu Leu Ala Ala
1 5 10 15
Pro Ala Ser Ala Leu Val Arg Ile Pro Leu His Lys Phe Thr Ser Ile
20 25 30
Arg Arg Thr Met Ser Glu Val Gly Gly Ser Val Glu Asp Leu Ile Ala
35 40 45
Lys Gly Pro Val Ser Lys Tyr Ser Gln Ala Val Pro Ala Val Thr Glu
50 55 60
Gly Pro Ile Pro Glu Val Leu Lys Asn Tyr Met Asp Ala Gln Tyr Tyr
65 70 75 80
Gly Glu Ile Gly Ile Gly Thr Pro Pro Gln Cys Phe Thr Val Val Phe
85 90 95
Asp Thr Gly Ser Ser Asn Leu Trp Val Pro Ser Ile His Cys Lys Leu
100 105 110
Leu Asp Ile Ala Cys Trp Ile His His Lys Tyr Asn Ser Asp Lys Ser
115 120 125
Ser Thr Tyr Val Lys Asn Gly Thr Ser Phe Asp Ile His Tyr Gly Ser
130 135 140
Gly Ser Leu Ser Gly Tyr Leu Ser Gln Asp Thr Val Ser Val Pro Cys
145 150 155 160
Gln Ser Ala Ser Ser Ala Ser Ala Leu Gly Gly Val Lys Val Glu Arg
165 170 175
Gln Val Phe Gly Glu Ala Thr Lys Gln Pro Gly Ile Thr Phe Ile Ala
180 185 190
Ala Lys Phe Asp Gly Ile Leu Gly Met Ala Tyr Pro Arg Ile Ser Val
195 200 205
Asn Asn Val Leu Pro Val Phe Asp Asn Leu Met Gln Gln Lys Leu Val
210 215 220
Asp Gln Asn Ile Phe Ser Phe Tyr Leu Ser Arg Asp Pro Asp Ala Gln
225 230 235 240
Pro Gly Gly Glu Leu Met Leu Gly Gly Thr Asp Ser Lys Tyr Tyr Lys
245 250 255
Gly Ser Leu Ser Tyr Leu Asn Val Thr Arg Lys Ala Tyr Trp Gln Val
260 265 270
His Leu Asp Gln Val Glu Val Ala Ser Gly Leu Thr Leu Cys Lys Glu
275 280 285
Gly Cys Glu Ala Ile Val Asp Thr Gly Thr Ser Leu Met Val Gly Pro
290 295 300
Val Asp Glu Val Arg Glu Leu Gln Lys Ala Ile Gly Ala Val Pro Leu
305 310 315 320
Ile Gln Gly Glu Tyr Met Ile Pro Cys Glu Lys Val Ser Thr Leu Pro
325 330 335
Ala Ile Thr Leu Lys Leu Gly Gly Lys Gly Tyr Lys Leu Ser Pro Glu
340 345 350
Asp Tyr Thr Leu Lys Val Ser Gln Ala Gly Lys Thr Leu Cys Leu Ser
355 360 365
Gly Phe Met Gly Met Asp Ile Pro Pro Pro Ser Gly Pro Leu Trp Ile
370 375 380
Leu Gly Asp Val Phe Ile Gly Arg Tyr Tyr Thr Val Phe Asp Arg Asp
385 390 395 400
Asn Asn Arg Val Gly Phe Ala Glu Ala Ala Arg Leu
405 410
<210>2
<211>414
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉kytoplasm isocitric dehydrogenase [NADP]
<222>(1)..(414)
＜223〉on Dec 6th, 2002 registration number: 075874
<400>2
Met Ser Lys Lys Ile Ser Gly Gly Ser Val Val Glu Met Gln Gly Asp
1 5 10 15
Glu Met Thr Arg Ile Ile Trp Glu Leu Ile Lys Glu Lys Leu Ile Phe
20 25 30
Pro Tyr Val Glu Leu Asp Leu His Ser Tyr Asp Leu Gly Ile Glu Asn
35 40 45
Arg Asp Ala Thr Asn Asp Gln Val Thr Lys Asp Ala Ala Glu Ala Ile
50 55 60
Lys Lys His Asn Val Gly Val Lys Cys Ala Thr Ile Thr Pro Asp Glu
65 70 75 80
Lys Arg Val Glu Glu Phe Lys Leu Lys Gln Met Trp Lys Ser Pro Asn
85 90 95
Gly Thr Ile Arg Asn Ile Leu Gly Gly Thr Val Phe Arg Glu Ala Ile
100 105 110
Ile Cys Lys Asn Ile Pro Arg Leu Val Ser Gly Trp Val Lys Pro Ile
115 120 125
Ile Ile Gly Arg His Ala Tyr Gly Asp Gln Tyr Arg Ala Thr Asp Phe
130 135 140
Val Val Pro Gly Pro Gly Lys Val Glu Ile Thr Tyr Thr Pro Ser Asp
145 150 155 160
Gly Thr Gln Lys Val Thr Tyr Leu Val His Asn Phe Glu Glu Gly Gly
165 170 175
Gly Val Ala Met Gly Met Tyr Asn Gln Asp Lys Ser Ile Glu Asp Phe
180 185 190
Ala His Ser Ser Phe Gln Met Ala Leu Ser Lys Gly Trp Pro Leu Tyr
195 200 205
Leu Ser Thr Lys Asn Thr Ile Leu Lys Lys Tyr Asp Gly Arg Phe Lys
210 215 220
Asp Ile Phe Gln Glu Ile Tyr Asp Lys Gln Tyr Lys Ser Gln Phe Glu
225 230 235 240
Ala Gln Lys Ile Trp Tyr Glu His Arg Leu Ile Asp Asp Met Val Ala
245 250 255
Gln Ala Met Lys Ser Glu Gly Gly Phe Ile Trp Ala Cys Lys Asn Tyr
260 265 270
Asp Gly Asp Val Gln Ser Asp Ser Val Ala Gln Gly Tyr Gly Ser Leu
275 280 285
Gly Met Met Thr Ser Val Leu Val Cys Pro Asp Gly Lys Thr Val Glu
290 295 300
Ala Glu Ala Ala His Gly Thr Val Thr Arg His Tyr Arg Met Tyr Gln
305 310 315 320
Lys Gly Gln Glu Thr Ser Thr Asn Pro Ile Ala Ser Ile Phe Ala Trp
325 330 335
Thr Arg Gly Leu Ala His Arg Ala Lys Leu Asp Asn Asn Lys Glu Leu
340 345 350
Ala Phe Phe Ala Asn Ala Leu Glu Glu Val Ser Ile Glu Thr Ile Glu
355 360 365
Ala Gly Phe Met Thr Lys Asp Leu Ala Ala Cys Ile Lys Gly Leu Pro
370 375 380
Asn Val Gln Arg Ser Asp Tyr Leu Asn Thr Phe Glu Phe Met Asp Lys
385 390 395 400
Leu Gly Glu Asn Leu Lys Ile Lys Leu Ala Gln Ala Lys Leu
405 410
<210>3
<211>782
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉pGSN precursor
<222>(1)..(782)
＜223〉on Dec 6th, 2002 registration number: P06396
<400>3
Met Ala Pro His Arg Pro Ala Pro Ala Leu Leu Cys Ala Leu Ser Leu
1 5 10 15
Ala Leu Cys Ala Leu Ser Leu Pro Val Arg Ala Ala Thr Ala Ser Arg
20 25 30
Gly Ala Ser Gln Ala Gly Ala Pro Gln Gly Arg Val Pro Glu Ala Arg
35 40 45
Pro Asn Ser Met Val Val Glu His Pro Glu Phe Leu Lys Ala Gly Lys
50 55 60
Glu Pro Gly Leu Gln Ile Trp Arg Val Glu Lys Phe Asp Leu Val Pro
65 70 75 80
Val Pro Thr Asn Leu Tyr Gly Asp Phe Phe Thr Gly Asp Ala Tyr Val
85 90 95
Ile Leu Lys Thr Val Gln Leu Arg Asn Gly Asn Leu Gln Tyr Asp Leu
100 105 110
His Tyr Trp Leu Gly Asn Glu Cys Ser Gln Asp Glu Ser Gly Ala Ala
115 120 125
Ala Ile Phe Thr Val Gln Leu Asp Asp Tyr Leu Asn Gly Arg Ala Val
130 135 140
Gln His Arg Glu Val Gln Gly Phe Glu Ser Ala Thr Phe Leu Gly Tyr
145 150 155 160
Phe Lys Ser Gly Leu Lys Tyr Lys Lys Gly Gly Val Ala Ser Gly Phe
165 170 175
Lys His Val Val Pro Asn Glu Val Val Val Gln Arg Leu Phe Gln Val
180 185 190
Lys Gly Arg Arg Val Val Arg Ala Thr Glu Val Pro Val Ser Trp Glu
195 200 205
Ser Phe Asn Asn Gly Asp Cys Phe Ile Leu Asp Leu Gly Asn Asn Ile
210 215 220
His Gln Trp Cys Gly Ser Asn Ser Asn Arg Tyr Glu Arg Leu Lys Ala
225 230 235 240
Thr Gln Val Ser Lys Gly Ile Arg Asp Asn Glu Arg Ser Gly Arg Ala
245 250 255
Arg Val His Val Ser Glu Glu Gly Thr Glu Pro Glu Ala Met Leu Gln
260 265 270
Val Leu Gly Pro Lys Pro Ala Leu Pro Ala Gly Thr Glu Asp Thr Ala
275 280 285
Lys Glu Asp Ala Ala Asn Arg Lys Leu Ala Lys Leu Tyr Lys Val Ser
290 295 300
Asn Gly Ala Gly Thr Met Ser Val Ser Leu Val Ala Asp Glu Asn Pro
305 310 315 320
Phe Ala Gln Gly Ala Leu Lys Ser Glu Asp Cys Phe Ile Leu Asp His
325 330 335
Gly Lys Asp Gly Lys Ile Phe Val Trp Lys Gly Lys Gln Ala Asn Thr
340 345 350
Glu Glu Arg Lys Ala Ala Leu Lys Thr Ala Ser Asp Phe Ile Thr Lys
355 360 365
Met Asp Tyr Pro Lys Gln Thr Gln Val Ser Val Leu Pro Glu Gly Gly
370 375 380
Glu Thr Pro Leu Phe Lys Gln Phe Phe Lys Asn Trp Arg Asp Pro Asp
385 390 395 400
Gln Thr Asp Gly Leu Gly Leu Ser Tyr Leu Ser Ser His Ile Ala Asn
405 410 415
Val Glu Arg Val Pro Phe Asp Ala Ala Thr Leu His Thr Ser Thr Ala
420 425 430
Met Ala Ala Gln His Gly Met Asp Asp Asp Gly Thr Gly Gln Lys Gln
435 440 445
Ile Trp Arg Ile Glu Gly Ser Asn Lys Val Pro Val Asp Pro Ala Thr
450 455 460
Tyr Gly Gln Phe Tyr Gly Gly Asp Ser Tyr Ile Ile Leu Tyr Asn Tyr
465 470 475 480
Arg His Gly Gly Arg Gln Gly Gln Ile Ile Tyr Asn Trp Gln Gly Ala
485 490 495
Gln Ser Thr Gln Asp Glu Val Ala Ala Ser Ala Ile Leu Thr Ala Gln
500 505 510
Leu Asp Glu Glu Leu Gly Gly Thr Pro Val Gln Ser Arg Val Val Gln
515 520 525
Gly Lys Glu Pro Ala His Leu Met Ser Leu Phe Gly Gly Lys Pro Met
530 535 540
Ile Ile Tyr Lys Gly Gly Thr Ser Arg Glu Gly Gly Gln Thr Ala Pro
545 550 555 560
Ala Ser Thr Arg Leu Phe Gln Val Arg Ala Asn Ser Ala Gly Ala Thr
565 570 575
Arg Ala Val Glu Val Leu Pro Lys Ala Gly Ala Leu Asn Ser Asn Asp
580 585 590
Ala Phe Val Leu Lys Thr Pro Ser Ala Ala Tyr Leu Trp Val Gly Thr
595 600 605
Gly Ala Ser Glu Ala Glu Lys Thr Gly Ala Gln Glu Leu Leu Arg Val
610 615 620
Leu Arg Ala Gln Pro Val Gln Val Ala Glu Gly Ser Glu Pro Asp Gly
625 630 635 640
Phe Trp Glu Ala Leu Gly Gly Lys Ala Ala Tyr Arg Thr Ser Pro Arg
645 650 655
Leu Lys Asp Lys Lys Met Asp Ala His Pro Pro Arg Leu Phe Ala Cys
660 665 670
Ser Asn Lys Ile Gly Arg Phe Val Ile Glu Glu Val Pro Gly Glu Leu
675 680 685
Met Gln Glu Asp Leu Ala Thr Asp Asp Val Met Leu Leu Asp Thr Trp
690 695 700
Asp Gln Val Phe Val Trp Val Gly Lys Asp Ser Gln Glu Glu Glu Lys
705 710 715 720
Thr Glu Ala Leu Thr Ser Ala Lys Arg Tyr Ile Glu Thr Asp Pro Ala
725 730 735
Asn Arg Asp Arg Arg Thr Pro Ile Thr Val Val Lys Gln Gly Phe Glu
740 745 750
Pro Pro Ser Phe Val Gly Trp Phe Leu Gly Trp Asp Asp Asp Tyr Trp
755 760 765
Ser Val Asp Pro Leu Asp Arg Ala Met Ala Glu Leu Ala Ala
770 775 780
<210>4
<211>764
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉complement factor B precursor
<222>(1)..(764)
＜223〉on Dec 6th, 2002 registration number: P00751
<400>4
Met Gly Ser Asn Leu Ser Pro Gln Leu Cys Leu Met Pro Phe Ile Leu
1 5 10 15
Gly Leu Leu Ser Gly Gly Val Thr Thr Thr Pro Trp Ser Leu Ala Arg
20 25 30
Pro Gln Gly Ser Cys Ser Leu Glu Gly Val Glu Ile Lys Gly Gly Ser
35 40 45
Phe Arg Leu Leu Gln Glu Gly Gln Ala Leu Glu Tyr Val Cys Pro Ser
50 55 60
Gly Phe Tyr Pro Tyr Pro Val Gln Thr Arg Thr Cys Arg Ser Thr Gly
65 70 75 80
Ser Trp Ser Thr Leu Lys Thr Gln Asp Gln Lys Thr Val Arg Lys Ala
85 90 95
Glu Cys Arg Ala Ile His Cys Pro Arg Pro His Asp Phe Glu Asn Gly
100 105 110
Glu Tyr Trp Pro Arg Ser Pro Tyr Tyr Asn Val Ser Asp Glu Ile Ser
115 120 125
Phe His Cys Tyr Asp Gly Tyr Thr Leu Arg Gly Ser Ala Asn Arg Thr
130 135 140
Cys Gln Val Asn Gly Arg Trp Ser Gly Gln Thr Ala Ile Cys Asp Asn
145 150 155 160
Gly Ala Gly Tyr Cys Ser Asn Pro Gly Ile Pro Ile Gly Thr Arg Lys
165 170 175
Val Gly Ser Gln Tyr Arg Leu Glu Asp Ser Val Thr Tyr His Cys Ser
180 185 190
Arg Gly Leu Thr Leu Arg Gly Ser Gln Arg Arg Thr Cys Gln Glu Gly
195 200 205
Gly Ser Trp Ser Gly Thr Glu Pro Ser Cys Gln Asp Ser Phe Met Tyr
210 215 220
Asp Thr Pro Gln Glu Val Ala Glu Ala Phe Leu Ser Ser Leu Thr Glu
225 230 235 240
Thr Ile Glu Gly Val Asp Ala Glu Asp Gly His Gly Pro Gly Glu Gln
245 250 255
Gln Lys Arg Lys Ile Val Leu Asp Pro Ser Gly Ser Met Asn Ile Tyr
260 265 270
Leu Val Leu Asp Gly Ser Asp Ser Ile Gly Ala Ser Asn Phe Thr Gly
275 280 285
Ala Lys Lys Cys Leu Val Asn Leu Ile Glu Lys Val Ala Ser Tyr Gly
290 295 300
Val Lys Pro Arg Tyr Gly Leu Val Thr Tyr Ala Thr Tyr Pro Lys Ile
305 310 315 320
Trp Val Lys Val Ser Glu Ala Asp Ser Ser Asn Ala Asp Trp Val Thr
325 330 335
Lys Gln Leu Asn Glu Ile Asn Tyr Glu Asp His Lys Leu Lys Ser Gly
340 345 350
Thr Asn Thr Lys Lys Ala Leu Gln Ala Val Tyr Ser Met Met Ser Trp
355 360 365
Pro Asp Asp Val Pro Pro Glu Gly Trp Asn Arg Thr Arg His Val Ile
370 375 380
Ile Leu Met Thr Asp Gly Leu His Asn Met Gly Gly Asp Pro Ile Thr
385 390 395 400
Val Ile Asp Glu Ile Arg Asp Leu Leu Tyr Ile Gly Lys Asp Arg Lys
405 410 415
Asn Pro Arg Glu Asp Tyr Leu Asp Val Tyr Val Phe Gly Val Gly Pro
420 425 430
Leu Val Asn Gln Val Asn Ile Asn Ala Leu Ala Ser Lys Lys Asp Asn
435 440 445
Glu Gln His Val Phe Lys Val Lys Asp Met Glu Asn Leu Glu Asp Val
450 455 460
Phe Tyr Gln Met Ile Asp Glu Ser Gln Ser Leu Ser Leu Cys Gly Met
465 470 475 480
Val Trp Glu His Arg Lys Gly Thr Asp Tyr His Lys Gln Pro Trp Gln
485 490 495
Ala Lys Ile Ser Val Ile Arg Pro Ser Lys Gly His Glu Ser Cys Met
500 505 510
Gly Ala Val Val Ser Glu Tyr Phe Val Leu Thr Ala Ala His Cys Phe
515 520 525
Thr Val Asp Asp Lys Glu His Ser Ile Lys Val Ser Val Gly Gly Glu
530 535 540
Lys Arg Asp Leu Glu Ile Glu Val Val Leu Phe His Pro Asn Tyr Asn
545 550 555 560
Ile Asn Gly Lys Lys Glu Ala Gly Ile Pro Glu Phe Tyr Asp Tyr Asp
565 570 575
Val Ala Leu Ile Lys Leu Lys Asn Lys Leu Lys Tyr Gly Gln Thr Ile
580 585 590
Arg Pro Ile Cys Leu Pro Cys Thr Glu Gly Thr Thr Arg Ala Leu Arg
595 600 605
Leu Pro Pro Thr Thr Thr Cys Gln Gln Gln Lys Glu Glu Leu Leu Pro
610 615 620
Ala Gln Asp Ile Lys Ala Leu Phe Val Ser Glu Glu Glu Lys Lys Leu
625 630 635 640
Thr Arg Lys Glu Val Tyr Ile Lys Asn Gly Asp Lys Lys Gly Ser Cys
645 650 655
Glu Arg Asp Ala Gln Tyr Ala Pro Gly Tyr Asp Lys Val Lys Asp Ile
660 665 670
Ser Glu Val Val Thr Pro Arg Phe Leu Cys Thr Gly Gly Val Ser Pro
675 680 685
Tyr Ala Asp Pro Asn Thr Cys Arg Gly Asp Ser Gly Gly Pro Leu Ile
690 695 700
Val His Lys Arg Ser Arg Phe Ile Gln Val Gly Val Ile Ser Trp Gly
705 710 715 720
Val Val Asp Val Cys Lys Asn Gln Lys Arg Gln Lys Gln Val Pro Ala
725 730 735
His Ala Arg Asp Phe His Ile Asn Leu Phe Gln Val Leu Pro Trp Leu
740 745 750
Lys Glu Lys Leu Gln Asp Glu Asp Leu Gly Phe Leu
755 760
<210>5
<211>911
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the Alpha-actinine 4
<222>(1)..(911)
＜223〉registration number: 043707
<400>5
Met Val Asp Tyr His Ala Ala Asn Gln Ser Tyr Gln Tyr Gly Pro Ser
1 5 10 15
Ser Ala Gly Asn Gly Ala Gly Gly Gly Gly Ser Met Gly Asp Tyr Met
20 25 30
Ala Gln Glu Asp Asp Trp Asp Arg Asp Leu Leu Leu Asp Pro Ala Trp
35 40 45
Glu Lys Gln Gln Arg Lys Thr Phe Thr Ala Trp Cys Asn Ser His Leu
50 55 60
Arg Lys Ala Gly Thr Gln Ile Glu Asn Ile Asp Glu Asp Phe Arg Asp
65 70 75 80
Gly Leu Lys Leu Met Leu Leu Leu Glu Val Ile Ser Gly Glu Arg Leu
85 90 95
Pro Lys Pro Glu Arg Gly Lys Met Arg Val His Lys Ile Asn Asn Val
100 105 110
Asn Lys Ala Leu Asp Phe Ile Ala Ser Lys Gly Val Lys Leu Val Ser
115 120 125
Ile Gly Ala Glu Glu Ile Val Asp Gly Asn Ala Lys Met Thr Leu Gly
130 135 140
Met Ile Trp Thr Ile Ile Leu Arg Phe Ala Ile Gln Asp Ile Ser Val
145 150 155 160
Glu Glu Thr Ser Ala Lys Glu Gly Leu Leu Leu Trp Cys Gln Arg Lys
165 170 175
Thr Ala Pro Tyr Lys Asn Val Asn Val Gln Asn Phe His Ile Ser Trp
180 185 190
Lys Asp Gly Leu Ala Phe Asn Ala Leu Ile His Arg His Arg Pro Glu
195 200 205
Leu Ile Glu Tyr Asp Lys Leu Arg Lys Asp Asp Pro Val Thr Asn Leu
210 215 220
Asn Asn Ala Phe Glu Val Ala Glu Lys Tyr Leu Asp Ile Pro Lys Met
225 230 235 240
Leu Asp Ala Glu Asp Ile Val Asn Thr Ala Arg Pro Asp Glu Lys Ala
245 250 255
Ile Met Thr Tyr Val Ser Ser Phe Tyr His Ala Phe Ser Gly Ala Gln
260 265 270
Lys Ala Glu Thr Ala Ala Asn Arg Ile Cys Lys Val Leu Ala Val Asn
275 280 285
Gln Glu Asn Glu His Leu Met Glu Asp Tyr Glu Lys Leu Ala Ser Asp
290 295 300
Leu Leu Glu Trp Ile Arg Arg Thr Ile Pro Trp Leu Glu Asp Arg Val
305 310 315 320
Pro Gln Lys Thr Ile Gln Glu Met Gln Gln Lys Leu Glu Asp Phe Arg
325 330 335
Asp Tyr Arg Arg Val His Lys Pro Pro Lys Val Gln Glu Lys Cys Gln
340 345 350
Leu Glu Ile Asn Phe Asn Thr Leu Gln Thr Lys Leu Arg Leu Ser Asn
355 360 365
Arg Pro Ala Phe Met Pro Ser Glu Gly Lys Met Val Ser Asp Ile Asn
370 375 380
Asn Gly Trp Gln His Leu Glu Gln Ala Glu Lys Gly Tyr Glu Glu Trp
385 390 395 400
Leu Leu Asn Glu Ile Arg Arg Leu Glu Arg Leu Asp His Leu Ala Glu
405 410 415
Lys Phe Arg Gln Lys Ala Ser Ile His Glu Ala Trp Thr Asp Gly Lys
420 425 430
Glu Ala Met Leu Lys His Arg Asp Tyr Glu Thr Ala Thr Leu Ser Asp
435 440 445
Ile Lys Ala Leu Ile Arg Lys His Glu Ala Phe Glu Ser Asp Leu Ala
450 455 460
Ala His Gln Asp Arg Val Glu Gln Ile Ala Ala Ile Ala Gln Glu Leu
465 470 475 480
Asn Glu Leu Asp Tyr Tyr Asp Ser His Asn Val Asn Thr Arg Cys Gln
485 490 495
Lys Ile Cys Asp Gln Trp Asp Ala Leu Gly Ser Leu Thr His Ser Arg
500 505 510
Arg Glu Ala Leu Glu Lys Thr Glu Lys Gln Leu Glu Ala Ile Asp Gln
515 520 525
Leu His Leu Glu Tyr Ala Lys Arg Ala Ala Pro Phe Asn Asn Trp Met
530 535 540
Glu Ser Ala Met Glu Asp Leu Gln Asp Met Phe Ile Val His Thr Ile
545 550 555 560
Glu Glu Ile Glu Gly Leu Ile Ser Ala His Asp Gln Phe Lys Ser Thr
565 570 575
Leu Pro Asp Ala Asp Arg Glu Arg Glu Ala Ile Leu Ala Ile His Lys
580 585 590
Glu Ala Gln Arg Ile Ala Glu Ser Asn His Ile Lys Leu Ser Gly Ser
595 600 605
Asn Pro Tyr Thr Thr Val Thr Pro Gln Ile Ile Asn Ser Lys Trp Glu
610 615 620
Lys Val Gln Gln Leu Val Pro Lys Arg Asp His Ala Leu Leu Glu Glu
625 630 635 640
Gln Ser Lys Gln Gln Ser Asn Glu His Leu Arg Arg Gln Phe Ala Ser
645 650 655
Gln Ala Asn Val Val Gly Pro Trp Ile Gln Thr Lys Met Glu Glu Ile
660 665 670
Gly Arg Ile Ser Ile Glu Met Asn Gly Thr Leu Glu Asp Gln Leu Ser
675 680 685
His Leu Lys Gln Tyr Glu Arg Ser Ile Val Asp Tyr Lys Pro Asn Leu
690 695 700
Asp Leu Leu Glu Gln Gln His Gln Leu Ile Gln Glu Ala Leu Ile Phe
705 710 715 720
Asp Asn Lys His Thr Asn Tyr Thr Met Glu His Ile Arg Val Gly Trp
725 730 735
Glu Gln Leu Leu Thr Thr Ile Ala Arg Thr Ile Asn Glu Val Glu Asn
740 745 750
Gln Ile Leu Thr Arg Asp Ala Lys Gly Ile Ser Gln Glu Gln Met Gln
755 760 765
Glu Phe Arg Ala Ser Phe Asn His Phe Asp Lys Asp His Gly Gly Ala
770 775 780
Leu Gly Pro Glu Glu Phe Lys Ala Cys Leu Ile Ser Leu Gly Tyr Asp
785 790 795 800
Val Glu Asn Asp Arg Gln Gly Glu Ala Glu Phe Asn Arg Ile Met Ser
805 810 815
Leu Val Asp Pro Asn His Ser Gly Leu Val Thr Phe Gln Ala Phe Ile
820 825 830
Asp Phe Met Ser Arg Glu Thr Thr Asp Thr Asp Thr Ala Asp Gln Val
835 840 845
Ile Ala Ser Phe Lys Val Leu Ala Gly Asp Lys Asn Phe Ile Thr Ala
850 855 860
Glu Glu Leu Arg Arg Glu Leu Pro Pro Asp Gln Ala Glu Tyr Cys Ile
865 870 875 880
Ala Arg Met Ala Pro Tyr Gln Gly Pro Asp Ala Val Pro Gly Ala Leu
885 890 895
Asp Tyr Lys Ser Phe Ser Thr Ala Leu Tyr Gly Glu Ser Asp Leu
900 905 910
<210>6
<211>683
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the TGF beta-protein I G-H3 precursor of inducing
<222>(1)..(683)
＜223〉on Dec 6th, 2002 registration number: Q15582
<400>6
Met Ala Leu Phe Val Arg Leu Leu Ala Leu Ala Leu Ala Leu Ala Leu
1 5 10 15
Gly Pro Ala Ala Thr Leu Ala Gly Pro Ala Lys Ser Pro Tyr Gln Leu
20 25 30
Val Leu Gln His Ser Arg Leu Arg Gly Arg Gln His Gly Pro Asn Val
35 40 45
Cys Ala Val Gln Lys Val Ile Gly Thr Asn Arg Lys Tyr Phe Thr Asn
50 55 60
Cys Lys Gln Trp Tyr Gln Arg Lys Ile Cys Gly Lys Ser Thr Val Ile
65 70 75 80
Ser Tyr Glu Cys Cys Pro Gly Tyr Glu Lys Val Pro Gly Glu Lys Gly
85 90 95
Cys Pro Ala Ala Leu Pro Leu Ser Asn Leu Tyr Glu Thr Leu Gly Val
100 105 110
Val Gly Ser Thr Thr Thr Gln Leu Tyr Thr Asp Arg Thr Glu Lys Leu
115 120 125
Arg Pro Glu Met Glu Gly Pro Gly Ser Phe Thr Ile Phe Ala Pro Ser
130 135 140
Asn Glu Ala Trp Ala Ser Leu Pro Ala Glu Val Leu Asp Ser Leu Val
145 150 155 160
Ser Asn Val Asn Ile Glu Leu Leu Asn Ala Leu Arg Tyr His Met Val
165 170 175
Gly Arg Arg Val Leu Thr Asp Glu Leu Lys His Gly Met Thr Leu Thr
180 185 190
Ser Met Tyr Gln Asn Ser Asn Ile Gln Ile His His Tyr Pro Asn Gly
195 200 205
Ile Val Thr Val Asn Cys Ala Arg Leu Leu Lys Ala Asp His His Ala
210 215 220
Thr Asn Gly Val Val His Leu Ile Asp Lys Val Ile Ser Thr Ile Thr
225 230 235 240
Asn Asn Ile Gln Gln Ile Ile Glu Ile Glu Asp Thr Phe Glu Thr Leu
245 250 255
Arg Ala Ala Val Ala Ala Ser Gly Leu Asn Thr Met Leu Glu Gly Asn
260 265 270
Gly Gln Tyr Thr Leu Leu Ala Pro Thr Asn Glu Ala Phe Glu Lys Ile
275 280 285
Pro Ser Glu Thr Leu Asn Arg Ile Leu Gly Asp Pro Glu Ala Leu Arg
290 295 300
Asp Leu Leu Asn Asn His Ile Leu Lys Ser Ala Met Cys Ala Glu Ala
305 310 315 320
Ile Val Ala Gly Leu Ser Val Glu Thr Leu Glu Gly Thr Thr Leu Glu
325 330 335
Val Gly Cys Ser Gly Asp Met Leu Thr Ile Asn Gly Lys Ala Ile Ile
340 345 350
Ser Asn Lys Asp Ile Leu Ala Thr Asn Gly Val Ile His Tyr Ile Asp
355 360 365
Glu Leu Leu Ile Pro Asp Ser Ala Lys Thr Leu Phe Glu Leu Ala Ala
370 375 380
Glu Ser Asp Val Ser Thr Ala Ile Asp Leu Phe Arg Gln Ala Gly Leu
385 390 395 400
Gly Asn His Leu Ser Gly Ser Glu Arg Leu Thr Leu Leu Ala Pro Leu
405 410 415
Asn Ser Val Phe Lys Asp Gly Thr Pro Pro Ile Asp Ala His Thr Arg
420 425 430
Asn Leu Leu Arg Asn His Ile Ile Lys Asp Gln Leu Ala Ser Lys Tyr
435 440 445
Leu Tyr His Gly Gln Thr Leu Glu Thr Leu Gly Gly Lys Lys Leu Arg
450 455 460
Val Phe Val Tyr Arg Asn Ser Leu Cys Ile Glu Asn Ser Cys Ile Ala
465 470 475 480
Ala His Asp Lys Arg Gly Arg Tyr Gly Thr Leu Phe Thr Met Asp Arg
485 490 495
Val Leu Thr Pro Pro Met Gly Thr Val Met Asp Val Leu Lys Gly Asp
500 505 510
Asn Arg Phe Ser Met Leu Val Ala Ala Ile Gln Ser Ala Gly Leu Thr
515 520 525
Glu Thr Leu Asn Arg Glu Gly Val Tyr Thr Val Phe Ala Pro Thr Asn
530 535 540
Glu Ala Phe Arg Ala Leu Pro Pro Arg Glu Arg Ser Arg Leu Leu Gly
545 550 555 560
Asp Ala Lys Glu Leu Ala Asn Ile Leu Lys Tyr His Ile Gly Asp Glu
565 570 575
Ile Leu Val Ser Gly Gly Ile Gly Ala Leu Val Arg Leu Lys Ser Leu
580 585 590
Gln Gly Asp Lys Leu Glu Val Ser Leu Lys Asn Asn Val Val Ser Val
595 600 605
Asn Lys Glu Pro Val Ala Glu Pro Asp Ile Met Ala Thr Asn Gly Val
610 615 620
Val His Val Ile Thr Asn Val Leu Gln Pro Pro Ala Asn Arg Pro Gln
625 630 635 640
Glu Arg Gly Asp Glu Leu Ala Asp Ser Ala Leu Glu Ile Phe Lys Gln
645 650 655
Ala Ser Ala Phe Ser Arg Ala Ser Gln Arg Ser Val Arg Leu Ala Pro
660 665 670
Val Tyr Gln Lys Leu Leu Glu Arg Met Lys His
675 680
<210>7
<211>892
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the Alpha-actinine 1
<222>(1)..(892)
＜223〉registration number: P12814
<400>7
Met Asp His Tyr Asp Ser Gln Gln Thr Asn Asp Tyr Met Gln Pro Glu
1 5 10 15
Glu Asp Trp Asp Arg Asp Leu Leu Leu Asp Pro Ala Trp Glu Lys Gln
20 25 30
Gln Arg Lys Thr Phe Thr Ala Trp Cys Asn Ser His Leu Arg Lys Ala
35 40 45
Gly Thr Gln Ile Glu Asn Ile Glu Glu Asp Phe Arg Asp Gly Leu Lys
50 55 60
Leu Met Leu Leu Leu Glu Val Ile Ser Gly Glu Arg Leu Ala Lys Pro
65 70 75 80
Glu Arg Gly Lys Met Arg Val His Lys Ile Ser Asn Val Asn Lys Ala
85 90 95
Leu Asp Phe Ile Ala Ser Lys Gly Val Lys Leu Val Ser Ile Gly Ala
100 105 110
Glu Glu Ile Val Asp Gly Asn Val Lys Met Thr Leu Gly Met Ile Trp
115 120 125
Thr Ile Ile Leu Arg Phe Ala Ile Gln Asp Ile Ser Val Glu Glu Thr
130 135 140
Ser Ala Lys Glu Gly Leu Leu Leu Trp Cys Gln Arg Lys Thr Ala Pro
145 150 155 160
Tyr Lys Asn Val Asn Ile Gln Asn Phe His Ile Ser Trp Lys Asp Gly
165 170 175
Leu Gly Phe Cys Ala Leu Ile His Arg His Arg Pro Glu Leu Ile Asp
180 185 190
Tyr Gly Lys Leu Arg Lys Asp Asp Pro Leu Thr Asn Leu Asn Thr Ala
195 200 205
Phe Asp Val Ala Glu Lys Tyr Leu Asp Ile Pro Lys Met Leu Asp Ala
210 215 220
Glu Asp Ile Val Gly Thr Ala Arg Pro Asp Glu Lys Ala Ile Met Thr
225 230 235 240
Tyr Val Ser Ser Phe Tyr His Ala Phe Ser Gly Ala Gln Lys Ala Glu
245 250 255
Thr Ala Ala Asn Arg Ile Cys Lys Val Leu Ala Val Asn Gln Glu Asn
260 265 270
Glu Gln Leu Met Glu Asp Tyr Glu Lys Leu Ala Ser Asp Leu Leu Glu
275 280 285
Trp Ile Arg Arg Thr Ile Pro Trp Leu Glu Asn Arg Val Pro Glu Asn
290 295 300
Thr Met His Ala Met Gln Gln Lys Leu Glu Asp Phe Arg Asp Tyr Arg
305 310 315 320
Arg Leu His Lys Pro Pro Lys Val Gln Glu Lys Cys Gln Leu Glu Ile
325 330 335
Asn Phe Asn Thr Leu Gln Thr Lys Leu Arg Leu Ser Asn Arg Pro Ala
340 345 350
Phe Met Pro Ser Glu Gly Arg Met Val Ser Asp Ile Asn Asn Ala Trp
355 360 365
Gly Cys Leu Glu Gln Val Glu Lys Gly Tyr Glu Glu Trp Leu Leu Asn
370 375 380
Glu Ile Arg Arg Leu Glu Arg Leu Asp His Leu Ala Glu Lys Phe Arg
385 390 395 400
Gln Lys Ala Ser Ile His Glu Ala Trp Thr Asp Gly Lys Glu Ala Met
405 410 415
Leu Arg Gln Lys Asp Tyr Glu Thr Ala Thr Leu Ser Glu Ile Lys Ala
420 425 430
Leu Leu Lys Lys His Glu Ala Phe Glu Ser Asp Leu Ala Ala His Gln
435 440 445
Asp Arg Val Glu Gln Ile Ala Ala Ile Ala Gln Glu Leu Asn Glu Leu
450 455 460
Asp Tyr Tyr Asp Ser Pro Ser Val Asn Ala Arg Cys Gln Lys Ile Cys
465 470 475 480
Asp Gln Trp Asp Asn Leu Gly Ala Leu Thr Gln Lys Arg Arg Glu Ala
485 490 495
Leu Glu Arg Thr Glu Lys Leu Leu Glu Thr Ile Asp Gln Leu Tyr Leu
500 505 510
Glu Tyr Ala Lys Arg Ala Ala Pro Phe Asn Asn Trp Met Glu Gly Ala
515 520 525
Met Glu Asp Leu Gln Asp Thr Phe Ile Val His Thr Ile Glu Glu Ile
530 535 540
Gln Gly Leu Thr Thr Ala His Glu Gln Phe Lys Ala Thr Leu Pro Asp
545 550 555 560
Ala Asp Lys Glu Arg Leu Ala Ile Leu Gly Ile His Asn Glu Val Ser
565 570 575
Lys Ile Val Gln Thr Tyr His Val Asn Met Ala Gly Thr Asn Pro Tyr
580 585 590
Thr Thr Ile Thr Pro Gln Glu Ile Asn Gly Lys Trp Asp His Val Arg
595 600 605
Gln Leu Val Pro Arg Arg Asp Gln Ala Leu Thr Glu Glu His Ala Arg
610 615 620
Gln Gln His Asn Glu Ser Val Arg Lys Gln Phe Gly Ala Gln Ala Asn
625 630 635 640
Val Ile Gly Pro Trp Ile Gln Thr Lys Met Glu Glu Ile Gly Arg Ile
645 650 655
Ser Ile Glu Met His Gly Thr Leu Glu Asp Gln Leu Ser His Leu Arg
660 665 670
Gln Tyr Glu Lys Ser Ile Val Asn Tyr Lys Pro Lys Ile Asp Gln Leu
675 680 685
Glu Gly Asp His Gln Leu Ile Gln Glu Ala Leu Ile Phe Asp Asn Lys
690 695 700
His Thr Asn Tyr Thr Met Glu His Ile Arg Val Gly Trp Glu Gln Leu
705 710 715 720
Leu Thr Thr Ile Ala Arg Thr Ile Asn Glu Val Glu Asn Gln Ile Leu
725 730 735
Thr Arg Asp Ala Lys Gly Ile Ser Gln Glu Gln Met Asn Glu Phe Arg
740 745 750
Ala Ser Phe Asn His Phe Asp Arg Asp His Ser Gly Thr Leu Gly Pro
755 760 765
Glu Glu Phe Lys Ala Cys Leu Ile Ser Leu Gly Tyr Asp Ile Gly Asn
770 775 780
Asp Pro Gln Gly Glu Ala Glu Phe Ala Arg Ile Met Ser Ile Val Asp
785 790 795 800
Pro Asn Arg Leu Gly Val Val Thr Phe Gln Ala Phe Ile Asp Phe Met
805 810 815
Ser Arg Glu Thr Ala Asp Thr Asp Thr Ala Asp Gln Val Met Ala Ser
820 825 830
Phe Lys Ile Leu Ala Gly Asp Lys Asn Tyr Ile Thr Met Asp Glu Leu
835 840 845
Arg Arg Glu Leu Pro Pro Asp Gln Ala Glu Tyr Cys Ile Ala Arg Met
850 855 860
Ala Pro Tyr Thr Gly Pro Asp Ser Val Pro Gly Ala Leu Asp Tyr Met
865 870 875 880
Ser Phe Ser Thr Ala Leu Tyr Gly Glu Ser Asp Leu
885 890
<210>8
<211>448
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉tubulin Alpha-4 chain
<222>(1)..(448)
＜223〉registration number: P05215
<400>8
Met Arg Glu Cys Ile Ser Val His Val Gly Gln Ala Gly Val Gln Met
1 5 10 15
Gly Asn Ala Cys Trp Glu Leu Tyr Cys Leu Glu His Gly Ile Gln Pro
20 25 30
Asp Gly Gln Met Pro Ser Asp Lys Thr Ile Gly Gly Gly Asp Asp Ser
35 40 45
Phe Thr Thr Phe Phe Cys Glu Thr Gly Ala Gly Lys His Val Pro Arg
50 55 60
Ala Val Phe Val Asp Leu Glu Pro Thr Val Ile Asp Glu Ile Arg Asn
65 70 75 80
Gly Pro Tyr Arg Gln Leu Phe His Pro Glu Gln Leu Ile Thr Gly Lys
85 90 95
Glu Asp Ala Ala Asn Asn Tyr Ala Arg Gly His Tyr Thr Ile Gly Lys
100 105 110
Glu Ile Ile Asp Pro Val Leu Asp Arg Ile Arg Lys Leu Ser Asp Gln
115 120 125
Cys Thr Gly Leu Gln Gly Phe Leu Val Phe His Ser Phe Gly Gly Gly
130 135 140
Thr Gly Ser Gly Phe Thr Ser Leu Leu Met Glu Arg Leu Ser Val Asp
145 150 155 160
Tyr Gly Lys Lys Ser Lys Leu Glu Phe Ser Ile Tyr Pro Ala Pro Gln
165 170 175
Val Ser Thr Ala Val Val Glu Pro Tyr Asn Ser Ile Leu Thr Thr His
180 185 190
Thr Thr Leu Glu His Ser Asp Cys Ala Phe Met Val Asp Asn Glu Ala
195 200 205
Ile Tyr Asp Ile Cys Arg Arg Asn Leu Asp Ile Glu Arg Pro Thr Tyr
210 215 220
Thr Asn Leu Asn Arg Leu Ile Ser Gln Ile Val Ser Ser Ile Thr Ala
225 230 235 240
Ser Leu Arg Phe Asp Gly Ala Leu Asn Val Asp Leu Thr Glu Phe Gln
245 250 255
Thr Asn Leu Val Pro Tyr Pro Arg Ile His Phe Pro Leu Ala Thr Tyr
260 265 270
Ala Pro Val Ile Ser Ala Glu Lys Ala Tyr His Glu Gln Leu Ser Val
275 280 285
Ala Glu Ile Thr Asn Ala Cys Phe Glu Pro Ala Asn Gln Met Val Lys
290 295 300
Cys Asp Pro Arg His Gly Lys Tyr Met Ala Cys Cys Leu Leu Tyr Arg
305 310 315 320
Gly Asp Val Val Pro Lys Asp Val Asn Ala Ala Ile Ala Ala Ile Lys
325 330 335
Thr Lys Arg Ser Ile Gln Phe Val Asp Trp Cys Pro Thr Gly Phe Lys
340 345 350
Val Gly Ile Asn Tyr Gln Pro Pro Thr Val Val Pro Gly Gly Asp Leu
355 360 365
Ala Lys Val Gln Arg Ala Val Cys Met Leu Ser Asn Thr Thr Ala Ile
370 375 380
Ala Glu Ala Trp Ala Arg Leu Asp His Lys Phe Asp Leu Met Tyr Ala
385 390 395 400
Lys Arg Ala Phe Val His Trp Tyr Val Gly Glu Gly Met Glu Glu Gly
405 410 415
Glu Phe Ser Glu Ala Arg Glu Asp Met Ala Ala Leu Glu Lys Asp Tyr
420 425 430
Glu Glu Val Gly Ile Asp Ser Tyr Glu Asp Glu Asp Glu Gly Glu Glu
435 440 445
<210>9
<211>2647
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉tenuin A
<222>(1)..(2647)
＜223〉registration number: P21333
<400>9
Met Ser Ser Ser His Ser Arg Ala Gly Gln Ser Ala Ala Gly Ala Ala
1 5 10 15
Pro Gly Gly Gly Val Asp Thr Arg Asp Ala Glu Met Pro Ala Thr Glu
20 25 30
Lys Asp Leu Ala Glu Asp Ala Pro Trp Lys Lys Ile Gln Gln Asn Thr
35 40 45
Phe Thr Arg Trp Cys Asn Glu His Leu Lys Cys Val Ser Lys Arg Ile
50 55 60
Ala Asn Leu Gln Thr Asp Leu Ser Asp Gly Leu Arg Leu Ile Ala Leu
65 70 75 80
Leu Glu Val Leu Ser Gln Lys Lys Met His Arg Lys His Asn Gln Arg
85 90 95
Pro Thr Phe Arg Gln Met Gln Leu Glu Asn Val Ser Val Ala Leu Glu
100 105 110
Phe Leu Asp Arg Glu Ser Ile Lys Leu Val Ser Ile Asp Ser Lys Ala
115 120 125
Ile Val Asp Gly Asn Leu Lys Leu Ile Leu Gly Leu Ile Trp Thr Leu
130 135 140
Ile Leu His Tyr Ser Ile Ser Met Pro Met Trp Asp Glu Glu Glu Asp
145 150 155 160
Glu Glu Ala Lys Lys Gln Thr Pro Lys Gln Arg Leu Leu Gly Trp Ile
165 170 175
Gln Asn Lys Leu Pro Gln Leu Pro Ile Thr Asn Phe Ser Arg Asp Trp
180 185 190
Gln Ser Gly Arg Ala Leu Gly Ala Leu Val Asp Ser Cys Ala Pro Gly
195 200 205
Leu Cys Pro Asp Trp Asp Ser Trp Asp Ala Ser Lys Pro Val Thr Asn
210 215 220
Ala Arg Glu Ala Met Gln Gln Ala Asp Asp Trp Leu Gly Ile Pro Gln
225 230 235 240
Val Ile Thr Pro Glu Glu Ile Val Asp Pro Asn Val Asp Glu His Ser
245 250 255
Val Met Thr Tyr Leu Ser Gln Phe Pro Lys Ala Lys Leu Lys Pro Gly
260 265 270
Ala Pro Leu Arg Pro Lys Leu Asn Pro Lys Lys Ala Arg Ala Tyr Gly
275 280 285
Pro Gly Ile Glu Pro Thr Gly Asn Met Val Lys Lys Arg Ala Glu Phe
290 295 300
Thr Val Glu Thr Arg Ser Ala Gly Gln Gly Glu Val Leu Val Tyr Val
305 310 315 320
Glu Asp Pro Ala Gly His Gln Glu Glu Ala Lys Val Thr Ala Asn Asn
325 330 335
Asp Lys Asn Arg Thr Phe Ser Val Trp Tyr Val Pro Glu Val Thr Gly
340 345 350
Thr His Lys Val Thr Val Leu Phe Ala Gly Gln His Ile Ala Lys Ser
355 360 365
Pro Phe Glu Val Tyr Val Asp Lys Ser Gln Gly Asp Ala Ser Lys Val
370 375 380
Thr Ala Gln Gly Pro Gly Leu Glu Pro Ser Gly Asn Ile Ala Asn Lys
385 390 395 400
Thr Thr Tyr Phe Glu Ile Phe Thr Ala Gly Ala Gly Thr Gly Glu Val
405 410 415
Glu Val Val Ile Gln Asp Pro Met Gly Gln Lys Gly Thr Val Glu Pro
420 425 430
Gln Leu Glu Ala Arg Gly Asp Ser Thr Tyr Arg Cys Ser Tyr Gln Pro
435 440 445
Thr Met Glu Gly Val His Thr Val His Val Thr Phe Ala Gly Val Pro
450 455 460
Ile Pro Arg Ser Pro Tyr Thr Val Thr Val Gly Gln Ala Cys Asn Pro
465 470 475 480
Ser Ala Cys Arg Ala Val Gly Arg Gly Leu Gln Pro Lys Gly Val Arg
485 490 495
Val Lys Glu Thr Ala Asp Phe Lys Val Tyr Thr Lys Gly Ala Gly Ser
500 505 510
Gly Glu Leu Lys Val Thr Val Lys Gly Pro Lys Gly Glu Glu Arg Val
515 520 525
Lys Gln Lys Asp Leu Gly Asp Gly Val Tyr Gly Phe Glu Tyr Tyr Pro
530 535 540
Met Val Pro Gly Thr Tyr Ile Val Thr Ile Thr Trp Gly Gly Gln Asn
545 550 555 560
Ile Gly Arg Ser Pro Phe Glu Val Lys Val Gly Thr Glu Cys Gly Asn
565 570 575
Gln Lys Val Arg Ala Trp Gly Pro Gly Leu Glu Gly Gly Val Val Gly
580 585 590
Lys Ser Ala Asp Phe Val Val Glu Ala Ile Gly Asp Asp Val Gly Thr
595 600 605
Leu Gly Phe Ser Val Glu Gly Pro Ser Gln Ala Lys Ile Glu Cys Asp
610 615 620
Asp Lys Gly Asp Gly Ser Cys Asp Val Arg Tyr Trp Pro Gln Glu Ala
625 630 635 640
Gly Glu Tyr Ala Val His Val Leu Cys Asn Ser Glu Asp Ile Arg Leu
645 650 655
Ser Pro Phe Met Ala Asp Ile Arg Asp Ala Pro Gln Asp Phe His Pro
660 665 670
Asp Arg Val Lys Ala Arg Gly Pro Gly Leu Glu Lys Thr Gly Val Ala
675 680 685
Val Asn Lys Pro Ala Glu Phe Thr Val Asp Ala Lys His Gly Gly Lys
690 695 700
Ala Pro Leu Arg Val Gln Val Gln Asp Asn Glu Gly Cys Pro Val Glu
705 710 715 720
Ala Leu Val Lys Asp Asn Gly Asn Gly Thr Tyr Ser Cys Ser Tyr Val
725 730 735
Pro Arg Lys Pro Val Lys His Thr Ala Met Val Ser Trp Gly Gly Val
740 745 750
Ser Ile Pro Asn Ser Pro Phe Arg Val Asn Val Gly Ala Gly Ser His
755 760 765
Pro Asn Lys Val Lys Val Tyr Gly Pro Gly Val Ala Lys Thr Gly Leu
770 775 780
Lys Ala His Glu Pro Thr Tyr Phe Thr Val Asp Cys Ala Glu Ala Gly
785 790 795 800
Gln Gly Asp Val Ser Ile Gly Ile Lys Cys Ala Pro Gly Val Val Gly
805 810 815
Pro Ala Glu Ala Asp Ile Asp Phe Asp Ile Ile Arg Asn Asp Asn Asp
820 825 830
Thr Phe Thr Val Lys Tyr Thr Pro Arg Gly Ala Gly Ser Tyr Thr Ile
835 840 845
Met Val Leu Phe Ala Asp Gln Ala Thr Pro Thr Ser Pro Ile Arg Val
850 855 860
Lys Val Glu Pro Ser His Asp Ala Ser Lys Val Lys Ala Glu Gly Pro
865 870 875 880
Gly Leu Ser Arg Thr Gly Val Glu Leu Gly Lys Pro Thr His Phe Thr
885 890 895
Val Asn Ala Lys Ala Ala Gly Lys Gly Lys Leu Asp Val Gln Phe Ser
900 905 910
Gly Leu Thr Lys Gly Asp Ala Val Arg Asp Val Asp Ile Ile Asp His
915 920 925
His Asp Asn Thr Tyr Thr Val Lys Tyr Thr Pro Val Gln Gln Gly Pro
930 935 940
Val Gly Val Asn Val Thr Tyr Gly Gly Asp Pro Ile Pro Lys Ser Pro
945 950 955 960
Phe Ser Val Ala Val Ser Pro Ser Leu Asp Leu Ser Lys Ile Lys Val
965 970 975
Ser Gly Leu Gly Glu Lys Val Asp Val Gly Lys Asp Gln Glu Phe Thr
980 985 990
Val Lys Ser Lys Gly Ala Gly Gly Gln Gly Lys Val Ala Ser Lys Ile
995 1000 1005
Val Gly Pro Ser Gly Ala Ala Val Pro Cys Lys Val Glu Pro Gly
1010 1015 1020
Leu Gly Ala Asp Asn Ser Val Val Arg Phe Leu Pro Arg Glu Glu
1025 1030 1035
Gly Pro Tyr Glu Val Glu Val Thr Tyr Asp Gly Val Pro Val Pro
1040 1045 1050
Gly Ser Pro Phe Pro Leu Glu Ala Val Ala Pro Thr Lys Pro Ser
1055 1060 1065
Lys Val Lys Ala Phe Gly Pro Gly Leu Gln Gly Gly Ser Ala Gly
1070 1075 1080
Ser Pro Ala Arg Phe Thr Ile Asp Thr Lys Gly Ala Gly Thr Gly
1085 1090 1095
Gly Leu Gly Leu Thr Val Glu Gly Pro Cys Glu Ala Gln Leu Glu
1100 1105 1110
Cys Leu Asp Asn Gly Asp Gly Thr Cys Ser Val Ser Tyr Val Pro
1115 1120 1125
Thr Glu Pro Gly Asp Tyr Asn Ile Asn Ile Leu Phe Ala Asp Thr
1130 1135 1140
His Ile Pro Gly Ser Pro Phe Lys Ala His Val Val Pro Cys Phe
1145 1150 1155
Asp Ala Ser Lys Val Lys Cys Ser Gly Pro Gly Leu Glu Arg Ala
1160 1165 1170
Thr Ala Gly Glu Val Gly Gln Phe Gln Val Asp Cys Ser Ser Ala
1175 1180 1185
Gly Ser Ala Glu Leu Thr Ile Glu Ile Cys Ser Glu Ala Gly Leu
1190 1195 1200
Pro Ala Glu Val Tyr Ile Gln Asp His Gly Asp Gly Thr His Thr
1205 1210 1215
Ile Thr Tyr Ile Pro Leu Cys Pro Gly Ala Tyr Thr Val Thr Ile
1220 1225 1230
Lys Tyr Gly Gly Gln Pro Val Pro Asn Phe Pro Ser Lys Leu Gln
1235 1240 1245
Val Glu Pro Ala Val Asp Thr Ser Gly Val Gln Cys Tyr Gly Pro
1250 1255 1260
Gly Ile Glu Gly Gln Gly Val Phe Arg Glu Ala Thr Thr Glu Phe
1265 1270 1275
Ser Val Asp Ala Arg Ala Leu Thr Gln Thr Gly Gly Pro His Val
1280 1285 1290
Lys Ala Arg Val Ala Asn Pro Ser Gly Asn Leu Thr Glu Thr Tyr
1295 1300 1305
Val Gln Asp Arg Gly Asp Gly Met Tyr Lys Val Glu Tyr Thr Pro
1310 1315 1320
Tyr Glu Glu Gly Leu His Ser Val Asp Val Thr Tyr Asp Gly Ser
1325 1330 1335
Pro Val Pro Ser Ser Pro Phe Gln Val Pro Val Thr Glu Gly Cys
1340 1345 1350
Asp Pro Ser Arg Val Arg Val His Gly Pro Gly Ile Gln Ser Gly
1355 1360 1365
Thr Thr Asn Lys Pro Asn Lys Phe Thr Val Glu Thr Arg Gly Ala
1370 1375 1380
Gly Thr Gly Gly Leu Gly Leu Ala Val Glu Gly Pro Ser Glu Ala
1385 1390 1395
Lys Met Ser Cys Met Asp Asn Lys Asp Gly Ser Cys Ser Val Glu
1400 1405 1410
Tyr Ile Pro Tyr Glu Ala Gly Thr Tyr Ser Leu Asn Val Thr Tyr
1415 1420 1425
Gly Gly His Gln Val Pro Gly Ser Pro Phe Lys Val Pro Val His
1430 1435 1440
Asp Val Thr Asp Ala Ser Lys Val Lys Cys Ser Gly Pro Gly Leu
1445 1450 1455
Ser Pro Gly Met Val Arg Ala Asn Leu Pro Gln Ser Phe Gln Val
1460 1465 1470
Asp Thr Ser Lys Ala Gly Val Ala Pro Leu Gln Val Lys Val Gln
1475 1480 1485
Gly Pro Lys Gly Leu Val Glu Pro Val Asp Val Val Asp Asn Ala
1490 1495 1500
Asp Gly Thr Gln Thr Val Asn Tyr Val Pro Ser Arg Glu Gly Pro
1505 1510 1515
Tyr Ser Ile Ser Val Leu Tyr Gly Asp Glu Glu Val Pro Arg Ser
1520 1525 1530
Pro Phe Lys Val Lys Val Leu Pro Thr His Asp Ala Ser Lys Val
1535 1540 1545
Lys Ala Ser Gly Pro Gly Leu Asn Thr Thr Gly Val Pro Ala Ser
1550 1555 1560
Leu Pro Val Glu Phe Thr Ile Asp Ala Lys Asp Ala Gly Glu Gly
1565 1570 1575
Leu Leu Ala Val Gln Ile Thr Asp Pro Glu Gly Lys Pro Lys Lys
1580 1585 1590
Thr His Ile Gln Asp Asn His Asp Gly Thr Tyr Thr Val Ala Tyr
1595 1600 1605
Val Pro Asp Val Thr Gly Arg Tyr Thr Ile Leu Ile Lys Tyr Gly
1610 1615 1620
Gly Asp Glu Ile Pro Phe Ser Pro Tyr Arg Val Arg Ala Val Pro
1625 1630 1635
Thr Gly Asp Ala Ser Lys Cys Thr Val Thr Val Ser Ile Gly Gly
1640 1645 1650
His Gly Leu Gly Ala Gly Ile Gly Pro Thr Ile Gln Ile Gly Glu
1655 1660 1665
Glu Thr Val Ile Thr Val Asp Thr Lys Ala Ala Gly Lys Gly Lys
1670 1675 1680
Val Thr Cys Thr Val Cys Thr Pro Asp Gly Ser Glu Val Asp Val
1685 1690 1695
Asp Val Val Glu Asn Glu Asp Gly Thr Phe Asp Ile Phe Tyr Thr
1700 1705 1710
Ala Pro Gln Pro Gly Lys Tyr Val Ile Cys Val Arg Phe Gly Gly
1715 1720 1725
Glu His Val Pro Asn Ser Pro Phe Gln Val Thr Ala Leu Ala Gly
1730 1735 1740
Asp Gln Pro Ser Val Gln Pro Pro Leu Arg Ser Gln Gln Leu Ala
1745 1750 1755
Pro Gln Tyr Thr Tyr Ala Gln Gly Gly Gln Gln Thr Trp Ala Pro
1760 1765 1770
Glu Arg Pro Leu Val Gly Val Asn Gly Leu Asp Val Thr Ser Leu
1775 1780 1785
Arg Pro Phe Asp Leu Val Ile Pro Phe Thr Ile Lys Lys Gly Glu
1790 1795 1800
Ile Thr Gly Glu Val Arg Met Pro Ser Gly Lys Val Ala Gln Pro
1805 1810 1815
Thr Ile Thr Asp Asn Lys Asp Gly Thr Val Thr Val Arg Tyr Ala
1820 1825 1830
Pro Ser Glu Ala Gly Leu His Glu Met Asp Ile Arg Tyr Asp Asn
1835 1840 1845
Met His Ile Pro Gly Ser Pro Leu Gln Phe Tyr Val Asp Tyr Val
1850 1855 1860
Asn Cys Gly His Val Thr Ala Tyr Gly Pro Gly Leu Thr His Gly
1865 1870 1875
Val Val Asn Lys Pro Ala Thr Phe Thr Val Asn Thr Lys Asp Ala
1880 1885 1890
Gly Glu Gly Gly Leu Ser Leu Ala Ile Glu Gly Pro Ser Lys Ala
1895 1900 1905
Glu Ile Ser Cys Thr Asp Asn Gln Asp Gly Thr Cys Ser Val Ser
1910 1915 1920
Tyr Leu Pro Val Leu Pro Gly Asp Tyr Ser Ile Leu Val Lys Tyr
1925 1930 1935
Asn Glu Gln His Val Pro Gly Ser Pro Phe Thr Ala Arg Val Thr
1940 1945 1950
Gly Asp Asp Ser Met Arg Met Ser His Leu Lys Val Gly Ser Ala
1955 1960 1965
Ala Asp Ile Pro Ile Asn Ile Ser Glu Thr Asp Leu Ser Leu Leu
1970 1975 1980
Thr Ala Thr Val Val Pro Pro Ser Gly Arg Glu Glu Pro Cys Leu
1985 1990 1995
Leu Lys Arg Leu Arg Asn Gly His Val Gly Ile Ser Phe Val Pro
2000 2005 2010
Lys Glu Thr Gly Glu His Leu Val His Val Lys Lys Asn Gly Gln
2015 2020 2025
His Val Ala Ser Ser Pro Ile Pro Val Val Ile Ser Gln Ser Glu
2030 2035 2040
Ile Gly Asp Ala Ser Arg Val Arg Val Ser Gly Gln Gly Leu His
2045 2050 2055
Glu Gly His Thr Phe Glu Pro Ala Glu Phe Ile Ile Asp Thr Arg
2060 2065 2070
Asp Ala Gly Tyr Gly Gly Leu Ser Leu Ser Ile Glu Gly Pro Ser
2075 2080 2085
Lys Val Asp Ile Asn Thr Glu Asp Leu Glu Asp Gly Thr Cys Arg
2090 2095 2100
Val Thr Tyr Cys Pro Thr Glu Pro Gly Asn Tyr Ile Ile Asn Ile
2105 2110 2115
Lys Phe Ala Asp Gln His Val Pro Gly Ser Pro Phe Ser Val Lys
2120 2125 2130
Val Thr Gly Glu Gly Arg Val Lys Glu Ser Ile Thr Arg Arg Arg
2135 2140 2145
Arg Ala Pro Ser Val Ala Asn Val Gly Ser His Cys Asp Leu Ser
2150 2155 2160
Leu Lys Ile Pro Glu Ile Ser Ile Gln Asp Met Thr Ala Gln Val
2165 2170 2175
Thr Ser Pro Ser Gly Lys Thr His Glu Ala Glu Ile Val Glu Gly
2180 2185 2190
Glu Asn His Thr Tyr Cys Ile Arg Phe Val Pro Ala Glu Met Gly
2195 2200 2205
Thr His Thr Val Ser Val Lys Tyr Lys Gly Gln His Val Pro Gly
2210 2215 2220
Ser Pro Phe Gln Phe Thr Val Gly Pro Leu Gly Glu Gly Gly Ala
2225 2230 2235
His Lys Val Arg Ala Gly Gly Pro Gly Leu Glu Arg Ala Glu Ala
2240 2245 2250
Gly Val Pro Ala Glu Phe Ser Ile Trp Thr Arg Glu Ala Gly Ala
2255 2260 2265
Gly Gly Leu Ala Ile Ala Val Glu Gly Pro Ser Lys Ala Glu Ile
2270 2275 2280
Ser Phe Glu Asp Arg Lys Asp Gly Ser Cys Gly Val Ala Tyr Val
2285 2290 2295
Val Gln Glu Pro Gly Asp Tyr Glu Val Ser Val Lys Phe Asn Glu
2300 2305 2310
Glu His Ile Pro Asp Ser Pro Phe Val Val Pro Val Ala Ser Pro
2315 2320 2325
Ser Gly Asp Ala Arg Arg Leu Thr Val Ser Ser Leu Gln Glu Ser
2330 2335 2340
Gly Leu Lys Val Asn Gln Pro Ala Ser Phe Ala Val Ser Leu Asn
2345 2350 2355
Gly Ala Lys Gly Ala Ile Asp Ala Lys Val His Ser Pro Ser Gly
2360 2365 2370
Ala Leu Glu Glu Cys Tyr Val Thr Glu Ile Asp Gln Asp Lys Tyr
2375 2380 2385
Ala Val Arg Phe Ile Pro Arg Glu Asn Gly Val Tyr Leu Ile Asp
2390 2395 2400
Val Lys Phe Asn Gly Thr His Ile Pro Gly Ser Pro Phe Lys Ile
2405 2410 2415
Arg Val Gly Glu Pro Gly His Gly Gly Asp Pro Gly Leu Val Ser
2420 2425 2430
Ala Tyr Gly Ala Gly Leu Glu Gly Gly Val Thr Gly Asn Pro Ala
2435 2440 2445
Glu Phe Val Val Asn Thr Ser Asn Ala Gly Ala Gly Ala Leu Ser
2450 2455 2460
Val Thr Ile Asp Gly Pro Ser Lys Val Lys Met Asp Cys Gln Glu
2465 2470 2475
Cys Pro Glu Gly Tyr Arg Val Thr Tyr Thr Pro Met Ala Pro Gly
2480 2485 2490
Ser Tyr Leu Ile Ser Ile Lys Tyr Gly Gly Pro Tyr His Ile Gly
2495 2500 2505
Gly Ser Pro Phe Lys Ala Lys Val Thr Gly Pro Arg Leu Val Ser
2510 2515 2520
Asn His Ser Leu His Glu Thr Ser Ser Val Phe Val Asp Ser Leu
2525 2530 2535
Thr Lys Ala Thr Cys Ala Pro Gln His Gly Ala Pro Gly Pro Gly
2540 2545 2550
Pro Ala Asp Ala Ser Lys Val Val Ala Lys Gly Leu Gly Leu Ser
2555 2560 2565
Lys Ala Tyr Val Gly Gln Lys Ser Ser Phe Thr Val Asp Cys Ser
2570 2575 2580
Lys Ala Gly Asn Asn Met Leu Leu Val Gly Val His Gly Pro Arg
2585 2590 2595
Thr Pro Cys Glu Glu Ile Leu Val Lys His Val Gly Ser Arg Leu
2600 2605 2610
Tyr Ser Val Ser Tyr Leu Leu Lys Asp Lys Gly Glu Tyr Thr Leu
2615 2620 2625
Val Val Lys Trp Gly His Glu His Ile Pro Gly Ser Pro Tyr Arg
2630 2635 2640
Val Val Val Pro
2645
<210>10
<211>199
<212>PRT
＜213〉people (Homo sapiens)
<220>
<221>Transgelin 2
<222>(1)..(199)
＜223〉on Dec 6th, 2002 registration number: P37802
<400>10
Met Ala Asn Arg Gly Pro Ala Tyr Gly Leu Ser Arg Glu Val Gln Gln
1 5 10 15
Lys Ile Glu Lys Gln Tyr Asp Ala Asp Leu Glu Gln Ile Leu Ile Gln
20 25 30
Trp Ile Thr Thr Gln Cys Arg Lys Asp Val Gly Arg Pro Gln Pro Gly
35 40 45
Arg Glu Asn Phe Gln Asn Trp Leu Lys Asp Gly Thr Val Leu Cys Glu
50 55 60
Leu Ile Asn Ala Leu Tyr Pro Glu Gly Gln Ala Pro Val Lys Lys Ile
65 70 75 80
Gln Ala Ser Thr Met Ala Phe Lys Gln Met Glu Gln Ile Ser Gln Phe
85 90 95
Leu Gln Ala Ala Glu Arg Tyr Gly Ile Asn Thr Thr Asp Ile Phe Gln
100 105 110
Thr Val Asp Leu Trp Glu Gly Lys Asn Met Ala Cys Val Gln Arg Thr
115 120 125
Leu Met Asn Leu Gly Gly Leu Ala Val Ala Arg Asp Asp Gly Leu Phe
130 135 140
Ser Gly Asp Pro Asn Trp Phe Pro Lys Lys Ser Lys Glu Asn Pro Arg
145 150 155 160
Asn Phe Ser Asp Asn Gln Leu Gln Glu Gly Lys Asn Val Ile Gly Leu
165 170 175
Gln Met Gly Thr Asn Arg Gly Ala Ser Gln Ala Gly Met Thr Gly Tyr
180 185 190
Gly Met Pro Arg Gln Ile Leu
195
<210>11
<211>248
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉tropomyosin Alpha-4 chain
<222>(1)..(248)
＜223〉registration number: P07226
<400>11
Met Ala Gly Leu Asn Ser Leu Glu Ala Val Lys Arg Lys Ile Gln Ala
1 5 10 15
Leu Gln Gln Gln Ala Asp Glu Ala Glu Asp Arg Ala Gln Gly Leu Gln
20 25 30
Arg Glu Leu Asp Gly Glu Arg Glu Arg Arg Glu Lys Ala Glu Gly Asp
35 40 45
Val Ala Ala Leu Asn Arg Arg Ile Gln Leu Val Glu Glu Glu Leu Asp
50 55 60
Arg Ala Gln Glu Arg Leu Ala Thr Ala Leu Gln Lys Leu Glu Glu Ala
65 70 75 80
Glu Lys Ala Ala Asp Glu Ser Glu Arg Gly Met Lys Val Ile Glu Asn
85 90 95
Arg Ala Met Lys Asp Glu Glu Lys Met Glu Ile Gln Glu Met Gln Leu
100 105 110
Lys Glu Ala Lys His Ile Ala Glu Glu Ala Asp Arg Lys Tyr Glu Glu
115 120 125
Val Ala Arg Lys Leu Val Ile Leu Glu Gly Glu Leu Glu Arg Ala Glu
130 135 140
Glu Arg Ala Glu Val Ser Glu Leu Lys Cys Gly Asp Leu Glu Glu Glu
145 150 155 160
Leu Lys Asn Val Thr Asn Asn Leu Lys Ser Leu Glu Ala Ala Ser Glu
165 170 175
Lys Tyr Ser Glu Lys Glu Asp Lys Tyr Glu Glu Glu Ile Lys Leu Leu
180 185 190
Ser Asp Lys Leu Lys Glu Ala Glu Thr Arg Ala Glu Phe Ala Glu Arg
195 200 205
Thr Val Ala Lys Leu Glu Lys Thr Ile Asp Asp Leu Glu Glu Lys Leu
210 215 220
Ala Gln Ala Lys Glu Glu Asn Val Gly Leu His Gln Thr Leu Asp Gln
225 230 235 240
Thr Leu Asn Glu Leu Asn Cys Ile
245
<210>12
<211>793
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉caldesmon
<222>(1)..(793)
＜223〉on Dec 6th, 2002 registration number: Q05682
<400>12
Met Asp Asp Phe Glu Arg Arg Arg Glu Leu Arg Arg Gln Lys Arg Glu
1 5 10 15
Glu Met Arg Leu Glu Ala Glu Arg Ile Ala Tyr Gln Arg Asn Asp Asp
20 25 30
Asp Glu Glu Glu Ala Ala Arg Glu Arg Arg Arg Arg Ala Arg Gln Glu
35 40 45
Arg Leu Arg Gln Lys Gln Glu Glu Glu Ser Leu Gly Gln Val Thr Asp
50 55 60
Gln Val Glu Val Asn Ala Gln Asn Ser Val Pro Asp Glu Glu Ala Lys
65 70 75 80
Thr Thr Thr Thr Asn Thr Gln Val Glu Gly Asp Asp Glu Ala Ala Phe
85 90 95
Leu Glu Arg Leu Ala Arg Arg Glu Glu Arg Arg Gln Lys Arg Leu Gln
100 105 110
Glu Ala Leu Glu Arg Gln Lys Glu Phe Asp Pro Thr Ile Thr Asp Ala
115 120 125
Ser Leu Ser Leu Pro Ser Arg Arg Met Gln Asn Asp Thr Ala Glu Asn
130 135 140
Glu Thr Thr Glu Lys Glu Glu Lys Ser Glu Ser Arg Gln Glu Arg Tyr
145 150 155 160
Glu Ile Glu Glu Thr Glu Thr Val Thr Lys Ser Tyr Gln Lys Asn Asp
165 170 175
Trp Arg Asp Ala Glu Glu Asn Lys Lys Glu Asp Lys Glu Lys Glu Glu
180 185 190
Glu Glu Glu Glu Lys Pro Lys Arg Gly Ser Ile Gly Glu Asn Gln Val
195 200 205
Glu Val Met Val Glu Glu Lys Thr Thr Glu Ser Gln Glu Glu Thr Val
210 215 220
Val Met Ser Leu Lys Asn Gly Gln Ile Ser Ser Glu Glu Pro Lys Gln
225 230 235 240
Glu Glu Glu Arg Glu Gln Gly Ser Asp Glu Ile Ser His His Glu Lys
245 250 255
Met Glu Glu Glu Asp Lys Glu Arg Ala Glu Ala Glu Arg Ala Arg Leu
260 265 270
Glu Ala Glu Glu Arg Glu Arg Ile Lys Ala Glu Gln Asp Lys Lys Ile
275 280 285
Ala Asp Glu Arg Ala Arg Ile Glu Ala Glu Glu Lys Ala Ala Ala Gln
290 295 300
Glu Arg Glu Arg Arg Glu Ala Glu Glu Arg Glu Arg Met Arg Glu Glu
305 310 315 320
Glu Lys Arg Ala Ala Glu Glu Arg Gln Arg Ile Lys Glu Glu Glu Lys
325 330 335
Arg Ala Ala Glu Glu Arg Gln Arg Ile Lys Glu Glu Glu Lys Arg Ala
340 345 350
Ala Glu Glu Arg Gln Arg Ile Lys Glu Glu Glu Lys Arg Ala Ala Glu
355 360 365
Glu Arg Gln Arg Ala Arg Ala Glu Glu Glu Glu Lys Ala Lys Val Glu
370 375 380
Glu Gln Lys Arg Asn Lys Gln Leu Glu Glu Lys Lys Arg Ala Met Gln
385 390 395 400
Glu Thr Lys Ile Lys Gly Glu Lys Val Glu Gln Lys Ile Glu Gly Lys
405 410 415
Trp Val Asn Glu Lys Lys Ala Gln Glu Asp Lys Leu Gln Thr Ala Val
420 425 430
Leu Lys Lys Gln Gly Glu Glu Lys Gly Thr Lys Val Gln Ala Lys Arg
435 440 445
Glu Lys Leu Gln Glu Asp Lys Pro Thr Phe Lys Lys Glu Glu Ile Lys
450 455 460
Asp Glu Lys Ile Lys Lys Asp Lys Glu Pro Lys Glu Glu Val Lys Ser
465 470 475 480
Phe Met Asp Arg Lys Lys Gly Phe Thr Glu Val Lys Ser Gln Asn Gly
485 490 495
Glu Phe Met Thr His Lys Leu Lys His Thr Glu Asn Thr Phe Ser Arg
500 505 510
Pro Gly Gly Arg Ala Ser Val Asp Thr Lys Glu Ala Glu Gly Ala Pro
515 520 525
Gln Val Glu Ala Gly Lys Arg Leu Glu Glu Leu Arg Arg Arg Arg Gly
530 535 540
Glu Thr Glu Ser Glu Glu Phe Glu Lys Leu Lys Gln Lys Gln Gln Glu
545 550 555 560
Ala Ala Leu Glu Leu Glu Glu Leu Lys Lys Lys Arg Glu Glu Arg Arg
565 570 575
Lys Val Leu Glu Glu Glu Glu Gln Arg Arg Lys Gln Glu Glu Ala Asp
580 585 590
Arg Lys Leu Arg Glu Glu Glu Glu Lys Arg Arg Leu Lys Glu Glu Ile
595 600 605
Glu Arg Arg Arg Ala Glu Ala Ala Glu Lys Arg Gln Lys Met Pro Glu
610 615 620
Asp Gly Leu Ser Asp Asp Lys Lys Pro Phe Lys Cys Phe Thr Pro Lys
625 630 635 640
Gly Ser Ser Leu Lys Ile Glu Glu Arg Ala Glu Phe Leu Asn Lys Ser
645 650 655
Val Gln Lys Ser Ser Gly Val Lys Ser Thr His Gln Ala Ala Ile Val
660 665 670
Ser Lys Ile Asp Ser Arg Leu Glu Gln Tyr Thr Ser Ala Ile Glu Gly
675 680 685
Thr Lys Ser Ala Lys Pro Thr Lys Pro Ala Ala Ser Asp Leu Pro Val
690 695 700
Pro Ala Glu Gly Val Arg Asn Ile Lys Ser Met Trp Glu Lys Gly Asn
705 710 715 720
Val Phe Ser Ser Pro Thr Ala Ala Gly Thr Pro Asn Lys Glu Thr Ala
725 730 735
Gly Leu Lys Val Gly Val Ser Ser Arg Ile Asn Glu Trp Leu Thr Lys
740 745 750
Thr Pro Asp Gly Asn Lys Ser Pro Ala Pro Lys Pro Ser Asp Leu Arg
755 760 765
Pro Gly Asp Val Ser Ser Lys Arg Asn Leu Trp Glu Lys Gln Ser Val
770 775 780
Asp Lys Val Thr Ser Pro Thr Lys Val
785 790
<210>13
<211>458
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉Alpha-enolase
<222>(1)..(458)
＜223〉on Dec 6th, 2002 registration number: Q05524
<400>13
Met Ser Ile Leu Lys Ile Ile His Ala Arg Asp Ile Phe Glu Ser Arg
1 5 10 15
Gly Asn Pro Thr Val Glu Val Asp Leu Tyr Thr Asn Lys Gly Gly Leu
20 25 30
Phe Gly Arg Ala Ala Val Pro Ser Gly Ala Ser Thr Gly Ile Tyr Glu
35 40 45
Ala Leu Leu Glu Leu Arg Asp Asn Asp Lys Thr Arg Tyr Met Gly Gly
50 55 60
Lys Gly Val Ser Lys Ala Val Glu His Ile Ile Asn Lys Thr Ile Ala
65 70 75 80
Pro Ala Leu Ile Ser Lys Asn Val Asn Val Val Glu Gln Asp Lys Ile
85 90 95
Asp Asn Leu Met Leu Asp Met Asp Gly Ser Glu Asn Lys Ser Lys Phe
100 105 110
Gly Ala Asn Ala Ile Leu Gly Val Ser Leu Ala Val Cys Ser Asn Ala
115 120 125
Gly Ala Thr Ala Glu Lys Gly Val Pro Leu Tyr Arg His Ile Ala Asp
130 135 140
Leu Ala Gly Asn Asn Pro Glu Val Ile Leu Pro Val Pro Ala Phe Asn
145 150 155 160
Val Ile Asn Gly Gly Ser His Ala Gly Asn Lys Leu Ala Met Gln Glu
165 170 175
Phe Met Ile Pro Pro Cys Gly Ala Asp Arg Phe Asn Asp Ala Ile Arg
180 185 190
Ile Gly Ala Glu Val Tyr His Asn Leu Lys Asn Val Ile Lys Glu Lys
195 200 205
Tyr Gly Lys Asp Ala Thr Asn Val Gly Asp Glu Gly Gly Phe Ala Pro
210 215 220
Asn Ile Leu Glu Asn Lys Glu Ala Leu Glu Leu Leu Lys Thr Ala Ile
225 230 235 240
Gly Lys Ala Gly Tyr Ser Asp Lys Val Val Ile Gly Met Asp Val Ala
245 250 255
Ala Ser Glu Phe Tyr Arg Asp Gly Lys Tyr Asp Leu Asp Phe Asn Ser
260 265 270
Pro Asp Asp Pro Ser Arg Tyr Ile Ser Pro Asp Gln Leu Ala Asp Leu
275 280 285
Tyr Lys Gly Phe Val Leu Gly His Ala Val Lys Asn Tyr Pro Val Gly
290 295 300
Val Ser Ile Glu Asp Pro Pro Phe Asp Gln Asp Asp Trp Gly Ala Trp
305 310 315 320
Lys Lys Leu Phe Thr Gly Ser Leu Val Gly Ile Gln Val Val Gly Asp
325 330 335
Asp Leu Thr Val Thr Lys Pro Glu Ala Arg Ile Ala Lys Ala Val Glu
340 345 350
Glu Val Lys Ala Cys Asn Cys Leu Leu Leu Leu Lys Val Asn Gln Ile
355 360 365
Gly Ser Val Thr Glu Ser Leu Gln Ala Cys Lys Leu Ala Gln Ser Asn
370 375 380
Gly Trp Gly Val Met Pro Val Ser His Arg Leu Ser Gly Glu Thr Glu
385 390 395 400
Asp Thr Phe Met Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile
405 410 415
Lys Thr Gly Pro Thr Cys Arg Ser Glu Arg Leu Ala Lys Tyr Asn Gln
420 425 430
Leu Leu Arg Ile Glu Glu Ala Glu Ala Gly Ser Lys Ala Arg Phe Ala
435 440 445
Gly Arg Asn Phe Arg Asn Pro Arg Ile Asn
450 455
<210>14
<211>408
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉ACY1
<222>(1)..(408)
＜223〉on Dec 6th, 2002 registration number: Q03154
<400>14
Met Thr Ser Lys Gly Pro Glu Glu Glu His Pro Ser Val Thr Leu Phe
1 5 10 15
Arg Gln Tyr Leu Arg Ile Arg Thr Val Gln Pro Lys Pro Asp Tyr Gly
20 25 30
Ala Ala Val Ala Phe Phe Glu Glu Thr Ala Arg Gln Leu Gly Leu Gly
35 40 45
Cys Gln Lys Val Glu Val Ala Pro Gly Tyr Val Val Thr Val Leu Thr
50 55 60
Trp Pro Gly Thr Asn Pro Thr Leu Ser Ser Ile Leu Leu Asn Ser His
65 70 75 80
Thr Asp Val Val Pro Val Phe Lys Glu His Trp Ser His Asp Pro Phe
85 90 95
Glu Ala Phe Lys Asp Ser Glu Gly Tyr Ile Tyr Ala Arg Gly Ala Gln
100 105 110
Asp Met Lys Cys Val Ser Ile Gln Tyr Leu Glu Ala Val Arg Arg Leu
115 120 125
Lys Val Glu Gly His Arg Phe Pro Arg Thr Ile His Met Thr Phe Val
130 135 140
Pro Asp Glu Glu Val Gly Gly His Gln Gly Met Glu Leu Phe Val Gln
145 150 155 160
Arg Pro Glu Phe His Ala Leu Arg Ala Gly Phe Ala Leu Asp Glu Gly
165 170 175
Ile Ala Asn Pro Thr Asp Ala Phe Thr Val Phe Tyr Ser Glu Arg Ser
180 185 190
Pro Trp Trp Val Arg Val Thr Ser Thr Gly Arg Pro Gly His Ala Ser
195 200 205
Arg Phe Met Glu Asp Thr Ala Ala Glu Lys Leu His Lys Val Val Asn
210 215 220
Ser Ile Leu Ala Phe Arg Glu Lys Glu Trp Gln Arg Leu Gln Ser Asn
225 230 235 240
Pro His Leu Lys Glu Gly Ser Val Thr Ser Val Asn Leu Thr Lys Leu
245 250 255
Glu Gly Gly Val Ala Tyr Asn Val Ile Pro Ala Thr Met Ser Ala Ser
260 265 270
Phe Asp Phe Arg Val Ala Pro Asp Val Asp Phe Lys Ala Phe Glu Glu
275 280 285
Gln Leu Gln Ser Trp Cys Gln Ala Ala Gly Glu Gly Val Thr Leu Glu
290 295 300
Phe Ala Gln Lys Trp Met His Pro Gln Val Thr Pro Thr Asp Asp Ser
305 310 315 320
Asn Pro Trp Trp Ala Ala Phe Ser Arg Val Cys Lys Asp Met Asn Leu
325 330 335
Thr Leu Glu Pro Glu Ile Met Pro Ala Ala Thr Asp Asn Arg Tyr Ile
340 345 350
Arg Ala Val Gly Val Pro Ala Leu Gly Phe Ser Pro Met Asn Arg Thr
355 360 365
Pro Val Leu Leu His Asp His Asp Glu Arg Leu His Glu Ala Val Phe
370 375 380
Leu Arg Gly Val Asp Ile Tyr Thr Arg Leu Leu Pro Ala Leu Ala Ser
385 390 395 400
Val Pro Ala Leu Pro Ser Asp Ser
405
<210>15
<211>277
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉F-capping protein beta-subunit
<222>(1)..(277)
＜223〉on Dec 6th, 2002 registration number: P47756
<400>15
Met Ser Asp Gln Gln Leu Asp Cys Ala Leu Asp Leu Met Arg Arg Leu
1 5 10 15
Pro Pro Gln Gln Ile Glu Lys Asn Leu Ser Asp Leu Ile Asp Leu Val
20 25 30
Pro Ser Leu Cys Glu Asp Leu Leu Ser Ser Val Asp Gln Pro Leu Lys
35 40 45
Ile Ala Arg Asp Lys Val Val Gly Lys Asp Tyr Leu Leu Cys Asp Tyr
50 55 60
Asn Arg Asp Gly Asp Ser Tyr Arg Ser Pro Trp Ser Asn Lys Tyr Asp
65 70 75 80
Pro Pro Leu Glu Asp Gly Ala Met Pro Ser Ala Arg Leu Arg Lys Leu
85 90 95
Glu Val Glu Ala Asn Asn Ala Phe Asp Gln Tyr Arg Asp Leu Tyr Phe
100 105 110
Glu Gly Gly Val Ser Ser Val Tyr Leu Trp Asp Leu Asp His Gly Phe
115 120 125
Ala Gly Val Ile Leu Ile Lys Lys Ala Gly Asp Gly Ser Lys Lys Ile
130 135 140
Lys Gly Cys Trp Asp Ser Ile His Val Val Glu Val Gln Glu Lys Ser
145 150 155 160
Ser Gly Arg Thr Ala His Tyr Lys Leu Thr Ser Thr Val Met Leu Trp
165 170 175
Leu Gln Thr Asn Lys Ser Gly Ser Gly Thr Met Asn Leu Gly Gly Ser
180 185 190
Leu Thr Arg Gln Met Glu Lys Asp Glu Thr Val Ser Asp Cys Ser Pro
195 200 205
His Ile Ala Asn Ile Gly Arg Leu Val Glu Asp Met Glu Asn Lys Ile
210 215 220
Arg Ser Thr Leu Asn Glu Ile Tyr Phe Gly Lys Thr Lys Asp Ile Val
225 230 235 240
Asn Gly Leu Arg Ser Ile Asp Ala Ile Pro Asp Asn Gln Lys Phe Lys
245 250 255
Gln Leu Gln Arg Glu Leu Ser Gln Val Leu Thr Gln Arg Gln Ile Tyr
260 265 270
Ile Gln Pro Asp Asn
275
<210>16
<211>289
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉inorganic pyrophosphatase
<222>(1)..(289)
＜223〉on Dec 6th, 2002 registration number: Q15181
<400>16
Met Ser Gly Phe Ser Thr Glu Glu Arg Ala Ala Pro Phe Ser Leu Glu
1 5 10 15
Tyr Arg Val Phe Leu Lys Asn Glu Lys Gly Gln Tyr Ile Ser Pro Phe
20 25 30
His Asp Ile Pro Ile Tyr Ala Asp Lys Asp Val Phe His Met Val Val
35 40 45
Glu Val Pro Arg Trp Ser Asn Ala Lys Met Glu Ile Ala Thr Lys Asp
50 55 60
Pro Leu Asn Pro Ile Lys Gln Asp Val Lys Lys Gly Lys Leu Arg Tyr
65 70 75 80
Val Ala Asn Leu Phe Pro Tyr Lys Gly Tyr Ile Trp Asn Tyr Gly Ala
85 90 95
Tle Pro Gln Thr Trp Glu Asp Pro Gly His Asn Asp Lys His Thr Gly
100 105 110
Cys Cys Gly Asp Asn Asp Pro Ile Asp Val Cys Glu Ile Gly Ser Lys
115 120 125
Val Cys Ala Arg Gly Glu Ile Ile Gly Val Lys Val Leu Gly Ile Leu
130 135 140
Ala Met Ile Asp Glu Gly Glu Thr Asp Trp Lys Val Ile Ala Ile Asn
145 150 155 160
Val Asp Asp Pro Asp Ala Ala Asn Tyr Asn Asp Ile Asn Asp Val Lys
165 170 175
Arg Leu Lys Pro Gly Tyr Leu Glu Ala Thr Val Asp Trp Phe Arg Arg
180 185 190
Tyr Lys Val Pro Asp Gly Lys Pro Glu Asn Glu Phe Ala Phe Asn Ala
195 200 205
Glu Phe Lys Asp Lys Asp Phe Ala Ile Asp Ile Ile Lys Ser Thr His
210 215 220
Asp His Trp Lys Ala Leu Val Thr Lys Lys Thr Asn Gly Lys Gly Ile
225 230 235 240
Ser Cys Met Asn Thr Thr Leu Ser Glu Ser Pro Phe Lys Cys Asp Pro
245 250 255
Asp Ala Ala Arg Ala Ile Val Asp Ala Leu Pro Pro Pro Cys Glu Ser
260 265 270
Ala Cys Thr Val Pro Thr Asp Val Asp Lys Trp Phe His His Gln Lys
275 280 285
Asn
<210>17
<211>250
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉Galectins 3 (the specific agglutinin 3 of galactose)
<222>(1)..(250)
＜223〉on Dec 6th, 2002 registration number: P17931
<400>17
Met Ala Asp Asn Phe Ser Leu His Asp Ala Leu Ser Gly Ser Gly Asn
1 5 10 15
Pro Asn Pro Gln Gly Trp Pro Gly Ala Trp Gly Asn Gln Pro Ala Gly
20 25 30
Ala Gly Gly Tyr Pro Gly Ala Ser Tyr Pro Gly Ala Tyr Pro Gly Gln
35 40 45
Ala Pro Pro Gly Ala Tyr Pro Gly Gln Ala Pro Pro Gly Ala Tyr His
50 55 60
Gly Ala Pro Gly Ala Tyr Pro Gly Ala Pro Ala Pro Gly Val Tyr Pro
65 70 75 80
Gly Pro Pro Ser Gly Pro Gly Ala Tyr Pro Ser Ser Gly Gln Pro Ser
85 90 95
Ala Pro Gly Ala Tyr Pro Ala Thr Gly Pro Tyr Gly Ala Pro Ala Gly
100 105 110
Pro Leu Ile Val Pro Tyr Asn Leu Pro Leu Pro Gly Gly Val Val Pro
115 120 125
Arg Met Leu Ile Thr Ile Leu Gly Thr Val Lys Pro Asn Ala Asn Arg
130 135 140
Ile Ala Leu Asp Phe Gln Arg Gly Asn Asp Val Ala Phe His Phe Asn
145 150 155 160
Pro Arg Phe Asn Glu Asn Asn Arg Arg Val Ile Val Cys Asn Thr Lys
165 170 175
Leu Asp Asn Asn Trp Gly Arg Glu Glu Arg Gln Ser Val Phe Pro Phe
180 185 190
Glu Ser Gly Lys Pro Phe Lys Ile Gln Val Leu Val Glu Pro Asp His
195 200 205
Phe Lys Val Ala Val Asn Asp Ala His Leu Leu Gln Tyr Asn His Arg
210 215 220
Val Lys Lys Leu Asn Glu Ile Ser Lys Leu Gly Ile Ser Gly Asp Ile
225 230 235 240
Asp Leu Thr Ser Ala Ser Tyr Thr Met Ile
245 250
<210>18
<211>347
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉voltage dependence anion selectivity channel protein 2 (VDAC-2)
<222>(1)..(347)
＜223〉on Dec 6th, 2002 registration number: P45880
<400>18
Met Ser Trp Cys Asn Glu Leu Arg Leu Pro Ala Leu Lys Gln His Ser
1 5 10 15
Ile Gly Arg Gly Leu Glu Ser His Ile Thr Met Cys Ile Pro Pro Ser
20 25 30
Tyr Ala Asp Leu Gly Lys Ala Ala Arg Asp Ile Phe Asn Lys Gly Phe
35 40 45
Gly Phe Gly Leu Val Lys Leu Asp Val Lys Thr Lys Ser Cys Ser Gly
50 55 60
Val Glu Phe Ser Thr Ser Gly Ser Ser Asn Thr Asp Thr Gly Lys Val
65 70 75 80
Thr Gly Thr Leu Glu Thr Lys Tyr Lys Trp Cys Glu Tyr Gly Leu Thr
85 90 95
Phe Thr Glu Lys Trp Asn Thr Asp Asn Thr Leu Gly Thr Glu Ile Ala
100 105 110
Ile Glu Asp Gln Ile Cys Gln Gly Leu Lys Leu Thr Phe Asp Thr Thr
115 120 125
Phe Ser Pro Asn Thr Gly Lys Lys Ser Gly Lys Ile Lys Ser Ser Tyr
130 135 140
Lys Arg Glu Cys Ile Asn Leu Gly Cys Asp Val Asp Phe Asp Phe Ala
145 150 155 160
Gly Pro Ala Ile His Gly Ser Ala Val Phe Gly Tyr Glu Gly Trp Leu
165 170 175
Ala Gly Tyr Gln Met Thr Phe Asp Ser Ala Lys Ser Lys Leu Thr Arg
180 185 190
Asn Asn Phe Ala Val Gly Tyr Arg Thr Gly Asp Phe Gln Leu His Thr
195 200 205
Asn Val Asn Asp Gly Thr Glu Phe Gly Gly Ser Ile Tyr Gln Lys Val
210 215 220
Cys Glu Asp Leu Asp Thr Ser Val Asn Leu Ala Trp Thr Ser Gly Thr
225 230 235 240
Asn Cys Thr Arg Phe Gly Ile Ala Ala Lys Tyr Gln Leu Asp Pro Thr
245 250 255
Ala Ser Ile Ser Ala Lys Val Asn Asn Ser Ser Leu Ile Gly Val Gly
260 265 270
Tyr Thr Gln Thr Leu Arg Pro Gly Val Lys Leu Thr Leu Ser Ala Leu
275 280 285
Val Asp Gly Lys Ser Ile Asn Ala Gly Gly His Lys Val Gly Ser Pro
290 295 300
Trp Ser Trp Arg Leu Asn Pro Ala Glu Arg Asn Leu Trp Glu Trp Ile
305 310 315 320
Ser Glu Asp Leu Ala Leu Ile Tyr Phe His Cys Asp Gln Gln Gln Ala
325 330 335
Phe Phe Pro Pro Glu Asp Asp Gln Asn Lys Gly
340 345
<210>19
<211>339
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉annexin II
<222>(1)..(339)
＜223〉on Dec 6th, 2002 registration number: P07355
<400>19
Met Ser Thr Val His Glu Ile Leu Cys Lys Leu Ser Leu Glu Gly Asp
1 5 10 15
His Ser Thr Pro Pro Ser Ala Tyr Gly Ser Val Lys Ala Tyr Thr Asn
20 25 30
Phe Asp Ala Glu Arg Asp Ala Leu Asn Ile Glu Thr Ala Ile Lys Thr
35 40 45
Lys Gly Val Asp Glu Val Thr Ile Val Asn Ile Leu Thr Asn Arg Ser
50 55 60
Asn Ala Gln Arg Gln Asp Ile Ala Phe Ala Tyr Gln Arg Arg Thr Lys
65 70 75 80
Lys Glu Leu Ala Ser Ala Leu Lys Ser Ala Leu Ser Gly His Leu Glu
85 90 95
Thr Val Ile Leu Gly Leu Leu Lys Thr Pro Ala Gln Tyr Asp Ala Ser
100 105 110
Glu Leu Lys Ala Ser Met Lys Gly Leu Gly Thr Asp Glu Asp Ser Leu
115 120 125
Ile Glu Ile Ile Cys Ser Arg Thr Asn Gln Glu Leu Gln Glu Ile Asn
130 135 140
Arg Val Tyr Lys Glu Met Tyr Lys Thr Asp Leu Glu Lys Asp Ile Ile
145 150 155 160
Ser Asp Thr Ser Gly Asp Phe Arg Lys Leu Met Val Ala Leu Ala Lys
165 170 175
Gly Arg Arg Ala Glu Asp Gly Ser Val Ile Asp Tyr Glu Leu Ile Asp
180 185 190
Gln Asp Ala Arg Asp Leu Tyr Asp Ala Gly Val Lys Arg Lys Gly Thr
195 200 205
Asp Val Pro Lys Trp Ile Ser Ile Met Thr Glu Arg Ser Val Pro His
210 215 220
Leu Gln Lys Val Phe Asp Arg Tyr Lys Ser Tyr Ser Pro Tyr Asp Met
225 230 235 240
Leu Glu Ser Ile Arg Lys Glu Val Lys Gly Asp Leu Glu Asn Ala Phe
245 250 255
Leu Asn Leu Val Gln Cys Ile Gln Asn Lys Pro Leu Tyr Phe Ala Asp
260 265 270
Arg Leu Tyr Asp Ser Met Lys Gly Lys Gly Thr Arg Asp Lys Val Leu
275 280 285
Ile Arg Ile Met Val Ser Arg Ser Glu Val Asp Met Leu Lys Ile Arg
290 295 300
Ser Glu Phe Lys Arg Lys Tyr Gly Lys Ser Leu Tyr Tyr Tyr Ile Gln
305 310 315 320
Gln Asp Thr Lys Gly Asp Tyr Gln Lys Ala Leu Leu Tyr Leu Cys Gly
325 330 335
Gly Asp Asp
<210>20
<211>418
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉collagen is in conjunction with albumen 2
<222>(1)..(418)
＜223〉on Dec 6th, 2002 registration number: P50454
<400>20
Met Arg Ser Leu Leu Leu Leu Ser Ala Phe Cys Leu Leu Glu Ala Ala
1 5 10 15
Leu Ala Ala Glu Val Lys Lys Pro Ala Ala Ala Ala Ala Pro Gly Thr
20 25 30
Ala Glu Lys Leu Ser Pro Lys Ala Ala Thr Leu Ala Glu Arg Ser Ala
35 40 45
Gly Leu Ala Phe Ser Leu Tyr Gln Ala Met Ala Lys Asp Gln Ala Val
50 55 60
Glu Asn Ile Leu Val Ser Pro Val Val Val Ala Ser Ser Leu Gly Leu
65 70 75 80
Val Ser Leu Gly Gly Lys Ala Thr Thr Ala Ser Gln Ala Lys Ala Val
85 90 95
Leu Ser Ala Glu Gln Leu Arg Asp Glu Glu Val His Ala Gly Leu Gly
100 105 110
Glu Leu Leu Arg Ser Leu Ser Asn Ser Thr Ala Arg Asn Val Thr Trp
115 120 125
Lys Leu Gly Ser Arg Leu Tyr Gly Pro Ser Ser Val Ser Phe Ala Asp
130 135 140
Asp Phe Val Arg Ser Ser Lys Gln His Tyr Asn Cys Glu His Ser Lys
145 150 155 160
Ile Asn Phe Arg Asp Lys Arg Ser Ala Leu Gln Ser Ile Asn Glu Trp
165 170 175
Ala Ala Gln Thr Thr Asp Gly Lys Leu Pro Glu Val Thr Lys Asp Val
180 185 190
Glu Arg Thr Asp Gly Ala Leu Leu Val Asn Ala Met Phe Phe Lys Pro
195 200 205
His Trp Asp Glu Lys Phe His His Lys Met Val Asp Asn Arg Gly Phe
210 215 220
Met Val Thr Arg Ser Tyr Thr Val Gly Val Met Met Met His Arg Thr
225 230 235 240
Gly Leu Tyr Asn Tyr Tyr Asp Asp Glu Lys Glu Lys Leu Gln Ile Val
245 250 255
Glu Met Pro Leu Ala His Lys Leu Ser Ser Leu Ile Ile Leu Met Pro
260 265 270
His His Val Glu Pro Leu Glu Arg Leu Glu Lys Leu Leu Thr Lys Glu
275 280 285
Gln Leu Lys Ile Trp Met Gly Lys Met Gln Lys Lys Ala Val Ala Ile
290 295 300
Ser Leu Pro Lys Gly Val Val Glu Val Thr His Asp Leu Gln Lys His
305 310 315 320
Leu Ala Gly Leu Gly Leu Thr Glu Ala Ile Asp Lys Asn Lys Ala Asp
325 330 335
Leu Ser Arg Met Ser Gly Lys Lys Asp Leu Tyr Leu Ala Ser Val Phe
340 345 350
His Ala Thr Ala Phe Glu Leu Asp Thr Asp Gly Asn Pro Phe Asp Gln
355 360 365
Asp Ile Tyr Gly Arg Glu Glu Leu Arg Ser Pro Lys Leu Phe Tyr Ala
370 375 380
Asp His Pro Phe Ile Phe Leu Val Arg Asp Thr Gln Ser Gly Ser Leu
385 390 395 400
Leu Phe Ile Gly Arg Leu Val Arg Pro Lys Gly Asp Lys Met Arg Asp
405 410 415
Glu Leu
<210>21
<211>166
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉non-muscle isotype Cofilin
<222>(1)..(166)
＜223〉on Dec 8th, 2002 registration number: P23528
<400>21
Met Ala Ser Gly Val Ala Val Ser Asp Gly Val Ile Lys Val Phe Asn
1 5 10 15
Asp Met Lys Val Arg Lys Ser Ser Thr Pro Glu Glu Val Lys Lys Arg
20 25 30
Lys Lys Ala Val Leu Phe Cys Leu Ser Glu Asp Lys Lys Asn Ile Ile
35 40 45
Leu Glu Glu Gly Lys Glu Ile Leu Val Gly Asp Val Gly Gln Thr Val
50 55 60
Asp Asp Pro Tyr Ala Thr Phe Val Lys Met Leu Pro Asp Lys Asp Cys
65 70 75 80
Arg Tyr Ala Leu Tyr Asp Ala Thr Tyr Glu Thr Lys Glu Ser Lys Lys
85 90 95
Glu Asp Leu Val Phe Ile Phe Trp Ala Pro Glu Ser Ala Pro Leu Lys
100 105 110
Ser Lys Met Ile Tyr Ala Ser Ser Lys Asp Ala Ile Lys Lys Lys Leu
115 120 125
Thr Gly Ile Lys His Glu Leu Gln Ala Asn Cys Tyr Glu Glu Val Lys
130 135 140
Asp Arg Cys Thr Leu Ala Glu Lys Leu Gly Gly Ser Ala Val Ile Ser
145 150 155 160
Leu Glu Gly Lys Pro Leu
165
<210>22
<211>165
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉peptidyl-propyl cis-trans isomerase A
<222>(1)..(165)
＜223〉on Dec 9th, 2002 registration number: P05092
<400>22
Met Val Asn Pro Thr Val Phe Phe Asp Ile Ala Val Asp Gly Glu Pro
1 5 10 15
Leu Gly Arg Val Ser Phe Glu Leu Phe Ala Asp Lys Val Pro Lys Thr
20 25 30
Ala Glu Asn Phe Arg Ala Leu Ser Thr Gly Glu Lys Gly Phe Gly Tyr
35 40 45
Lys Gly Ser Cys Phe His Arg Ile Ile Pro Gly Phe Met Cys Gln Gly
50 55 60
Gly Asp Phe Thr Arg His Asn Gly Thr Gly Gly Lys Ser Ile Tyr Gly
65 70 75 80
Glu Lys Phe Glu Asp Glu Asn Phe Ile Leu Lys His Thr Gly Pro Gly
85 90 95
Ile Leu Ser Met Ala Asn Ala Gly Pro Asn Thr Asn Gly Ser Gln Phe
100 105 110
Phe Ile Cys Thr Ala Lys Thr Glu Trp Leu Asp Gly Lys His Val Val
115 120 125
Phe Gly Lys Val Lys Glu Gly Met Asn Ile Val Glu Ala Met Glu Arg
130 135 140
Phe Gly Ser Arg Asn Gly Lys Thr Ser Lys Lys Ile Thr Ile Ala Asp
145 150 155 160
Cys Gly Gln Leu Glu
165
<210>23
<211>638
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉kytoplasm dynein intermediate chain
<222>(1)..(638)
＜223〉on Dec 9th, 2002 registration number: Q13409
<400>23
Met Ser Asp Lys Ser Glu Leu Lys Ala Glu Leu Glu Arg Lys Lys Gln
1 5 10 15
Arg Leu Ala Gln Ile Arg Glu Glu Lys Lys Arg Lys Glu Glu Glu Arg
20 25 30
Lys Lys Lys Glu Thr Asp Gln Lys Lys Glu Ala Val Ala Pro Val Gln
35 40 45
Glu Glu Ser Asp Leu Glu Lys Lys Arg Arg Glu Ala Glu Ala Leu Leu
50 55 60
Gln Ser Met Gly Leu Thr Pro Glu Ser Pro Ile Val Phe Ser Glu Tyr
65 70 75 80
Trp Val Pro Pro Pro Met Ser Pro Ser Ser Lys Ser Val Ser Thr Pro
85 90 95
Ser Glu Ala Gly Ser Gln Asp Ser Gly Asp Gly Ala Val Gly Ser Arg
100 105 110
Thr Leu His Trp Asp Thr Asp Pro Ser Val Leu Gln Leu His Ser Asp
115 120 125
Ser Asp Leu Gly Arg Gly Pro Ile Lys Leu Gly Met Ala Lys Ile Thr
130 135 140
Gln Val Asp Phe Pro Pro Arg Glu Ile Val Thr Tyr Thr Lys Glu Thr
145 150 155 160
Gln Thr Pro Val Met Ala Gln Pro Lys Glu Asp Glu Glu Glu Asp Asp
165 170 175
Asp Val Val Ala Pro Lys Pro Pro Ile Glu Pro Glu Glu Glu Lys Thr
180 185 190
Leu Lys Lys Asp Glu Glu Asn Asp Ser Lys Ala Pro Pro His Glu Leu
195 200 205
Thr Glu Glu Glu Lys Gln Gln Ile Leu His Ser Glu Glu Phe Leu Ser
210 215 220
Phe Phe Asp His Ser Thr Arg Ile Val Glu Arg Ala Leu Ser Glu Gln
225 230 235 240
Ile Asn Ile Phe Phe Asp Tyr Ser Gly Arg Asp Leu Glu Asp Lys Glu
245 250 255
Gly Glu Ile Gln Ala Gly Ala Lys Leu Ser Leu Asn Arg Gln Phe Phe
260 265 270
Asp Glu Arg Trp Ser Lys His Arg Val Val Ser Cys Leu Asp Trp Ser
275 280 285
Ser Gln Tyr Pro Glu Leu Leu Val Ala Ser Tyr Asn Asn Asn Glu Asp
290 295 300
Ala Pro His Glu Pro Asp Gly Val Ala Leu Val Trp Asn Met Lys Tyr
305 310 315 320
Lys Lys Thr Thr Pro Glu Tyr Val Phe His Cys Gln Ser Ala Val Met
325 330 335
Ser Ala Thr Phe Ala Lys Phe His Pro Asn Leu Val Val Gly Gly Thr
340 345 350
Tyr Ser Gly Gln Ile Val Leu Trp Asp Asn Arg Ser Asn Lys Arg Thr
355 360 365
Pro Val Gln Arg Thr Pro Leu Ser Ala Ala Ala His Thr His Pro Val
370 375 380
Tyr Cys Val Asn Val Val Gly Thr Gln Asn Ala His Asn Leu Ile Ser
385 390 395 400
Ile Ser Thr Asp Gly Lys Ile Cys Ser Trp Ser Leu Asp Met Leu Ser
405 410 415
His Pro Gln Asp Ser Met Glu Leu Val His Lys Gln Ser Lys Ala Val
420 425 430
Ala Val Thr Ser Met Ser Phe Pro Val Gly Asp Val Asn Asn Phe Val
435 440 445
Val Gly Ser Glu Glu Gly Ser Val Tyr Thr Ala Cys Arg His Gly Ser
450 455 460
Lys Ala Gly Ile Ser Glu Met Phe Glu Gly His Gln Gly Pro Ile Thr
465 470 475 480
Gly Ile His Cys His Ala Ala Val Gly Ala Val Asp Phe Ser His Leu
485 490 495
Phe Val Thr Ser Ser Phe Asp Trp Thr Val Lys Leu Trp Thr Thr Lys
500 505 510
Asn Asn Lys Pro Leu Tyr Ser Phe Glu Asp Asn Ala Asp Tyr Val Tyr
515 520 525
Asp Val Met Trp Ser Pro Thr His Pro Ala Leu Phe Ala Cys Val Asp
530 535 540
Gly Met Gly Arg Leu Asp Leu Trp Asn Leu Asn Asn Asp Thr Glu Val
545 550 555 560
Pro Thr Ala Ser Ile Ser Val Glu Gly Asn Pro Ala Leu Asn Arg Val
565 570 575
Arg Trp Thr His Ser Gly Arg Glu Ile Ala Val Gly Asp Ser Glu Gly
580 585 590
Gln Ile Val Ile Tyr Asp Val Gly Glu Gln Ile Ala Val Pro Arg Asn
595 600 605
Asp Glu Trp Ala Arg Phe Gly Arg Thr Leu Ala Glu Ile Asn Ala Asn
610 615 620
Arg Ala Asp Ala Glu Glu Glu Ala Ala Thr Arg Ile Pro Ala
625 630 635
<210>24
<211>328
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉mitochondria Delta 3, and 5-Delta 2,4-dienol coacetylase isomerase precursor
<222>(1)..(328)
＜223〉on Dec 9th, 2002 registration number: Q13011
<400>24
Met Ala Ala Gly Ile Val Ala Ser Arg Arg Leu Arg Asp Leu Leu Thr
1 5 10 15
Arg Arg Leu Thr Gly Ser Asn Tyr Pro Gly Leu Ser Ile Ser Leu Arg
20 25 30
Leu Thr Gly Ser Ser Ala Gln Glu Glu Ala Ser Gly Val Ala Leu Gly
35 40 45
Glu Ala Pro Asp His Ser Tyr Glu Ser Leu Arg Val Thr Ser Ala Gln
50 55 60
Lys His Val Leu His Val Gln Leu Asn Arg Pro Asn Lys Arg Asn Ala
65 70 75 80
Met Asn Lys Val Phe Trp Arg Glu Met Val Glu Cys Phe Asn Lys Ile
85 90 95
Ser Arg Asp Ala Asp Cys Arg Ala Val Val Ile Ser Gly Ala Gly Lys
100 105 110
Met Phe Thr Ala Gly Ile Asp Leu Met Asp Met Ala Ser Asp Ile Leu
115 120 125
Gln Pro Lys Gly Asp Asp Val Ala Arg Ile Ser Trp Tyr Leu Arg Asp
130 135 140
Ile Ile Thr Arg Tyr Gln Glu Thr Phe Asn Val Ile Glu Arg Cys Pro
145 150 155 160
Lys Pro Val Ile Ala Ala Val His Gly Gly Cys Ile Gly Gly Gly Val
165 170 175
Asp Leu Val Thr Ala Cys Asp Ile Arg Tyr Cys Ala Gln Asp Ala Phe
180 185 190
Phe Gln Val Lys Glu Val Asp Val Gly Leu Ala Ala Asp Val Gly Thr
195 200 205
Leu Glu Arg Leu Pro Lys Val Ile Gly Asn Gln Ser Leu Val Asn Glu
210 215 220
Leu Ala Phe Thr Ala His Lys Met Met Ala Asp Glu Ala Leu Asp Ser
225 230 235 240
Gly Leu Val Ser Arg Val Phe Pro Asp Lys Glu Val Met Leu Asp Ala
245 250 255
Ala Leu Pro Leu Ala Pro Glu Ile Ser Ser Lys Thr Thr Val Leu Val
260 265 270
Gln Ser Thr Lys Val Asn Leu Leu Tyr Ser Arg Asp His Ser Val Ala
275 280 285
Glu Ser Leu Asn Tyr Val Ala Ser Trp Asn Met Ser Met Leu Gln Thr
290 295 300
Gln Asp Leu Val Lys Ser Val Gln Pro Thr Thr Glu Asn Lys Glu Leu
305 310 315 320
Lys Thr Val Thr Phe Ser Lys Leu
325
<210>25
<211>1657
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉class Ras gtpase activating protein IQGAP1
<222>(1)..(1657)
＜223〉on Dec 9th, 2002 registration number: P46940
<400>25
Met Ser Ala Ala Asp Glu Val Asp Gly Leu Gly Val Ala Arg Pro His
1 5 10 15
Tyr Gly Ser Val Leu Asp Asn Glu Arg Leu Thr Ala Glu Glu Met Asp
20 25 30
Glu Arg Arg Arg Gln Asn Val Ala Tyr Glu Tyr Leu Cys His Leu Glu
35 40 45
Glu Ala Lys Arg Trp Met Glu Ala Cys Leu Gly Glu Asp Leu Pro Pro
50 55 60
Thr Thr Glu Leu Glu Glu Gly Leu Arg Asn Gly Val Tyr Leu Ala Lys
65 70 75 80
Leu Gly Asn Phe Phe Ser Pro Lys Val Val Ser Leu Lys Lys Ile Tyr
85 90 95
Asp Arg Glu Gln Thr Arg Tyr Lys Ala Thr Gly Leu His Phe Arg His
100 105 110
Thr Asp Asn Val Ile Gln Trp Leu Asn Ala Met Asp Glu Ile Gly Leu
115 120 125
Pro Lys Ile Phe Tyr Pro Glu Thr Thr Asp Ile Tyr Asp Arg Lys Asn
130 135 140
Met Pro Arg Cys Ile Tyr Cys Ile His Ala Leu Ser Leu Tyr Leu Phe
145 150 155 160
Lys Leu Gly Leu Ala Pro Gln Ile Gln Asp Leu Tyr Gly Lys Val Asp
165 170 175
Phe Thr Glu Glu Glu Ile Asn Asn Met Lys Thr Glu Leu Glu Lys Tyr
180 185 190
Gly Ile Gln Met Pro Ala Phe Ser Lys Ile Gly Gly Ile Leu Ala Asn
195 200 205
Glu Leu Ser Val Asp Glu Ala Ala Leu His Ala Ala Val Ile Ala Ile
210 215 220
Asn Glu Ala Ile Asp Arg Arg Ile Pro Ala Asp Thr Phe Ala Ala Leu
225 230 235 240
Lys Asn Pro Asn Ala Met Leu Val Asn Leu Glu Glu Pro Leu Ala Ser
245 250 255
Thr Tyr Gln Asp Ile Leu Tyr Gln Ala Lys Gln Asp Lys Met Thr Asn
260 265 270
Ala Lys Asn Arg Thr Glu Asn Ser Glu Arg Glu Arg Asp Val Tyr Glu
275 280 285
Glu Leu Leu Thr Gln Ala Glu Ile Gln Gly Asn Ile Asn Lys Val Asn
290 295 300
Thr Phe Ser Ala Leu Ala Asn Ile Asp Leu Ala Leu Glu Gln Gly Asp
305 310 315 320
Ala Leu Ala Leu Phe Arg Ala Leu Gln Ser Pro Ala Leu Gly Leu Arg
325 330 335
Gly Leu Gln Gln Gln Asn Ser Asp Trp Tyr Leu Lys Gln Leu Leu Ser
340 345 350
Asp Lys Gln Gln Lys Arg Gln Ser Gly Gln Thr Asp Pro Leu Gln Lys
355 360 365
Glu Glu Leu Gln Ser Gly Val Asp Ala Ala Asn Ser Ala Ala Gln Gln
370 375 380
Tyr Gln Arg Arg Leu Ala Ala Val Ala Leu Ile Asn Ala Ala Ile Gln
385 390 395 400
Lys Gly Val Ala Glu Lys Thr Val Leu Glu Leu Met Asn Pro Glu Ala
405 410 415
Gln Leu Pro Gln Val Tyr Pro Phe Ala Ala Asp Leu Tyr Gln Lys Glu
420 425 430
Leu Ala Thr Leu Gln Arg Gln Ser Pro Glu His Asn Leu Thr His Pro
435 440 445
Glu Leu Ser Val Ala Val Glu Met Leu Ser Ser Val Ala Leu Ile Asn
450 455 460
Arg Ala Leu Glu Ser Gly Asp Val Asn Thr Val Trp Lys Gln Leu Ser
465 470 475 480
Ser Ser Val Thr Gly Leu Thr Asn Ile Glu Glu Glu Asn Cys Gln Arg
485 490 495
Tyr Leu Asp Glu Leu Met Lys Leu Lys Ala Gln Ala His Ala Glu Asn
500 505 510
Asn Glu Phe Ile Thr Trp Asn Asp Ile Gln Ala Cys Val Asp His Val
515 520 525
Asn Leu Val Val Gln Glu Glu His Glu Arg Ile Leu Ala Ile Gly Leu
530 535 540
Ile Asn Glu Ala Leu Asp Glu Gly Asp Ala Gln Lys Thr Leu Gln Ala
545 550 555 560
Leu Gln Ile Pro Ala Ala Lys Leu Glu Gly Val Leu Ala Glu Val Ala
565 570 575
Gln His Tyr Gln Asp Thr Leu Ile Arg Ala Lys Arg Glu Lys Ala Gln
580 585 590
Glu Ile Gln Asp Glu Ser Ala Val Leu Trp Leu Asp Glu Ile Gln Gly
595 600 605
Gly Ile Trp Gln Ser Asn Lys Asp Thr Gln Glu Ala Gln Lys Phe Ala
610 615 620
Leu Gly Ile Phe Ala Ile Asn Glu Ala Val Glu Ser Gly Asp Val Gly
625 630 635 640
Lys Thr Leu Ser Ala Leu Arg Ser Pro Asp Val Gly Leu Tyr Gly Val
645 650 655
Ile Pro Glu Cys Gly Glu Thr Tyr His Ser Asp Leu Ala Glu Ala Lys
660 665 670
Lys Lys Lys Leu Ala Val Gly Asp Asn Asn Ser Lys Trp Val Lys His
675 680 685
Trp Val Lys Gly Gly Tyr Tyr Tyr Tyr His Asn Leu Glu Thr Gln Glu
690 695 700
Gly Gly Trp Asp Glu Pro Pro Asn Phe Val Gln Asn Ser Met Gln Leu
705 710 715 720
Ser Arg Glu Glu Ile Gln Ser Ser Ile Ser Gly Val Thr Ala Ala Tyr
725 730 735
Asn Arg Glu Gln Leu Trp Leu Ala Asn Glu Gly Leu Ile Thr Arg Leu
740 745 750
Gln Ala Arg Cys Arg Gly Tyr Leu Val Arg Gln Glu Phe Arg Ser Arg
755 760 765
Met Asn Phe Leu Lys Lys Gln Ile Pro Ala Ile Thr Cys Ile Gln Ser
770 775 780
Gln Trp Arg Gly Tyr Lys Gln Lys Lys Ala Tyr Gln Asp Arg Leu Ala
785 790 795 800
Tyr Leu Arg Ser His Lys Asp Glu Val Val Lys Ile Gln Ser Leu Ala
805 810 815
Arg Met His Gln Ala Arg Lys Arg Tyr Arg Asp Arg Leu Gln Tyr Phe
820 825 830
Arg Asp His Ile Asn Asp Ile Ile Lys Ile Gln Ala Phe Ile Arg Ala
835 840 845
Asn Lys Ala Arg Asp Asp Tyr Lys Thr Leu Ile Asn Ala Glu Asp Pro
850 855 860
Pro Met Val Val Val Arg Lys Phe Val His Leu Leu Asp Gln Ser Asp
865 870 875 880
Gln Asp Phe Gln Glu Glu Leu Asp Leu Met Lys Met Arg Glu Glu Val
885 890 895
Ile Thr Leu Ile Arg Ser Asn Gln Gln Leu Glu Asn Asp Leu Asn Leu
900 905 910
Met Asp Ile Lys Ile Gly Leu Leu Val Lys Asn Lys Ile Thr Leu Gln
915 920 925
Asp Val Val Ser His Ser Lys Lys Leu Thr Lys Lys Asn Lys Glu Gln
930 935 940
Leu Ser Asp Met Met Met Ile Asn Lys Gln Lys Gly Gly Leu Lys Ala
945 950 955 960
Leu Ser Lys Glu Lys Arg Glu Lys Leu Glu Ala Tyr Gln His Leu Phe
965 970 975
Tyr Leu Leu Gln Thr Asn Pro Thr Tyr Leu Ala Lys Leu Ile Phe Gln
980 985 990
Met Pro Gln Asn Lys Ser Thr Lys Phe Met Asp Ser Val Ile Phe Thr
995 1000 1005
Leu Tyr Asn Tyr Ala Ser Asn Gln Arg Glu Glu Tyr Leu Leu Leu
1010 1015 1020
Arg Leu Phe Lys Thr Ala Leu Gln Glu Glu Ile Lys Ser Lys Val
1025 1030 1035
Asp Gln Ile Gln Glu Ile Val Thr Gly Asn Pro Thr Val Ile Lys
1040 1045 1050
Met Val Val Ser Phe Asn Arg Gly Ala Arg Gly Gln Asn Ala Leu
1055 1060 1065
Arg Gln Ile Leu Ala Pro Val Val Lys Glu Ile Met Asp Asp Lys
1070 1075 1080
Ser Leu Asn Ile Lys Thr Asp Pro Val Asp Ile Tyr Lys Ser Trp
1085 1090 1095
Val Asn Gln Met Glu Ser Gln Thr Gly Glu Ala Ser Lys Leu Pro
1100 1105 1110
Tyr Asp Val Thr Pro Glu Gln Ala Leu Ala His Glu Glu Val Lys
1115 1120 1125
Thr Arg Leu Asp Ser Ser Ile Arg Asn Met Arg Ala Val Thr Asp
1130 1135 1140
Lys Phe Leu Ser Ala Ile Val Ser Ser Val Asp Lys Ile Pro Tyr
1145 1150 1155
Gly Met Arg Phe Ile Ala Lys Val Leu Lys Asp Ser Leu His Glu
1160 1165 1170
Lys Phe Pro Asp Ala Gly Glu Asp Glu Leu Leu Lys Ile Ile Gly
1175 1180 1185
Asn Leu Leu Tyr Tyr Arg Tyr Met Asn Pro Ala Ile Val Ala Pro
1190 1195 1200
Asp Ala Phe Asp Ile Ile Asp Leu Ser Ala Gly Gly Gln Leu Thr
1205 1210 1215
Thr Asp Gln Arg Arg Asn Leu Gly Ser Ile Ala Lys Met Leu Gln
1220 1225 1230
His Ala Ala Ser Asn Lys Met Phe Leu Gly Asp Asn Ala His Leu
1235 1240 1245
Ser Ile Ile Asn Glu Tyr Leu Ser Gln Ser Tyr Gln Lys Phe Arg
1250 1255 1260
Arg Phe Phe Gln Thr Ala Cys Asp Val Pro Glu Leu Gln Asp Lys
1265 1270 1275
Phe Asn Val Asp Glu Tyr Ser Asp Leu Val Thr Leu Thr Lys Pro
1280 1285 1290
Val Ile Tyr Ile Ser Ile Gly Glu Ile Ile Asn Thr His Thr Leu
1295 1300 1305
Leu Leu Asp His Gln Asp Ala Ile Ala Pro Glu His Asn Asp Pro
1310 1315 1320
Ile His Glu Leu Leu Asp Asp Leu Gly Glu Val Pro Thr Ile Glu
1325 1330 1335
Ser Leu Ile Gly Glu Ser Ser Gly Asn Leu Asn Asp Pro Asn Lys
1340 1345 1350
Glu Ala Leu Ala Lys Thr Glu Val Ser Leu Thr Leu Thr Asn Lys
1355 1360 1365
Phe Asp Val Pro Gly Asp Glu Asn Ala Glu Met Asp Ala Arg Thr
1370 1375 1380
Ile Leu Leu Asn Thr Lys Arg Leu Ile Val Asp Val Ile Arg Phe
1385 1390 1395
Gln Pro Gly Glu Thr Leu Thr Glu Ile Leu Glu Thr Pro Ala Thr
1400 1405 1410
Ser Glu Gln Glu Ala Glu His Gln Arg Ala Met Gln Arg Arg Ala
1415 1420 1425
Ile Arg Asp Ala Lys Thr Pro Asp Lys Met Lys Lys Ser Lys Ser
1430 1435 1440
Val Lys Glu Asp Ser Asn Leu Thr Leu Gln Glu Lys Lys Glu Lys
1445 1450 1455
Ile Gln Thr Gly Leu Lys Lys Leu Thr Glu Leu Gly Thr Val Asp
1460 1465 1470
Pro Lys Asn Lys Tyr Gln Glu Leu Ile Asn Asp Ile Ala Arg Asp
1475 1480 1485
Ile Arg Asn Gln Arg Arg Tyr Arg Gln Arg Arg Lys Ala Glu Leu
1490 1495 1500
Val Lys Leu Gln Gln Thr Tyr Ala Ala Leu Asn Ser Lys Ala Thr
1505 1510 1515
Phe Tyr Gly Glu Gln Val Asp Tyr Tyr Lys Ser Tyr Ile Lys Thr
1520 1525 1530
Cys Leu Asp Asn Leu Ala Ser Lys Gly Lys Val Ser Lys Lys Pro
1535 1540 1545
Arg Glu Met Lys Gly Lys Lys Ser Lys Lys Ile Ser Leu Lys Tyr
1550 1555 1560
Thr Ala Ala Arg Leu His Glu Lys Gly Val Leu Leu Glu Ile Glu
1565 1570 1575
Asp Leu Gln Val Asn Gln Phe Lys Asn Val Ile Phe Glu Ile Ser
1580 1585 1590
Pro Thr Glu Glu Val Gly Asp Phe Glu Val Lys Ala Lys Phe Met
1595 1600 1605
Gly Val Gln Met Glu Thr Phe Met Leu His Tyr Gln Asp Leu Leu
1610 1615 1620
Gln Leu Gln Tyr Glu Gly Val Ala Val Met Lys Leu Phe Asp Arg
1625 1630 1635
Ala Lys Val Asn Val Asn Leu Leu Ile Phe Leu Leu Asn Lys Lys
1640 1645 1650
Phe Tyr Gly Lys
1655
<210>26
<211>627
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉L-fimbrin (lymphocyte cytoplasmic protein 1)
<222>(1)..(627)
＜223〉on Dec 9th, 2002 registration number: P13796
<400>26
Met Ala Arg Gly Ser Val Ser Asp Glu Glu Met Met Glu Leu Arg Glu
1 5 10 15
Ala Phe Ala Lys Val Asp Thr Asp Gly Asn Gly Tyr Ile Ser Phe Asn
20 25 30
Glu Leu Asn Asp Leu Phe Lys Ala Ala Cys Leu Pro Leu Pro Gly Tyr
35 40 45
Arg Val Arg Glu Ile Thr Glu Asn Leu Met Ala Thr Gly Asp Leu Asp
50 55 60
Gln Asp Gly Arg Ile Ser Phe Asp Glu Phe Ile Lys Ile Phe His Gly
65 70 75 80
Leu Lys Ser Thr Asp Val Ala Lys Thr Phe Arg Lys Ala Ile Asn Lys
85 90 95
Lys Glu Gly Ile Cys Ala Ile Gly Gly Thr Ser Glu Gln Ser Ser Val
100 105 110
Gly Thr Gln His Ser Tyr Ser Glu Glu Glu Lys Tyr Ala Phe Val Asn
115 120 125
Trp Ile Asn Lys Ala Leu Glu Asn Asp Pro Asp Cys Arg His Val Ile
130 135 140
Pro Met Asn Pro Asn Thr Asn Asp Leu Phe Asn Ala Val Gly Asp Gly
145 150 155 160
Ile Val Leu Cys Lys Met Ile Asn Leu Ser Val Pro Asp Thr Ile Asp
165 170 175
Glu Arg Thr Ile Asn Lys Lys Lys Leu Thr Pro Phe Thr Ile Gln Glu
180 185 190
Asn Leu Asn Leu Ala Leu Asn Ser Ala Ser Ala Ile Gly Cys His Val
195 200 205
Val Asn Ile Gly Ala Glu Asp Leu Lys Glu Gly Lys Pro Tyr Leu Val
210 215 220
Leu Gly Leu Leu Trp Gln Val Ile Lys Ile Gly Leu Phe Ala Asp Ile
225 230 235 240
Glu Leu Ser Arg Asn Glu Ala Leu Ile Ala Leu Leu Arg Glu Gly Glu
245 250 255
Ser Leu Glu Asp Leu Met Lys Leu Ser Pro Glu Glu Leu Leu Leu Arg
260 265 270
Trp Ala Asn Tyr His Leu Glu Asn Ala Gly Cys Asn Lys Ile Gly Asn
275 280 285
Phe Ser Thr Asp Ile Lys Asp Ser Lys Ala Tyr Tyr His Leu Leu Glu
290 295 300
Gln Val Ala Pro Lys Gly Asp Glu Glu Gly Val Pro Ala Val Val Ile
305 310 315 320
Asp Met Ser Gly Leu Arg Glu Lys Asp Asp Ile Gln Arg Ala Glu Cys
325 330 335
Met Leu Gln Gln Ala Glu Arg Leu Gly Cys Arg Gln Phe Val Thr Ala
340 345 350
Thr Asp Val Val Arg Gly Asn Pro Lys Leu Asn Leu Ala Phe Ile Ala
355 360 365
Asn Leu Phe Asn Arg Tyr Pro Ala Leu His Lys Pro Glu Asn Gln Asp
370 375 380
Ile Asp Trp Gly Ala Leu Glu Gly Glu Thr Arg Glu Glu Arg Thr Phe
385 390 395 400
Arg Asn Trp Met Asn Ser Leu Gly Val Asn Pro Arg Val Asn His Leu
405 410 415
Tyr Ser Asp Leu Ser Asp Ala Leu Val Ile Phe Gln Leu Tyr Glu Lys
420 425 430
Ile Lys Val Pro Val Asp Trp Asn Arg Val Asn Lys Pro Pro Tyr Pro
435 440 445
Lys Leu Gly Gly Asn Met Lys Lys Leu Glu Asn Cys Asn Tyr Ala Val
450 455 460
Glu Leu Gly Lys Asn Gln Ala Lys Phe Ser Leu Val Gly Ile Gly Gly
465 470 475 480
Gln Asp Leu Asn Glu Gly Asn Arg Thr Leu Thr Leu Ala Leu Ile Trp
485 490 495
Gln Leu Met Arg Arg Tyr Thr Leu Asn Ile Leu Glu Glu Ile Gly Gly
500 505 510
Gly Gln Lys Val Asn Asp Asp Ile Ile Val Asn Trp Val Asn Glu Thr
515 520 525
Leu Arg Glu Ala Glu Lys Ser Ser Ser Ile Ser Ser Phe Lys Asp Pro
530 535 540
Lys Ile Ser Thr Ser Leu Pro Val Leu Asp Leu Ile Asp Ala Ile Gln
545 550 555 560
Pro Gly Ser Ile Asn Tyr Asp Leu Leu Lys Thr Glu Asn Leu Asn Asp
565 570 575
Asp Glu Lys Leu Asn Asn Ala Lys Tyr Ala Ile Ser Met Ala Arg Lys
580 585 590
Ile Gly Ala Arg Val Tyr Ala Leu Pro Glu Asp Leu Val Glu Val Asn
595 600 605
Pro Lys Met Val Met Thr Val Phe Ala Cys Leu Met Gly Lys Gly Met
610 615 620
Lys Arg Val
625
<210>27
<211>216
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉GTP-syncaryon albumen RAN
<222>(1)..(216)
＜223〉on Dec 9th, 2002 registration number: P17080
<400>27
Met Ala Ala Gln Gly Glu Pro Gln Val Gln Phe Lys Leu Val Leu Val
1 5 10 15
Gly Asp Gly Gly Thr Gly Lys Thr Thr Phe Val Lys Arg His Leu Thr
20 25 30
Gly Glu Phe Glu Lys Lys Tyr Val Ala Thr Leu Gly Val Glu Val His
35 40 45
Pro Leu Val Phe His Thr Asn Arg Gly Pro Ile Lys Phe Asn Val Trp
50 55 60
Asp Thr Ala Gly Gln Glu Lys Phe Gly Gly Leu Arg Asp Gly Tyr Tyr
65 70 75 80
Ile Gln Ala Gln Cys Ala Ile Ile Met Phe Asp Val Thr Ser Arg Val
85 90 95
Thr Tyr Lys Asn Val Pro Asn Trp His Arg Asp Leu Val Arg Val Cys
100 105 110
Glu Asn Ile Pro Ile Val Leu Cys Gly Asn Lys Val Asp Ile Lys Asp
115 120 125
Arg Lys Val Lys Ala Lys Ser Ile Val Phe His Arg Lys Lys Asn Leu
130 135 140
Gln Tyr Tyr Asp Ile Ser Ala Lys Ser Asn Tyr Asn Phe Glu Lys Pro
145 150 155 160
Phe Leu Trp Leu Ala Arg Lys Leu Ile Gly Asp Pro Asn Leu Glu Phe
165 170 175
Val Ala Met Pro Ala Leu Ala Pro Pro Glu Val Val Met Asp Pro Ala
180 185 190
Leu Ala Ala Gln Tyr Glu His Asp Leu Glu Val Ala Gln Thr Thr Ala
195 200 205
Leu Pro Asp Glu Asp Asp Asp Leu
210 215
<210>28
<211>463
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉non-homogeneous ribonucleoprotein (RNP) K in the nuclear
<222>(1)..(463)
＜223〉on Dec 9th, 2002 registration number: Q07244
<400>28
Met Glu Thr Glu Gln Pro Glu Glu Thr Phe Pro Asn Thr Glu Thr Asn
1 5 10 15
Gly Glu Phe Gly Lys Arg Pro Ala Glu Asp Met Glu Glu Glu Gln Ala
20 25 30
Phe Lys Arg Ser Arg Asn Thr Asp Glu Met Val Glu Leu Arg Ile Leu
35 40 45
Leu Gln Ser Lys Asn Ala Gly Ala Val Ile Gly Lys Gly Gly Lys Asn
50 55 60
Ile Lys Ala Leu Arg Thr Asp Tyr Asn Ala Ser Val Ser Val Pro Asp
65 70 75 80
Ser Ser Gly Pro Glu Arg Ile Leu Ser Ile Ser Ala Asp Ile Glu Thr
85 90 95
Ile Gly Glu Ile Leu Lys Lys Ile Ile Pro Thr Leu Glu Glu Gly Leu
100 105 110
Gln Leu Pro Ser Pro Thr Ala Thr Ser Gln Leu Pro Leu Glu Ser Asp
115 120 125
Ala Val Glu Cys Leu Asn Tyr Gln His Tyr Lys Gly Ser Asp Phe Asp
130 135 140
Cys Glu Leu Arg Leu Leu Ile His Gln Ser Leu Ala Gly Gly Ile Ile
145 150 155 160
Gly Val Lys Gly Ala Lys Ile Lys Glu Leu Arg Glu Asn Thr Gln Thr
165 170 175
Thr Ile Lys Leu Phe Gln Glu Cys Cys Pro His Ser Thr Asp Arg Val
180 185 190
Val Leu Ile Gly Gly Lys Pro Asp Arg Val Val Glu Cys Ile Lys Ile
195 200 205
Ile Leu Asp Leu Ile Ser Glu Ser Pro Ile Lys Gly Arg Ala Gln Pro
210 215 220
Tyr Asp Pro Asn Phe Tyr Asp Glu Thr Tyr Asp Tyr Gly Gly Phe Thr
225 230 235 240
Met Met Phe Asp Asp Arg Arg Gly Arg Pro Val Gly Phe Pro Met Arg
245 250 255
Gly Arg Gly Gly Phe Asp Arg Met Pro Pro Gly Arg Gly Gly Arg Pro
260 265 270
Met Pro Pro Ser Arg Arg Asp Tyr Asp Asp Met Ser Pro Arg Arg Gly
275 280 285
Pro Pro Pro Pro Pro Pro Gly Arg Gly Gly Arg Gly Gly Ser Arg Ala
290 295 300
Arg Asn Leu Pro Leu Pro Pro Pro Pro Pro Pro Arg Gly Gly Asp Leu
305 310 315 320
Met Ala Tyr Asp Arg Arg Gly Arg Pro Gly Asp Arg Tyr Asp Gly Met
325 330 335
Val Gly Phe Ser Ala Asp Glu Thr Trp Asp Ser Ala Ile Asp Thr Trp
340 345 350
Ser Pro Ser Glu Trp Gln Met Ala Tyr Glu Pro Gln Gly Gly Ser Gly
355 360 365
Tyr Asp Tyr Ser Tyr Ala Gly Gly Arg Gly Ser Tyr Gly Asp Leu Gly
370 375 380
Gly Pro Ile Ile Thr Thr Gln Val Thr Ile Pro Lys Asp Leu Ala Gly
385 390 395 400
Ser Ile Ile Gly Lys Gly Gly Gln Arg Ile Lys Gln Ile Arg His Glu
405 410 415
Ser Gly Ala Ser Ile Lys Ile Asp Glu Pro Leu Glu Gly Ser Glu Asp
420 425 430
Arg Ile Ile Thr Ile Thr Gly Thr Gln Asp Gln Ile Gln Asn Ala Gln
435 440 445
Tyr Leu Leu Gln Asn Ser Val Lys Gln Tyr Ser Gly Lys Phe Phe
450 455 460
<210>29
<211>172
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉oncoprotein of translational control (TCTP)
<222>(1)..(172)
＜223〉on Dec 9th, 2002 registration number: P13693
<400>29
Met Ile Ile Tyr Arg Asp Leu Ile Ser His Asp Glu Met Phe Ser Asp
1 5 10 15
Ile Tyr Lys Ile Arg Glu Ile Ala Asp Gly Leu Cys Leu Glu Val Glu
20 25 30
Gly Lys Met Val Ser Arg Thr Glu Gly Asn Ile Asp Asp Ser Leu Ile
35 40 45
Gly Gly Asn Ala Ser Ala Glu Gly Pro Glu Gly Glu Gly Thr Glu Ser
50 55 60
Thr Val Ile Thr Gly Val Asp Ile Val Met Asn His His Leu Gln Glu
65 70 75 80
Thr Ser Phe Thr Lys Glu Ala Tyr Lys Lys Tyr Ile Lys Asp Tyr Met
85 90 95
Lys Ser Ile Lys Gly Lys Leu Glu Glu Gln Arg Pro Glu Arg Val Lys
100 105 110
Pro Phe Met Thr Gly Ala Ala Glu Gln Ile Lys His Ile Leu Ala Asn
115 120 125
Phe Lys Asn Tyr Gln Phe Phe Ile Gly Glu Asn Met Asn Pro Asp Gly
130 135 140
Met Val Ala Leu Leu Asp Tyr Arg Glu Asp Gly Val Thr Pro Tyr Met
145 150 155 160
Ile Phe Phe Lys Asp Gly Leu Glu Met Glu Lys Cys
165 170
<210>30
<211>284
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉tropomyosin 1-alpha chain
<222>(1)..(284)
＜223〉on Dec 6th, 2002 registration number: P09493
<400>30
Met Asp Ala Ile Lys Lys Lys Met Gln Met Leu Lys Leu Asp Lys Glu
1 5 10 15
Asn Ala Leu Asp Arg Ala Glu Gln Ala Glu Ala Asp Lys Lys Ala Ala
20 25 30
Glu Asp Arg Ser Lys Gln Leu Glu Asp Glu Leu Val Ser Leu Gln Lys
35 40 45
Lys Leu Lys Gly Thr Glu Asp Glu Leu Asp Lys Tyr Ser Glu Ala Leu
50 55 60
Lys Asp Ala Gln Glu Lys Leu Glu Leu Ala Glu Lys Lys Ala Thr Asp
65 70 75 80
Ala Glu Ala Asp Val Ala Ser Leu Asn Arg Arg Ile Gln Leu Val Glu
85 90 95
Glu Glu Leu Asp Arg Ala Gln Glu Arg Leu Ala Thr Ala Leu Gln Lys
100 105 110
Leu Glu Glu Ala Glu Lys Ala Ala Asp Glu Ser Glu Arg Gly Met Lys
115 120 125
Val Ile Glu Ser Arg Ala Gln Lys Asp Glu Glu Lys Met Glu Ile Gln
130 135 140
Glu Ile Gln Leu Lys Glu Ala Lys His Ile Ala Glu Asp Ala Asp Arg
145 150 155 160
Lys Tyr Glu Glu Val Ala Arg Lys Leu Val Ile Ile Glu Ser Asp Leu
165 170 175
Glu Arg Ala Glu Glu Arg Ala Glu Leu Ser Glu Gly Lys Cys Ala Glu
180 185 190
Leu Glu Glu Glu Leu Lys Thr Val Thr Asn Asn Leu Lys Ser Leu Glu
195 200 205
Ala Gln Ala Glu Lys Tyr Ser Gln Lys Glu Asp Arg Tyr Glu Glu Glu
210 215 220
Ile Lys Val Leu Ser Asp Lys Leu Lys Glu Ala Glu Thr Arg Ala Glu
225 230 235 240
Phe Ala Glu Arg Ser Val Thr Lys Leu Glu Lys Ser Ile Asp Asp Leu
245 250 255
Glu Asp Glu Leu Tyr Ala Gln Lys Leu Lys Tyr Lys Ala Ile Ser Glu
260 265 270
Glu Leu Asp His Ala Leu Asn Asp Met Thr Ser Ile
275 280
<210>31
<211>482
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉thymidine phosphorylase precursor
<222>(1)..(482)
＜223〉on Dec 9th, 2002 registration number: P19971
<400>31
Met Ala Ala Leu Met Thr Pro Gly Thr Gly Ala Pro Pro Ala Pro Gly
1 5 10 15
Asp Phe Ser Gly Glu Gly Ser Gln Gly Leu Pro Asp Pro Ser Pro Glu
20 25 30
Pro Lys Gln Leu Pro Glu Leu Ile Arg Met Lys Arg Asp Gly Gly Arg
35 40 45
Leu Ser Glu Ala Asp Ile Arg Gly Phe Val Ala Ala Val Val Asn Gly
50 55 60
Ser Ala Gln Gly Ala Gln Ile Gly Ala Met Leu Met Ala Ile Arg Leu
65 70 75 80
Arg Gly Met Asp Leu Glu Glu Thr Ser Val Leu Thr Gln Ala Leu Ala
85 90 95
Gln Ser Gly Gln Gln Leu Glu Trp Pro Glu Ala Trp Arg Gln Gln Leu
100 105 110
Val Asp Lys His Ser Thr Gly Gly Val Gly Asp Lys Val Ser Leu Val
115 120 125
Leu Ala Pro Ala Leu Ala Ala Cys Gly Cys Lys Val Pro Met Ile Ser
130 135 140
Gly Arg Gly Leu Gly His Thr Gly Gly Thr Leu Asp Lys Leu Glu Ser
145 150 155 160
Ile Pro Gly Phe Asn Val Ile Gln Ser Pro Glu Gln Met Gln Val Leu
165 170 175
Leu Asp Gln Ala Gly Cys Cys Ile Val Gly Gln Ser Glu Gln Leu Val
180 185 190
Pro Ala Asp Gly Ile Leu Tyr Ala Ala Arg Asp Val Thr Ala Thr Val
195 200 205
Asp Ser Leu Pro Leu Ile Thr Ala Ser Ile Leu Ser Lys Lys Leu Val
210 215 220
Glu Gly Leu Ser Ala Leu Val Val Asp Val Lys Phe Gly Gly Ala Ala
225 230 235 240
Val Phe Pro Asn Gln Glu Gln Ala Arg Glu Leu Ala Lys Thr Leu Val
245 250 255
Gly Val Gly Ala Ser Leu Gly Leu Arg Val Ala Ala Ala Leu Thr Ala
260 265 270
Met Asp Lys Pro Leu Gly Arg Cys Val Gly His Ala Leu Glu Val Glu
275 280 285
Glu Ala Leu Leu Cys Met Asp Gly Ala Gly Pro Pro Asp Leu Arg Asp
290 295 300
Leu Val Thr Thr Leu Gly Gly Ala Leu Leu Trp Leu Ser Gly His Ala
305 310 315 320
Gly Thr Gln Ala Gln Gly Ala Ala Arg Val Ala Ala Ala Leu Asp Asp
325 330 335
Gly Ser Ala Leu Gly Arg Phe Glu Arg Met Leu Ala Ala Gln Gly Val
340 345 350
Asp Pro Gly Leu Ala Arg Ala Leu Cys Ser Gly Ser Pro Ala Glu Arg
355 360 365
Arg Gln Leu Leu Pro Arg Ala Arg Glu Gln Glu Glu Leu Leu Ala Pro
370 375 380
Ala Asp Gly Thr Val Glu Leu Val Arg Ala Leu Pro Leu Ala Leu Val
385 390 395 400
Leu His Glu Leu Gly Ala Gly Arg Ser Arg Ala Gly Glu Pro Leu Arg
405 410 415
Leu Gly Val Gly Ala Glu Leu Leu Val Asp Val Gly Gln Arg Leu Arg
420 425 430
Arg Gly Thr Pro Trp Leu Arg Val His Arg Asp Gly Pro Ala Leu Ser
435 440 445
Gly Pro Gln Ser Arg Ala Leu Gln Glu Ala Leu Val Leu Ser Asp Arg
450 455 460
Ala Pro Phe Ala Ala Pro Leu Pro Phe Ala Glu Leu Val Leu Pro Pro
465 470 475 480
Gln Gln
<210>32
<211>488
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉kytoplasm solute amination enzyme
<222>(1)..(488)
＜223〉on Dec 9th, 2002 registration number: P28838
<400>32
Met Thr Lys Gly Leu Val Leu Gly Ile Tyr Ser Lys Glu Lys Glu Asp
1 5 10 15
Asp Val Pro Gln Phe Thr Ser Ala Gly Glu Asn Phe Asp Lys Leu Leu
20 25 30
Ala Gly Lys Leu Arg Glu Thr Leu Asn Ile Ser Gly Pro Pro Leu Lys
35 40 45
Ala Gly Lys Thr Arg Thr Phe Tyr Gly Leu His Gln Asp Phe Pro Ser
50 55 60
Val Val Leu Val Gly Leu Gly Lys Lys Ala Ala Gly Ile Asp Glu Gln
65 70 75 80
Glu Asn Trp His Glu Gly Lys Glu Asn Ile Arg Ala Ala Val Ala Ala
85 90 95
Gly Cys Arg Gln Ile Gln Asp Leu Glu Leu Ser Ser Val Glu Val Asp
100 105 110
Pro Cys Gly Asp Ala Gln Ala Ala Ala Glu Gly Ala Val Leu Gly Leu
115 120 125
Tyr Glu Tyr Asp Asp Leu Lys Gln Lys Lys Lys Met Ala Val Ser Ala
130 135 140
Lys Leu Tyr Gly Ser Gly Asp Gln Glu Ala Trp Gln Lys Gly Val Leu
145 150 155 160
Phe Ala Ser Gly Gln Asn Leu Ala Arg Gln Leu Met Glu Thr Pro Ala
165 170 175
Asn Glu Met Thr Pro Thr Arg Phe Ala Glu Ile Ile Glu Lys Asn Leu
180 185 190
Lys Ser Ala Ser Ser Lys Thr Glu Val His Ile Arg Pro Lys Ser Trp
195 200 205
Ile Glu Glu Gln Ala Met Gly Ser Phe Leu Ser Val Ala Lys Gly Ser
210 215 220
Asp Glu Pro Pro Val Phe Leu Glu Ile His Tyr Lys Gly Ser Pro Asn
225 230 235 240
Ala Asn Glu Pro Pro Leu Val Phe Val Gly Lys Gly Ile Thr Phe Asp
245 250 255
Ser Gly Gly Ile Ser Ile Lys Ala Ser Ala Asn Met Asp Leu Met Arg
260 265 270
Ala Asp Met Gly Gly Ala Ala Thr Ile Cys Ser Ala Ile Val Ser Ala
275 280 285
Ala Lys Leu Asn Leu Pro Ile Asn Ile Ile Gly Leu Ala Pro Leu Cys
290 295 300
Glu Asn Met Pro Ser Gly Lys Ala Asn Lys Pro Gly Asp Val Val Arg
305 310 315 320
Ala Lys Asn Gly Lys Thr Ile Gln Val Asp Asn Thr Asp Ala Glu Gly
325 330 335
Arg Leu Ile Leu Ala Asp Ala Leu Cys Tyr Ala His Thr Phe Asn Pro
340 345 350
Lys Val Ile Leu Asn Ala Ala Thr Leu Thr Gly Ala Met Asp Val Ala
355 360 365
Leu Gly Ser Gly Ala Thr Gly Val Phe Thr Asn Ser Ser Trp Leu Trp
370 375 380
Asn Lys Leu Phe Glu Ala Ser Ile Glu Thr Gly Asp Arg Val Trp Arg
385 390 395 400
Met Pro Leu Phe Glu His Tyr Thr Arg Gln Val Val Asp Cys Gln Leu
405 410 415
Ala Asp Val Asn Asn Ile Gly Lys Tyr Arg Ser Ala Gly Ala Cys Thr
420 425 430
Ala Ala Ala Phe Leu Lys Glu Phe Val Thr His Pro Lys Trp Ala His
435 440 445
Leu Asp Ile Ala Gly Val Met Thr Asn Lys Asp Glu Val Pro Tyr Leu
450 455 460
Arg Lys Gly Met Thr Gly Arg Pro Thr Arg Thr Leu Ile Glu Phe Leu
465 470 475 480
Leu Arg Phe Ser Gln Asp Asn Ala
485
<210>33
<211>400
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉I type cytoskeleton 19 keratin
<222>(1)..(400)
＜223〉on Dec 9th, 2002 registration number: P08727
<400>33
Met Thr Ser Tyr Ser Tyr Arg Gln Ser Ser Ala Thr Ser Ser Phe Gly
1 5 10 15
Gly Leu Gly Gly Gly Ser Val Arg Phe Gly Pro Gly Val Ala Phe Arg
20 25 30
Ala Pro Ser Ile His Gly Gly Ser Gly Gly Arg Gly Val Ser Val Ser
35 40 45
Ser Ala Arg Phe Val Ser Ser Ser Ser Ser Gly Gly Tyr Gly Gly Gly
50 55 60
Tyr Gly Gly Val Leu Thr Ala Ser Asp Gly Leu Leu Ala Gly Asn Glu
65 70 75 80
Lys Leu Thr Met Gln Asn Leu Asn Asp Arg Leu Ala Ser Tyr Leu Asp
85 90 95
Lys Val Arg Ala Leu Glu Ala Ala Asn Gly Glu Leu Glu Val Lys Ile
100 105 110
Arg Asp Trp Tyr Gln Lys Gln Gly Pro Gly Pro Ser Arg Asp Tyr Ser
115 120 125
His Tyr Tyr Thr Thr Ile Gln Asp Leu Arg Asp Lys Ile Leu Gly Ala
130 135 140
Thr Ile Glu Asn Ser Arg Ile Val Leu Gln Ile Asp Asn Ala Arg Leu
145 150 155 160
Ala Ala Asp Asp Phe Arg Thr Lys Phe Glu Thr Glu Gln Ala Leu Arg
165 170 175
Met Ser Val Glu Ala Asp Ile Asn Gly Leu Arg Arg Val Leu Asp Glu
180 185 190
Leu Thr Leu Ala Arg Thr Asp Leu Glu Met Gln Ile Glu Gly Leu Lys
195 200 205
Glu Glu Leu Ala Tyr Leu Lys Lys Asn His Glu Glu Glu Ile Ser Thr
210 215 220
Leu Arg Gly Gln Val Gly Gly Gln Val Ser Val Glu Val Asp Ser Ala
225 230 235 240
Pro Gly Thr Asp Leu Ala Lys Ile Leu Ser Asp Met Arg Ser Gln Tyr
245 250 255
Glu Val Met Ala Glu Gln Asn Arg Lys Asp Ala Glu Ala Trp Phe Thr
260 265 270
Ser Arg Thr Glu Glu Leu Asn Arg Glu Val Ala Gly His Thr Glu Gln
275 280 285
Leu Gln Met Ser Arg Ser Glu Val Thr Asp Leu Arg Arg Thr Leu Gln
290 295 300
Gly Leu Glu Ile Glu Leu Gln Ser Gln Leu Ser Met Lys Ala Ala Leu
305 310 315 320
Glu Asp Thr Leu Ala Glu Thr Glu Ala Arg Phe Gly Ala Gln Leu Ala
325 330 335
His Ile Gln Ala Leu Ile Ser Gly Ile Glu Ala Gln Leu Ala Asp Val
340 345 350
Arg Ala Asp Ser Glu Arg Gln Asn Gln Glu Tyr Gln Arg Leu Met Asp
355 360 365
Ile Lys Ser Arg Leu Glu Gln Glu Ile Ala Thr Tyr Arg Ser Leu Leu
370 375 380
Glu Gly Gln Glu Asp His Tyr Asn Asn Leu Ser Ala Ser Lys Val Leu
385 390 395 400
<210>34
<211>325
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉alcohol dehydrogenase [NADP+]
<222>(1)..(325)
＜223〉on Dec 9th, 2002 registration number: P14550
<400>34
Met Ala Ala Ser Cys Val Leu Leu His Thr Gly Gln Lys Met Pro Leu
1 5 10 15
Ile Gly Leu Gly Thr Trp Lys Ser Glu Pro Gly Gln Val Lys Ala Ala
20 25 30
Val Lys Tyr Ala Leu Ser Val Gly Tyr Arg His Ile Asp Cys Ala Ala
35 40 45
Ile Tyr Gly Asn Glu Pro Glu Ile Gly Glu Ala Leu Lys Glu Asp Val
50 55 60
Gly Pro Gly Lys Ala Val Pro Arg Glu Glu Leu Phe Val Thr Ser Lys
65 70 75 80
Leu Trp Asn Thr Lys His His Pro Glu Asp Val Glu Pro Ala Leu Arg
85 90 95
Lys Thr Leu Ala Asp Leu Gln Leu Glu Tyr Leu Asp Leu Tyr Leu Met
100 105 110
His Trp Pro Tyr Ala Phe Glu Arg Gly Asp Asn Pro Phe Pro Lys Asn
115 120 125
Ala Asp Gly Thr Ile Cys Tyr Asp Ser Thr His Tyr Lys Glu Thr Trp
130 135 140
Lys Ala Leu Glu Ala Leu Val Ala Lys Gly Leu Val Gln Ala Leu Gly
145 150 155 160
Leu Ser Asn Phe Asn Ser Arg Gln Ile Asp Asp Ile Leu Ser Val Ala
165 170 175
Ser Val Arg Pro Ala Val Leu Gln Val Glu Cys His Pro Tyr Leu Ala
180 185 190
Gln Asn Glu Leu Ile Ala His Cys Gln Ala Arg Gly Leu Glu Val Thr
195 200 205
Ala Tyr Ser Pro Leu Gly Ser Ser Asp Arg Ala Trp Arg Asp Pro Asp
210 215 220
Glu Pro Val Leu Leu Glu Glu Pro Val Val Leu Ala Leu Ala Glu Lys
225 230 235 240
Tyr Gly Arg Ser Pro Ala Gln Ile Leu Leu Arg Trp Gln Val Gln Arg
245 250 255
Lys Val Ile Cys Ile Pro Lys Ser Ile Thr Pro Ser Arg Ile Leu Gln
260 265 270
Asn Ile Lys Val Phe Asp Phe Thr Phe Ser Pro Glu Glu Met Lys Gln
275 280 285
Leu Asn Ala Leu Asn Lys Asn Trp Arg Tyr Ile Val Pro Met Leu Thr
290 295 300
Val Asp Gly Lys Arg Val Pro Arg Asp Ala Gly His Pro Leu Tyr Pro
305 310 315 320
Phe Asn Asp Pro Tyr
325
<210>35
<211>270
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉elastoser IIIA precursor
<222>(1)..(270)
＜223〉on Dec 9th, 2002 registration number: P09093
<400>35
Met Met Leu Arg Leu Leu Ser Ser Leu Leu Leu Val Ala Val Ala Ser
1 5 10 15
Gly Tyr Gly Pro Pro Ser Ser His Ser Ser Ser Arg Val Val His Gly
20 25 30
Glu Asp Ala Val Pro Tyr Ser Trp Pro Trp Gln Val Ser Leu Gln Tyr
35 40 45
Glu Lys Ser Gly Ser Phe Tyr His Thr Cys Gly Gly Ser Leu Ile Ala
50 55 60
Pro Asp Trp Val Val Thr Ala Gly His Cys Ile Ser Arg Asp Leu Thr
65 70 75 80
Tyr Gln Val Val Leu Gly Glu Tyr Asn Leu Ala Val Lys Glu Gly Pro
85 90 95
Glu Gln Val Ile Pro Ile Asn Ser Glu Glu Leu Phe Val His Pro Leu
100 105 110
Trp Asn Arg Ser Cys Val Ala Cys Gly Asn Asp Ile Ala Leu Ile Lys
115 120 125
Leu Ser Arg Ser Ala Gln Leu Gly Asp Ala Val Gln Leu Ala Ser Leu
130 135 140
Pro Pro Ala Gly Asp Ile Leu Pro Asn Lys Thr Pro Cys Tyr Ile Thr
145 150 155 160
Gly Trp Gly Arg Leu Tyr Thr Asn Gly Pro Leu Pro Asp Lys Leu Gln
165 170 175
Gln Ala Arg Leu Pro Val Val Asp Tyr Lys His Cys Ser Arg Trp Asn
180 185 190
Trp Trp Gly Ser Thr Val Lys Lys Thr Met Val Cys Ala Gly Gly Tyr
195 200 205
Ile Arg Ser Gly Cys Asn Gly Asp Ser Gly Gly Pro Leu Asn Cys Pro
210 215 220
Thr Glu Asp Gly Gly Trp Gln Val His Gly Val Thr Ser Phe Val Ser
225 230 235 240
Gly Phe Gly Cys Asn Phe Ile Trp Lys Pro Thr Val Phe Thr Arg Val
245 250 255
Ser Ala Phe Ile Asp Trp Ile Glu Glu Thr Ile Ala Ser His
260 265 270
<210>36
<211>509
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉mitochondria dihydrolipoamide dehydrogenase precursor
<222>(1)..(509)
＜223〉on Dec 9th, 2002 registration number: P09622
<400>36
Met Gln Ser Trp Ser Arg Val Tyr Cys Ser Leu Ala Lys Arg Gly His
1 5 10 15
Phe Asn Arg Ile Ser His Gly Leu Gln Gly Leu Ser Ala Val Pro Leu
20 25 30
Arg Thr Tyr Ala Asp Gln Pro Ile Asp Ala Asp Val Thr Val Ile Gly
35 40 45
Ser Gly Pro Gly Gly Tyr Val Ala Ala Ile Lys Ala Ala Gln Leu Gly
50 55 60
Phe Lys Thr Val Cys Ile Glu Lys Asn Glu Thr Leu Gly Gly Thr Cys
65 70 75 80
Leu Asn Val Gly Cys Ile Pro Ser Lys Ala Leu Leu Asn Asn Ser His
85 90 95
Tyr Tyr His Met Ala His Gly Thr Asp Phe Ala Ser Arg Gly Ile Glu
100 105 110
Met Ser Glu Val Arg Leu Asn Leu Asp Lys Met Met Glu Gln Lys Ser
115 120 125
Thr Ala Val Lys Ala Leu Thr Gly Gly Ile Ala His Leu Phe Lys Gln
130 135 140
Asn Lys Val Val His Val Asn Gly Tyr Gly Lys Ile Thr Gly Lys Asn
145 150 155 160
Gln Val Thr Ala Thr Lys Ala Asp Gly Gly Thr Gln Val Ile Asp Thr
165 170 175
Lys Asn Ile Leu Ile Ala Thr Gly Ser Glu Val Thr Pro Phe Pro Gly
180 185 190
Ile Thr Ile Asp Glu Asp Thr Ile Val Ser Ser Thr Gly Ala Leu Ser
195 200 205
Leu Lys Lys Val Pro Glu Lys Met Val Val Ile Gly Ala Gly Val Ile
210 215 220
Gly Val Glu Leu Gly Ser Val Trp Gln Arg Leu Gly Ala Asp Val Thr
225 230 235 240
Ala Val Glu Phe Leu Gly His Val Gly Gly Val Gly Ile Asp Met Glu
245 250 255
Ile Ser Lys Asn Phe Gln Arg Ile Leu Gln Lys Gln Gly Phe Lys Phe
260 265 270
Lys Leu Asn Thr Lys Val Thr Gly Ala Thr Lys Lys Ser Asp Gly Lys
275 280 285
Ile Asp Val Ser Ile Glu Ala Ala Ser Gly Gly Lys Ala Glu Val Ile
290 295 300
Thr Cys Asp Val Leu Leu Val Cys Ile Gly Arg Arg Pro Phe Thr Lys
305 310 315 320
Asn Leu Gly Leu Glu Glu Leu Gly Ile Glu Leu Asp Pro Arg Gly Arg
325 330 335
Ile Pro Val Asn Thr Arg Phe Gln Thr Lys Ile Pro Asn Ile Tyr Ala
340 345 350
Ile Gly Asp Val Val Ala Gly Pro Met Leu Ala His Lys Ala Glu Asp
355 360 365
Glu Gly Ile Ile Cys Val Glu Gly Met Ala Gly Gly Ala Val His Ile
370 375 380
Asp Tyr Asn Cys Val Pro Ser Val Ile Tyr Thr His Pro Glu Val Ala
385 390 395 400
Trp Val Gly Lys Ser Glu Glu Gln Leu Lys Glu Glu Gly Ile Glu Tyr
405 410 415
Lys Val Gly Lys Phe Pro Phe Ala Ala Asn Ser Arg Ala Lys Thr Asn
420 425 430
Ala Asp Thr Asp Gly Met Val Lys Ile Leu Gly Gln Lys Ser Thr Asp
435 440 445
Arg Val Leu Gly Ala His Ile Leu Gly Pro Gly Ala Gly Glu Met Val
450 455 460
Asn Glu Ala Ala Leu Ala Leu Glu Tyr Gly Ala Ser Cys Glu Asp Ile
465 470 475 480
Ala Arg Val Cys His Ala His Pro Thr Leu Ser Glu Ala Phe Arg Glu
485 490 495
Ala Asn Leu Ala Ala Ser Phe Gly Lys Ser Ile Asn Phe
500 505
<210>37
<211>290
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉mitochondria enoyl-CoA hydratase precursor
<222>(1)..(290)
＜223〉on Dec 9th, 2002 registration number: P30084
<400>37
Met Ala Ala Leu Arg Val Leu Leu Ser Cys Ala Arg Gly Pro Leu Arg
1 5 10 15
Pro Pro Val Arg Cys Pro Ala Trp Arg Pro Phe Ala Ser Gly Ala Asn
20 25 30
Phe Glu Tyr Ile Ile Ala Glu Lys Arg Gly Lys Asn Asn Thr Val Gly
35 40 45
Leu Ile Gln Leu Asn Arg Pro Lys Ala Leu Asn Ala Leu Cys Asp Gly
50 55 60
Leu Ile Asp Glu Leu Asn Gln Ala Leu Lys Ile Phe Glu Glu Asp Pro
65 70 75 80
Ala Val Gly Ala Ile Val Leu Thr Gly Gly Asp Lys Ala Phe Ala Ala
85 90 95
Gly Ala Asp Ile Lys Glu Met Gln Asn Leu Ser Phe Gln Asp Cys Tyr
100 105 110
Ser Ser Lys Phe Leu Lys His Trp Asp His Leu Thr Gln Val Lys Lys
115 120 125
Pro Val Ile Ala Ala Val Asn Gly Tyr Ala Phe Gly Gly Gly Cys Glu
130 135 140
Leu Ala Met Met Cys Asp Ile Ile Tyr Ala Gly Glu Lys Ala Gln Phe
145 150 155 160
Ala Gln Pro Glu Ile Leu Ile Gly Thr Ile Pro Gly Ala Gly Gly Thr
165 170 175
Gln Arg Leu Thr Arg Ala Val Gly Lys Ser Leu Ala Met Glu Met Val
180 185 190
Leu Thr Gly Asp Arg Ile Ser Ala Gln Asp Ala Lys Gln Ala Gly Leu
195 200 205
Val Ser Lys Ile Cys Pro Val Glu Thr Leu Val Glu Glu Ala Ile Gln
210 215 220
Cys Ala Glu Lys Ile Ala Ser Asn Ser Lys Ile Val Val Ala Met Ala
225 230 235 240
Lys Glu Ser Val Asn Ala Ala Phe Glu Met Thr Leu Thr Glu Gly Ser
245 250 255
Lys Leu Glu Lys Lys Leu Phe Tyr Ser Thr Phe Ala Thr Asp Asp Arg
260 265 270
Lys Glu Gly Met Thr Ala Phe Val Glu Lys Arg Lys Ala Asn Phe Lys
275 280 285
Asp Gln
290
<210>38
<211>160
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉class heat shock 20kDa albumen p20
<222>(1)..(160)
＜223〉on Dec 9th, 2002 registration number: 014558
<400>38
Met Glu Ile Pro Val Pro Val Gln Pro Ser Trp Leu Arg Arg Ala Ser
1 5 10 15
Ala Pro Leu Pro Gly Leu Ser Ala Pro Gly Arg Leu Phe Asp Gln Arg
20 25 30
Phe Gly Glu Gly Leu Leu Glu Ala Glu Leu Ala Ala Leu Cys Pro Thr
35 40 45
Thr Leu Ala Pro Tyr Tyr Leu Arg Ala Pro Ser Val Ala Leu Pro Val
50 55 60
Ala Gln Val Pro Thr Asp Pro Gly His Phe Ser Val Leu Leu Asp Val
65 70 75 80
Lys His Phe Ser Pro Glu Glu Ile Ala Val Lys Val Val Gly Glu His
85 90 95
Val Glu Val His Ala Arg His Glu Glu Arg Pro Asp Glu His Gly Phe
100 105 110
Val Ala Arg Glu Phe His Arg Arg Tyr Arg Leu Pro Pro Gly Val Asp
115 120 125
Pro Ala Ala Val Thr Ser Ala Leu Ser Pro Glu Gly Val Leu Ser Ile
130 135 140
Gln Ala Ala Pro Ala Ser Ala Gln Ala Pro Pro Pro Ala Ala Ala Lys
145 150 155 160
<210>39
<211>151
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉non-muscle isotype alkalescence myosin light chain
<222>(1)..(151)
＜223〉on Dec 9th, 2002 registration number: P16475
<400>39
Met Cys Asp Phe Thr Glu Asp Gln Thr Ala Glu Phe Lys Glu Ala Phe
1 5 10 15
Gln Leu Phe Asp Arg Thr Gly Asp Gly Lys Ile Leu Tyr Ser Gln Cys
20 25 30
Gly Asp Val Met Arg Ala Leu Gly Gln Asn Pro Thr Asn Ala Glu Val
35 40 45
Leu Lys Val Leu Gly Asn Pro Lys Ser Asp Glu Met Asn Val Lys Val
50 55 60
Leu Asp Phe Glu His Phe Leu Pro Met Leu Gln Thr Val Ala Lys Asn
65 70 75 80
Lys Asp Gln Gly Thr Tyr Glu Asp Tyr Val Glu Gly Leu Arg Val Phe
85 90 95
Asp Lys Glu Gly Asn Gly Thr Val Met Gly Ala Glu Ile Arg His Val
100 105 110
Leu Val Thr Leu Gly Glu Lys Met Thr Glu Glu Glu Val Glu Met Leu
115 120 125
Val Ala Gly His Glu Asp Ser Asn Gly Cys Ile Asn Tyr Glu Ala Phe
130 135 140
Val Arg His Ile Leu Ser Gly
145 150
<210>40
<211>592
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉calnexin precursor
<222>(1)..(592)
＜223〉on Dec 9th, 2002 registration number: P27824
<400>40
Met Glu Gly Lys Trp Leu Leu Cys Met Leu Leu Val Leu Gly Thr Ala
1 5 10 15
Ile Val Glu Ala His Asp Gly His Asp Asp Asp Val Ile Asp Ile Glu
20 25 30
Asp Asp Leu Asp Asp Val Ile Glu Glu Val Glu Asp Ser Lys Pro Asp
35 40 45
Thr Thr Ala Pro Pro Ser Ser Pro Lys Val Thr Tyr Lys Ala Pro Val
50 55 60
Pro Thr Gly Glu Val Tyr Phe Ala Asp Ser Phe Asp Arg Gly Thr Leu
65 70 75 80
Ser Gly Trp Ile Leu Ser Lys Ala Lys Lys Asp Asp Thr Asp Asp Glu
85 90 95
Ile Ala Lys Tyr Asp Gly Lys Trp Glu Val Glu Glu Met Lys Glu Ser
100 105 110
Lys Leu Pro Gly Asp Lys Gly Leu Val Leu Met Ser Arg Ala Lys His
115 120 125
His Ala Ile Ser Ala Lys Leu Asn Lys Pro Phe Leu Phe Asp Thr Lys
130 135 140
Pro Leu Ile Val Gln Tyr Glu Val Asn Phe Gln Asn Gly Ile Glu Cys
145 150 155 160
Gly Gly Ala Tyr Val Lys Leu Leu Ser Lys Thr Pro Glu Leu Asn Leu
165 170 175
Asp Gln Phe His Asp Lys Thr Pro Tyr Thr Ile Met Phe Gly Pro Asp
180 185 190
Lys Cys Gly Glu Asp Tyr Lys Leu His Phe Ile Phe Arg His Lys Asn
195 200 205
Pro Lys Thr Gly Ile Tyr Glu Glu Lys His Ala Lys Arg Pro Asp Ala
210 215 220
Asp Leu Lys Thr Tyr Phe Thr Asp Lys Lys Thr His Leu Tyr Thr Leu
225 230 235 240
Ile Leu Asn Pro Asp Asn Ser Phe Glu Ile Leu Val Asp Gln Ser Val
245 250 255
Val Asn Ser Gly Asn Leu Leu Asn Asp Met Thr Pro Pro Val Asn Pro
260 265 270
Ser Arg Glu Ile Glu Asp Pro Glu Asp Arg Lys Pro Glu Asp Trp Asp
275 280 285
Glu Arg Pro Lys Ile Pro Asp Pro Glu Ala Val Lys Pro Asp Asp Trp
290 295 300
Asp Glu Asp Ala Pro Ala Lys Ile Pro Asp Glu Glu Ala Thr Lys Pro
305 310 315 320
Glu Gly Trp Leu Asp Asp Glu Pro Glu Tyr Val Pro Asp Pro Asp Ala
325 330 335
Glu Lys Pro Glu Asp Trp Asp Glu Asp Met Asp Gly Glu Trp Glu Ala
340 345 350
Pro Gln Ile Ala Asn Pro Arg Cys Glu Ser Ala Pro Gly Cys Gly Val
355 360 365
Trp Gln Arg Pro Val Ile Asp Asn Pro Asn Tyr Lys Gly Lys Trp Lys
370 375 380
Pro Pro Met Ile Asp Asn Pro Ser Tyr Gln Gly Ile Trp Lys Pro Arg
385 390 395 400
Lys Ile Pro Asn Pro Asp Phe Phe Glu Asp Leu Glu Pro Phe Arg Met
405 410 415
Thr Pro Phe Ser Ala Ile Gly Leu Glu Leu Trp Ser Met Thr Ser Asp
420 425 430
Ile Phe Phe Asp Asn Phe Ile Ile Cys Ala Asp Arg Arg Ile Val Asp
435 440 445
Asp Trp Ala Asn Asp Gly Trp Gly Leu Lys Lys Ala Ala Asp Gly Ala
450 455 460
Ala Glu Pro Gly Val Val Gly Gln Met Ile Glu Ala Ala Glu Glu Arg
465 470 475 480
Pro Trp Leu Trp Val Val Tyr Ile Leu Thr Val Ala Leu Pro Val Phe
485 490 495
Leu Val Ile Leu Phe Cys Cys Ser Gly Lys Lys Gln Thr Ser Gly Met
500 505 510
Glu Tyr Lys Lys Thr Asp Ala Pro Gln Pro Asp Val Lys Glu Glu Glu
515 520 525
Glu Glu Lys Glu Glu Glu Lys Asp Lys Gly Asp Glu Glu Glu Glu Gly
530 535 540
Glu Glu Lys Leu Glu Glu Lys Gln Lys Ser Asp Ala Glu Glu Asp Gly
545 550 555 560
Gly Thr Val Ser Gln Glu Glu Glu Asp Arg Lys Pro Lys Ala Glu Glu
565 570 575
Asp Glu Ile Leu Asn Arg Ser Pro Arg Asn Arg Lys Pro Arg Arg Glu
580 585 590
<210>41
<211>282
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉complement component 1
<222>(1)..(282)
＜223〉on Dec 9th, 2002 registration number: Q07021
<400>41
Met Leu Pro Leu Leu Arg Cys Val Pro Arg Val Leu Gly Ser Ser Val
1 5 10 15
Ala Gly Leu Arg Ala Ala Ala Pro Ala Ser Pro Phe Arg Gln Leu Leu
20 25 30
Gln Pro Ala Pro Arg Leu Cys Thr Arg Pro Phe Gly Leu Leu Ser Val
35 40 45
Arg Ala Gly Ser Glu Arg Arg Pro Gly Leu Leu Arg Pro Arg Gly Pro
50 55 60
Cys Ala Cys Gly Cys Gly Cys Gly Ser Leu His Thr Asp Gly Asp Lys
65 70 75 80
Ala Phe Val Asp Phe Leu Ser Asp Glu Ile Lys Glu Glu Arg Lys Ile
85 90 95
Gln Lys His Lys Thr Leu Pro Lys Met Ser Gly Gly Trp Glu Leu Glu
100 105 110
Leu Asn Gly Thr Glu Ala Lys Leu Val Arg Lys Val Ala Gly Glu Lys
115 120 125
Ile Thr Val Thr Phe Asn Ile Asn Asn Ser Ile Pro Pro Thr Phe Asp
130 135 140
Gly Glu Glu Glu Pro Ser Gln Gly Gln Lys Val Glu Glu Gln Glu Pro
145 150 155 160
Glu Leu Thr Ser Thr Pro Asn Phe Val Val Glu Val Ile Lys Asn Asp
165 170 175
Asp Gly Lys Lys Ala Leu Val Leu Asp Cys His Tyr Pro Glu Asp Glu
180 185 190
Val Gly Gln Glu Asp Glu Ala Glu Ser Asp Ile Phe Ser Ile Arg Glu
195 200 205
Val Ser Phe Gln Ser Thr Gly Glu Ser Glu Trp Lys Asp Thr Asn Tyr
210 215 220
Thr Leu Asn Thr Asp Ser Leu Asp Trp Ala Leu Tyr Asp His Leu Met
225 230 235 240
Asp Phe Leu Ala Asp Arg Gly Val Asp Asn Thr Phe Ala Asp Glu Leu
245 250 255
Val Glu Leu Ser Thr Ala Leu Glu His Gln Glu Tyr Ile Thr Phe Leu
260 265 270
Glu Asp Leu Lys Ser Phe Val Lys Ser Gln
275 280
<210>42
<211>727
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉mitochondria NADH-CoQ oxide-reductase 75kDa subunit precursor
<222>(1)..(727)
＜223〉on Dec 9th, 2002 registration number: P28331
<400>42
Met Leu Arg Ile Pro Val Arg Arg Ala Leu Val Gly Leu Ser Lys Ser
1 5 10 15
Pro Lys Gly Cys Val Arg Thr Thr Ala Thr Ala Ala Ser Asn Leu Ile
20 25 30
Glu Val Phe Val Asp Gly Gln Ser Val Met Val Glu Pro Gly Thr Thr
35 40 45
Val Leu Gln Ala Cys Glu Lys Val Gly Met Gln Ile Pro Arg Phe Cys
50 55 60
Tyr His Glu Arg Leu Ser Val Ala Gly Asn Cys Arg Met Cys Leu Val
65 70 75 80
Glu Ile Glu Lys Ala Pro Lys Val Val Ala Ala Cys Ala Met Pro Val
85 90 95
Met Lys Gly Trp Asn Ile Leu Thr Asn Ser Glu Lys Ser Lys Lys Ala
100 105 110
Arg Glu Gly Val Met Glu Phe Leu Leu Ala Asn His Pro Leu Asp Cys
115 120 125
Pro Ile Cys Asp Gln Gly Gly Glu Cys Asp Leu Gln Asp Gln Ser Met
130 135 140
Met Phe Gly Asn Asp Arg Ser Arg Phe Leu Glu Gly Lys Arg Ala Val
145 150 155 160
Glu Asp Lys Asn Ile Gly Pro Leu Val Lys Thr Ile Met Thr Arg Cys
165 170 175
Ile Gln Cys Thr Arg Cys Ile Arg Phe Ala Ser Glu Ile Ala Gly Val
180 185 190
Asp Asp Leu Gly Thr Thr Gly Arg Gly Asn Asp Met Gln Val Gly Thr
195 200 205
Tyr Ile Glu Lys Met Phe Met Ser Glu Leu Ser Gly Asn Ile Ile Asp
210 215 220
Ile Cys Pro Val Gly Ala Leu Thr Ser Lys Pro Tyr Ala Phe Thr Ala
225 230 235 240
Arg Pro Trp Glu Thr Arg Lys Thr Glu Ser Ile Asp Val Met Asp Ala
245 250 255
Val Gly Ser Asn Ile Val Val Ser Thr Arg Thr Gly Glu Val Met Arg
260 265 270
Ile Leu Pro Arg Met His Glu Asp Ile Asn Glu Glu Trp Ile Ser Asp
275 280 285
Lys Thr Arg Phe Ala Tyr Asp Gly Leu Lys Arg Gln Arg Leu Thr Glu
290 295 300
Pro Met Val Arg Asn Glu Lys Gly Leu Leu Thr Tyr Thr Ser Trp Glu
305 310 315 320
Asp Ala Leu Ser Arg Val Ala Gly Met Leu Gln Ser Phe Gln Gly Lys
325 330 335
Asp Val Ala Ala Ile Ala Gly Gly Leu Val Asp Ala Glu Ala Leu Val
340 345 350
Ala Leu Lys Asp Leu Leu Asn Arg Val Asp Ser Asp Thr Leu Cys Thr
355 360 365
Glu Glu Val Phe Pro Thr Ala Gly Ala Gly Thr Asp Leu Arg Ser Asn
370 375 380
Tyr Leu Leu Asn Thr Thr Ile Ala Gly Val Glu Glu Ala Asp Val Val
385 390 395 400
Leu Leu Val Gly Thr Asn Pro Arg Phe Glu Ala Pro Leu Phe Asn Ala
405 410 415
Trp Ile Arg Lys Ser Trp Leu His Asn Asp Leu Lys Val Ala Leu Ile
420 425 430
Gly Ser Pro Val Asp Leu Thr Tyr Thr Tyr Asp His Leu Gly Asp Ser
435 440 445
Pro Lys Ile Leu Gln Asp Ile Ala Ser Gly Ser His Pro Phe Ser Gln
450 455 460
Val Leu Lys Glu Ala Lys Lys Pro Met Val Val Leu Gly Ser Ser Ala
465 470 475 480
Leu Gln Arg Asn Asp Gly Ala Ala Ile Leu Ala Ala Val Ser Ser Ile
485 490 495
Ala Gln Lys Ile Arg Met Thr Ser Gly Val Thr Gly Asp Trp Lys Val
500 505 510
Met Asn Ile Leu His Arg Ile Ala Ser Gln Val Ala Ala Leu Asp Leu
515 520 525
Gly Tyr Lys Pro Gly Val Glu Ala Ile Arg Lys Asn Pro Pro Lys Val
530 535 540
Leu Phe Leu Leu Gly Ala Asp Gly Gly Cys Ile Thr Arg Gln Asp Leu
545 550 555 560
Pro Lys Asp Cys Phe Ile Ile Tyr Gln Gly His His Gly Asp Val Gly
565 570 575
Ala Pro Ile Ala Asp Val Ile Leu Pro Gly Ala Ala Tyr Thr Glu Lys
580 585 590
Ser Ala Thr Tyr Val Asn Thr Glu Gly Arg Ala Gln Gln Thr Lys Val
595 600 605
Ala Val Thr Pro Pro Gly Leu Ala Arg Glu Asp Trp Lys Ile Ile Arg
610 615 620
Ala Leu Ser Glu Ile Ala Gly Met Thr Leu Pro Tyr Asp Thr Leu Asp
625 630 635 640
Gln Val Arg Asn Arg Leu Glu Glu Phe Ser Pro Asn Leu Val Arg Tyr
645 650 655
Asp Asp Ile Glu Gly Ala Asn Tyr Phe Gln Gln Ala Asn Glu Leu Ser
660 665 670
Lys Leu Val Asn Gln Gln Leu Leu Ala Asp Pro Leu Val Pro Pro Gln
675 680 685
Leu Thr Leu Lys Asp Phe Tyr Met Thr Asp Ser Ile Ser Arg Ala Ser
690 695 700
Gln Thr Met Ala Lys Cys Val Lys Ala Val Thr Glu Gly Ala Gln Ala
705 710 715 720
Val Glu Glu Pro Ser Ile Cys
725
<210>43
<211>491
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉pre B cell enhancer precursor
<222>(1)..(491)
＜223〉on Dec 9th, 2002 registration number: P43490
<400>43
Met Asn Pro Ala Ala Glu Ala Glu Phe Asn Ile Leu Leu Ala Thr Asp
1 5 10 15
Ser Tyr Lys Val Thr His Tyr Lys Gln Tyr Pro Pro Asn Thr Ser Lys
20 25 30
Val Tyr Ser Tyr Phe Glu Cys Arg Glu Lys Lys Thr Glu Asn Ser Lys
35 40 45
Leu Arg Lys Val Lys Tyr Glu Glu Thr Val Phe Tyr Gly Leu Gln Tyr
50 55 60
Ile Leu Asn Lys Tyr Leu Lys Gly Lys Val Val Thr Lys Glu Lys Ile
65 70 75 80
Gln Glu Ala Lys Asp Val Tyr Lys Glu His Phe Gln Asp Asp Val Phe
85 90 95
Asn Glu Lys Gly Trp Asn Tyr Ile Leu Glu Lys Tyr Asp Gly His Leu
100 105 110
Pro Ile Glu Ile Lys Ala Val Pro Glu Gly Phe Val Ile Pro Arg Gly
115 120 125
Asn Val Leu Phe Thr Val Glu Asn Thr Asp Pro Glu Cys Tyr Trp Leu
130 135 140
Thr Asn Trp Ile Glu Thr Ile Leu Val Gln Ser Trp Tyr Pro Ile Thr
145 150 155 160
Val Ala Thr Asn Ser Arg Glu Gln Lys Lys Ile Leu Ala Lys Tyr Leu
165 170 175
Leu Glu Thr Ser Gly Asn Leu Asp Gly Leu Glu Tyr Lys Leu His Asp
180 185 190
Phe Gly Tyr Arg Gly Val Ser Ser Gln Glu Thr Ala Gly Ile Gly Ala
195 200 205
Ser Ala His Leu Val Asn Phe Lys Gly Thr Asp Thr Val Ala Gly Leu
210 215 220
Ala Leu Ile Lys Lys Tyr Tyr Gly Thr Lys Asp Pro Val Pro Gly Tyr
225 230 235 240
Ser Val Pro Ala Ala Glu His Ser Thr Ile Thr Ala Trp Gly Lys Asp
245 250 255
His Glu Lys Asp Ala Phe Glu His Ile Val Thr Gln Phe Ser Ser Val
260 265 270
Pro Val Ser Val Val Ser Asp Ser Tyr Asp Ile Tyr Asn Ala Cys Glu
275 280 285
Lys Ile Trp Gly Glu Asp Leu Arg His Leu Ile Val Ser Arg Ser Thr
290 295 300
Gln Ala Pro Leu Ile Ile Arg Pro Asp Ser Gly Asn Pro Leu Asp Thr
305 310 315 320
Val Leu Lys Val Leu Glu Ile Leu Gly Lys Lys Phe Pro Val Thr Glu
325 330 335
Asn Ser Lys Gly Tyr Lys Leu Leu Pro Pro Tyr Leu Arg Val Ile Gln
340 345 350
Gly Asp Gly Val Asp Ile Asn Thr Leu Gln Glu Ile Val Glu Gly Met
355 360 365
Lys Gln Lys Met Trp Ser Ile Glu Asn Ile Ala Phe Gly Ser Gly Gly
370 375 380
Gly Leu Leu Gln Lys Leu Thr Arg Asp Leu Leu Asn Cys Ser Phe Lys
385 390 395 400
Cys Ser Tyr Val Val Thr Asn Gly Leu Gly Ile Asn Val Phe Lys Asp
405 410 415
Pro Val Ala Asp Pro Asn Lys Arg Ser Lys Lys Gly Arg Leu Ser Leu
420 425 430
His Arg Thr Pro Ala Gly Asn Phe Val Thr Leu Glu Glu Gly Lys Gly
435 440 445
Asp Leu Glu Glu Tyr Gly Gln Asp Leu Leu His Thr Val Phe Lys Asn
450 455 460
Gly Lys Val Thr Lys Ser Tyr Ser Phe Asp Glu Ile Arg Lys Asn Ala
465 470 475 480
Gln Leu Asn Ile Glu Leu Glu Ala Ala His His
485 490
<210>44
<211>135
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉cellular retinol binding protein I
<222>(1)..(135)
＜223〉on Dec 9th, 2002 registration number: P09455
<400>44
Met Pro Val Asp Phe Thr Gly Tyr Trp Lys Met Leu Val Asn Glu Asn
1 5 10 15
Phe Glu Glu Tyr Leu Arg Ala Leu Asp Val Asn Val Ala Leu Arg Lys
20 25 30
Ile Ala Asn Leu Leu Lys Pro Asp Lys Glu Ile Val Gln Asp Gly Asp
35 40 45
His Met Ile Ile Arg Thr Leu Ser Thr Phe Arg Asn Tyr Ile Met Asp
50 55 60
Phe Gln Val Gly Lys Glu Phe Glu Glu Asp Leu Thr Gly Ile Asp Asp
65 70 75 80
Arg Lys Cys Met Thr Thr Val Ser Trp Asp Gly Asp Lys Leu Gln Cys
85 90 95
Val Gln Lys Gly Glu Lys Glu Gly Arg Gly Trp Thr Gln Trp Ile Glu
100 105 110
Gly Asp Glu Leu His Leu Glu Met Arg Val Glu Gly Val Val Cys Lys
115 120 125
Gln Val Phe Lys Lys Val Gln
130 135
<210>45
<211>544
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the T-complex proteins 1, the gamma-subunit
<222>(1)..(544)
＜223〉on Dec 9th, 2002 registration number: P49368
<400>45
Met Gly His Arg Pro Val Leu Val Leu Ser Gln Asn Thr Lys Arg Glu
1 5 10 15
Ser Gly Arg Lys Val Gln Ser Gly Asn Ile Asn Ala Ala Lys Thr Ile
20 25 30
Ala Asp Ile Ile Arg Thr Cys Leu Gly Pro Lys Ser Met Met Lys Met
35 40 45
Leu Leu Asp Pro Met Gly Gly Ile Val Met Thr Asn Asp Gly Asn Ala
50 55 60
Ile Leu Arg Glu Ile Gln Val Gln His Pro Ala Ala Lys Ser Met Ile
65 70 75 80
Glu Ile Ser Arg Thr Gln Asp Glu Glu Val Gly Asp Gly Thr Thr Ser
85 90 95
Val Ile Ile Leu Ala Gly Glu Met Leu Ser Val Ala Glu His Phe Leu
100 105 110
Glu Gln Gln Met His Pro Thr Val Val Ile Ser Ala Tyr Arg Lys Ala
115 120 125
Leu Asp Asp Met Ile Ser Thr Leu Lys Lys Ile Ser Ile Pro Val Asp
130 135 140
Ile Ser Asp Ser Asp Met Met Leu Asn Ile Ile Asn Ser Ser Ile Thr
145 150 155 160
Thr Lys Ala Ile Ser Arg Trp Ser Ser Leu Ala Cys Asn Ile Ala Leu
165 170 175
Asp Ala Val Lys Met Val Gln Phe Glu Glu Asn Gly Arg Lys Glu Ile
180 185 190
Asp Ile Lys Lys Tyr Ala Arg Val Glu Lys Ile Pro Gly Gly Ile Ile
195 200 205
Glu Asp Ser Cys Val Leu Arg Gly Val Met Ile Asn Lys Asp Val Thr
210 215 220
His Pro Arg Met Arg Arg Tyr Ile Lys Asn Pro Arg Ile Val Leu Leu
225 230 235 240
Asp Ser Ser Leu Glu Tyr Lys Lys Gly Glu Ser Gln Thr Asp Ile Glu
245 250 255
Ile Thr Arg Glu Glu Asp Phe Thr Arg Ile Leu Gln Met Glu Glu Glu
260 265 270
Tyr Ile Gln Gln Leu Cys Glu Asp Ile Ile Gln Leu Lys Pro Asp Val
275 280 285
Val Ile Thr Glu Lys Gly Ile Ser Asp Leu Ala Gln His Tyr Leu Met
290 295 300
Arg Ala Asn Ile Thr Ala Ile Arg Arg Val Arg Lys Thr Asp Asn Asn
305 310 315 320
Arg Ile Ala Arg Ala Cys Gly Ala Arg Ile Val Ser Arg Pro Glu Glu
325 330 335
Leu Arg Glu Asp Asp Val Gly Thr Gly Ala Gly Leu Leu Glu Ile Lys
340 345 350
Lys Ile Gly Asp Glu Tyr Phe Thr Phe Ile Thr Asp Cys Lys Asp Pro
355 360 365
Lys Ala Cys Thr Ile Leu Leu Arg Gly Ala Ser Lys Glu Ile Leu Ser
370 375 380
Glu Val Glu Arg Asn Leu Gln Asp Ala Met Gln Val Cys Arg Asn Val
385 390 395 400
Leu Leu Asp Pro Gln Leu Val Pro Gly Gly Gly Ala Ser Glu Met Ala
405 410 415
Val Ala His Ala Leu Thr Glu Lys Ser Lys Ala Met Thr Gly Val Glu
420 425 430
Gln Trp Pro Tyr Arg Ala Val Ala Gln Ala Leu Glu Val Ile Pro Arg
435 440 445
Thr Leu Ile Gln Asn Cys Gly Ala Ser Thr Ile Arg Leu Leu Thr Ser
450 455 460
Leu Arg Ala Lys His Thr Gln Glu Asn Cys Glu Thr Trp Gly Val Asn
465 470 475 480
Gly Glu Thr Gly Thr Leu Val Asp Met Lys Glu Leu Gly Ile Trp Glu
485 490 495
Pro Leu Ala Val Lys Leu Gln Thr Tyr Lys Thr Ala Val Glu Thr Ala
500 505 510
Val Leu Leu Leu Arg Ile Asp Asp Ile Val Ser Gly His Lys Lys Lys
515 520 525
Gly Asp Asp Gln Ser Arg Gln Gly Gly Ala Pro Asp Ala Gly Gln Glu
530 535 540
<210>46
<211>461
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉placental ribonuclease inhibitor
<222>(1)..(461)
＜223〉on Dec 9th, 2002 registration number: P13489
<400>46
Met Ser Leu Asp Ile Gln Ser Leu Asp Ile Gln Cys Glu Glu Leu Ser
1 5 10 15
Asp Ala Arg Trp Ala Glu Leu Leu Pro Leu Leu Gln Gln Cys Gln Val
20 25 30
Val Arg Leu Asp Asp Cys Gly Leu Thr Glu Ala Arg Cys Lys Asp Ile
35 40 45
Ser Ser Ala Leu Arg Val Asn Pro Ala Leu Ala Glu Leu Asn Leu Arg
50 55 60
Ser Asn Glu Leu Gly Asp Val Gly Val His Cys Val Leu Gln Gly Leu
65 70 75 80
Gln Thr Pro Ser Cys Lys Ile Gln Lys Leu Ser Leu Gln Asn Cys Cys
85 90 95
Leu Thr Gly Ala Gly Cys Gly Val Leu Ser Ser Thr Leu Arg Thr Leu
100 105 110
Pro Thr Leu Gln Glu Leu His Leu Ser Asp Asn Leu Leu Gly Asp Ala
115 120 125
Gly Leu Gln Leu Leu Cys Glu Gly Leu Leu Asp Pro Gln Cys Arg Leu
130 135 140
Glu Lys Leu Gln Leu Glu Tyr Cys Ser Leu Ser Ala Ala Ser Cys Glu
145 150 155 160
Pro Leu Ala Ser Val Leu Arg Ala Lys Pro Asp Phe Lys Glu Leu Thr
165 170 175
Val Ser Asn Asn Asp Ile Asn Glu Ala Gly Val Arg Val Leu Cys Gln
180 185 190
Gly Leu Lys Asp Ser Pro Cys Gln Leu Glu Ala Leu Lys Leu Glu Ser
195 200 205
Cys Gly Val Thr Ser Asp Asn Cys Arg Asp Leu Cys Gly Ile Val Ala
210 215 220
Ser Lys Ala Ser Leu Arg Glu Leu Ala Leu Gly Ser Asn Lys Leu Gly
225 230 235 240
Asp Val Gly Met Ala Glu Leu Cys Pro Gly Leu Leu His Pro Ser Ser
245 250 255
Arg Leu Arg Thr Leu Trp Ile Trp Glu Cys Gly Ile Thr Ala Lys Gly
260 265 270
Cys Gly Asp Leu Cys Arg Val Leu Arg Ala Lys Glu Ser Leu Lys Glu
275 280 285
Leu Ser Leu Ala Gly Asn Glu Leu Gly Asp Glu Gly Ala Arg Leu Leu
290 295 300
Cys Glu Thr Leu Leu Glu Pro Gly Cys Gln Leu Glu Ser Leu Trp Val
305 310 315 320
Lys Ser Cys Ser Phe Thr Ala Ala Cys Cys Ser His Phe Ser Ser Val
325 330 335
Leu Ala Gln Asn Arg Phe Leu Leu Glu Leu Gln Ile Ser Asn Asn Arg
340 345 350
Leu Glu Asp Ala Gly Val Arg Glu Leu Cys Gln Gly Leu Gly Gln Pro
355 360 365
Gly Ser Val Leu Arg Val Leu Trp Leu Ala Asp Cys Asp Val Ser Asp
370 375 380
Ser Ser Cys Ser Ser Leu Ala Ala Thr Leu Leu Ala Asn His Ser Leu
385 390 395 400
Arg Glu Leu Asp Leu Ser Asn Asn Cys Leu Gly Asp Ala Gly Ile Leu
405 410 415
Gln Leu Val Glu Ser Val Arg Gln Pro Gly Cys Leu Leu Glu Gln Leu
420 425 430
Val Leu Tyr Asp Ile Tyr Trp Ser Glu Glu Met Glu Asp Arg Leu Gln
435 440 445
Ala Leu Glu Lys Asp Lys Pro Ser Leu Arg Val Ile Ser
450 455 460
<210>47
<211>317
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉class guanine-nucleotide-binding protein beta-protein subunit 12.3
<222>(1)..(317)
＜223〉on Dec 9th, 2002 registration number: P25388
<400>47
Met Thr Glu Gln Met Thr Leu Arg Gly Thr Leu Lys Gly His Asn Gly
1 5 10 15
Trp Val Thr Gln Ile Ala Thr Thr Pro Gln Phe Pro Asp Met Ile Leu
20 25 30
Ser Ala Ser Arg Asp Lys Thr Ile Ile Met Trp Lys Leu Thr Arg Asp
35 40 45
Glu Thr Asn Tyr Gly Ile Pro Gln Arg Ala Leu Arg Gly His Ser His
50 55 60
Phe Val Ser Asp Val Val Ile Ser Ser Asp Gly Gln Phe Ala Leu Ser
65 70 75 80
Gly Ser Trp Asp Gly Thr Leu Arg Leu Trp Asp Leu Thr Thr Gly Thr
85 90 95
Thr Thr Arg Arg Phe Val Gly His Thr Lys Asp Val Leu Ser Val Ala
100 105 110
Phe Ser Ser Asp Asn Arg Gln Ile Val Ser Gly Ser Arg Asp Lys Thr
115 120 125
Ile Lys Leu Trp Asn Thr Leu Gly Val Cys Lys Tyr Thr Val Gln Asp
130 135 140
Glu Ser His Ser Glu Trp Val Ser Cys Val Arg Phe Ser Pro Asn Ser
145 150 155 160
Ser Asn Pro Ile Ile Val Ser Cys Gly Trp Asp Lys Leu Val Lys Val
165 170 175
Trp Asn Leu Ala Asn Cys Lys Leu Lys Thr Asn His Ile Gly His Thr
180 185 190
Gly Tyr Leu Asn Thr Val Thr Val Ser Pro Asp Gly Ser Leu Cys Ala
195 200 205
Ser Gly Gly Lys Asp Gly Gln Ala Met Leu Trp Asp Leu Asn Glu Gly
210 215 220
Lys His Leu Tyr Thr Leu Asp Gly Gly Asp Ile Ile Asn Ala Leu Cys
225 230 235 240
Phe Ser Pro Asn Arg Tyr Trp Leu Cys Ala Ala Thr Gly Pro Ser Ile
245 250 255
Lys Ile Trp Asp Leu Glu Gly Lys Ile Ile Val Asp Glu Leu Lys Gln
260 265 270
Glu Val Ile Ser Thr Ser Ser Lys Ala Glu Pro Pro Gln Cys Thr Ser
275 280 285
Leu Ala Trp Ser Ala Asp Gly Gln Thr Leu Phe Ala Gly Tyr Thr Asp
290 295 300
Asn Leu Val Arg Val Trp Gln Val Thr Ile Gly Thr Arg
305 310 315
<210>48
<211>172
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉light chain 2 of myosin adjusting
<222>(1)..(172)
＜223〉on Dec 9th, 2002 registration number: P24844
<400>48
Met Ser Ser Lys Arg Ala Lys Ala Lys Thr Thr Lys Lys Arg Pro Gln
1 5 10 15
Arg Ala Thr Ser Asn Val Phe Ala Met Phe Asp Gln Ser Gln Ile Gln
20 25 30
Glu Phe Lys Glu Ala Phe Asn Met Ile Asp Gln Asn Arg Asp Gly Phe
35 40 45
Ile Asp Lys Glu Asp Leu His Asp Met Leu Ala Ser Leu Gly Lys Asn
50 55 60
Pro Thr Asp Glu Tyr Leu Glu Gly Met Met Ser Glu Ala Pro Gly Pro
65 70 75 80
Ile Asn Phe Thr Met Phe Leu Thr Met Phe Gly Glu Lys Leu Asn Gly
85 90 95
Thr Asp Pro Glu Asp Val Ile Arg Asn Ala Phe Ala Cys Phe Asp Glu
100 105 110
Glu Ala Ser Gly Phe Ile His Glu Asp His Leu Arg Glu Leu Leu Thr
115 120 125
Thr Met Gly Asp Arg Phe Thr Asp Glu Glu Val Asp Glu Met Tyr Arg
130 135 140
Glu Ala Pro Ile Asp Lys Lys Gly Asn Phe Asn Tyr Val Glu Phe Thr
145 150 155 160
Arg Ile Leu Lys His Gly Ala Lys Asp Lys Asp Asp
165 170
<210>49
<211>114
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉calgranulin B
<222>(1)..(114)
＜223〉on Dec 10th, 2002 registration number: P06702
<400>49
Met Thr Cys Lys Met Ser Gln Leu Glu Arg Asn Ile Glu Thr Ile Ile
1 5 10 15
Asn Thr Phe His Gln Tyr Ser Val Lys Leu Gly His Pro Asp Thr Leu
20 25 30
Asn Gln Gly Glu Phe Lys Glu Leu Val Arg Lys Asp Leu Gln Asn Phe
35 40 45
Leu Lys Lys Glu Asn Lys Asn Glu Lys Val Ile Glu His Ile Met Glu
50 55 60
Asp Leu Asp Thr Asn Ala Asp Lys Gln Leu Ser Phe Glu Glu Phe Ile
65 70 75 80
Met Leu Met Ala Arg Leu Thr Trp Ala Ser His Glu Lys Met His Glu
85 90 95
Gly Asp Glu Gly Pro Gly His His His Lys Pro Gly Leu Gly Glu Gly
100 105 110
Thr Pro
<210>50
<211>348
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉macrophage capping protein
<222>(1)..(348)
＜223〉on Dec 10th, 2002 registration number: P40121
<400>50
Met Tyr Thr Ala Ile Pro Gln Ser Gly Ser Pro Phe Pro Gly Ser Val
1 5 10 15
Gln Asp Pro Gly Leu His Val Trp Arg Val Glu Lys Leu Lys Pro Val
20 25 30
Pro Val Ala Gln Glu Asn Gln Gly Val Phe Phe Ser Gly Asp Ser Tyr
35 40 45
Leu Val Leu His Asn Gly Pro Glu Glu Val Ser His Leu His Leu Trp
50 55 60
Ile Gly Gln Gln Ser Ser Arg Asp Glu Gln Gly Ala Cys Ala Val Leu
65 70 75 80
Ala Val His Leu Asn Thr Leu Leu Gly Glu Arg Pro Val Gln His Arg
85 90 95
Glu Val Gln Gly Asn Glu Ser Asp Leu Phe Met Ser Tyr Phe Pro Arg
100 105 110
Gly Leu Lys Tyr Gln Glu Gly Gly Val Glu Ser Ala Phe His Lys Thr
115 120 125
Ser Thr Gly Ala Pro Ala Ala Ile Lys Lys Leu Tyr Gln Val Lys Gly
130 135 140
Lys Lys Asn Ile Arg Ala Thr Glu Arg Ala Leu Asn Trp Asp Ser Phe
145 150 155 160
Asn Thr Gly Asp Cys Phe Ile Leu Asp Leu Gly Gln Asn Ile Phe Ala
165 170 175
Trp Cys Gly Gly Lys Ser Asn Ile Leu Glu Arg Asn Lys Ala Arg Asp
180 185 190
Leu Ala Leu Ala Ile Arg Asp Ser Glu Arg Gln Gly Lys Ala Gln Val
195 200 205
Glu Ile Val Thr Asp Gly Glu Glu Pro Ala Glu Met Ile Gln Val Leu
210 215 220
Gly Pro Lys Pro Ala Leu Lys Glu Gly Asn Pro Glu Glu Asp Leu Thr
225 230 235 240
Ala Asp Lys Ala Asn Ala Gln Ala Ala Ala Leu Tyr Lys Val Ser Asp
245 250 255
Ala Thr Gly Gln Met Asn Leu Thr Lys Val Ala Asp Ser Ser Pro Phe
260 265 270
Ala Leu Glu Leu Leu Ile Ser Asp Asp Cys Phe Val Leu Asp Asn Gly
275 280 285
Leu Cys Gly Lys Ile Tyr Ile Trp Lys Gly Arg Lys Ala Asn Glu Lys
290 295 300
Glu Arg Gln Ala Ala Leu Gln Val Ala Glu Gly Phe Ile Ser Arg Met
305 310 315 320
Gln Tyr Ala Pro Asn Thr Gln Val Glu Ile Leu Pro Gln Gly Arg Glu
325 330 335
Ser Pro Ile Phe Lys Gln Phe Phe Lys Asp Trp Lys
340 345
<210>51
<211>346
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉annexin I
<222>(1)..(346)
＜223〉on Dec 10th, 2002 registration number: P04083
<400>51
Met Ala Met Val Ser Glu Phe Leu Lys Gln Ala Trp Phe Ile Glu Asn
1 5 10 15
Glu Glu Gln Glu Tyr Val Gln Thr Val Lys Ser Ser Lys Gly Gly Pro
20 25 30
Gly Ser Ala Val Ser Pro Tyr Pro Thr Phe Asn Pro Ser Ser Asp Val
35 40 45
Ala Ala Leu His Lys Ala Ile Met Val Lys Gly Val Asp Glu Ala Thr
50 55 60
Ile Ile Asp Ile Leu Thr Lys Arg Asn Asn Ala Gln Arg Gln Gln Ile
65 70 75 80
Lys Ala Ala Tyr Leu Gln Glu Thr Gly Lys Pro Leu Asp Glu Thr Leu
85 90 95
Lys Lys Ala Leu Thr Gly His Leu Glu Glu Val Val Leu Ala Leu Leu
100 105 110
Lys Thr Pro Ala Gln Phe Asp Ala Asp Glu Leu Arg Ala Ala Met Lys
115 120 125
Gly Leu Gly Thr Asp Glu Asp Thr Leu Ile Glu Ile Leu Ala Ser Arg
130 135 140
Thr Asn Lys Glu Ile Arg Asp Ile Asn Arg Val Tyr Arg Glu Glu Leu
145 150 155 160
Lys Arg Asp Leu Ala Lys Asp Ile Thr Ser Asp Thr Ser Gly Asp Phe
165 170 175
Arg Asn Ala Leu Leu Ser Leu Ala Lys Gly Asp Arg Ser Glu Asp Phe
180 185 190
Gly Val Asn Glu Asp Leu Ala Asp Ser Asp Ala Arg Ala Leu Tyr Glu
195 200 205
Ala Gly Glu Arg Arg Lys Gly Thr Asp Val Asn Val Phe Asn Thr Ile
210 215 220
Leu Thr Thr Arg Ser Tyr Pro Gln Leu Arg Arg Val Phe Gln Lys Tyr
225 230 235 240
Thr Lys Tyr Ser Lys His Asp Met Asn Lys Val Leu Asp Leu Glu Leu
245 250 255
Lys Gly Asp Ile Glu Lys Cys Leu Thr Ala Ile Val Lys Cys Ala Thr
260 265 270
Ser Lys Pro Ala Phe Phe Ala Glu Lys Leu His Gln Ala Met Lys Gly
275 280 285
Val Gly Thr Arg His Lys Ala Leu Ile Arg Ile Met Val Ser Arg Ser
290 295 300
Glu Ile Asp Met Asn Asp Ile Lys Ala Phe Tyr Gln Lys Met Tyr Gly
305 310 315 320
Ile Ser Leu Cys Gln Ala Ile Leu Asp Glu Thr Lys Gly Asp Tyr Glu
325 330 335
Lys Ile Leu Val Ala Leu Cys Gly Gly Asn
340 345
<210>52
<211>469
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉II type cytoskeleton 7 keratin
<222>(1)..(469)
＜223〉on Dec 10th, 2002 registration number: P08729
<400>52
Met Ser Ile His Phe Ser Ser Pro Val Phe Thr Ser Arg Ser Ala Ala
1 5 10 15
Phe Ser Gly Arg Gly Ala Gln Val Arg Leu Ser Ser Ala Arg Pro Gly
20 25 30
Gly Leu Gly Ser Ser Ser Leu Tyr Gly Leu Gly Ala Ser Arg Pro Arg
35 40 45
Val Ala Val Arg Ser Ala Tyr Gly Gly Pro Val Gly Ala Gly Ile Arg
50 55 60
Glu Val Thr Ile Asn Gln Ser Leu Leu Ala Pro Leu Arg Leu Asp Ala
65 70 75 80
Asp Pro Ser Leu Gln Arg Val Arg Gln Glu Glu Ser Glu Gln Ile Lys
85 90 95
Thr Leu Asn Asn Lys Phe Ala Ser Phe Ile Asp Lys Val Arg Phe Leu
100 105 110
Glu Gln Gln Asn Lys Leu Leu Glu Thr Lys Trp Thr Leu Leu Gln Glu
115 120 125
Gln Lys Ser Ala Lys Ser Ser Arg Leu Pro Asp Ile Phe Glu Ala Gln
130 135 140
Ile Ala Gly Leu Arg Gly Gln Leu Glu Ala Leu Gln Val Asp Gly Gly
145 150 155 160
Arg Leu Glu Gln Gly Leu Arg Thr Met Gln Asp Val Val Glu Asp Phe
165 170 175
Lys Asn Lys Tyr Glu Asp Glu Ile Asn Arg Arg Thr Ala Ala Glu Asn
180 185 190
Glu Phe Val Val Leu Lys Lys Asp Val Asp Ala Ala Tyr Met Ser Lys
195 200 205
Val Glu Leu Glu Ala Lys Val Asp Ala Leu Asn Asp Glu Ile Asn Phe
210 215 220
Leu Arg Thr Leu Asn Glu Thr Glu Leu Thr Glu Leu Gln Ser Gln Ile
225 230 235 240
Ser Asp Thr Ser Val Val Leu Ser Met Asp Asn Ser Arg Ser Leu Asp
245 250 255
Leu Asp Gly Ile Ile Ala Glu Val Lys Ala Gln Tyr Glu Glu Met Ala
260 265 270
Lys Cys Ser Arg Ala Glu Ala Glu Ala Trp Tyr Gln Thr Lys Phe Glu
275 280 285
Thr Leu Gln Ala Gln Ala Gly Lys His Gly Asp Asp Leu Arg Asn Thr
290 295 300
Arg Asn Glu Ile Ser Glu Met Asn Arg Ala Ile Gln Arg Leu Gln Ala
305 310 315 320
Glu Ile Asp Asn Ile Lys Asn Gln Arg Ala Lys Leu Glu Ala Ala Ile
325 330 335
Ala Glu Ala Glu Glu Arg Gly Glu Leu Ala Leu Lys Asp Ala Arg Ala
340 345 350
Lys Gln Glu Glu Leu Glu Ala Ala Leu Gln Arg Ala Lys Gln Asp Met
355 360 365
Ala Arg Gln Leu Arg Glu Tyr Gln Glu Leu Met Ser Val Lys Leu Ala
370 375 380
Leu Asp Ile Glu Ile Ala Thr Tyr Arg Lys Leu Leu Glu Gly Glu Glu
385 390 395 400
Ser Arg Leu Ala Gly Asp Gly Val Gly Ala Val Asn Ile Ser Val Met
405 410 415
Asn Ser Thr Gly Gly Ser Ser Ser Gly Gly Gly Ile Gly Leu Thr Leu
420 425 430
Gly Gly Thr Met Gly Ser Asn Ala Leu Ser Phe Ser Ser Ser Ala Gly
435 440 445
Pro Gly Leu Leu Lys Ala Tyr Ser Ile Arg Thr Ala Ser Ala Ser Arg
450 455 460
Arg Ser Ala Arg Asp
465
<210>53
<211>836
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉Gegenbaur's cell specific factor 2 precursors
<222>(1)..(836)
＜223〉on Dec 10th, 2002 registration number: Q15063
<400>53
Met Ile Pro Phe Leu Pro Met Phe Ser Leu Leu Leu Leu Leu Ile Val
1 5 10 15
Asn Pro Ile Asn Ala Asn Asn His Tyr Asp Lys Ile Leu Ala His Ser
20 25 30
Arg Ile Arg Gly Arg Asp Gln Gly Pro Asn Val Cys Ala Leu Gln Gln
35 40 45
Ile Leu Gly Thr Lys Lys Lys Tyr Phe Ser Thr Cys Lys Asn Trp Tyr
50 55 60
Lys Lys Ser Ile Cys Gly Gln Lys Thr Thr Val Leu Tyr Glu Cys Cys
65 70 75 80
Pro Gly Tyr Met Arg Met Glu Gly Met Lys Gly Cys Pro Ala Val Leu
85 90 95
Pro Ile Asp His Val Tyr Gly Thr Leu Gly Ile Val Gly Ala Thr Thr
100 105 110
Thr Gln Arg Tyr Ser Asp Ala Ser Lys Leu Arg Glu Glu Ile Glu Gly
115 120 125
Lys Gly Ser Phe Thr Tyr Phe Ala Pro Ser Asn Glu Ala Trp Asp Asn
130 135 140
Leu Asp Ser Asp Ile Arg Arg Gly Leu Glu Ser Asn Val Asn Val Glu
145 150 155 160
Leu Leu Asn Ala Leu His Ser His Met Ile Asn Lys Arg Met Leu Thr
165 170 175
Lys Asp Leu Lys Asn Gly Met Ile Ile Pro Ser Met Tyr Asn Asn Leu
180 185 190
Gly Leu Phe Ile Asn His Tyr Pro Asn Gly Val Val Thr Val Asn Cys
195 200 205
Ala Arg Ile Ile His Gly Asn Gln Ile Ala Thr Asn Gly Val Val His
210 215 220
Val Ile Asp Arg Val Leu Thr Gln Ile Gly Thr Ser Ile Gln Asp Phe
225 230 235 240
Ile Glu Ala Glu Asp Asp Leu Ser Ser Phe Arg Ala Ala Ala Ile Thr
245 250 255
Ser Asp Ile Leu Glu Ala Leu Gly Arg Asp Gly His Phe Thr Leu Phe
260 265 270
Ala Pro Thr Asn Glu Ala Phe Glu Lys Leu Pro Arg Gly Val Leu Glu
275 280 285
Arg Phe Met Gly Asp Lys Val Ala Ser Glu Ala Leu Met Lys Tyr His
290 295 300
Ile Leu Asn Thr Leu Gln Cys Ser Glu Ser Ile Met Gly Gly Ala Val
305 310 315 320
Phe Glu Thr Leu Glu Gly Asn Thr Ile Glu Ile Gly Cys Asp Gly Asp
325 330 335
Ser Ile Thr Val Asn Gly Ile Lys Met Val Asn Lys Lys Asp Ile Val
340 345 350
Thr Asn Asn Gly Val Ile His Leu Ile Asp Gln Val Leu Ile Pro Asp
355 360 365
Ser Ala Lys Gln Val Ile Glu Leu Ala Gly Lys Gln Gln Thr Thr Phe
370 375 380
Thr Asp Leu Val Ala Gln Leu Gly Leu Ala Ser Ala Leu Arg Pro Asp
385 390 395 400
Gly Glu Tyr Thr Leu Leu Ala Pro Val Asn Asn Ala Phe Ser Asp Asp
405 410 415
Thr Leu Ser Met Val Gln Arg Leu Leu Lys Leu Ile Leu Gln Asn His
420 425 430
Ile Leu Lys Val Lys Val Gly Leu Asn Glu Leu Tyr Asn Gly Gln Ile
435 440 445
Leu Glu Thr Ile Gly Gly Lys Gln Leu Arg Val Phe Val Tyr Arg Thr
450 455 460
Ala Val Cys Ile Glu Asn Ser Cys Met Glu Lys Gly Ser Lys Gln Gly
465 470 475 480
Arg Asn Gly Ala Ile His Ile Phe Arg Glu Ile Ile Lys Pro Ala Glu
485 490 495
Lys Ser Leu His Glu Lys Leu Lys Gln Asp Lys Arg Phe Ser Thr Phe
500 505 510
Leu Ser Leu Leu Glu Ala Ala Asp Leu Lys Glu Leu Leu Thr Gln Pro
515 520 525
Gly Asp Trp Thr Leu Phe Val Pro Thr Asn Asp Ala Phe Lys Gly Met
530 535 540
Thr Ser Glu Glu Lys Glu Ile Leu Ile Arg Asp Lys Asn Ala Leu Gln
545 550 555 560
Asn Ile Ile Leu Tyr His Leu Thr Pro Gly Val Phe Ile Gly Lys Gly
565 570 575
Phe Glu Pro Gly Val Thr Asn Ile Leu Lys Thr Thr Gln Gly Ser Lys
580 585 590
Ile Phe Leu Lys Glu Val Asn Asp Thr Leu Leu Val Asn Glu Leu Lys
595 600 605
Ser Lys Glu Ser Asp Ile Met Thr Thr Asn Gly Val Ile His Val Val
610 615 620
Asp Lys Leu Leu Tyr Pro Ala Asp Thr Pro Val Gly Asn Asp Gln Leu
625 630 635 640
Leu Glu Ile Leu Asn Lys Leu Ile Lys Tyr Ile Gln Ile Lys Phe Val
645 650 655
Arg Gly Ser Thr Phe Lys Glu Ile Pro Val Thr Val Tyr Thr Thr Lys
660 665 670
Ile Ile Thr Lys Val Val Glu Pro Lys Ile Lys Val Ile Glu Gly Ser
675 680 685
Leu Gln Pro Ile Ile Lys Thr Glu Gly Pro Thr Leu Thr Lys Val Lys
690 695 700
Ile Glu Gly Glu Pro Glu Phe Arg Leu Ile Lys Glu Gly Glu Thr Ile
705 710 715 720
Thr Glu Val Ile His Gly Glu Pro Ile Ile Lys Lys Tyr Thr Lys Ile
725 730 735
Ile Asp Gly Val Pro Val Glu Ile Thr Glu Lys Glu Thr Arg Glu Glu
740 745 750
Arg Ile Ile Thr Gly Pro Glu Ile Lys Tyr Thr Arg Ile Ser Thr Gly
755 760 765
Gly Gly Glu Thr Glu Glu Thr Leu Lys Lys Leu Leu Gln Glu Glu Val
770 775 780
Thr Lys Val Thr Lys Phe Ile Glu Gly Gly Asp Gly His Leu Phe Glu
785 790 795 800
Asp Glu Glu lle Lys Arg Leu Leu Gln Gly Asp Thr Pro Val Arg Lys
805 810 815
Leu Gln Ala Asn Lys Lys Val Gln Gly Ser Arg Arg Arg Leu Arg Glu
820 825 830
Gly Arg Ser Gln
835
<210>54
<211>687
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉albumen-glutamine gamma-glutamyl transferase
<222>(1)..(687)
＜223〉registration number P21980
<400>54
Met Ala Glu Glu Leu Val Leu Glu Arg Cys Asp Leu Glu Leu Glu Thr
1 5 10 15
Asn Gly Arg Asp His His Thr Ala Asp Leu Cys Arg Glu Lys Leu Val
20 25 30
Val Arg Arg Gly Gln Pro Phe Trp Leu Thr Leu His Phe Glu Gly Arg
35 40 45
Asn Tyr Glu Ala Ser Val Asp Ser Leu Thr Phe Ser Val Val Thr Gly
50 55 60
Pro Ala Pro Ser Gln Glu Ala Gly Thr Lys Ala Arg Phe Pro Leu Arg
65 70 75 80
Asp Ala Val Glu Glu Gly Asp Trp Thr Ala Thr Val Val Asp Gln Gln
85 90 95
Asp Cys Thr Leu Ser Leu Gln Leu Thr Thr Pro Ala Asn Ala Pro Ile
100 105 110
Gly Leu Tyr Arg Leu Ser Leu Glu Ala Ser Thr Gly Tyr Gln Gly Ser
115 120 125
Ser Phe Val Leu Gly His Phe Ile Leu Leu Phe Asn Ala Trp Cys Pro
130 135 140
Ala Asp Ala Val Tyr Leu Asp Ser Glu Glu Glu Arg Gln Glu Tyr Val
145 150 155 160
Leu Thr Gln Gln Gly Phe Ile Tyr Gln Gly Ser Ala Lys Phe Ile Lys
165 170 175
Asn Ile Pro Trp Asn Phe Gly Gln Phe Glu Asp Gly Ile Leu Asp Ile
180 185 190
Cys Leu Ile Leu Leu Asp Val Asn Pro Lys Phe Leu Lys Asn Ala Gly
195 200 205
Arg Asp Cys Ser Arg Arg Ser Ser Pro Val Tyr Val Gly Arg Val Val
210 215 220
Ser Gly Met Val Asn Cys Asn Asp Asp Gln Gly Val Leu Leu Gly Arg
225 230 235 240
Trp Asp Asn Asn Tyr Gly Asp Gly Val Ser Pro Met Ser Trp Ile Gly
245 250 255
Ser Val Asp Ile Leu Arg Arg Trp Lys Asn His Gly Cys Gln Arg Val
260 265 270
Lys Tyr Gly Gln Cys Trp Val Phe Ala Ala Val Ala Cys Thr Val Leu
275 280 285
Arg Cys Leu Gly Ile Pro Thr Arg Val Val Thr Asn Tyr Asn Ser Ala
290 295 300
His Asp Gln Asn Ser Asn Leu Leu Ile Glu Tyr Phe Arg Asn Glu Phe
305 310 315 320
Gly Glu Ile Gln Gly Asp Lys Ser Glu Met Ile Trp Asn Phe His Cys
325 330 335
Trp Val Glu Ser Trp Met Thr Arg Pro Asp Leu Gln Pro Gly Tyr Glu
340 345 350
Gly Trp Gln Ala Leu Asp Pro Thr Pro Gln Glu Lys Ser Glu Gly Thr
355 360 365
Tyr Cys Cys Gly Pro Val Pro Val Arg Ala Ile Lys Glu Gly Asp Leu
370 375 380
Ser Thr Lys Tyr Asp Ala Pro Phe Val Phe Ala Glu Val Asn Ala Asp
385 390 395 400
Val Val Asp Trp Ile Gln Gln Asp Asp Gly Ser Val His Lys Ser Ile
405 410 415
Asn Arg Ser Leu Ile Val Gly Leu Lys Ile Ser Thr Lys Ser Val Gly
420 425 430
Arg Asp Glu Arg Glu Asp Ile Thr His Thr Tyr Lys Tyr Pro Glu Gly
435 440 445
Ser Ser Glu Glu Arg Glu Ala Phe Thr Arg Ala Asn His Leu Asn Lys
450 455 460
Leu Ala Glu Lys Glu Glu Thr Gly Met Ala Met Arg Ile Arg Val Gly
465 470 475 480
Gln Ser Met Asn Met Gly Ser Asp Phe Asp Val Phe Ala His Ile Thr
485 490 495
Asn Asn Thr Ala Glu Glu Tyr Val Cys Arg Leu Leu Leu Cys Ala Arg
500 505 510
Thr Val Ser Tyr Asn Gly Ile Leu Gly Pro Glu Cys Gly Thr Lys Tyr
515 520 525
Leu Leu Asn Leu Asn Leu Glu Pro Phe Ser Glu Lys Ser Val Pro Leu
530 535 540
Cys Ile Leu Tyr Glu Lys Tyr Arg Asp Cys Leu Thr Glu Ser Asn Leu
545 550 555 560
Ile Lys Val Arg Ala Leu Leu Val Glu Pro Val Ile Asn Ser Tyr Leu
565 570 575
Leu Ala Glu Arg Asp Leu Tyr Leu Glu Asn Pro Glu Ile Lys Ile Arg
580 585 590
Ile Leu Gly Glu Pro Lys Gln Lys Arg Lys Leu Val Ala Glu Val Ser
595 600 605
Leu Gln Asn Pro Leu Pro Val Ala Leu Glu Gly Cys Thr Phe Thr Val
610 615 620
Glu Gly Ala Gly Leu Thr Glu Glu Gln Lys Thr Val Glu Ile Pro Asp
625 630 635 640
Pro Val Glu Ala Gly Glu Glu Val Lys Val Arg Met Asp Leu Leu Pro
645 650 655
Leu His Met Gly Leu His Lys Leu Val Val Asn Phe Glu Ser Asp Lys
660 665 670
Leu Lys Ala Val Lys Gly Phe Arg Asn Val Ile Ile Gly Pro Ala
675 680 685
<210>55
<211>204
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the Rho GDP-inhibitor 1 that dissociates
<222>(1)..(204)
＜223〉on Dec 10th, 2002 registration number: P52565
<400>55
Met Ala Glu Gln Glu Pro Thr Ala Glu Gln Leu Ala Gln Ile Ala Ala
1 5 10 15
Glu Asn Glu Glu Asp Glu His Ser Val Asn Tyr Lys Pro Pro Ala Gln
20 25 30
Lys Ser Ile Gln Glu Ile Gln Glu Leu Asp Lys Asp Asp Glu Ser Leu
35 40 45
Arg Lys Tyr Lys Glu Ala Leu Leu Gly Arg Val Ala Val Ser Ala Asp
50 55 60
Pro Asn Val Pro Asn Val Val Val Thr Gly Leu Thr Leu Val Cys Ser
65 70 75 80
Ser Ala Pro Gly Pro Leu Glu Leu Asp Leu Thr Gly Asp Leu Glu Ser
85 90 95
Phe Lys Lys Gln Ser Phe Val Leu Lys Glu Gly Val Glu Tyr Arg Ile
100 105 110
Lys Ile Ser Phe Arg Val Asn Arg Glu Ile Val Ser Gly Met Lys Tyr
115 120 125
Ile Gln His Thr Tyr Arg Lys Gly Val Lys Ile Asp Lys Thr Asp Tyr
130 135 140
Met Val Gly Ser Tyr Gly Pro Arg Ala Glu Glu Tyr Glu Phe Leu Thr
145 150 155 160
Pro Val Glu Glu Ala Pro Lys Gly Met Leu Ala Arg Gly Ser Tyr Ser
165 170 175
Ile Lys Ser Arg Phe Thr Asp Asp Asp Lys Thr Asp His Leu Ser Trp
180 185 190
Glu Trp Asn Leu Thr Ile Lys Lys Asp Trp Lys Asp
195 200
<210>56
<211>492
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the flesh fasciclin 2
<222>(1)..(492)
＜223〉on August 29th, 2003 registration number: 014926
<400>56
Met Pro Thr Asn Gly Leu His Gln Val Leu Lys Ile Gln Phe Gly Leu
1 5 10 15
Val Asn Asp Thr Asp Arg Tyr Leu Thr Ala Glu Ser Phe Gly Phe Lys
20 25 30
Val Asn Ala Ser Ala Pro Ser Leu Lys Arg Lys Gln Thr Trp Val Leu
35 40 45
Glu Pro Asp Pro Gly Gln Gly Thr Ala Val Leu Leu Arg Ser Ser His
50 55 60
Leu Gly Arg Tyr Leu Ser Ala Glu Glu Asp Gly Arg Val Ala Cys Glu
65 70 75 80
Ala Glu Gln Pro Gly Arg Asp Cys Arg Phe Leu Val Leu Pro Gln Pro
85 90 95
Asp Gly Arg Trp Val Leu Arg Ser Glu Pro His Gly Arg Phe Phe Gly
100 105 110
Gly Thr Glu Asp Gln Leu Ser Cys Phe Ala Thr Ala Val Ser Pro Ala
115 120 125
Glu Leu Trp Thr Val His Leu Ala Ile His Pro Gln Ala His Leu Leu
130 135 140
Ser Val Ser Arg Arg Arg Tyr Val His Leu Cys Pro Arg Glu Asp Glu
145 150 155 160
Met Ala Ala Asp Gly Asp Lys Pro Trp Gly Val Asp Ala Leu Leu Thr
165 170 175
Leu lle Phe Arg Ser Arg Arg Tyr Cys Leu Lys Ser Cys Asp Ser Arg
180 185 190
Tyr Leu Arg Ser Asp Gly Arg Leu Val Trp Glu Pro Glu Pro Arg Ala
195 200 205
Cys Tyr Thr Leu Glu Phe Lys Ala Gly Lys Leu Ala Phe Lys Asp Cys
210 215 220
Asp Gly His Tyr Leu Ala Pro Val Gly Pro Ala Gly Thr Leu Lys Ala
225 230 235 240
Gly Arg Asn Thr Arg Pro Gly Lys Asp Glu Leu Phe Asp Leu Glu Glu
245 250 255
Ser His Pro Gln Val Val Leu Val Ala Ala Asn His Arg Tyr Val Ser
260 265 270
Val Arg Gln Gly Val Asn Val Ser Ala Asn Gln Asp Asp Glu Leu Asp
275 280 285
His Glu Thr Phe Leu Met Gln Ile Asp Gln Glu Thr Lys Lys Cys Thr
290 295 300
Phe Tyr Ser Ser Thr Gly Gly Tyr Trp Thr Leu Val Thr His Gly Gly
305 310 315 320
Ile His Ala Thr Ala Thr Gln Val Ser Ala Asn Thr Met Phe Glu Met
325 330 335
Glu Trp Arg Gly Arg Arg Val Ala Leu Lys Ala Ser Asn Gly Arg Tyr
340 345 350
Val Cys Met Lys Lys Asn Gly Gln Leu Ala Ala Ile Ser Asp Phe Val
355 360 365
Gly Lys Asp Glu Glu Phe Thr Leu Lys Leu Ile Asn Arg Pro Ile Leu
370 375 380
Val Leu Arg Gly Leu Asp Gly Phe Val Cys His His Arg Gly Ser Asn
385 390 395 400
Gln Leu Asp Thr Asn Arg Ser Val Tyr Asp Val Phe His Leu Ser Phe
405 410 415
Ser Asp Gly Ala Tyr Arg Ile Arg Gly Arg Asp Gly Gly Phe Trp Tyr
420 425 430
Thr Gly Ser His Gly Ser Val Cys Ser Asp Gly Glu Arg Ala Glu Asp
435 440 445
Phe Val Phe Glu Phe Arg Glu Arg Gly Arg Leu Ala Ile Arg Ala Arg
450 455 460
Ser Gly Lys Tyr Leu Arg Gly Gly Ala Ser Gly Leu Leu Arg Ala Asp
465 470 475 480
Ala Asp Ala Pro Ala Gly Thr Ala Leu Trp Glu Tyr
485 490
<210>57
<211>165
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉Destrin (actin depolymerizing factor) (ADF)
<222>(1)..(165)
＜223〉on August 29th, 2003 registration number: P18282
<400>57
Met Ala Ser Gly Val Gln Val Ala Asp Glu Val Cys Arg Ile Phe Tyr
1 5 10 15
Asp Met Lys Val Arg Lys Cys Ser Thr Pro Glu Glu Ile Lys Lys Arg
20 25 30
Lys Lys Ala Val Ile Phe Cys Leu Ser Ala Asp Lys Lys Cys Ile Ile
35 40 45
Val Glu Glu Gly Lys Glu Ile Leu Val Gly Asp Val Gly Val Thr Ile
50 55 60
Thr Asp Pro Phe Lys His Phe Val Gly Met Leu Pro Glu Lys Asp Cys
65 70 75 80
Arg Tyr Ala Leu Tyr Asp Ala Ser Phe Glu Thr Lys Glu Ser Arg Lys
85 90 95
Glu Glu Leu Met Phe Phe Leu Trp Ala Pro Glu Leu Ala Pro Leu Lys
100 105 110
Ser Lys Met Ile Tyr Ala Ser Ser Lys Asp Ala Ile Lys Lys Lys Phe
115 120 125
Gln Gly Ile Lys His Glu Cys Gln Ala Asn Gly Pro Glu Asp Leu Asn
130 135 140
Arg Ala Cys Ile Ala Glu Lys Leu Gly Gly Ser Leu Ile Val Ala Phe
145 150 155 160
Glu Gly Cys Pro Val
165
<210>58
<211>492
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉flesh fasciclin
<222>(1)..(492)
＜223〉on August 29th, 2003 registration number: Q16658
<400>58
Thr Ala Asn Gly Thr Ala Glu Ala Val Gln Ile Gln Phe Gly Leu Ile
1 5 10 15
Asn Cys Gly Asn Lys Tyr Leu Thr Ala Glu Ala Phe Gly Phe Lys Val
20 25 30
Asn Ala Ser Ala Ser Ser Leu Lys Lys Lys Gln Ile Trp Thr Leu Glu
35 40 45
Gln Pro Pro Asp Glu Ala Gly Ser Ala Ala Val Cys Leu Arg Ser His
50 55 60
Leu Gly Arg Tyr Leu Ala Ala Asp Lys Asp Gly Asn Val Thr Cys Glu
65 70 75 80
Arg Glu Val Pro Gly Pro Asp Cys Arg Phe Leu Ile Val Ala His Asp
85 90 95
Asp Gly Arg Trp Ser Leu Gln Ser Glu Ala His Arg Arg Tyr Phe Gly
100 105 110
Gly Thr Glu Asp Arg Leu Ser Cys Phe Ala Gln Thr Val Ser Pro Ala
115 120 125
Glu Lys Trp Ser Val His Ile Ala Met His Pro Gln Val Asn Ile Tyr
130 135 140
Ser Val Thr Arg Lys Arg Tyr Ala His Leu Ser Ala Arg Pro Ala Asp
145 150 155 160
Glu Ile Ala Val Asp Arg Asp Val Pro Trp Gly Val Asp Ser Leu Ile
165 170 175
Thr Leu Ala Phe Gln Asp Gln Arg Tyr Ser Val Gln Thr Ala Asp His
180 185 190
Arg Phe Leu Arg His Asp Gly Arg Leu Val Ala Arg Pro Glu Pro Ala
195 200 205
Thr Gly Tyr Thr Leu Glu Phe Arg Ser Gly Lys Val Ala Phe Arg Asp
210 215 220
Cys Glu Gly Arg Tyr Leu Ala Pro Ser Gly Pro Ser Gly Thr Leu Lys
225 230 235 240
Ala Gly Lys Ala Thr Lys Val Gly Lys Asp Glu Leu Phe Ala Leu Glu
245 250 255
Gln Ser Cys Ala Gln Val Val Leu Gln Ala Ala Asn Glu Arg Asn Val
260 265 270
Ser Thr Arg Gln Gly Met Asp Leu Ser Ala Asn Gln Asp Glu Glu Thr
275 280 285
Asp Gln Glu Thr Phe Gln Leu Glu Ile Asp Arg Asp Thr Lys Lys Cys
290 295 300
Ala Phe Arg Thr His Thr Gly Lys Tyr Trp Thr Leu Thr Ala Thr Gly
305 310 315 320
Gly Val Gln Ser Thr Ala Ser Ser Lys Asn Ala Ser Cys Tyr Phe Asp
325 330 335
Ile Glu Trp Arg Asp Arg Arg Ile Thr Leu Arg Ala Ser Asn Gly Lys
340 345 350
Phe Val Thr Ser Lys Lys Asn Gly Gln Leu Ala Ala Ser Val Glu Thr
355 360 365
Ala Gly Asp Ser Glu Leu Phe Leu Met Lys Leu Ile Asn Arg Pro Ile
370 375 380
Ile Val Phe Arg Gly Glu His Gly Phe Ile Gly Cys Arg Lys Val Thr
385 390 395 400
Gly Thr Leu Asp Ala Asn Arg Ser Ser Tyr Asp Val Phe Gln Leu Glu
405 410 415
Phe Asn Asp Gly Ala Tyr Asn Ile Lys Asp Ser Thr Gly Lys Tyr Trp
420 425 430
Thr Val Gly Ser Asp Ser Ala Val Thr Ser Ser Gly Asp Thr Pro Val
435 440 445
Asp Phe Phe Phe Glu Phe Cys Asp Tyr Asn Lys Val Ala Ile Lys Val
450 455 460
Gly Gly Arg Tyr Leu Lys Gly Asp His Ala Gly Val Leu Lys Ala Ser
465 470 475 480
Ala Glu Thr Val Asp Pro Ala Ser Leu Trp Glu Tyr
485 490
<210>59
<211>317
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉apolipoprotein-E precursor
<222>(1)..(317)
＜223〉on August 29th, 2003 registration number: P02649
<400>59
Met Lys Val Leu Trp Ala Ala Leu Leu Val Thr Phe Leu Ala Gly Cys
1 5 10 15
Gln Ala Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu
20 25 30
Arg Gln Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu
35 40 45
Gly Arg Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln
50 55 60
Val Gln Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala
65 70 75 80
Leu Met Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu
85 90 95
Glu Glu Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser
100 105 110
Lys Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp
115 120 125
Val Cys Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu
130 135 140
Gly Gln Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His Leu Arg
145 150 155 160
Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Gln Lys Arg
165 170 175
Leu Ala Val Tyr Gln Ala Gly Ala Arg Glu Gly Ala Glu Arg Gly Leu
180 185 190
Ser Ala Ile Arg Glu Arg Leu Gly Pro Leu Val Glu Gln Gly Arg Val
195 200 205
Arg Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg
210 215 220
Ala Gln Ala Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly
225 230 235 240
Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu
245 250 255
Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala
260 265 270
Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu
275 280 285
Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala
290 295 300
Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His
305 310 315
<210>60
<211>838
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the false 88.6kDa albumen of intending
<222>(1)..(838)
＜223〉on August 29th, 2003 registration number: Q96C61
<400>60
Met Pro Ser Gly Lys Val Ala Gln Pro Thr Ile Thr Asp Asn Lys Asp
1 5 10 15
Gly Thr Val Thr Val Arg Tyr Ala Pro Ser Glu Ala Gly Leu His Glu
20 25 30
Met Asp Ile Arg Tyr Asp Asn Met His Ile Pro Gly Ser Pro Leu Gln
35 40 45
Phe Tyr Val Asp Tyr Val Asn Cys Gly His Val Thr Ala Tyr Gly Pro
50 55 60
Gly Leu Thr His Gly Val Val Asn Lys Pro Ala Thr Phe Thr Val Asn
65 70 75 80
Thr Lys Asp Ala Gly Glu Gly Gly Leu Ser Leu Ala Ile Glu Gly Pro
85 90 95
Ser Lys Ala Glu Ile Ser Cys Thr Asp Asn Gln Asp Gly Thr Cys Ser
100 105 110
Val Ser Tyr Leu Pro Val Leu Pro Gly Asp Tyr Ser Ile Leu Val Lys
115 120 125
Tyr Asn Glu Gln His Val Pro Gly Ser Pro Phe Thr Ala Arg Val Thr
130 135 140
Gly Asp Asp Ser Met Arg Met Ser His Leu Lys Val Gly Ser Ala Ala
145 150 155 160
Asp Ile Pro Ile Asn Ile Ser Glu Thr Asp Leu Ser Leu Leu Thr Ala
165 170 175
Thr Val Val Pro Pro Ser Gly Arg Glu Glu Pro Cys Leu Leu Lys Arg
180 185 190
Leu Arg Asn Gly His Val Gly Ile Ser Phe Val Pro Lys Glu Thr Gly
195 200 205
Glu His Leu Val His Val Lys Lys Asn Gly Gln His Val Ala Ser Ser
210 215 220
Pro Ile Pro Val Val Ile Ser Gln Ser Glu Ile Gly Asp Ala Ser Arg
225 230 235 240
Val Arg Val Ser Gly Gln Gly Leu His Glu Gly His Thr Phe Glu Pro
245 250 255
Ala Glu Phe Ile Ile Asp Thr Arg Asp Ala Gly Tyr Gly Gly Leu Ser
260 265 270
Leu Ser Ile Glu Gly Pro Ser Lys Val Asp Ile Asn Thr Glu Asp Leu
275 280 285
Glu Asp Gly Thr Cys Arg Val Thr Tyr Cys Pro Thr Glu Pro Gly Asn
290 295 300
Tyr Ile Ile Asn Ile Lys Phe Ala Asp Gln His Val Pro Gly Ser Pro
305 310 315 320
Phe Ser Val Lys Val Thr Gly Glu Gly Arg Val Lys Glu Ser Ile Thr
325 330 335
Arg Arg Arg Arg Ala Pro Ser Val Ala Asn Val Gly Ser His Cys Asp
340 345 350
Leu Ser Leu Lys Ile Pro Glu Ile Ser Ile Gln Asp Met Thr Ala Gln
355 360 365
Val Thr Ser Pro Ser Gly Lys Thr His Glu Ala Glu Ile Val Glu Gly
370 375 380
Glu Asn His Thr Tyr Cys Ile Arg Phe Val Pro Ala Glu Met Gly Thr
385 390 395 400
His Thr Val Ser Val Lys Tyr Lys Gly Gln His Val Pro Gly Ser Pro
405 410 415
Phe Gln Phe Thr Val Gly Pro Leu Gly Glu Gly Gly Ala His Lys Val
420 425 430
Arg Ala Gly Gly Pro Gly Leu Glu Arg Ala Glu Ala Gly Val Pro Ala
435 440 445
Glu Phe Ser Ile Trp Thr Arg Glu Ala Gly Ala Gly Gly Leu Ala Ile
450 455 460
Ala Val Glu Gly Pro Ser Lys Ala Glu Ile Ser Phe Glu Asp Arg Lys
465 470 475 480
Asp Gly Ser Cys Gly Val Ala Tyr Val Val Gln Glu Pro Gly Asp Tyr
485 490 495
Glu Val Ser Val Lys Phe Asn Glu Glu His Ile Pro Asp Ser Pro Phe
500 505 5l0
Val Val Pro Val Ala Ser Pro Ser Gly Asp Ala Arg Arg Leu Thr Val
515 520 525
Ser Ser Leu Gln Glu Ser Gly Leu Lys Val Asn Gln Pro Ala Ser Phe
530 535 540
Ala Val Ser Leu Asn Gly Ala Lys Gly Ala Ile Asp Ala Lys Val His
545 550 555 560
Ser Pro Ser Gly Ala Leu Glu Glu Cys Tyr Val Thr Glu Ile Asp Gln
565 570 575
Asp Lys Tyr Ala Val Arg Phe Ile Pro Arg Glu Asn Gly Val Tyr Leu
580 585 590
Ile Asp Val Lys Phe Asn Gly Thr His Ile Pro Gly Ser Pro Phe Lys
595 600 605
Ile Arg Val Gly Glu Pro Gly His Gly Gly Asp Pro Gly Leu Val Ser
610 615 620
Ala Tyr Gly Ala Gly Leu Glu Gly Gly Val Thr Gly Asn Pro Ala Glu
625 630 635 640
Phe Val Val Asn Thr Ser Asn Ala Gly Ala Gly Ala Leu Ser Val Thr
645 650 655
Ile Asp Gly Pro Ser Lys Val Lys Met Asp Cys Gln Glu Cys Pro Glu
660 665 670
Gly Tyr Arg Val Thr Tyr Thr Pro Met Ala Pro Gly Ser Tyr Leu Ile
675 680 685
Ser Ile Lys Tyr Gly Gly Pro Tyr His Ile Gly Gly Ser Pro Phe Lys
690 695 700
Ala Lys Val Thr Gly Pro Arg Leu Val Ser Asn His Ser Leu His Glu
705 710 715 720
Thr Ser Ser Val Phe Val Asp Ser Leu Thr Lys Ala Thr Cys Ala Pro
725 730 735
Gln His Gly Ala Pro Gly Pro Gly Pro Ala Asp Ala Ser Lys Val Val
740 745 750
Ala Lys Gly Leu Gly Leu Ser Lys Ala Tyr Val Gly Gln Lys Ser Ser
755 760 765
Phe Thr Val Asp Cys Ser Lys Ala Gly Asn Asn Met Leu Leu Val Gly
770 775 780
Val His Gly Pro Arg Thr Pro Cys Glu Glu Ile Leu Val Lys His Val
785 790 795 800
Gly Ser Arg Leu Tyr Ser Val Ser Tyr Leu Leu Lys Asp Lys Gly Glu
805 810 815
Tyr Thr Leu Val Val Lys Trp Gly Asp Glu His Ile Pro Gly Ser Pro
820 825 830
Tyr Arg Val Val Val Pro
835
<210>61
<211>433
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉human alpha-enolase
<222>(1)..(433)
＜223〉on August 29th, 2003 registration number: P06733
<400>61
Ser Ile Leu Lys Ile His Ala Arg Glu Ile Phe Asp Ser Arg Gly Asn
1 5 10 15
Pro Thr Val Glu Val Asp Leu Phe Thr Ser Lys Gly Leu Phe Arg Ala
20 25 30
Ala Val Pro Ser Gly Ala Ser Thr Gly Ile Tyr Glu Ala Leu Glu Leu
35 40 45
Arg Asp Asn Asp Lys Thr Arg Tyr Met Gly Lys Gly Val Ser Lys Ala
50 55 60
Val Glu His Ile Asn Lys Thr Ile Ala Pro Ala Leu Val Ser Lys Lys
65 70 75 80
Leu Asn Val Thr Glu Gln Glu Lys Ile Asp Lys Leu Met Ile Glu Met
85 90 95
Asp Gly Thr Glu Asn Lys Ser Lys Phe Gly Ala Asn Ala Ile Leu Gly
100 105 110
Val Ser Leu Ala Val Cys Lys Ala Gly Ala Val Glu Lys Gly Val Pro
115 120 125
Leu Tyr Arg His Ile Ala Asp Leu Ala Gly Asn Ser Glu Val Ile Leu
130 135 140
Pro Val Pro Ala Phe Asn Val Ile Asn Gly Gly Ser His Ala Gly Asn
145 150 155 160
Lys Leu Ala Met Gln Glu Phe Met Ile Leu Pro Val Gly Ala Ala Asn
165 170 175
Phe Arg Glu Ala Met Arg Ile Gly Ala Glu Val Tyr His Asn Leu Lys
180 185 190
Asn Val Ile Lys Glu Lys Tyr Gly Lys Asp Ala Thr Asn Val Gly Asp
195 200 205
Glu Gly Gly Phe Ala Pro Asn Ile Leu Glu Asn Lys Glu Gly Leu Glu
210 215 220
Leu Leu Lys Thr Ala Ile Gly Lys Ala Gly Tyr Thr Asp Lys Val Val
225 230 235 240
Ile Gly Met Asp Val Ala Ala Ser Glu Phe Phe Arg Ser Gly Lys Tyr
245 250 255
Asp Leu Asp Phe Lys Ser Pro Asp Asp Pro Ser Arg Tyr Ile Ser Pro
260 265 270
Asp Gln Leu Ala Asp Leu Tyr Lys Ser Phe Ile Lys Asp Tyr Pro Val
275 280 285
Val Ser Ile Glu Asp Pro Phe Asp Gln Asp Asp Trp Gly Ala Trp Gln
290 295 300
Lys Phe Thr Ala Ser Ala Gly Ile Gln Val Val Gly Asp Asp Leu Thr
305 310 315 320
Val Thr Asn Pro Lys Arg Ile Ala Lys Ala Val Asn Glu Lys Ser Cys
325 330 335
Asn Cys Leu Leu Leu Lys Val Asn Gln Ile Gly Ser Val Thr Glu Ser
340 345 350
Leu Gln Ala Cys Lys Leu Ala Gln Ala Asn Gly Trp Gly Val Met Val
355 360 365
Ser His Arg Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val
370 375 380
Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg Ser
385 390 395 400
Glu Arg Leu Ala Lys Tyr Asn Gln Leu Leu Arg Ile Glu Glu Glu Leu
405 410 415
Gly Ser Lys Ala Lys Phe Ala Gly Arg Asn Phe Arg Asn Pro Leu Ala
420 425 430
Lys
<210>62
<211>471
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉tryptophane tRNA synzyme
<222>(1)..(471)
＜223〉on August 29th, 2003 registration number: P23381
<400>62
Met Pro Asn Ser Glu Pro Ala Ser Leu Leu Glu Leu Phe Asn Ser Ile
1 5 10 15
Ala Thr Gln Gly Glu Leu Val Arg Ser Leu Lys Ala Gly Asn Ala Ser
20 25 30
Lys Asp Glu Ile Asp Ser Ala Val Lys Met Leu Val Ser Leu Lys Met
35 40 45
Ser Tyr Lys Ala Ala Ala Gly Glu Asp Tyr Lys Ala Asp Cys Pro Pro
50 55 60
Gly Asn Pro Ala Pro Thr Ser Asn His Gly Pro Asp Ala Thr Glu Ala
65 70 75 80
Glu Glu Asp Phe Val Asp Pro Trp Thr Val Gln Thr Ser Ser Ala Lys
85 90 95
Gly Ile Asp Tyr Asp Lys Leu Ile Val Arg Phe Gly Ser Ser Lys Ile
100 105 110
Asp Lys Glu Leu Ile Asn Arg Ile Glu Arg Ala Thr Gly Gln Arg Pro
115 120 125
His His Phe Leu Arg Arg Gly Ile Phe Phe Ser His Arg Asp Met Asn
130 135 140
Gln Val Leu Asp Ala Tyr Glu Asn Lys Lys Pro Phe Tyr Leu Tyr Thr
145 150 155 160
Gly Arg Gly Pro Ser Ser Glu Ala Met His Val Gly His Leu Ile Pro
165 170 175
Phe Ile Phe Thr Lys Trp Leu Gln Asp Val Phe Asn Val Pro Leu Val
180 185 190
Ile Gln Met Thr Asp Asp Glu Lys Tyr Leu Trp Lys Asp Leu Thr Leu
195 200 205
Asp Gln Ala Tyr Ser Tyr Ala Val Glu Asn Ala Lys Asp Ile Ile Ala
210 215 220
Cys Gly Phe Asp Ile Asn Lys Thr Phe Ile Phe Ser Asp Leu Asp Tyr
225 230 235 240
Met Gly Met Ser Ser Gly Phe Tyr Lys Asn Val Val Lys Ile Gln Lys
245 250 255
His Val Thr Phe Asn Gln Val Lys Gly Ile Phe Gly Phe Thr Asp Ser
260 265 270
Asp Cys Ile Gly Lys Ile Ser Phe Pro Ala Ile Gln Ala Ala Pro Ser
275 280 285
Phe Ser Asn Ser Phe Pro Gln Ile Phe Arg Asp Arg Thr Asp Ile Gln
290 295 300
Cys Leu Ile Pro Cys Ala Ile Asp Gln Asp Pro Tyr Phe Arg Met Thr
305 310 315 320
Arg Asp Val Ala Pro Arg Ile Gly Tyr Pro Lys Pro Ala Leu Leu His
325 330 335
Ser Thr Phe Phe Pro Ala Leu Gln Gly Ala Gln Thr Lys Met Ser Ala
340 345 350
Ser Asp Pro Asn Ser Ser Ile Phe Leu Thr Asp Thr Ala Lys Gln Ile
355 360 365
Lys Thr Lys Val Asn Lys His Ala Phe Ser Gly Gly Arg Asp Thr Ile
370 375 380
Glu Glu His Arg Gln Phe Gly Gly Asn Cys Asp Val Asp Val Ser Phe
385 390 395 400
Met Tyr Leu Thr Phe Phe Leu Glu Asp Asp Asp Lys Leu Glu Gln Ile
405 410 415
Arg Lys Asp Tyr Thr Ser Gly Ala Met Leu Thr Gly Glu Leu Lys Lys
420 425 430
Ala Leu Ile Glu Val Leu Gln Pro Leu Ile Ala Glu His Gln Ala Arg
435 440 445
Arg Lys Glu Val Thr Asp Glu Ile Val Lys Glu Phe Met Thr Pro Arg
450 455 460
Lys Leu Ser Phe Asp Phe Gln
465 470
<210>63
<211>106
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉Ig kappa chain C district I
<222>(1)..(106)
＜223〉on August 29th, 2003 registration number: P01834
<400>63
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
1 5 10 15
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
20 25 30
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
35 40 45
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
50 55 60
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
65 70 75 80
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
85 90 95
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105
<210>64
<211>758
<212>PRT
＜213〉people (Homo sapiens)
<220>
<221>Mitofilin
<222>(1)..(758)
＜223〉on August 29th, 2003 registration number: Q16891
<400>64
Met Leu Arg Ala Cys Gln Leu Ser Gly Val Thr Ala Ala Ala Gln Ser
1 5 10 15
Cys Leu Cys Gly Lys Phe Val Leu Arg Pro Leu Arg Pro Cys Arg Arg
20 25 30
Tyr Ser Thr Ser Gly Ser Ser Gly Leu Thr Thr Gly Lys Ile Ala Gly
35 40 45
Ala Gly Leu Leu Phe Val Gly Gly Gly Ile Gly Gly Thr Ile Leu Tyr
50 55 60
Ala Lys Trp Asp Ser His Phe Arg Glu Ser Val Glu Lys Thr Ile Pro
65 70 75 80
Tyr Ser Asp Lys Leu Phe Glu Met Val Leu Gly Pro Ala Ala Tyr Asn
85 90 95
Val Pro Leu Pro Lys Lys Ser Ile Gln Ser Gly Pro Leu Lys Ile Ser
100 105 110
Ser Val Ser Glu Val Met Lys Glu Ser Lys Gln Pro Ala Ser Gln Leu
115 120 125
Gln Lys Gln Lys Gly Asp Thr Pro Ala Ser Ala Thr Ala Pro Thr Glu
130 135 140
Ala Ala Gln Ile Ile Ser Ala Ala Gly Asp Thr Leu Ser Val Pro Ala
145 150 155 160
Pro Ala Val Gln Pro Glu Glu Ser Leu Lys Thr Asp His Pro Glu Ile
165 170 175
Gly Glu Gly Lys Pro Thr Pro Ala Leu Ser Glu Glu Ala Ser Ser Ser
180 185 190
Ser Ile Arg Glu Arg Pro Pro Glu Glu Val Ala Ala Arg Leu Ala Gln
195 200 205
Gln Glu Lys Gln Glu Gln Val Lys Ile Glu Ser Leu Ala Lys Ser Leu
210 215 220
Glu Asp Ala Leu Arg Gln Thr Ala Ser Val Thr Leu Gln Ala Ile Ala
225 230 235 240
Ala Gln Asn Ala Ala Val Gln Ala Val Asn Ala His Ser Asn Ile Leu
245 250 255
Lys Ala Ala Met Asp Asn Ser Glu Ile Ala Gly Glu Lys Lys Ser Ala
260 265 270
Gln Trp Arg Thr Val Glu Gly Ala Leu Lys Glu Arg Arg Lys Ala Val
275 280 285
Asp Glu Ala Ala Asp Ala Leu Leu Lys Ala Lys Glu Glu Leu Glu Lys
290 295 300
Met Lys Ser Val Ile Glu Asn Ala Lys Lys Lys Glu Val Ala Gly Ala
305 310 315 320
Lys Pro His Ile Thr Ala Ala Glu Gly Lys Leu His Asn Met Ile Val
325 330 335
Asp Leu Asp Asn Val Val Lys Lys Val Gln Ala Ala Gln Ser Glu Ala
340 345 350
Lys Val Val Ser Gln Tyr His Glu Leu Val Val Gln Ala Arg Asp Asp
355 360 365
Phe Lys Arg Glu Leu Asp Ser Ile Thr Pro Glu Val Leu Pro Gly Trp
370 375 380
Lys Gly Met Ser Val Ser Asp Leu Ala Asp Lys Leu Ser Thr Asp Asp
385 390 395 400
Leu Asn Ser Leu Ile Ala His Ala His Arg Arg Ile Asp Gln Leu Asn
405 410 415
Arg Glu Leu Ala Glu Gln Lys Ala Thr Glu Lys Gln His Ile Thr Leu
420 425 430
Ala Leu Glu Lys Gln Lys Leu Glu Glu Lys Arg Ala Phe Asp Ser Ala
435 440 445
Val Ala Lys Ala Leu Glu His His Arg Ser Glu Ile Gln Ala Glu Gln
450 455 460
Asp Arg Lys Ile Glu Glu Val Arg Asp Ala Met Glu Asn Glu Met Arg
465 470 475 480
Thr Gln Leu Arg Arg Gln Ala Ala Ala His Thr Asp His Leu Arg Asp
485 490 495
Val Leu Arg Val Gln Glu Gln Glu Leu Lys Ser Glu Phe Glu Gln Asn
500 505 510
Leu Ser Glu Lys Leu Ser Glu Gln Glu Leu Gln Phe Arg Arg Leu Ser
515 520 525
Gln Glu Gln Val Asp Asn Phe Thr Leu Asp Ile Asn Thr Ala Tyr Ala
530 535 540
Arg Leu Arg Gly Ile Glu Gln Ala Val Gln Ser His Ala Val Ala Glu
545 550 555 560
Glu Glu Ala Arg Lys Ala His Gln Leu Trp Leu Ser Val Glu Ala Leu
565 570 575
Lys Tyr Ser Met Lys Thr Ser Ser Ala Glu Thr Pro Thr Ile Pro Leu
580 585 590
Gly Ser Ala Val Glu Ala Ile Lys Ala Asn Cys Ser Asp Asn Glu Phe
595 600 605
Thr Gln Ala Leu Thr Ala Ala Ile Pro Pro Glu Ser Leu Thr Arg Gly
610 615 620
Val Tyr Ser Glu Glu Thr Leu Arg Ala Arg Phe Tyr Ala Val Gln Lys
625 630 635 640
Leu Ala Arg Arg Val Ala Met Ile Asp Glu Thr Arg Asn Ser Leu Tyr
645 650 655
Gln Tyr Phe Leu Ser Tyr Leu Gln Ser Leu Leu Leu Phe Pro Pro Gln
660 665 670
Gln Leu Lys Pro Pro Pro Glu Leu Cys Pro Glu Asp Ile Asn Thr Phe
675 680 685
Lys Leu Leu Ser Tyr Ala Ser Tyr Cys Ile Glu His Gly Asp Leu Glu
690 695 700
Leu Ala Ala Lys Phe Val Asn Gln Leu Lys Gly Glu Ser Arg Arg Val
705 710 715 720
Ala Gln Asp Trp Leu Lys Glu Ala Arg Met Thr Leu Glu Thr Lys Gln
725 730 735
Ile Val Glu Ile Leu Thr Ala Tyr Ala Ser Ala Val Gly Ile Gly Thr
740 745 750
Thr Gln Val Gln Pro Glu
755
<210>65
<211>1410
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉ribophorin 1
<222>(1)..(1410)
＜223〉on August 29th, 2003 registration number: 075300
<400>65
Met Asp Ile Tyr Asp Thr Gln Thr Leu Gly Val Val Val Phe Gly Gly
1 5 10 15
Phe Met Val Val Ser Ala Ile Gly Ile Phe Leu Val Ser Thr Phe Ser
20 25 30
Met Lys Glu Thr Ser Tyr Glu Glu Ala Leu Ala Asn Gln Arg Lys Glu
35 40 45
Met Ala Lys Thr His His Gln Lys Val Glu Lys Lys Lys Lys Glu Lys
50 55 60
Thr Val Glu Lys Lys Gly Lys Thr Lys Lys Lys Glu Glu Lys Pro Asn
65 70 75 80
Gly Lys Ile Pro Asp His Asp Pro Ala Pro Asn Val Thr Val Leu Leu
85 90 95
Arg Glu Pro Val Arg Ala Pro Ala Val Ala Val Ala Pro Thr Pro Val
100 105 110
Gln Pro Pro Ile Ile Val Ala Pro Val Ala Thr Val Pro Ala Met Pro
115 120 125
Gln Glu Lys Leu Ala Ser Ser Pro Lys Asp Lys Lys Lys Lys Glu Lys
130 135 140
Lys Val Ala Lys Val Glu Pro Ala Val Ser Ser Val Val Asn Ser Ile
145 150 155 160
Gln Val Leu Thr Ser Lys Ala Ala Ile Leu Glu Thr Ala Pro Lys Glu
165 170 175
Val Pro Met Val Val Val Pro Pro Val Gly Ala Lys Gly Asn Thr Pro
180 185 190
Ala Thr Gly Thr Thr Gln Gly Lys Lys Ala Glu Gly Thr Gln Asn Gln
195 200 205
Ser Lys Lys Ala Glu Gly Ala Pro Asn Gln Gly Arg Lys Ala Glu Gly
210 215 220
Thr Pro Asn Gln Gly Lys Lys Thr Glu Gly Thr Pro Asn Gln Gly Lys
225 230 235 240
Lys Ala Glu Gly Thr Pro Asn Gln Gly Lys Lys Ala Glu Gly Thr Pro
245 250 255
Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Val
260 265 270
Asp Thr Thr Pro Asn Gln Gly Lys Lys Val Glu Gly Ala Pro Thr Gln
275 280 285
Gly Arg Lys Ala Glu Gly Ala Gln Asn Gln Ala Lys Lys Val Glu Gly
290 295 300
Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys
305 310 315 320
Lys Gly Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln
325 330 335
Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala
340 345 350
Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln
355 360 365
Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Ser Glu Gly
370 375 380
Ala Gln Asn Gln Gly Lys Lys Val Glu Gly Ala Gln Asn Gln Gly Lys
385 390 395 400
Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln
405 410 415
Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala
420 425 430
Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln
435 440 445
Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly
450 455 460
Ala Gln Asn Gln Gly Lys Lys Val Glu Gly Ala Gln Asn Gln Gly Lys
465 470 475 480
Lys Ala Glu Gly Ala Gln Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln
485 490 495
Asn Gln Gly Lys Lys Ala Glu Gly Ala Gln Asn Gln Gly Gln Lys Gly
500 505 510
Glu Gly Ala Gln Asn Gln Gly Lys Lys Thr Glu Gly Ala Gln Gly Lys
515 520 525
Lys Ala Glu Arg Ser Pro Asn Gln Gly Lys Lys Gly Glu Gly Ala Pro
530 535 540
Ile Gln Gly Lys Lys Ala Asp Ser Val Ala Asn Gln Gly Thr Lys Val
545 550 555 560
Glu Gly Ile Thr Asn Gln Gly Lys Lys Ala Glu Gly Ser Pro Ser Glu
565 570 575
Gly Lys Lys Ala Glu Gly Ser Pro Asn Gln Gly Lys Lys Ala Asp Ala
580 585 590
Ala Ala Asn Gln Gly Lys Lys Thr Glu Ser Ala Ser Val Gln Gly Arg
595 600 605
Asn Thr Asp Val Ala Gln Ser Pro Glu Ala Pro Lys Gln Glu Ala Pro
610 615 620
Ala Lys Lys Lys Ser Gly Ser Lys Lys Lys Gly Glu Pro Gly Pro Pro
625 630 635 640
Asp Ala Asp Gly Pro Leu Tyr Leu Pro Tyr Lys Thr Leu Val Ser Thr
645 650 655
Val Gly Ser Met Val Phe Asn Glu Gly Glu Ala Gln Arg Leu Ile Glu
660 665 670
Ile Leu Ser Glu Lys Ala Gly Ile Ile Gln Asp Thr Trp His Lys Ala
675 680 685
Thr Gln Lys Gly Asp Pro Val Ala Ile Leu Lys Arg Gln Leu Glu Glu
690 695 700
Lys Glu Lys Leu Leu Ala Thr Glu Gln Glu Asp Ala Ala Val Ala Lys
705 710 715 720
Ser Lys Leu Arg Glu Leu Asn Lys Glu Met Ala Ala Glu Lys Ala Lys
725 730 735
Ala Ala Ala Gly Glu Ala Lys Val Lys Lys Gln Leu Val Ala Arg Glu
740 745 750
Gln Glu Ile Thr Ala Val Gln Ala Arg Met Gln Ala Ser Tyr Arg Glu
755 760 765
His Val Lys Glu Val Gln Gln Leu Gln Gly Lys Ile Arg Thr Leu Gln
770 775 780
Glu Gln Leu Glu Asn Gly Pro Asn Thr Gln Leu Ala Arg Leu Gln Gln
785 790 795 800
Glu Asn Ser Ile Leu Arg Asp Ala Leu Asn Gln Ala Thr Ser Gln Val
805 810 815
Glu Ser Lys Gln Asn Ala Glu Leu Ala Lys Leu Arg Gln Glu Leu Ser
820 825 830
Lys Val Ser Lys Glu Leu Val Glu Lys Ser Glu Ala Val Arg Gln Asp
835 840 845
Glu Gln Gln Arg Lys Ala Leu Glu Ala Lys Ala Ala Ala Phe Glu Lys
850 855 860
Gln Val Leu Gln Leu Gln Ala Ser His Arg Glu Ser Glu Glu Ala Leu
865 870 875 880
Gln Lys Arg Leu Asp Glu Val Ser Arg Glu Leu Cys His Thr Gln Ser
885 890 895
Ser His Ala Ser Leu Arg Ala Asp Ala Glu Lys Ala Gln Glu Gln Gln
900 905 910
Gln Gln Met Ala Glu Leu His Ser Lys Leu Gln Ser Ser Glu Ala Glu
915 920 925
Val Arg Ser Lys Cys Glu Glu Leu Ser Gly Leu His Gly Gln Leu Gln
930 935 940
Glu Ala Arg Ala Glu Asn Ser Gln Leu Thr Glu Arg Ile Arg Ser Ile
945 950 955 960
Glu Ala Leu Leu Glu Ala Gly Gln Ala Arg Asp Ala Gln Asp Val Gln
965 970 975
Ala Ser Gln Ala Glu Ala Asp Gln Gln Gln Thr Arg Leu Lys Glu Leu
980 985 990
Glu Ser Gln Val Ser Gly Leu Glu Lys Glu Ala Ile Glu Leu Arg Glu
995 1000 1005
Ala Val Glu Gln Gln Lys Val Lys Asn Asn Asp Leu Arg Glu Lys
1010 1015 1020
Asn Trp Lys Ala Met Glu Ala Leu Ala Thr Ala Glu Gln Ala Cys
1025 1030 1035
Lys Glu Lys Leu Leu Ser Leu Thr Gln Ala Lys Glu Glu Ser Glu
1040 1045 1050
Lys Gln Leu Cys Leu Ile Glu Ala Gln Thr Met Glu Ala Leu Leu
1055 1060 1065
Ala Leu Leu Pro Glu Leu Ser Val Leu Ala Gln Gln Asn Tyr Thr
1070 1075 1080
Glu Trp Leu Gln Asp Leu Lys Glu Lys Gly Pro Thr Leu Leu Lys
1085 1090 1095
His Pro Pro Ala Pro Ala Glu Pro Ser Ser Asp Leu Ala Ser Lys
1100 1105 1110
Leu Arg Glu Ala Glu Glu Thr Gln Ser Thr Leu Gln Ala Glu Cys
1115 1120 1125
Asp Gln Tyr Arg Ser Ile Leu Ala Glu Thr Glu Gly Met Leu Arg
1130 1135 1140
Asp Leu Gln Lys Ser Val Glu Glu Glu Glu Gln Val Trp Arg Ala
1145 1150 1155
Lys Val Gly Ala Ala Glu Glu Glu Leu Gln Lys Ser Arg Val Thr
1160 1165 1170
Val Lys His Leu Glu Glu Ile Val Glu Lys Leu Lys Gly Glu Leu
1175 1180 1185
Glu Ser Ser Asp Gln Val Arg Glu His Thr Ser His Leu Glu Ala
1190 1195 1200
Glu Leu Glu Lys His Met Ala Ala Ala Ser Ala Glu Cys Gln Asn
1205 1210 1215
Tyr Ala Lys Glu Val Ala Gly Leu Arg Gln Leu Leu Leu Glu Ser
1220 1225 1230
Gln Ser Gln Leu Asp Ala Ala Lys Ser Glu Ala Gln Lys Gln Ser
1235 1240 1245
Asp Glu Leu Ala Leu Val Arg Gln Gln Leu Ser Glu Met Lys Ser
1250 1255 1260
His Val Glu Asp Gly Asp Ile Ala Gly Ala Pro Ala Ser Ser Pro
1265 1270 1275
Glu Ala Pro Pro Ala Glu Gln Asp Pro Val Gln Leu Lys Thr Gln
1280 1285 1290
Leu Glu Trp Thr Glu Ala Ile Leu Glu Asp Glu Gln Thr Gln Arg
1295 1300 1305
Gln Lys Leu Thr Ala Glu Phe Glu Glu Ala Gln Thr Ser Ala Cys
1310 1315 1320
Arg Leu Gln Glu Glu Leu Glu Lys Leu Arg Thr Ala Gly Pro Leu
1325 1330 1335
Glu Ser Ser Glu Thr Glu Glu Ala Ser Gln Leu Lys Glu Arg Leu
1340 1345 1350
Glu Lys Glu Lys Lys Leu Thr Ser Asp Leu Gly Arg Ala Ala Thr
1355 1360 1365
Arg Leu Gln Glu Leu Leu Lys Thr Thr Gln Glu Gln Leu Ala Arg
1370 1375 1380
Glu Lys Asp Thr Val Lys Lys Leu Gln Glu Gln Leu Glu Lys Ala
1385 1390 1395
Glu Asp Gly Ser Ser Ser Lys Glu Gly Thr Ser Val
1400 1405 1410
<210>66
<211>453
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉fibrinogen gamma-chain precursor
<222>(1)..(453)
＜223〉on August 29th, 2003 registration number: P02679
<400>66
Met Ser Trp Ser Leu His Pro Arg Asn Leu Ile Leu Tyr Phe Tyr Ala
1 5 10 15
Leu Leu Phe Leu Ser Ser Thr Cys Val Ala Tyr Val Ala Thr Arg Asp
20 25 30
Asn Cys Cys Ile Leu Asp Glu Arg Phe Gly Ser Tyr Cys Pro Thr Thr
35 40 45
Cys Gly Ile Ala Asp Phe Leu Ser Thr Tyr Gln Thr Lys Val Asp Lys
50 55 60
Asp Leu Gln Ser Leu Glu Asp Ile Leu His Gln Val Glu Asn Lys Thr
65 70 75 80
Ser Glu Val Lys Gln Leu Ile Lys Ala Ile Gln Leu Thr Tyr Asn Pro
85 90 95
Asp Glu Ser Ser Lys Pro Asn Met Ile Asp Ala Ala Thr Leu Lys Ser
100 105 110
Arg Lys Met Leu Glu Glu Ile Met Lys Tyr Glu Ala Ser Ile Leu Thr
115 120 125
His Asp Ser Ser Ile Arg Tyr Leu Gln Glu Ile Tyr Asn Ser Asn Asn
130 135 140
Gln Lys Ile Val Asn Leu Lys Glu Lys Val Ala Gln Leu Glu Ala Gln
145 150 155 160
Cys Gln Glu Pro Cys Lys Asp Thr Val Gln Ile His Asp Ile Thr Gly
165 170 175
Lys Asp Cys Gln Asp Ile Ala Asn Lys Gly Ala Lys Gln Ser Gly Leu
180 185 190
Tyr Phe Ile Lys Pro Leu Lys Ala Asn Gln Gln Phe Leu Val Tyr Cys
195 200 205
Glu Ile Asp Gly Ser Gly Asn Gly Trp Thr Val Phe Gln Lys Arg Leu
210 215 220
Asp Gly Ser Val Asp Phe Lys Lys Asn Trp Ile Gln Tyr Lys Glu Gly
225 230 235 240
Phe Gly His Leu Ser Pro Thr Gly Thr Thr Glu Phe Trp Leu Gly Asn
245 250 255
Glu Lys Ile His Leu Ile Ser Thr Gln Ser Ala Ile Pro Tyr Ala Leu
260 265 270
Arg Val Glu Leu Glu Asp Trp Asn Gly Arg Thr Ser Thr Ala Asp Tyr
275 280 285
Ala Met Phe Lys Val Gly Pro Glu Ala Asp Lys Tyr Arg Leu Thr Tyr
290 295 300
Ala Tyr Phe Ala Gly Gly Asp Ala Gly Asp Ala Phe Asp Gly Phe Asp
305 310 315 320
Phe Gly Asp Asp Pro Ser Asp Lys Phe Phe Thr Ser His Asn Gly Met
325 330 335
Gln Phe Ser Thr Trp Asp Asn Asp Asn Asp Lys Phe Glu Gly Asn Cys
340 345 350
Ala Glu Gln Asp Gly Ser Gly Trp Trp Met Asn Lys Cys His Ala Gly
355 360 365
His Leu Asn Gly Val Tyr Tyr Gln Gly Gly Thr Tyr Ser Lys Ala Ser
370 375 380
Thr Pro Asn Gly Tyr Asp Asn Gly Ile Ile Trp Ala Thr Trp Lys Thr
385 390 395 400
Arg Trp Tyr Ser Met Lys Lys Thr Thr Met Lys Ile Ile Pro Phe Asn
405 410 415
Arg Leu Thr Ile Gly Glu Gly Gln Gln His His Leu Gly Gly Ala Lys
420 425 430
Gln Val Arg Pro Glu His Pro Ala Glu Thr Glu Tyr Asp Ser Leu Tyr
435 440 445
Pro Glu Asp Asp Leu
450
<210>67
<211>622
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉factor precursor
<222>(1)..(622)
＜223〉on August 29th, 2003 registration number: P00734
<400>67
Met Ala His Val Arg Gly Leu Gln Leu Pro Gly Cys Leu Ala Leu Ala
1 5 10 15
Ala Leu Cys Ser Leu Val His Ser Gln His Val Phe Leu Ala Pro Gln
20 25 30
Gln Ala Arg Ser Leu Leu Gln Arg Val Arg Arg Ala Asn Thr Phe Leu
35 40 45
Glu Glu Val Arg Lys Gly Asn Leu Glu Arg Glu Cys Val Glu Glu Thr
50 55 60
Cys Ser Tyr Glu Glu Ala Phe Glu Ala Leu Glu Ser Ser Thr Ala Thr
65 70 75 80
Asp Val Phe Trp Ala Lys Tyr Thr Ala Cys Glu Thr Ala Arg Thr Pro
85 90 95
Arg Asp Lys Leu Ala Ala Cys Leu Glu Gly Asn Cys Ala Glu Gly Leu
100 105 110
Gly Thr Asn Tyr Arg Gly His Val Asn Ile Thr Arg Ser Gly Ile Glu
115 120 125
Cys Gln Leu Trp Arg Ser Arg Tyr Pro His Lys Pro Glu Ile Asn Ser
130 135 140
Thr Thr His Pro Gly Ala Asp Leu Gln Glu Asn Phe Cys Arg Asn Pro
145 150 155 160
Asp Ser Ser Thr Thr Gly Pro Trp Cys Tyr Thr Thr Asp Pro Thr Val
165 170 175
Arg Arg Gln Glu Cys Ser Ile Pro Val Cys Gly Gln Asp Gln Val Thr
180 185 190
Val Ala Met Thr Pro Arg Ser Glu Gly Ser Ser Val Asn Leu Ser Pro
195 200 205
Pro Leu Glu Gln Cys Val Pro Asp Arg Gly Gln Gln Tyr Gln Gly Arg
210 215 220
Leu Ala Val Thr Thr His Gly Leu Pro Cys Leu Ala Trp Ala Ser Ala
225 230 235 240
Gln Ala Lys Ala Leu Ser Lys His Gln Asp Phe Asn Ser Ala Val Gln
245 250 255
Leu Val Glu Asn Phe Cys Arg Asn Pro Asp Gly Asp Glu Glu Gly Val
260 265 270
Trp Cys Tyr Val Ala Gly Lys Pro Gly Asp Phe Gly Tyr Cys Asp Leu
275 280 285
Asn Tyr Cys Glu Glu Ala Val Glu Glu Glu Thr Gly Asp Gly Leu Asp
290 295 300
Glu Asp Ser Asp Arg Ala Ile Glu Gly Arg Thr Ala Thr Ser Glu Tyr
305 310 315 320
Gln Thr Phe Phe Asn Pro Arg Thr Phe Gly Ser Gly Glu Ala Asp Cys
325 330 335
Gly Leu Arg Pro Leu Phe Glu Lys Lys Ser Leu Glu Asp Lys Thr Glu
340 345 350
Arg Glu Leu Leu Glu Ser Tyr Ile Asp Gly Arg Ile Val Glu Gly Ser
355 360 365
Asp Ala Glu Ile Gly Met Ser Pro Trp Gln Val Met Leu Phe Arg Lys
370 375 380
Ser Pro Gln Glu Leu Leu Cys Gly Ala Ser Leu Ile Ser Asp Arg Trp
385 390 395 400
Val Leu Thr Ala Ala His Cys Leu Leu Tyr Pro Pro Trp Asp Lys Asn
405 410 415
Phe Thr Glu Asn Asp Leu Leu Val Arg Ile Gly Lys His Ser Arg Thr
420 425 430
Arg Tyr Glu Arg Asn Ile Glu Lys Ile Ser Met Leu Glu Lys Ile Tyr
435 440 445
Ile His Pro Arg Tyr Asn Trp Arg Glu Asn Leu Asp Arg Asp Ile Ala
450 455 460
Leu Met Lys Leu Lys Lys Pro Val Ala Phe Ser Asp Tyr Ile His Pro
465 470 475 480
Val Cys Leu Pro Asp Arg Glu Thr Ala Ala Ser Leu Leu Gln Ala Gly
485 490 495
Tyr Lys Gly Arg Val Thr Gly Trp Gly Asn Leu Lys Glu Thr Trp Thr
500 505 510
Ala Asn Val Gly Lys Gly Gln Pro Ser Val Leu Gln Val Val Asn Leu
515 520 525
Pro Ile Val Glu Arg Pro Val Cys Lys Asp Ser Thr Arg Ile Arg Ile
530 535 540
Thr Asp Asn Met Phe Cys Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg
545 550 555 560
Gly Asp Ala Cys Glu Gly Asp Ser Gly Gly Pro Phe Val Met Lys Ser
565 570 575
Pro Phe Asn Asn Arg Trp Tyr Gln Met Gly Ile Val Ser Trp Gly Glu
580 585 590
Gly Cys Asp Arg Asp Gly Lys Tyr Gly Phe Tyr Thr His Val Phe Arg
595 600 605
Leu Lys Lys Trp Ile Gln Lys Val Ile Asp Gln Phe Gly Glu
610 615 620
<210>68
<211>530
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉pyruvate kinase
<222>(1)..(530)
＜223〉on August 29th, 2003 registration number: P14618
<400>68
Ser Lys Pro His Ser Glu Ala Gly Thr Ala Phe Ile Gln Thr Gln Gln
1 5 10 15
Leu His Ala Ala Met Ala Asp Thr Phe Leu Glu His Met Cys Arg Leu
20 25 30
Asp Ile Asp Ser Pro Pro Ile Thr Ala Arg Asn Thr Gly Ile Ile Cys
35 40 45
Thr Ile Gly Pro Ala Ser Arg Ser Val Glu Thr Leu Lys Glu Met Ile
50 55 60
Lys Ser Gly Met Asn Val Ala Arg Leu Asn Phe Ser His Gly Thr His
65 70 75 80
Glu Tyr His Ala Glu Thr Ile Lys Asn Val Arg Thr Ala Thr Glu Ser
85 90 95
Phe Ala Ser Asp Pro Ile Leu Tyr Arg Pro Val Ala Val Ala Leu Asp
100 105 110
Thr Lys Gly Pro Glu Ile Arg Thr Gly Leu Ile Lys Gly Ser Gly Thr
115 120 125
Ala Glu Val Glu Leu Lys Lys Gly Ala Thr Leu Lys Ile Thr Leu Asp
130 135 140
Asn Ala Tyr Met Glu Lys Cys Asp Glu Asn Ile Leu Trp Leu Asp Tyr
145 150 155 160
Lys Asn Ile Cys Lys Val Val Glu Val Gly Ser Lys Ile Tyr Val Asp
165 170 175
Asp Gly Leu Ile Ser Leu Gln Val Lys Gln Lys Gly Ala Asp Phe Leu
180 185 190
Val Thr Glu Val Glu Asn Gly Gly Ser Leu Gly Ser Lys Lys Gly Val
195 200 205
Asn Leu Pro Gly Ala Ala Val Asp Leu Pro Ala Val Ser Glu Lys Asp
210 215 220
Ile Gln Asp Leu Lys Phe Gly Val Glu Gln Asp Val Asp Met Val Phe
225 230 235 240
Ala Ser Phe Ile Arg Lys Ala Ser Asp Val His Glu Val Arg Lys Val
245 250 255
Leu Gly Glu Lys Gly Lys Asn Ile Lys Ile Ile Ser Lys Ile Glu Asn
260 265 270
His Glu Gly Val Arg Arg Phe Asp Glu Ile Leu Glu Ala Ser Asp Gly
275 280 285
Ile Met Val Ala Arg Gly Asp Leu Gly Ile Glu Ile Pro Ala Glu Lys
290 295 300
Val Phe Leu Ala Gln Lys Met Met Ile Gly Arg Cys Asn Arg Ala Gly
305 310 315 320
Lys Pro Val Ile Cys Ala Thr Gln Met Leu Glu Ser Met Ile Lys Lys
325 330 335
Pro Arg Pro Thr Arg Ala Glu Gly Ser Asp Val Ala Asn Ala Val Leu
340 345 350
Asp Gly Ala Asp Cys Ile Met Leu Ser Gly Glu Thr Ala Lys Gly Asp
355 360 365
Tyr Pro Leu Glu Ala Val Arg Met Gln His Leu Ile Ala Arg Glu Ala
370 375 380
Glu Ala Ala Ile Tyr His Leu Gln Leu Phe Glu Glu Leu Arg Arg Leu
385 390 395 400
Ala Pro Ile Thr Ser Asp Pro Thr Glu Ala Thr Ala Val Gly Ala Val
405 410 415
Glu Ala Ser Phe Lys Cys Cys Ser Gly Ala Ile Ile Val Leu Thr Lys
420 425 430
Ser Gly Arg Ser Ala His Gln Val Ala Arg Tyr Arg Pro Arg Ala Pro
435 440 445
Ile Ile Ala Val Thr Arg Asn Pro Gln Thr Ala Arg Gln Ala His Leu
450 455 460
Tyr Arg Gly Ile Phe Pro Val Leu Cys Lys Asp Pro Val Gln Glu Ala
465 470 475 480
Trp Ala Glu Asp Val Asp Leu Arg Val Asn Phe Ala Met Asn Val Gly
485 490 495
Lys Ala Arg Gly Phe Phe Lys Lys Gly Asp Val Val Ile Val Leu Thr
500 505 510
Gly Trp Arg Pro Gly Ser Gly Phe Thr Asn Thr Met Arg Val Val Pro
515 520 525
Val Pro
530
<2l0>69
<211>328
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉net calcium desmin 3 precursors
<222>(1)..(328)
＜223〉on August 29th, 2003 registration number: Q96D15
<400>69
Met Met Trp Arg Pro Ser Val Leu Leu Leu Leu Leu Leu Leu Arg His
1 5 10 15
Gly Ala Gln Gly Lys Pro Ser Pro Asp Ala Gly Pro His Gly Gln Gly
20 25 30
Arg Val His Gln Ala Ala Pro Leu Ser Asp Ala Pro His Asp Asp Ala
35 40 45
His Gly Asn Phe Gln Tyr Asp His Glu Ala Phe Leu Gly Arg Glu Val
50 55 60
Ala Lys Glu Phe Asp Gln Leu Thr Pro Glu Glu Ser Gln Ala Arg Leu
65 70 75 80
Gly Arg Ile Val Asp Arg Met Asp Arg Ala Gly Asp Gly Asp Gly Trp
85 90 95
Val Ser Leu Ala Glu Leu Arg Ala Trp Ile Ala His Thr Gln Gln Arg
100 105 110
His Ile Arg Asp Ser Val Ser Ala Ala Trp Asp Thr Tyr Asp Thr Asp
115 120 125
Arg Asp Gly Arg Val Gly Trp Glu Glu Leu Arg Asn Ala Thr Tyr Gly
130 135 140
His Tyr Ala Pro Gly Glu Glu Phe His Asp Val Glu Asp Ala Glu Thr
145 150 155 160
Tyr Lys Lys Met Leu Ala Arg Asp Glu Arg Arg Phe Arg Val Ala Asp
165 170 175
Gln Asp Gly Asp Ser Met Ala Thr Arg Glu Glu Leu Thr Ala Phe Leu
180 185 190
His Pro Glu Glu Phe Pro His Met Arg Asp Ile Val Ile Ala Glu Thr
195 200 205
Leu Glu Asp Leu Asp Arg Asn Lys Asp Gly Tyr Val Gln Val Glu Glu
210 215 220
Tyr Ile Ala Asp Leu Tyr Ser Ala Glu Pro Gly Glu Glu Glu Pro Ala
225 230 235 240
Trp Val Gln Thr Glu Arg Gln Gln Phe Arg Asp Phe Arg Asp Leu Asn
245 250 255
Lys Asp Gly His Leu Asp Gly Ser Glu Val Gly His Trp Val Leu Pro
260 265 270
Pro Ala Gln Asp Gln Pro Leu Val Glu Ala Asn His Leu Leu His Glu
275 280 285
Ser Asp Thr Asp Lys Asp Gly Arg Leu Ser Lys Ala Glu Ile Leu Gly
290 295 300
Asn Trp Asn Met Phe Val Gly Ser Gln Ala Thr Asn Tyr Gly Glu Asp
305 310 315 320
Leu Thr Arg His His Asp Glu Leu
325
<210>70
<211>469
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉desmin
<222>(1)..(469)
＜223〉on August 29th, 2003 registration number: P17661
<400>70
Ser Gln Ala Tyr Ser Ser Ser Gln Arg Val Ser Ser Tyr Arg Arg Thr
1 5 10 15
Phe Gly Gly Ala Pro Gly Phe Pro Leu Gly Ser Pro Leu Ser Ser Pro
20 25 30
Val Phe Pro Arg Ala Gly Phe Gly Ser Lys Gly Ser Ser Ser Ser Val
35 40 45
Thr Ser Arg Val Tyr Gln Val Ser Arg Thr Ser Gly Gly Ala Gly Gly
50 55 60
Leu Gly Ser Leu Arg Ala Ser Arg Leu Gly Thr Thr Arg Thr Pro Ser
65 70 75 80
Ser Tyr Gly Ala Gly Glu Leu Leu Asp Phe Ser Leu Ala Asp Ala Val
85 90 95
Asn Gln Glu Phe Leu Thr Thr Arg Thr Asn Glu Lys Val Glu Leu Gln
100 105 110
Glu Leu Asn Asp Arg Phe Ala Asn Tyr Ile Glu Lys Val Arg Phe Leu
115 120 125
Glu Gln Gln Asn Ala Ala Leu Ala Ala Glu Val Asn Arg Leu Lys Gly
130 135 140
Arg Glu Pro Thr Arg Val Ala Glu Leu Tyr Glu Glu Glu Leu Arg Glu
145 150 155 160
Leu Arg Arg Gln Val Glu Val Leu Thr Asn Gln Arg Ala Arg Val Asp
165 170 175
Val Glu Arg Asp Asn Leu Leu Asp Asp Leu Gln Arg Leu Lys Ala Lys
180 185 190
Leu Gln Glu Glu Ile Gln Leu Lys Glu Glu Ala Glu Asn Asn Leu Ala
195 200 205
Ala Phe Arg Ala Asp Val Asp Ala Ala Thr Leu Ala Arg Ile Asp Leu
210 215 220
Glu Arg Arg Ile Glu Ser Leu Asn Glu Glu Ile Ala Phe Leu Lys Lys
225 230 235 240
Val His Glu Glu Glu Ile Arg Glu Leu Gln Ala Gln Leu Gln Glu Gln
245 250 255
Gln Val Gln Val Glu Met Asp Met Ser Lys Pro Asp Leu Thr Ala Ala
260 265 270
Leu Arg Asp Ile Arg Ala Gln Tyr Glu Thr Ile Ala Ala Lys Asn Ile
275 280 285
Ser Glu Ala Glu Glu Trp Tyr Lys Ser Lys Val Ser Asp Leu Thr Gln
290 295 300
Ala Ala Asn Lys Asn Asn Asp Ala Leu Arg Gln Ala Lys Gln Glu Met
305 310 315 320
Met Glu Tyr Arg His Gln Ile Gln Ser Tyr Thr Cys Glu Ile Asp Ala
325 330 335
Leu Lys Gly Thr Asn Asp Ser Leu Met Arg Gln Met Arg Glu Leu Glu
340 345 350
Asp Arg Phe Ala Ser Glu Ala Ser Gly Tyr Gln Asp Asn Ile Ala Arg
355 360 365
Leu Glu Glu Glu Ile Arg His Leu Lys Asp Glu Met Ala Arg His Leu
370 375 380
Arg Glu Tyr Gln Asp Leu Leu Asn Val Lys Met Ala Leu Asp Val Glu
385 390 395 400
Ile Ala Thr Tyr Arg Lys Leu Leu Glu Gly Glu Glu Ser Arg Ile Asn
405 410 415
Leu Pro Ile Gln Thr Tyr Ser Ala Leu Asn Phe Arg Glu Thr Ser Pro
420 425 430
Glu Gln Arg Gly Ser Glu Val His Thr Lys Lys Thr Val Met Ile Lys
435 440 445
Thr Ile Glu Thr Arg Asp Gly Glu Val Val Ser Glu Ala Thr Gln Gln
450 455 460
Gln His Glu Val Leu
465
<210>71
<211>417
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉protaminase precursor
<222>(1)..(417)
＜223〉on August 29th, 2003 registration number: P15086
<400>71
Met Leu Ala Leu Leu Val Leu Val Thr Val Ala Leu Ala Ser Ala His
1 5 10 15
His Gly Gly Glu His Phe Glu Gly Glu Lys Val Phe Arg Val Asn Val
20 25 30
Glu Asp Glu Asn His Ile Asn Ile Ile Arg Glu Leu Ala Ser Thr Thr
35 40 45
Gln Ile Asp Phe Trp Lys Pro Asp Ser Val Thr Gln Ile Lys Pro His
50 55 60
Ser Thr Val Asp Phe Arg Val Lys Ala Glu Asp Thr Val Thr Val Glu
65 70 75 80
Asn Val Leu Lys Gln Asn Glu Leu Gln Tyr Lys Val Leu Ile Ser Asn
85 90 95
Leu Arg Asn Val Val Glu Ala Gln Phe Asp Ser Arg Val Arg Ala Thr
100 105 110
Gly His Ser Tyr Glu Lys Tyr Asn Lys Trp Glu Thr Ile Glu Ala Trp
115 120 125
Thr Gln Gln Val Ala Thr Glu Asn Pro Ala Leu Ile Ser Arg Ser Val
130 135 140
Ile Gly Thr Thr Phe Glu Gly Arg Ala Ile Tyr Leu Leu Lys Val Gly
145 150 155 160
Lys Ala Gly Gln Asn Lys Pro Ala Ile Phe Met Asp Cys Gly Phe His
165 170 175
Ala Arg Glu Trp Ile Ser Pro Ala Phe Cys Gln Trp Phe Val Arg Glu
180 185 190
Ala Val Arg Thr Tyr Gly Arg Glu Ile Gln Val Thr Glu Leu Leu Asp
195 200 205
Lys Leu Asp Phe Tyr Val Leu Pro Val Leu Asn Ile Asp Gly Tyr Ile
210 215 220
Tyr Thr Trp Thr Lys Ser Arg Phe Trp Arg Lys Thr Arg Ser Thr His
225 230 235 240
Thr Gly Ser Ser Cys Ile Gly Thr Asp Pro Asn Arg Asn Phe Asp Ala
245 250 255
Gly Trp Cys Glu Ile Gly Ala Ser Arg Asn Pro Cys Asp Glu Thr Tyr
260 265 270
Cys Gly Pro Ala Ala Glu Ser Glu Lys Glu Thr Lys Ala Leu Ala Asp
275 280 285
Phe Ile Arg Asn Lys Leu Ser Ser Ile Lys Ala Tyr Leu Thr Ile His
290 295 300
Ser Tyr Ser Gln Met Met Ile Tyr Pro Tyr Ser Tyr Ala Tyr Lys Leu
305 310 315 320
Gly Glu Asn Asn Ala Glu Leu Asn Ala Leu Ala Lys Ala Thr Val Lys
325 330 335
Glu Leu Ala Ser Leu His Gly Thr Lys Tyr Thr Tyr Gly Pro Gly Ala
340 345 350
Thr Thr Ile Tyr Pro Ala Ala Gly Gly Ser Asp Asp Trp Ala Tyr Asp
355 360 365
Gln Gly Ile Arg Tyr Ser Phe Thr Phe Glu Leu Arg Asp Thr Gly Arg
370 375 380
Tyr Gly Phe Leu Leu Pro Glu Ser Gln Ile Arg Ala Thr Cys Glu Glu
385 390 395 400
Thr Phe Leu Ala Ile Lys Tyr Val Ala Ser Tyr Val Leu Glu His Leu
405 410 415
Tyr
<210>72
<211>419
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉Carboxypeptidase A 1 precursor
<222>(1)..(419)
＜223〉on August 29th, 2003 registration number: P15085
<400>72
Met Arg Gly Leu Leu Val Leu Ser Val Leu Leu Gly Ala Val Phe Gly
1 5 10 15
Lys Glu Asp Phe Val Gly His Gln Val Leu Arg Ile Ser Val Ala Asp
20 25 30
Glu Ala Gln Val Gln Lys Val Lys Glu Leu Glu Asp Leu Glu His Leu
35 40 45
Gln Leu Asp Phe Trp Arg Gly Pro Ala His Pro Gly Ser Pro Ile Asp
50 55 60
Val Arg Val Pro Phe Pro Ser Ile Gln Ala Val Lys Ile Phe Leu Glu
65 70 75 80
Ser His Gly Ile Ser Tyr Glu Thr Met Ile Glu Asp Val Gln Ser Leu
85 90 95
Leu Asp Glu Glu Gln Glu Gln Met Phe Ala Phe Arg Ser Arg Ala Arg
100 105 110
Ser Thr Asp Thr Phe Asn Tyr Ala Thr Tyr His Thr Leu Glu Glu Ile
115 120 125
Tyr Asp Phe Leu Asp Leu Leu Val Ala Glu Asn Pro His Leu Val Ser
130 135 140
Lys Ile Gln Ile Gly Asn Thr Tyr Glu Gly Arg Pro Ile Tyr Val Leu
145 150 155 160
Lys Phe Ser Thr Gly Gly Ser Lys Arg Pro Ala Ile Trp Ile Asp Thr
165 170 175
Gly Ile His Ser Arg Glu Trp Val Thr Gln Ala Ser Gly Val Trp Phe
180 185 190
Ala Lys Lys Ile Thr Gln Asp Tyr Gly Gln Asp Ala Ala Phe Thr Ala
195 200 205
Ile Leu Asp Thr Leu Asp Ile Phe Leu Glu Ile Val Thr Asn Pro Asp
210 215 220
Gly Phe Ala Phe Thr His Ser Thr Asn Arg Met Trp Arg Lys Thr Arg
225 230 235 240
Ser His Thr Ala Gly Ser Leu Cys Ile Gly Val Asp Pro Asn Arg Asn
245 250 255
Trp Asp Ala Gly Phe Gly Leu Ser Gly Ala Ser Ser Asn Pro Cys Ser
260 265 270
Glu Thr Tyr His Gly Lys Phe Ala Asn Ser Glu Val Glu Val Lys Ser
275 280 285
Ile Val Asp Phe Val Lys Asp His Gly Asn Ile Lys Ala Phe Ile Ser
290 295 300
Ile His Ser Tyr Ser Gln Leu Leu Met Tyr Pro Tyr Gly Tyr Lys Thr
305 310 315 320
Glu Pro Val Pro Asp Gln Asp Glu Leu Asp Gln Leu Ser Lys Ala Ala
325 330 335
Val Thr Ala Leu Ala Ser Leu Tyr Gly Thr Lys Phe Asn Tyr Gly Ser
340 345 350
Ile Ile Lys Ala Ile Tyr Gln Ala Ser Gly Ser Thr Ile Asp Trp Thr
355 360 365
Tyr Ser Gln Gly Ile Lys Tyr Ser Phe Thr Phe Glu Leu Arg Asp Thr
370 375 380
Gly Arg Tyr Gly Phe Leu Leu Pro Ala Ser Gln Ile Ile Pro Thr Ala
385 390 395 400
Lys Glu Thr Trp Leu Ala Leu Leu Thr Ile Met Glu His Thr Leu Asn
405 410 415
His Pro Tyr
<210>73
<211>418
<212>PRT
＜213〉people (Homo sapiens)
<220>
<221>Colligin 2
<222>(1)..(418)
＜223〉on August 29th, 2003 registration number: P50454
<400>73
Met Arg Ser Leu Leu Leu Leu Ser Ala Phe Cys Leu Leu Glu Ala Ala
1 5 10 15
Leu Ala Ala Glu Val Lys Lys Pro Ala Ala Ala Ala Ala Pro Gly Thr
20 25 30
Ala Glu Lys Leu Ser Pro Lys Ala Ala Thr Leu Ala Glu Arg Ser Ala
35 40 45
Gly Leu Ala Phe Ser Leu Tyr Gln Ala Met Ala Lys Asp Gln Ala Val
50 55 60
Glu Asn Ile Leu Val Ser Pro Val Val Val Ala Ser Ser Leu Gly Leu
65 70 75 80
Val Ser Leu Gly Gly Lys Ala Thr Thr Ala Ser Gln Ala Lys Ala Val
85 90 95
Leu Ser Ala Glu Gln Leu Arg Asp Glu Glu Val His Ala Gly Leu Gly
100 105 110
Glu Leu Leu Arg Ser Leu Ser Asn Ser Thr Ala Arg Asn Val Thr Trp
115 120 125
Lys Leu Gly Ser Arg Leu Tyr Gly Pro Ser Ser Val Ser Phe Ala Asp
130 135 140
Asp Phe Val Arg Ser Ser Lys Gln His Tyr Asn Cys Glu His Ser Lys
145 150 155 160
Ile Asn Phe Arg Asp Lys Arg Ser Ala Leu Gln Ser Ile Asn Glu Trp
165 170 175
Ala Ala Gln Thr Thr Asp Gly Lys Leu Pro Glu Val Thr Lys Asp Val
180 185 190
Glu Arg Thr Asp Gly Ala Leu Leu Val Asn Ala Met Phe Phe Lys Pro
195 200 205
His Trp Asp Glu Lys Phe His His Lys Met Val Asp Asn Arg Gly Phe
210 215 220
Met Val Thr Arg Ser Tyr Thr Val Gly Val Met Met Met His Arg Thr
225 230 235 240
Gly Leu Tyr Asn Tyr Tyr Asp Asp Glu Lys Glu Lys Leu Gln Ile Val
245 250 255
Glu Met Pro Leu Ala His Lys Leu Ser Ser Leu Ile Ile Leu Met Pro
260 265 270
His His Val Glu Pro Leu Glu Arg Leu Glu Lys Leu Leu Thr Lys Glu
275 280 285
Gln Leu Lys Ile Trp Met Gly Lys Met Gln Lys Lys Ala Val Ala Ile
290 295 300
Ser Leu Pro Lys Gly Val Val Glu Val Thr His Asp Leu Gln Lys His
305 310 315 320
Leu Ala Gly Leu Gly Leu Thr Glu Ala Ile Asp Lys Asn Lys Ala Asp
325 330 335
Leu Ser Arg Met Ser Gly Lys Lys Asp Leu Tyr Leu Ala Ser Val Phe
340 345 350
His Ala Thr Ala Phe Glu Leu Asp Thr Asp Gly Asn Pro Phe Asp Gln
355 360 365
Asp Ile Tyr Gly Arg Glu Glu Leu Arg Ser Pro Lys Leu Phe Tyr Ala
370 375 380
Asp His Pro Phe Ile Phe Leu Val Arg Asp Thr Gln Ser Gly Ser Leu
385 390 395 400
Leu Phe Ile Gly Arg Leu Val Arg Pro Lys Gly Asp Lys Met Arg Asp
405 410 415
Glu Leu
<210>74
<211>263
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉chymotrypsinogen B precursor
<222>(1)..(263)
＜223〉on August 29th, 2003 registration number: P17538
<400>74
Met Ala Phe Leu Trp Leu Leu Ser Cys Trp Ala Leu Leu Gly Thr Thr
1 5 10 15
Phe Gly Cys Gly Val Pro Ala Ile His Pro Val Leu Ser Gly Leu Ser
20 25 30
Arg Ile Val Asn Gly Glu Asp Ala Val Pro Gly Ser Trp Pro Trp Gln
35 40 45
Val Ser Leu Gln Asp Lys Thr Gly Phe His Phe Cys Gly Gly Ser Leu
50 55 60
Ile Ser Glu Asp Trp Val Val Thr Ala Ala His Cys Gly Val Arg Thr
65 70 75 80
Ser Asp Val Val Val Ala Gly Glu Phe Asp Gln Gly Ser Asp Glu Glu
85 90 95
Asn Ile Gln Val Leu Lys Ile Ala Lys Val Phe Lys Asn Pro Lys Phe
100 105 110
Ser Ile Leu Thr Val Asn Asn Asp Ile Thr Leu Leu Lys Leu Ala Thr
115 120 125
Pro Ala Arg Phe Ser Gln Thr Val Ser Ala Val Cys Leu Pro Ser Ala
130 135 140
Asp Asp Asp Phe Pro Ala Gly Thr Leu Cys Ala Thr Thr Gly Trp Gly
145 150 155 160
Lys Thr Lys Tyr Asn Ala Asn Lys Thr Pro Asp Lys Leu Gln Gln Ala
165 170 175
Ala Leu Pro Leu Leu Ser Asn Ala Glu Cys Lys Lys Ser Trp Gly Arg
180 185 190
Arg Ile Thr Asp Val Met Ile Cys Ala Gly Ala Ser Gly Val Ser Ser
195 200 205
Cys Met Gly Asp Ser Gly Gly Pro Leu Val Cys Gln Lys Asp Gly Ala
210 215 220
Trp Thr Leu Val Gly Ile Val Ser Trp Gly Ser Asp Thr Cys Ser Thr
225 230 235 240
Ser Ser Pro Gly Val Tyr Ala Arg Val Thr Lys Leu Ile Pro Trp Val
245 250 255
Gln Lys Ile Leu Ala Ala Asn
260
<210>75
<211>247
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉trypsase I precursor
<222>(1)..(247)
＜223〉on August 29th, 2003 registration number: P07477
<400>75
Met Asn Pro Leu Leu Ile Leu Thr Phe Val Ala Ala Ala Leu Ala Ala
1 5 10 15
Pro Phe Asp Asp Asp Asp Lys Ile Val Gly Gly Tyr Asn Cys Glu Glu
20 25 30
Asn Ser Val Pro Tyr Gln Val Ser Leu Asn Ser Gly Tyr His Phe Cys
35 40 45
Gly Gly Ser Leu Ile Asn Glu Gln Trp Val Val Ser Ala Gly His Cys
50 55 60
Tyr Lys Ser Arg Ile Gln Val Arg Leu Gly Glu His Asn Ile Glu Val
65 70 75 80
Leu Glu Gly Asn Glu Gln Phe Ile Asn Ala Ala Lys Ile Ile Arg His
85 90 95
Pro Gln Tyr Asp Arg Lys Thr Leu Asn Asn Asp Ile Met Leu Ile Lys
100 105 110
Leu Ser Ser Arg Ala Val Ile Asn Ala Arg Val Ser ThrIle Ser Leu
115 120 125
Pro Thr Ala Pro Pro Ala Thr Gly Thr Lys Cys Leu Ile Ser Gly Trp
130 135 140
Gly Asn Thr Ala Ser Ser Gly Ala Asp Tyr Pro Asp Glu Leu Gln Cys
145 150 155 160
Leu Asp Ala Pro Val Leu Ser Gln Ala Lys Cys Glu Ala Ser Tyr Pro
165 170 175
Gly Lys Ile Thr Ser Asn Met Phe Cys Val Gly Phe Leu Glu Gly Gly
180 185 190
Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Val Val Cys Asn Gly
195 200 205
Gln Leu Gln Gly Val Val Ser Trp Gly Asp Gly Cys Ala Gln Lys Asn
210 215 220
Lys Pro Gly Val Tyr Thr Lys Val Tyr Asn Tyr Val Lys Trp Ile Lys
225 230 235 240
Asn Thr Ile Ala Ala Asn Ser
245
<210>76
<211>247
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉trypsase II precursor
<222>(1)..(247)
＜223〉on August 29th, 2003 registration number: P07478
<400>76
Met Asn Leu Leu Leu Ile Leu Thr Phe Val Ala Ala Ala Val Ala Ala
1 5 10 15
Pro Phe Asp Asp Asp Asp Lys Ile Val Gly Gly Tyr Ile Cys Glu Glu
20 25 30
Asn Ser Val Pro Tyr Gln Val Ser Leu Asn Ser Gly Tyr His Phe Cys
35 40 45
Gly Gly Ser Leu Ile Ser Glu Gln Trp Val Val Ser Ala Gly His Cys
50 55 60
Tyr Lys Ser Arg Ile Gln Val Arg Leu Gly Glu His Asn Ile Glu Val
65 70 75 80
Leu Glu Gly Asn Glu Gln Phe Ile Asn Ala Ala Lys Ile Ile Arg His
85 90 95
Pro Lys Tyr Asn Ser Arg Thr Leu Asp Asn Asp Ile Leu Leu Ile Lys
100 105 110
Leu Ser Ser Pro Ala Val Ile Asn Ser Arg Val Ser Ala Ile Ser Leu
115 120 125
Pro Thr Ala Pro Pro Ala Ala Gly Thr Glu Ser Leu Ile Ser Gly Trp
130 135 140
Gly Asn Thr Leu Ser Ser Gly Ala Asp Tyr Pro Asp Glu Leu Gln Cys
145 150 155 160
Leu Asp Ala Pro Val Leu Ser Gln Ala Glu Cys Glu Ala Ser Tyr Pro
165 170 175
Gly Lys Ile Thr Asn Asn Met Phe Cys Val Gly Phe Leu Glu Gly Gly
180 185 190
Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Val Val Ser Asn Gly
195 200 205
Glu Leu Gln Gly Ile Val Ser Trp Gly Tyr Gly Cys Ala Gln Lys Asn
210 215 220
Arg Pro Gly Val Tyr Thr Lys Val Tyr Asn Tyr Val Asp Trp Ile Lys
225 230 235 240
Asp Thr Ile Ala Ala Asn Ser
245
<210>77
<211>379
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉inhibitors of neutrophil elastase (LEI)
<222>(1)..(379)
＜223〉on August 29th, 2003 registration number: P30740
<400>77
Met Glu Gln Leu Ser Ser Ala Asn Thr Arg Phe Ala Leu Asp Leu Phe
1 5 10 15
Leu Ala Leu Ser Glu Asn Asn Pro Ala Gly Asn Ile Phe Ile Ser Pro
20 25 30
Phe Ser Ile Ser Ser Ala Met Ala Met Val Phe Leu Gly Thr Arg Gly
35 40 45
Asn Thr Ala Ala Gln Leu Ser Lys Thr Phe His Phe Asn Thr Val Glu
50 55 60
Glu Val His Ser Arg Phe Gln Ser Leu Asn Ala Asp Ile Asn Lys Arg
65 70 75 80
Gly Ala Ser Tyr Ile Leu Lys Leu Ala Asn Arg Leu Tyr Gly Glu Lys
85 90 95
Thr Tyr Asn Phe Leu Pro Glu Phe Leu Val Ser Thr Gln Lys Thr Tyr
100 105 110
Gly Ala Asp Leu Ala Ser Val Asp Phe Gln His Ala Ser Glu Asp Ala
115 120 125
Arg Lys Thr Ile Asn Gln Trp Val Lys Gly Gln Thr Glu Gly Lys Ile
130 135 140
Pro Glu Leu Leu Ala Ser Gly Met Val Asp Asn Met Thr Lys Leu Val
145 150 155 160
Leu Val Asn Ala Ile Tyr Phe Lys Gly Asn Trp Lys Asp Lys Phe Met
165 170 175
Lys Glu Ala Thr Thr Asn Ala Pro Phe Arg Leu Asn Lys Lys Asp Arg
180 185 190
Lys Thr Val Lys Met Met Tyr Gln Lys Lys Lys Phe Ala Tyr Gly Tyr
195 200 205
Ile Glu Asp Leu Lys Cys Arg Val Leu Glu Leu Pro Tyr Gln Gly Glu
210 215 220
Glu Leu Ser Met Val Ile Leu Leu Pro Asp Asp Ile Glu Asp Glu Ser
225 230 235 240
Thr Gly Leu Lys Lys Ile Glu Glu Gln Leu Thr Leu Glu Lys Leu His
245 250 255
Glu Trp Thr Lys Pro Glu Asn Leu Asp Phe Ile Glu Val Asn Val Ser
260 265 270
Leu Pro Arg Phe Lys Leu Glu Glu Ser Tyr Thr Leu Asn Ser Asp Leu
275 280 285
Ala Arg Leu Gly Val Gln Asp Leu Phe Asn Ser Ser Lys Ala Asp Leu
290 295 300
Ser Gly Met Ser Gly Ala Arg Asp Ile Phe Ile Ser Lys Ile Val His
305 310 315 320
Lys Ser Phe Val Glu Val Asn Glu Glu Gly Thr Glu Ala Ala Ala Ala
325 330 335
Thr Ala Gly Ile Ala Thr Phe Cys Met Leu Met Pro Glu Glu Asn Phe
340 345 350
Thr Ala Asp His Pro Phe Leu Phe Phe Ile Arg His Asn Ser Ser Gly
355 360 365
Ser Ile Leu Phe Leu Gly Arg Phe Ser Ser Pro
370 375
<210>78
<211>573
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉heat shock protein Hsp60
<222>(1)..(573)
＜223〉on August 29th, 2003 registration number: P10809
<400>78
Met Leu Arg Leu Pro Thr Val Phe Arg Gln Met Arg Pro Val Ser Arg
1 5 10 15
Val Leu Ala Pro His Leu Thr Arg Ala Tyr Ala Lys Asp Val Lys Phe
20 25 30
Gly Ala Asp Ala Arg Ala Leu Met Leu Gln Gly Val Asp Leu Leu Ala
35 40 45
Asp Ala Val Ala Val Thr Met Gly Pro Lys Gly Arg Thr Val Ile Ile
50 55 60
Glu Gln Ser Trp Gly Ser Pro Lys Val Thr Lys Asp Gly Val Thr Val
65 70 75 80
Ala Lys Ser Ile Asp Leu Lys Asp Lys Tyr Lys Asn Ile Gly Ala Lys
85 90 95
Leu Val Gln Asp Val Ala Asn Asn Thr Asn Glu Glu Ala Gly Asp Gly
100 105 110
Thr Thr Thr Ala Thr Val Leu Ala Arg Ser Ile Ala Lys Glu Gly Phe
115 120 125
Glu Lys Ile Ser Lys Gly Ala Asn Pro Val Glu Ile Arg Arg Gly Val
130 135 140
Met Leu Ala Val Asp Ala Val Ile Ala Glu Leu Lys Lys Gln Ser Lys
145 150 155 160
Pro Val Thr Thr Pro Glu Glu Ile Ala Gln Val Ala Thr Ile Ser Ala
165 170 175
Asn Gly Asp Lys Glu Ile Gly Asn Ile Ile Ser Asp Ala Met Lys Lys
180 185 190
Val Gly Arg Lys Gly Val Ile Thr Val Lys Asp Gly Lys Thr Leu Asn
195 200 205
Asp Glu Leu Glu Ile Ile Glu Gly Met Lys Phe Asp Arg Gly Tyr Ile
210 215 220
Ser Pro Tyr Phe Ile Asn Thr Ser Lys Gly Gln Lys Cys Glu Phe Gln
225 230 235 240
Asp Ala Tyr Val Leu Leu Ser Glu Lys Lys Ile Ser Ser Ile Gln Ser
245 250 255
Ile Val Pro Ala Leu Glu Ile Ala Asn Ala His Arg Lys Pro Leu Val
260 265 270
Ile Ile Ala Glu Asp Val Asp Gly Glu Ala Leu Ser Thr Leu Val Leu
275 280 285
Asn Arg Leu Lys Val Gly Leu Gln Val Val Ala Val Lys Ala Pro Gly
290 295 300
Phe Gly Asp Asn Arg Lys Asn Gln Leu Lys Asp Met Ala Ile Ala Thr
305 310 315 320
Gly Gly Ala Val Phe Gly Glu Glu Gly Leu Thr Leu Asn Leu Glu Asp
325 330 335
Val Gln Pro His Asp Leu Gly Lys Val Gly Glu Val Ile Val Thr Lys
340 345 350
Asp Asp Ala Met Leu Leu Lys Gly Lys Gly Asp Lys Ala Gln Ile Glu
355 360 365
Lys Arg Ile Gln Glu Ile Ile Glu Gln Leu Asp Val Thr Thr Ser Glu
370 375 380
Tyr Glu Lys Glu Lys Leu Asn Glu Arg Leu Ala Lys Leu Ser Asp Gly
385 390 395 400
Val Ala Val Leu Lys Val Gly Gly Thr Ser Asp Val Glu Val Asn Glu
405 410 415
Lys Lys Asp Arg Val Thr Asp Ala Leu Asn Ala Thr Arg Ala Ala Val
420 425 430
Glu Glu Gly Ile Val Leu Gly Gly Gly Cys Ala Leu Leu Arg Cys Ile
435 440 445
Pro Ala Leu Asp Ser Leu Thr Pro Ala Asn Glu Asp Gln Lys Ile Gly
450 455 460
Ile Glu Ile Ile Lys Arg Thr Leu Lys Ile Pro Ala Met Thr Ile Ala
465 470 475 480
Lys Asn Ala Gly Val Glu Gly Ser Leu Ile Val Glu Lys Ile Met Gln
485 490 495
Ser Ser Ser Glu Val Gly Tyr Asp Ala Met Ala Gly Asp Phe Val Asn
500 505 510
Met Val Glu Lys Gly Ile Ile Asp Pro Thr Lys Val Val Arg Thr Ala
515 520 525
Leu Leu Asp Ala Ala Gly Val Ala Ser Leu Leu Thr Thr Ala Glu Val
530 535 540
Val Val Thr Glu Ile Pro Lys Glu Glu Lys Asp Pro Gly Met Gly Ala
545 550 555 560
Met Gly Gly Met Gly Gly Gly Met Gly Gly Gly Met Phe
565 570
<210>79
<211>803
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉Grp94 amyloid protein precursor (GRP94)
<222>(1)..(803)
＜223〉on August 29th, 2003 registration number: P14625
<400>79
Met Arg Ala Leu Trp Val Leu Gly Leu Cys Cys Val Leu Leu Thr Phe
1 5 10 15
Gly Ser Val Arg Ala Asp Asp Glu Val Asp Val Asp Gly Thr Val Glu
20 25 30
Glu Asp Leu Gly Lys Ser Arg Glu Gly Ser Arg Thr Asp Asp Glu Val
35 40 45
Val Gln Arg Glu Glu Glu Ala Ile Gln Leu Asp Gly Leu Asn Ala Ser
50 55 60
Gln Ile Arg Glu Leu Arg Glu Lys Ser Glu Lys Phe Ala Phe Gln Ala
65 70 75 80
Glu Val Asn Arg Met Met Lys Leu Ile Ile Asn Ser Leu Tyr Lys Asn
85 90 95
Lys Glu Ile Phe Leu Arg Glu Leu Ile Ser Asn Ala Ser Asp Ala Leu
100 105 110
Asp Lys Ile Arg Leu Ile Ser Leu Thr Asp Glu Asn Ala Leu Ser Gly
115 120 125
Asn Glu Glu Leu Thr Val Lys Ile Lys Cys Asp Lys Glu Lys Asn Leu
130 135 140
Leu His Val Thr Asp Thr Gly Val Gly Met Thr Arg Glu Glu Leu Val
145 150 155 160
Lys Asn Leu Gly Thr Ile Ala Lys Ser Gly Thr Ser Glu Phe Leu Asn
165 170 175
Lys Met Thr Glu Ala Gln Glu Asp Gly Gln Ser Thr Ser Glu Leu Ile
180 185 190
Gly Gln Phe Gly Val Gly Phe Tyr Ser Ala Phe Leu Val Ala Asp Lys
195 200 205
Val Ile Val Thr Ser Lys His Asn Asn Asp Thr Gln His Ile Trp Glu
210 215 220
Ser Asp Ser Asn Glu Phe Ser Val Ile Ala Asp Pro Arg Gly Asn Thr
225 230 235 240
Leu Gly Arg Gly Thr Thr Ile Thr Leu Val Leu Lys Glu Glu Ala Ser
245 250 255
Asp Tyr Leu Glu Leu Asp Thr Ile Lys Asn Leu Val Lys Lys Tyr Ser
260 265 270
Gln Phe Ile Asn Phe Pro Ile Tyr Val Trp Ser Ser Lys Thr Glu Thr
275 280 285
Val Glu Glu Pro Met Glu Glu Glu Glu Ala Ala Lys Glu Glu Lys Glu
290 295 300
Glu Ser Asp Asp Glu Ala Ala Val Glu Glu Glu Glu Glu Glu Lys Lys
305 310 315 320
Pro Lys Thr Lys Lys Val Glu Lys Thr Val Trp Asp Trp Glu Leu Met
325 330 335
Asn Asp Ile Lys Pro Ile Trp Gln Arg Pro Ser Lys Glu Val Glu Glu
340 345 350
Asp Glu Tyr Lys Ala Phe Tyr Lys Ser Phe Ser Lys Glu Ser Asp Asp
355 360 365
Pro Met Ala Tyr Ile His Phe Thr Ala Glu Gly Glu Val Thr Phe Lys
370 375 380
Ser Ile Leu Phe Val Pro Thr Ser Ala Pro Arg Gly Leu Phe Asp Glu
385 390 395 400
Tyr Gly Ser Lys Lys Ser Asp Tyr Ile Lys Leu Tyr Val Arg Arg Val
405 410 415
Phe Ile Thr Asp Asp Phe His Asp Met Met Pro Lys Tyr Leu Asn Phe
420 425 430
Val Lys Gly Val Val Asp Ser Asp Asp Leu Pro Leu Asn Val Ser Arg
435 440 445
Glu Thr Leu Gln Gln His Lys Leu Leu Lys Val Ile Arg Lys Lys Leu
450 455 460
Val Arg Lys Thr Leu Asp Met Ile Lys Lys Ile Ala Asp Asp Lys Tyr
465 470 475 480
Asn Asp Thr Phe Trp Lys Glu Phe Gly Thr Asn Ile Lys Leu Gly Val
485 490 495
Ile Glu Asp His Ser Asn Arg Thr Arg Leu Ala Lys Leu Leu Arg Phe
500 505 510
Gln Ser Ser His His Pro Thr Asp Ile Thr Ser Leu Asp Gln Tyr Val
515 520 525
Glu Arg Met Lys Glu Lys Gln Asp Lys Ile Tyr Phe Met Ala Gly Ser
530 535 540
Ser Arg Lys Glu Ala Glu Ser Ser Pro Phe Val Glu Arg Leu Leu Lys
545 550 555 560
Lys Gly Tyr Glu Val Ile Tyr Leu Thr Glu Pro Val Asp Glu Tyr Cys
565 570 575
Ile Gln Ala Leu Pro Glu Phe Asp Gly Lys Arg Phe Gln Asn Val Ala
580 585 590
Lys Glu Gly Val Lys Phe Asp Glu Ser Glu Lys Thr Lys Glu Ser Arg
595 600 605
Glu Ala Val Glu Lys Glu Phe Glu Pro Leu Leu Asn Trp Met Lys Asp
610 615 620
Lys Ala Leu Lys Asp Lys Ile Glu Lys Ala Val Val Ser Gln Arg Leu
625 630 635 640
Thr Glu Ser Pro Cys Ala Leu Val Ala Ser Gln Tyr Gly Trp Ser Gly
645 650 655
Asn Met Glu Arg Ile Met Lys Ala Gln Ala Tyr Gln Thr Gly Lys Asp
660 665 670
Ile Ser Thr Asn Tyr Tyr Ala Ser Gln Lys Lys Thr Phe Glu Ile Asn
675 680 685
Pro Arg His Pro Leu Ile Arg Asp Met Leu Arg Arg Ile Lys Glu Asp
690 695 700
Glu Asp Asp Lys Thr Val Leu Asp Leu Ala Val Val Leu Phe Glu Thr
705 710 715 720
Ala Thr Leu Arg Ser Gly Tyr Leu Leu Pro Asp Thr Lys Ala Tyr Gly
725 730 735
Asp Arg Ile Glu Arg Met Leu Arg Leu Ser Leu Asn Ile Asp Pro Asp
740 745 750
Ala Lys Val Glu Glu Glu Pro Glu Glu Glu Pro Glu Glu Thr Ala Glu
755 760 765
Asp Thr Thr Glu Asp Thr Glu Gln Asp Glu Asp Glu Glu Met Asp Val
770 775 780
Gly Thr Asp Glu Glu Glu Glu Thr Ala Lys Glu Ser Thr Ala Glu Lys
785 790 795 800
Asp Glu Leu
<210>80
<211>261
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉endoplasmic reticulum albumen ERp29 precursor (ERp31) (ERp28)
<222>(1)..(261)
＜223〉on August 29th, 2003 registration number: P30040
<400>80
Met Ala Ala Ala Val Pro Arg Ala Ala Phe Leu Ser Pro Leu Leu Pro
1 5 10 15
Leu Leu Leu Gly Phe Leu Leu Leu Ser Ala Pro His Gly Gly Ser Gly
20 25 30
Leu His Thr Lys Gly Ala Leu Pro Leu Asp Thr Val Thr Phe Tyr Lys
35 40 45
Val Ile Pro Lys Ser Lys Phe Val Leu Val Lys Phe Asp Thr Gln Tyr
50 55 60
Pro Tyr Gly Glu Lys Gln Asp Glu Phe Lys Arg Leu Ala Glu Asn Ser
65 70 75 80
Ala Ser Ser Asp Asp Leu Leu Val Ala Glu Val Gly Ile Ser Asp Tyr
85 90 95
Gly Asp Lys Leu Asn Met Glu Leu Ser Glu Lys Tyr Lys Leu Asp Lys
100 105 110
Glu Ser Tyr Pro Val Phe Tyr Leu Phe Arg Asp Gly Asp Phe Glu Asn
115 120 125
Pro Val Pro Tyr Thr Gly Ala Val Lys Val Gly Ala Ile Gln Arg Trp
130 135 140
Leu Lys Gly Gln Gly Val Tyr Leu Gly Met Pro Gly Cys Leu Pro Val
145 150 155 160
Tyr Asp Ala Leu Ala Gly Glu Phe Ile Arg Ala Ser Gly Val Glu Ala
165 170 175
Arg Gln Ala Leu Leu Lys Gln Gly Gln Asp Asn Leu Ser Ser Val Lys
180 185 190
Glu Thr Gln Lys Lys Trp Ala Glu Gln Tyr Leu Lys Ile Met Gly Lys
195 200 205
Ile Leu Asp Gln Gly Glu Asp Phe Pro Ala Ser Glu Met Thr Arg Ile
210 215 220
Ala Arg Leu Ile Glu Lys Asn Lys Met Ser Asp Gly Lys Lys Glu Glu
225 230 235 240
Leu Gln Lys Ser Leu Asn Ile Leu Thr Ala Phe Gln Lys Lys Gly Ala
245 250 255
Glu Lys Glu Glu Leu
260
<210>81
<211>525
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉protein disulphideisomerase A2 precursor
<222>(1)..(525)
＜223〉on August 29th, 2003 registration number: Q13087
<400>81
Met Ser Arg Gln Leu Leu Pro Val Leu Leu Leu Leu Leu Leu Arg Ala
1 5 10 15
Ser Cys Pro Trp Gly Gln Glu Gln Gly Ala Arg Ser Pro Ser Glu Glu
20 25 30
Pro Pro Glu Glu Glu Ile Pro Lys Glu Asp Gly Ile Leu Val Leu Ser
35 40 45
Arg His Thr Leu Gly Leu Ala Leu Arg Glu His Pro Ala Leu Leu Val
50 55 60
Glu Phe Tyr Ala Pro Trp Cys Gly His Cys Gln Ala Leu Ala Pro Glu
65 70 75 80
Tyr Ser Lys Ala Ala Ala Val Leu Ala Ala Glu Ser Met Val Val Thr
85 90 95
Leu Ala Lys Val Asp Gly Pro Ala Gln Arg Glu Leu Ala Glu Glu Phe
100 105 110
Gly Val Thr Glu Tyr Pro Thr Leu Lys Phe Phe Arg Asn Gly Asn Arg
115 120 125
Thr His Pro Glu Glu Tyr Thr Gly Pro Arg Asp Ala Glu Gly Ile Ala
130 135 140
Glu Trp Leu Arg Arg Arg Val Gly Pro Ser Ala Met Arg Leu Glu Asp
145 150 155 160
Glu Ala Ala Ala Gln Ala Leu Ile Gly Gly Arg Asp Leu Val Val Ile
165 170 175
Gly Phe Phe Gln Asp Leu Gln Asp Glu Asp Val Ala Thr Phe Leu Ala
180 185 190
Leu Ala Gln Asp Ala Leu Asp Met Thr Phe Gly Leu Thr Asp Arg Pro
195 200 205
Arg Leu Phe Gln Gln Phe Gly Leu Thr Lys Asp Thr Val Val Leu Phe
210 215 220
Lys Lys Phe Asp Glu Gly Arg Ala Asp Phe Pro Val Asp Glu Glu Leu
225 230 235 240
Gly Leu Asp Leu Gly Asp Leu Ser Arg Phe Leu Val Thr His Ser Met
245 250 255
Arg Leu Val Thr Glu Phe Asn Ser Gln Thr Ser Ala Lys Ile Phe Ala
260 265 270
Ala Arg Ile Leu Asn His Leu Leu Leu Phe Val Asn Gln Thr Leu Ala
275 280 285
Ala His Arg Glu Leu Leu Ala Gly Phe Gly Glu Ala Ala Pro Arg Phe
290 295 300
Arg Gly Gln Val Leu Phe Val Val Val Asp Val Ala Ala Asp Asn Glu
305 310 315 320
His Val Leu Gln Tyr Phe Gly Leu Lys Ala Glu Ala Ala Pro Thr Leu
325 330 335
Arg Leu Val Asn Leu Glu Thr Thr Lys Lys Tyr Ala Pro Val Asp Gly
340 345 350
Gly Pro Val Thr Ala Ala Ser Ile Thr Ala Phe Cys His Ala Val Leu
355 360 365
Asn Gly Gln Val Lys Pro Tyr Leu Leu Ser Gln Glu Ile Pro Pro Asp
370 375 380
Trp Asp Gln Arg Pro Val Lys Thr Leu Val Gly Lys Asn Phe Glu Gln
385 390 395 400
Val Ala Phe Asp Glu Thr Lys Asn Val Phe Val Lys Phe Tyr Ala Pro
405 410 415
Trp Cys Thr His Cys Lys Glu Met Ala Pro Ala Trp Glu Ala Leu Ala
420 425 430
Glu Lys Tyr Gln Asp His Glu Asp Ile Ile Ile Ala Glu Leu Asp Ala
435 440 445
Thr Ala Asn Glu Leu Asp Ala Phe Ala Val His Gly Phe Pro Thr Leu
450 455 460
Lys Tyr Phe Pro Ala Gly Pro Gly Arg Lys Val Ile Glu Tyr Lys Ser
465 470 475 480
Thr Arg Asp Leu Glu Thr Phe Ser Lys Phe Leu Asp Asn Gly Gly Val
485 490 495
Leu Pro Thr Glu Glu Pro Pro Glu Glu Pro Ala Ala Pro Phe Pro Glu
500 505 510
Pro Pro Ala Asn Ser Thr Met Gly Ser Lys Glu Glu Leu
515 520 525
<210>82
<211>505
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉protein disulphideisomerase A3 precursor
<222>(1)..(505)
＜223〉on August 29th, 2003 registration number: P30101
<400>82
Met Arg Leu Arg Arg Leu Ala Leu Phe Pro Gly Val Ala Leu Leu Leu
1 5 10 15
Ala Ala Ala Arg Leu Ala Ala Ala Ser Asp Val Leu Glu Leu Thr Asp
20 25 30
Asp Asn Phe Glu Ser Arg Ile Ser Asp Thr Gly Ser Ala Gly Leu Met
35 40 45
Leu Val Glu Phe Phe Ala Pro Trp Cys Gly His Cys Lys Arg Leu Ala
50 55 60
Pro Glu Tyr Glu Ala Ala Ala Thr Arg Leu Lys Gly Ile Val Pro Leu
65 70 75 80
Ala Lys Val Asp Cys Thr Ala Asn Thr Asn Thr Cys Asn Lys Tyr Gly
85 90 95
Val Ser Gly Tyr Pro Thr Leu Lys Ile Phe Arg Asp Gly Glu Glu Ala
100 105 110
Gly Ala Tyr Asp Gly Pro Arg Thr Ala Asp Gly Ile Val Ser His Leu
115 120 125
Lys Lys Gln Ala Gly Pro Ala Ser Val Pro Leu Arg Thr Glu Glu Glu
130 135 140
Phe Lys Lys Phe Ile Ser Asp Lys Asp Ala Ser Ile Val Gly Phe Phe
145 150 155 160
Asp Asp Ser Phe Ser Glu Ala His Ser Glu Phe Leu Lys Ala Ala Ser
165 170 175
Asn Leu Arg Asp Asn Tyr Arg Phe Ala His Thr Asn Val Glu Ser Leu
180 185 190
Val Asn Glu Tyr Asp Asp Asn Gly Glu Gly Ile Ile Leu Phe Arg Pro
195 200 205
Ser His Leu Thr Asn Lys Phe Glu Asp Lys Thr Val Ala Tyr Thr Glu
210 215 220
Gln Lys Met Thr Ser Gly Lys Ile Lys Lys Phe Ile Gln Glu Asn Ile
225 230 235 240
Phe Gly Ile Cys Pro His Met Thr Glu Asp Asn Lys Asp Leu Ile Gln
245 250 255
Gly Lys Asp Leu Leu Ile Ala Tyr Tyr Asp Val Asp Tyr Glu Lys Asn
260 265 270
Ala Lys Gly Ser Asn Tyr Trp Arg Asn Arg Val Met Met Val Ala Lys
275 280 285
Lys Phe Leu Asp Ala Gly His Lys Leu Asn Phe Ala Val Ala Ser Arg
290 295 300
Lys Thr Phe Ser His Glu Leu Ser Asp Phe Gly Leu Glu Ser Thr Ala
305 310 315 320
Gly Glu Ile Pro Val Val Ala Ile Arg Thr Ala Lys Gly Glu Lys Phe
325 330 335
Val Met Gln Glu Glu Phe Ser Arg Asp Gly Lys Ala Leu Glu Arg Phe
340 345 350
Leu Gln Asp Tyr Phe Asp Gly Asn Leu Lys Arg Tyr Leu Lys Ser Glu
355 360 365
Pro Ile Pro Glu Ser Asn Asp Gly Pro Val Lys Val Val Val Ala Glu
370 375 380
Asn Phe Asp Glu Ile Val Asn Asn Glu Asn Lys Asp Val Leu Ile Glu
385 390 395 400
Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Asn Leu Glu Pro Lys Tyr
405 410 415
Lys Glu Leu Gly Glu Lys Leu Ser Lys Asp Pro Asn Ile Val Ile Ala
420 425 430
Lys Met Asp Ala Thr Ala Asn Asp Val Pro Ser Pro Tyr Glu Val Arg
435 440 445
Gly Phe Pro Thr Ile Tyr Phe Ser Pro Ala Asn Lys Lys Leu Asn Pro
450 455 460
Lys Lys Tyr Glu Gly Gly Arg Glu Leu Ser Asp Phe Ile Ser Tyr Leu
465 470 475 480
Gln Arg Glu Ala Thr Asn Pro Pro Val Ile Gln Glu Glu Lys Pro Lys
485 490 495
Lys Lys Lys Lys Ala Gln Glu Asp Leu
500 505
<210>83
<211>374
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉alcohol dehydrogenase beta-chain
<222>(1)..(374)
＜223〉on August 29th, 2003 registration number: P00325
<400>83
Ser Thr Ala Gly Lys Val Ile Lys Cys Lys Ala Ala Val Leu Trp Glu
1 5 10 15
Val Lys Lys Pro Phe Ser Ile Glu Asp Val Glu Val Ala Pro Pro Lys
20 25 30
Ala Tyr Glu Val Arg Ile Lys Met Val Ala Val Gly Ile Cys Arg Thr
35 40 45
Asp Asp His Val Val Ser Gly Asn Leu Val Thr Pro Leu Pro Val Ile
50 55 60
Leu Gly His Glu Ala Ala Gly Ile Val Glu Ser Val Gly Glu Gly Val
65 70 75 80
Thr Thr Val Lys Pro Gly Asp Lys Val Ile Pro Leu Phe Thr Pro Gln
85 90 95
Cys Gly Lys Cys Arg Val Cys Lys Asn Pro Glu Ser Asn Tyr Cys Leu
100 105 110
Lys Asn Asp Leu Gly Asn Pro Arg Gly Thr Leu Gln Asp Gly Thr Arg
115 120 125
Arg Phe Thr Cys Arg Gly Lys Pro Ile His His Phe Leu Gly Thr Ser
130 135 140
Thr Phe Ser Gln Tyr Thr Val Val Asp Glu Asn Ala Val Ala Lys Ile
145 150 155 160
Asp Ala Ala Ser Pro Leu Glu Lys Val Cys Leu Ile Gly Cys Gly Phe
165 170 175
Ser Thr Gly Tyr Gly Ser Ala Val Asn Val Ala Lys Val Thr Pro Gly
180 185 190
Ser Thr Cys Ala Val Phe Gly Leu Gly Gly Val Gly Leu Ser Ala Val
195 200 205
Met Gly Cys Lys Ala Ala Gly Ala Ala Arg Ile Ile Ala Val Asp Ile
210 215 220
Asn Lys Asp Lys Phe Ala Lys Ala Lys Glu Leu Gly Ala Thr Glu Cys
225 230 235 240
Ile Asn Pro Gln Asp Tyr Lys Lys Pro Ile Gln Glu Val Leu Lys Glu
245 250 255
Met Thr Asp Gly Gly Val Asp Phe Ser Phe Glu Val Ile Gly Arg Leu
260 265 270
Asp Thr Met Met Ala Ser Leu Leu Cys Cys His Glu Ala Cys Gly Thr
275 280 285
Ser Val Ile Val Gly Val Pro Pro Ala Ser Gln Asn Leu Ser lle Asn
290 295 300
Pro Met Leu Leu Leu Thr Gly Arg Thr Trp Lys Gly Ala Val Tyr Gly
305 310 315 320
Gly Phe Lys Ser Lys Glu Gly Ile Pro Lys Leu Val Ala Asp Phe Met
325 330 335
Ala Lys Lys Phe Ser Leu Asp Ala Leu Ile Thr His Val Leu Pro Phe
340 345 350
Glu Lys Ile Asn Glu Gly Phe Asp Leu Leu His Ser Gly Lys Ser Ile
355 360 365
Arg Thr Val Leu Thr Phe
370
<210>84
<211>241
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the sweet Guang peptidyl transferase of paddy omega-1
<222>(1)..(241)
＜223〉on August 29th, 2003 registration number: P78417
<400>84
Met Ser Gly Glu Ser Ala Arg Ser Leu Gly Lys Gly Ser Ala Pro Pro
1 5 10 15
Gly Pro Val Pro Glu Gly Ser Ile Arg Ile Tyr Ser Met Arg Phe Cys
20 25 30
Pro Phe Ala Glu Arg Thr Arg Leu Val Leu Lys Ala Lys Gly Ile Arg
35 40 45
His Glu Val Ile Asn Ile Asn Leu Lys Asn Lys Pro Glu Trp Phe Phe
50 55 60
Lys Lys Asn Pro Phe Gly Leu Val Pro Val Leu Glu Asn Ser Gln Gly
65 70 75 80
Gln Leu Ile Tyr Glu Ser Ala Ile Thr Cys Glu Tyr Leu Asp Glu Ala
85 90 95
Tyr Pro Gly Lys Lys Leu Leu Pro Asp Asp Pro Tyr Glu Lys Ala Cys
100 105 110
Gln Lys Met Ile Leu Glu Leu Phe Ser Lys Val Pro Ser Leu Val Gly
115 120 125
Ser Phe Ile Arg Ser Gln Asn Lys Glu Asp Tyr Ala Gly Leu Lys Glu
130 135 140
Glu Phe Arg Lys Glu Phe Thr Lys Leu Glu Glu Val Leu Thr Asn Lys
145 150 155 160
Lys Thr Thr Phe Phe Gly Gly Asn Ser Ile Ser Met Ile Asp Tyr Leu
165 170 175
Ile Trp Pro Trp Phe Glu Arg Leu Glu Ala Met Lys Leu Asn Glu Cys
180 185 190
Val Asp His Thr Pro Lys Leu Lys Leu Trp Met Ala Ala Met Lys Glu
195 200 205
Asp Pro Thr Val Ser Ala Leu Leu Thr Ser Glu Lys Asp Trp Gln Gly
210 215 220
Phe Leu Glu Leu Tyr Leu Gln Asn Ser Pro Glu Ala Cys Asp Tyr Gly
225 230 235 240
Leu
<210>85
<211>999
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉amyloid protein precursor (Orp150) of 150kDa oxygen adjusting
<222>(1)..(999)
＜223〉on August 29th, 2003 registration number: Q9Y4L1
<400>85
Met Ala Asp Lys Val Arg Arg Gln Arg Pro Arg Arg Arg Val Cys Trp
1 5 10 15
Ala Leu Val Ala Val Leu Leu Ala Asp Leu Leu Ala Leu Ser Asp Thr
20 25 30
Leu Ala Val Met Ser Val Asp Leu Gly Ser Glu Ser Met Lys Val Ala
35 40 45
Ile Val Lys Pro Gly Val Pro Met Glu Ile Val Leu Asn Lys Glu Ser
50 55 60
Arg Arg Lys Thr Pro Val Ile Val Thr Leu Lys Glu Asn Glu Arg Phe
65 70 75 80
Phe Gly Asp Ser Ala Ala Ser Met Ala Ile Lys Asn Pro Lys Ala Thr
85 90 95
Leu Arg Tyr Phe Gln His Leu Leu Gly Lys Gln Ala Asp Asn Pro His
100 105 110
Val Ala Leu Tyr Gln Ala Arg Phe Pro Glu His Glu Leu Thr Phe Asp
115 120 125
Pro Gln Arg Gln Thr Val His Phe Gln Ile Ser Ser Gln Leu Gln Phe
130 135 140
Ser Pro Glu Glu Val Leu Gly Met Val Leu Asn Tyr Ser Arg Ser Leu
145 150 155 160
Ala Glu Asp Phe Ala Glu Gln Pro Ile Lys Asp Ala Val Ile Thr Val
165 170 175
Pro Val Phe Phe Asn Gln Ala Glu Arg Arg Ala Val Leu Gln Ala Ala
180 185 190
Arg Met Ala Gly Leu Lys Val Leu Gln Leu Ile Asn Asp Asn Thr Ala
195 200 205
Thr Ala Leu Ser Tyr Gly Val Phe Arg Arg Lys Asp Ile Asn Thr Thr
210 215 220
Ala Gln Asn Ile Met Phe Tyr Asp Met Gly Ser Gly Ser Thr Val Cys
225 230 235 240
Thr Ile Val Thr Tyr Gln Met Val Lys Thr Lys Glu Ala Gly Met Gln
245 250 255
Pro Gln Leu Gln Ile Arg Gly Val Gly Phe Asp Arg Thr Leu Gly Gly
260 265 270
Leu Glu Met Glu Leu Arg Leu Arg Glu Arg Leu Ala Gly Leu Phe Asn
275 280 285
Glu Gln Arg Lys Gly Gln Arg Ala Lys Asp Val Arg Glu Asn Pro Arg
290 295 300
Ala Met Ala Lys Leu Leu Arg Glu Ala Asn Arg Leu Lys Thr Val Leu
305 310 315 320
Ser Ala Asn Ala Asp His Met Ala Gln Ile Glu Gly Leu Met Asp Asp
325 330 335
Val Asp Phe Lys Ala Lys Val Thr Arg Val Glu Phe Glu Glu Leu Cys
340 345 350
Ala Asp Leu Phe Glu Arg Val Pro Gly Pro Val Gln Gln Ala Leu Gln
355 360 365
Ser Ala Glu Met Ser Leu Asp Glu Ile Glu Gln Val Ile Leu Val Gly
370 375 380
Gly Ala Thr Arg Val Pro Arg Val Gln Glu Val Leu Leu Lys Ala Val
385 390 395 400
Gly Lys Glu Glu Leu Gly Lys Asn Ile Asn Ala Asp Glu Ala Ala Ala
405 410 415
Met Gly Ala Val Tyr Gln Ala Ala Ala Leu Ser Lys Ala Phe Lys Val
420 425 430
Lys Pro Phe Val Val Arg Asp Ala Val Val Tyr Pro Ile Leu Val Glu
435 440 445
Phe Thr Arg Glu Val Glu Glu Glu Pro Gly Ile His Ser Leu Lys His
450 455 460
Asn Lys Arg Val Leu Phe Ser Arg Met Gly Pro Tyr Pro Gln Arg Lys
465 470 475 480
Val Ile Thr Phe Asn Arg Tyr Ser His Asp Phe Asn Phe His Ile Asn
485 490 495
Tyr Gly Asp Leu Gly Phe Leu Gly Pro Glu Asp Leu Arg Val Phe Gly
500 505 510
Ser Gln Asn Leu Thr Thr Val Lys Leu Lys Gly Val Gly Asp Ser Phe
515 520 525
Lys Lys Tyr Pro Asp Tyr Glu Ser Lys Gly Ile Lys Ala His Phe Asn
530 535 540
Leu Asp Glu Ser Gly Val Leu Ser Leu Asp Arg Val Glu Ser Val Phe
545 550 555 560
Glu Thr Leu Val Glu Asp Ser Ala Glu Glu Glu Ser Thr Leu Thr Lys
565 570 575
Leu Gly Asn Thr Ile Ser Ser Leu Phe Gly Gly Gly Thr Thr Pro Asp
580 585 590
Ala Lys Glu Asn Gly Thr Asp Thr Val Gln Glu Glu Glu Glu Ser Pro
595 600 605
Ala Glu Gly Ser Lys Asp Glu Pro Gly Glu Gln Val Glu Leu Lys Glu
610 615 620
Glu Ala Glu Ala Pro Val Glu Asp Gly Ser Gln Pro Pro Pro Pro Glu
625 630 635 640
Pro Lys Gly Asp Ala Thr Pro Glu Gly Glu Lys Ala Thr Glu Lys Glu
645 650 655
Asn Gly Asp Lys Ser Glu Ala Gln Lys Pro Ser Glu Lys Ala Glu Ala
660 665 670
Gly Pro Glu Gly Val Ala Pro Ala Pro Glu Gly Glu Lys Lys Gln Lys
675 680 685
Pro Ala Arg Lys Arg Arg Met Val Glu Glu Ile Gly Val Glu Leu Val
690 695 700
Val Leu Asp Leu Pro Asp Leu Pro Glu Asp Lys Leu Ala Gln Ser Val
705 710 715 720
Gln Lys Leu Gln Asp Leu Thr Leu Arg Asp Leu Glu Lys Gln Glu Arg
725 730 735
Glu Lys Ala Ala Asn Ser Leu Glu Ala Phe Ile Phe Glu Thr Gln Asp
740 745 750
Lys Leu Tyr Gln Pro Glu Tyr Gln Glu Val Ser Thr Glu Glu Gln Arg
755 760 765
Glu Glu Ile Ser Gly Lys Leu Ser Ala Ala Ser Thr Trp Leu Glu Asp
770 775 780
Glu Gly Val Gly Ala Thr Thr Val Met Leu Lys Glu Lys Leu Ala Glu
785 790 795 800
Leu Arg Lys Leu Cys Gln Gly Leu Phe Phe Arg Val Glu Glu Arg Lys
805 810 815
Lys Trp Pro Glu Arg Leu Ser Ala Leu Asp Asn Leu Leu Asn His Ser
820 825 830
Ser Met Phe Leu Lys Gly Ala Arg Leu Ile Pro Glu Met Asp Gln Ile
835 840 845
Phe Thr Glu Val Glu Met Thr Thr Leu Glu Lys Val Ile Asn Glu Thr
850 855 860
Trp Ala Trp Lys Asn Ala Thr Leu Ala Glu Gln Ala Lys Leu Pro Ala
865 870 875 880
Thr Glu Lys Pro Val Leu Leu Ser Lys Asp Ile Glu Ala Lys Met Met
885 890 895
Ala Leu Asp Arg Glu Val Gln Tyr Leu Leu Asn Lys Ala Lys Phe Thr
900 905 910
Lys Pro Arg Pro Arg Pro Lys Asp Lys Asn Gly Thr Arg Ala Glu Pro
915 920 925
Pro Leu Asn Ala Ser Ala Ser Asp Gln Gly Glu Lys Val Ile Pro Pro
930 935 940
Ala Gly Gln Thr Glu Asp Ala Glu Pro Ile Ser Glu Pro Glu Lys Val
945 950 955 960
Glu Thr Gly Ser Glu Pro Gly Asp Thr Glu Pro Leu Glu Leu Gly Gly
965 970 975
Pro Gly Ala Glu Pro Glu Gln Lys Glu Gln Ser Thr Gly Gln Lys Arg
980 985 990
Pro Leu Lys Asn Asp Glu Leu
995
<210>86
<211>271
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the peroxidating reductase 4
<222>(1)..(271)
＜223〉on August 29th, 2003 registration number: Q13162
<400>86
Met Glu Ala Leu Pro Leu Leu Ala Ala Thr Thr Pro Asp His Gly Arg
1 5 10 15
His Arg Arg Leu Leu Leu Leu Pro Leu Leu Leu Phe Leu Leu Pro Ala
20 25 30
Gly Ala Val Gln Gly Trp Glu Thr Glu Glu Arg Pro Arg Thr Arg Glu
35 40 45
Glu Glu Cys His Phe Tyr Ala Gly Gly Gln Val Tyr Pro Gly Glu Ala
50 55 60
Ser Arg Val Ser Val Ala Asp His Ser Leu His Leu Ser Lys Ala Lys
65 70 75 80
Ile Ser Lys Pro Ala Pro Tyr Trp Glu Gly Thr Ala Val Ile Asp Gly
85 90 95
Glu Phe Lys Glu Leu Lys Leu Thr Asp Tyr Arg Gly Lys Tyr Leu Val
100 105 110
Phe Phe Phe Tyr Pro Leu Asp Phe Thr Phe Val Cys Pro Thr Glu Ile
115 120 125
Ile Ala Phe Gly Asp Arg Leu Glu Glu Phe Arg Ser Ile Asn Thr Glu
130 135 140
Val Val Ala Cys Ser Val Asp Ser Gln Phe Thr His Leu Ala Trp Ile
145 150 155 160
Asn Thr Pro Arg Arg Gln Gly Gly Leu Gly Pro Ile Arg Ile Pro Leu
165 170 175
Leu Ser Asp Leu Thr His Gln Ile Ser Lys Asp Tyr Gly Val Tyr Leu
180 185 190
Glu Asp Ser Gly His Thr Leu Arg Gly Leu Phe Ile Ile Asp Asp Lys
195 200 205
Gly Ile Leu Arg Gln Ile Thr Leu Asn Asp Leu Pro Val Gly Arg Ser
210 215 220
Val Asp Glu Thr Leu Arg Leu Val Gln Ala Phe Gln Tyr Thr Asp Lys
225 230 235 240
His Gly Glu Val Cys Pro Ala Gly Trp Lys Pro Gly Ser Glu Thr Ile
245 250 255
Ile Pro Asp Pro Ala Gly Lys Leu Lys Tyr Phe Asp Lys Leu Asn
260 265 270
<210>87
<211>288
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉MAWD is in conjunction with albumen
<222>(1)..(288)
＜223〉on August 29th, 2003 registration number: P30039
<400>87
Met Lys Leu Pro Ile Phe Ile Ala Asp Ala Phe Thr Ala Arg Ala Phe
1 5 10 15
Arg Gly Asn Pro Ala Ala Val Cys Leu Leu Glu Asn Glu Leu Asp Glu
20 25 30
Asp Met His Gln Lys Ile Ala Arg Glu Met Asn Leu Ser Glu Thr Ala
35 40 45
Phe Ile Arg Lys Leu His Pro Thr Asp Asn Phe Ala Gln Ser Ser Cys
50 55 60
Phe Gly Leu Arg Trp Phe Thr Pro Ala Ser Glu Val Pro Leu Cys Gly
65 70 75 80
His Ala Thr Leu Ala Ser Ala Ala Val Leu Phe His Lys Ile Lys Asn
85 90 95
Met Asn Ser Thr Leu Thr Phe Val Thr Leu Ser Gly Glu Leu Arg Ala
100 105 110
Arg Arg Ala Glu Asp Gly Ile Val Leu Asp Leu Pro Leu Tyr Pro Ala
115 120 125
His Pro Gln Asp Phe His Glu Val Glu Asp Leu Ile Lys Thr Ala Ile
130 135 140
Gly Asn Thr Leu Val Gln Asp Ile Cys Tyr Ser Pro Asp Thr Gln Lys
145 150 155 160
Leu Leu Val Arg Leu Ser Asp Val Tyr Asn Arg Ser Phe Leu Glu Asn
165 170 175
Leu Lys Val Asn Thr Glu Asn Leu Leu Gln Val Glu Asn Thr Gly Lys
180 185 190
Val Lys Gly Leu Ile Leu Thr Leu Lys Gly Glu Pro Gly Gly Gln Thr
195 200 205
Gln Ala Phe Asp Phe Tyr Ser Arg Tyr Phe Ala Pro Trp Val Gly Val
210 215 220
Ala Glu Asp Pro Val Thr Gly Ser Ala His Ala Val Leu Ser Ser Tyr
225 230 235 240
Trp Ser Gln His Leu Gly Lys Lys Glu Met His Ala Phe Gln Cys Ser
245 250 255
His Arg Gly Gly Glu Leu Gly Ile Ser Leu Arg Pro Asp Gly Arg Val
260 265 270
Asp Ile Arg Gly Gly Ala Ala Val Val Leu Glu Gly Thr Leu Thr Ala
275 280 285
<210>88
<211>511
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉Alpha-diastase 2B precursor
<222>(1)..(511)
＜223〉on August 29th, 2003 registration number: P19961
<400>88
Met Lys Phe Phe Leu Leu Leu Phe Thr Ile Gly Phe Cys Trp Ala Gln
1 5 10 15
Tyr Ser Pro Asn Thr Gln Gln Gly Arg Thr Ser Ile Val His Leu Phe
20 25 30
Glu Trp Arg Trp Val Asp Ile Ala Leu Glu Cys Glu Arg Tyr Leu Ala
35 40 45
Pro Lys Gly Phe Gly Gly Val Gln Val Ser Pro Pro Asn Glu Asn Val
50 55 60
Ala Ile His Asn Pro Phe Arg Pro Trp Trp Glu Arg Tyr Gln Pro Val
65 70 75 80
Ser Tyr Lys Leu Cys Thr Arg Ser Gly Asn Glu Asp Glu Phe Arg Asn
85 90 95
Met Val Thr Arg Cys Asn Asn Val Gly Val Arg Ile Tyr Val Asp Ala
100 105 110
Val Ile Asn His Met Ser Gly Asn Ala Val Ser Ala Gly Thr Ser Ser
115 120 125
Thr Cys Gly Ser Tyr Phe Asn Pro Gly Ser Arg Asp Phe Pro Ala Val
130 135 140
Pro Tyr Ser Gly Trp Asp Phe Asn Asp Gly Lys Cys Lys Thr Gly Ser
145 150 155 160
Gly Asp Ile Glu Asn Tyr Asn Asp Ala Thr Gln Val Arg Asp Cys Arg
165 170 175
Leu Val Gly Leu Leu Asp Leu Ala Leu Glu Lys Asp Tyr Val Arg Ser
180 185 190
Lys Ile Ala Glu Tyr Met Asn His Leu Ile Asp Ile Gly Val Ala Gly
195 200 205
Phe Arg Leu Asp Ala Ser Lys His Met Trp Pro Gly Asp Ile Lys Ala
210 215 220
Ile Leu Asp Lys Leu His Asn Leu Asn Ser Asn Trp Phe Pro Ala Gly
225 230 235 240
Ser Lys Pro Phe Ile Tyr Gln Glu Val Ile Asp Leu Gly Gly Glu Pro
245 250 255
Ile Lys Ser Ser Asp Tyr Phe Gly Asn Gly Arg Val Thr Glu Phe Lys
260 265 270
Tyr Gly Ala Lys Leu Gly Thr Val Ile Arg Lys Trp Asn Gly Glu Lys
275 280 285
Met Ser Tyr Leu Lys Asn Trp Gly Glu Gly Trp Gly Phe Met Pro Ser
290 295 300
Asp Arg Ala Leu Val Phe Val Asp Asn His Asp Asn Gln Arg Gly His
305 310 315 320
Gly Ala Gly Gly Ala Ser Ile Leu Thr Phe Trp Asp Ala Arg Leu Tyr
325 330 335
Lys Met Ala Val Gly Phe Met Leu Ala His Pro Tyr Gly Phe Thr Arg
340 345 350
Val Met Ser Ser Tyr Arg Trp Pro Arg Gln Phe Gln Asn Gly Asn Asp
355 360 365
Val Asn Asp Trp Val Gly Pro Pro Asn Asn Asn Gly Val Ile Lys Glu
370 375 380
Val Thr Ile Asn Pro Asp Thr Thr Cys Gly Asn Asp Trp Val Cys Glu
385 390 395 400
His Arg Trp Arg Gln Ile Arg Asn Met Val Asn Phe Arg Asn Val Val
405 410 415
Asp Gly Gln Pro Phe Thr Asn Trp Tyr Asp Asn Gly Ser Asn Gln Val
420 425 430
Ala Phe Gly Arg Gly Asn Arg Gly Phe Ile Val Phe Asn Asn Asp Asp
435 440 445
Trp Thr Phe Ser Leu Thr Leu Gln Thr Gly Leu Pro Ala Gly Thr Tyr
450 455 460
Cys Asp Val Ile Ser Gly Asp Lys Ile Asn Gly Asn Cys Thr Gly Ile
465 470 475 480
Lys Ile Tyr Val Ser Asp Asp Gly Lys Ala His Phe Ser Ile Ser Asn
485 490 495
Ser Ala Glu Asp Pro Phe Ile Ala Ile His Ala Glu Ser Lys Leu
500 505 510
<210>89
<211>511
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉pancreas Alpha-diastase precursor
<222>(1)..(511)
＜223〉on August 29th, 2003 registration number: P04746
<400>89
Met Lys Phe Phe Leu Leu Leu Phe Thr Ile Gly Phe Cys Trp Ala Gln
1 5 10 15
Tyr Ser Pro Asn Thr Gln Gln Gly Arg Thr Ser Ile Val His Leu Phe
20 25 30
Glu Trp Arg Trp Val Asp Ile Ala Leu Glu Cys Glu Arg Tyr Leu Ala
35 40 45
Pro Lys Gly Phe Gly Gly Val Gln Val Ser Pro Pro Asn Glu Asn Val
50 55 60
Ala Ile Tyr Asn Pro Phe Arg Pro Trp Trp Glu Arg Tyr Gln Pro Val
65 70 75 80
Ser Tyr Lys Leu Cys Thr Arg Ser Gly Asn Glu Asp Glu Phe Arg Asn
85 90 95
Met Val Thr Arg Cys Asn Asn Val Gly Val Arg Ile Tyr Val Asp Ala
100 105 110
Val Ile Asn His Met Cys Gly Asn Ala Val Ser Ala Gly Thr Ser Ser
115 120 125
Thr Cys Gly Ser Tyr Phe Asn Pro Gly Ser Arg Asp Phe Pro Ala Val
130 135 140
Pro Tyr Ser Gly Trp Asp Phe Asn Asp Gly Lys Cys Lys Thr Gly Ser
145 150 155 160
Gly Asp Ile Glu Asn Tyr Asn Asp Ala Thr Gln Val Arg Asp Cys Arg
165 170 175
Leu Thr Gly Leu Leu Asp Leu Ala Leu Glu Lys Asp Tyr Val Arg Ser
180 185 190
Lys Ile Ala Glu Tyr Met Asn His Leu Ile Asp Ile Gly Val Ala Gly
195 200 205
Phe Arg Leu Asp Ala Ser Lys His Met Trp Pro Gly Asp Ile Lys Ala
210 215 220
Ile Leu Asp Lys Leu His Asn Leu Asn Ser Asn Trp Phe Pro Ala Gly
225 230 235 240
Ser Lys Pro Phe Ile Tyr Gln Glu Val Ile Asp Leu Gly Gly Glu Pro
245 250 255
Ile Lys Ser Ser Asp Tyr Phe Gly Asn Gly Arg Val Thr Glu Phe Lys
260 265 270
Tyr Gly Ala Lys Leu Gly Thr Val Ile Arg Lys Trp Asn Gly Glu Lys
275 280 285
Met Ser Tyr Leu Lys Asn Trp Gly Glu Gly Trp Gly Phe Val Pro Ser
290 295 300
Asp Arg Ala Leu Val Phe Val Asp Asn His Asp Asn Gln Arg Gly His
305 310 315 320
Gly Ala Gly Gly Ala Ser Ile Leu Thr Phe Trp Asp Ala Arg Leu Tyr
325 330 335
Lys Met Ala Val Gly Phe Met Leu Ala His Pro Tyr Gly Phe Thr Arg
340 345 350
Val Met Ser Ser Tyr Arg Trp Pro Arg Gln Phe Gln Asn Gly Asn Asp
355 360 365
Val Asn Asp Trp Val Gly Pro Pro Asn Asn Asn Gly Val Ile Lys Glu
370 375 380
Val Thr Ile Asn Pro Asp Thr Thr Cys Gly Asn Asp Trp Val Cys Glu
385 390 395 400
His Arg Trp Arg Gln Ile Arg Asn Met Val Ile Phe Arg Asn Val Val
405 410 415
Asp Gly Gln Pro Phe Thr Asn Trp Tyr Asp Asn Gly Ser Asn Gln Val
420 425 430
Ala Phe Gly Arg Gly Asn Arg Gly Phe Ile Val Phe Asn Asn Asp Asp
435 440 445
Trp Ser Phe Ser Leu Thr Leu Gln Thr Gly Leu Pro Ala Gly Thr Tyr
450 455 460
Cys Asp Val Ile Ser Gly Asp Lys Ile Asn Gly Asn Cys Thr Gly Ile
465 470 475 480
Lys Ile Tyr Val Ser Asp Asp Gly Lys Ala His Phe Ser Ile Ser Asn
485 490 495
Ser Ala Glu Asp Pro Phe Ile Ala Ile His Ala Glu Ser Lys Leu
500 505 510
<210>90
<211>553
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉ATP synzyme Alpha-chain
<222>(1)..(553)
＜223〉on August 29th, 2003 registration number: P25705
<400>90
Met Leu Ser Val Arg Val Ala Ala Ala Val Val Arg Ala Leu Pro Arg
1 5 10 15
Arg Ala Gly Leu Val Ser Arg Asn Ala Leu Gly Ser Ser Phe Ile Ala
20 25 30
Ala Arg Asn Phe His Ala Ser Asn Thr His Leu Gln Lys Thr Gly Thr
35 40 45
Ala Glu Met Ser Ser Ile Leu Glu Glu Arg Ile Leu Gly Ala Asp Thr
50 55 60
Ser Val Asp Leu Glu Glu Thr Gly Arg Val Leu Ser Ile Gly Asp Gly
65 70 75 80
Ile Ala Arg Val His Gly Leu Arg Asn Val Gln Ala Glu Glu Met Val
85 90 95
Glu Phe Ser Ser Gly Leu Lys Gly Met Ser Leu Asn Leu Glu Pro Asp
100 105 110
Asn Val Gly Val Val Val Phe Gly Asn Asp Lys Leu Ile Lys Glu Gly
115 120 125
Asp Ile Val Lys Arg Thr Gly Ala Ile Val Asp Val Pro Val Gly Glu
130 135 140
Glu Leu Leu Gly Arg Val Val Asp Ala Leu Gly Asn Ala Ile Asp Gly
145 150 155 160
Lys Gly Pro Ile Gly Ser Lys Thr Arg Arg Arg Val Gly Leu Lys Ala
165 170 175
Pro Gly Ile Ile Pro Arg Ile Ser Val Arg Glu Pro Met Gln Thr Gly
180 185 190
Ile Lys Ala Val Asp Ser Leu Val Pro Ile Gly Arg Gly Gln Arg Glu
195 200 205
Leu Ile Ile Gly Asp Arg Gln Thr Gly Lys Thr Ser Ile Ala Ile Asp
210 215 220
Thr Ile Ile Asn Gln Lys Arg Phe Asn Asp Gly Ser Asp Glu Lys Lys
225 230 235 240
Lys Leu Tyr Cys Ile Tyr Val Ala Ile Gly Gln Lys Arg Ser Thr Val
245 250 255
Ala Gln Leu Val Lys Arg Leu Thr Asp Ala Asp Ala Met Lys Tyr Thr
260 265 270
Ile Val Val Ser Ala Thr Ala Ser Asp Ala Ala Pro Leu Gln Tyr Leu
275 280 285
Ala Pro Tyr Ser Gly Cys Ser Met Gly Glu Tyr Phe Arg Asp Asn Gly
290 295 300
Lys His Ala Leu Ile Ile Tyr Asp Asp Leu Ser Lys Gln Ala Val Ala
305 310 315 320
Tyr Arg Gln Met Ser Leu Leu Leu Arg Arg Pro Pro Gly Arg Glu Ala
325 330 335
Tyr Pro Gly Asp Val Phe Tyr Leu His Ser Arg Leu Leu Glu Arg Ala
340 345 350
Ala Lys Met Asn Asp Ala Phe Gly Gly Gly Ser Leu Thr Ala Leu Pro
355 360 365
Val Ile Glu Thr Gln Ala Gly Asp Val Ser Ala Tyr Ile Pro Thr Asn
370 375 380
Val Ile Ser Ile Thr Asp Gly Gln Ile Phe Leu Glu Thr Glu Leu Phe
385 390 395 400
Tyr Lys Gly Ile Arg Pro Ala Ile Asn Val Gly Leu Ser Val Ser Arg
405 410 415
Val Gly Ser Ala Ala Gln Thr Arg Ala Met Lys Gln Val Ala Gly Thr
420 425 430
Met Lys Leu Glu Leu Ala Gln Tyr Arg Glu Val Ala Ala Phe Ala GTn
435 440 445
Phe Gly Ser Asp Leu Asp Ala Ala Thr GTn Gln Leu Leu Ser Arg Gly
450 455 460
Val Arg Leu Thr Glu Leu Leu Lys GTn Gly Gln Tyr Ser Pro Met Ala
465 470 475 480
Ile Glu Glu Gln Val Ala Val Ile Tyr Ala Gly Val Arg Gly Tyr Leu
485 490 495
Asp Lys Leu Glu Pro Ser Lys Ile Thr Lys Phe Glu Asn Ala Phe Leu
500 505 510
Ser His Val Val Ser GTn His Gln Ala Leu Leu Gly Thr Ile Arg Ala
515 520 525
Asp Gly Lys Ile Ser Glu GTn Ser Asp Ala Lys Leu Lys Glu Ile Val
530 535 540
Thr Asn Phe Leu Ala Gly Phe Glu Ala
545 550
<210>91
<211>742
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the lipase precursor of bile salt activation
<222>(1)..(742)
＜223〉on August 29th, 2003 registration number: P19835
<400>91
Met Gly Arg Leu Gln Leu Val Val Leu Gly Leu Thr Cys Cys Trp Ala
1 5 10 15
Val Ala Ser Ala Ala Lys Leu Gly Ala Val Tyr Thr Glu Gly Gly Phe
20 25 30
Val Glu Gly Val Asn Lys Lys Leu Gly Leu Leu Gly Asp Ser Val Asp
35 40 45
Ile Phe Lys Gly Ile Pro Phe Ala Ala Pro Thr Lys Ala Leu Glu Asn
50 55 60
Pro Gln Pro His Pro Gly Trp Gln Gly Thr Leu Lys Ala Lys Asn Phe
65 70 75 80
Lys Lys Arg Cys Leu GTn Ala Thr Ile Thr GTn Asp Ser Thr Tyr Gly
85 90 95
Asp Glu Asp Cys Leu Tyr Leu Asn Ile Trp Val Pro Gln Gly Arg Lys
100 105 110
Gln Val Ser Arg Asp Leu Pro Val Met Ile Trp Ile Tyr Gly Gly Ala
115 120 125
Phe Leu Met Gly Ser Gly His Gly Ala Asn Phe Leu Asn Asn Tyr Leu
130 135 140
Tyr Asp Gly Glu Glu Ile Ala Thr Arg Gly Asn Val Ile Val Val Thr
145 150 155 160
Phe Asn Tyr Arg Val Gly Pro Leu Gly Phe Leu Ser Thr Gly Asp Ala
165 170 175
Asn Leu Pro Gly Asn Tyr Gly Leu Arg Asp Gln His Met Ala Ile Ala
180 185 190
Trp Val Lys Arg Asn Ile Ala Ala Phe Gly Gly Asp Pro Asn Asn Ile
195 200 205
Thr Leu Phe Gly Glu Ser Ala Gly Gly Ala Ser Val Ser Leu Gln Thr
210 215 220
Leu Ser Pro Tyr Asn Lys Gly Leu Ile Arg Arg Ala Ile Ser Gln Ser
225 230 235 240
Gly Val Ala Leu Ser Pro Trp Val Ile Gln Lys Asn Pro Leu Phe Trp
245 250 255
Ala Lys Lys Val Ala Glu Lys Val Gly Cys Pro Val Gly Asp Ala Ala
260 265 270
Arg Met Ala Gln Cys Leu Lys Val Thr Asp Pro Arg Ala Leu Thr Leu
275 280 285
Ala Tyr Lys Val Pro Leu Ala Gly Leu Glu Tyr Pro Met Leu His Tyr
290 295 300
Val Gly Phe Val Pro Val Ile Asp Gly Asp Phe Ile Pro Ala Asp Pro
305 310 315 320
Ile Asn Leu Tyr Ala Asn Ala Ala Asp Ile Asp Tyr Ile Ala Gly Thr
325 330 335
Asn Asn Met Asp Gly His Ile Phe Ala Ser Ile Asp Met Pro Ala Ile
340 345 350
Asn Lys Gly Asn Lys Lys Val Thr Glu Glu Asp Phe Tyr Lys Leu Val
355 360 365
Ser Glu Phe Thr Ile Thr Lys Gly Leu Arg Gly Ala Lys Thr Thr Phe
370 375 380
Asp Val Tyr Thr Glu Ser Trp Ala Gln Asp Pro Ser Gln Glu Asn Lys
385 390 395 400
Lys Lys Thr Val Val Asp Phe Glu Thr Asp Val Leu Phe Leu Val Pro
405 410 415
Thr Glu Ile Ala Leu Ala Gln His Arg Ala Asn Ala Lys Ser Ala Lys
420 425 430
Thr Tyr Ala Tyr Leu Phe Ser His Pro Ser Arg Met Pro Val Tyr Pro
435 440 445
Lys Trp Val Gly Ala Asp His Ala Asp Asp Ile Gln Tyr Val Phe Gly
450 455 460
Lys Pro Phe Ala Thr Pro Thr Gly Tyr Arg Pro Gln Asp Arg Thr Val
465 470 475 480
Ser Lys Ala Met Ile Ala Tyr Trp Thr Asn Phe Ala Lys Thr Gly Asp
485 490 495
Pro Asn Met Gly Asp Ser Ala Val Pro Thr His Trp Glu Pro Tyr Thr
500 505 510
Thr Glu Asn Ser Gly Tyr Leu Glu Ile Thr Lys Lys Met Gly Ser Ser
515 520 525
Ser Met Lys Arg Ser Leu Arg Thr Asn Phe Leu Arg Tyr Trp Thr Leu
530 535 540
Thr Tyr Leu Ala Leu Pro Thr Val Thr Asp Gln Glu Ala Thr Pro Val
545 550 555 560
Pro Pro Thr Gly Asp Ser Glu Ala Thr Pro Val Pro Pro Thr Gly Asp
565 570 575
Ser Glu Thr Ala Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro
580 585 590
Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly
595 600 605
Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro
610 615 620
Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr
625 630 635 640
Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala
645 650 655
Pro Pro Val Pro Pro Thr Gly Asp Ala Gly Pro Pro Pro Val Pro Pro
660 665 670
Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly
675 680 685
Ala Pro Pro Val Thr Pro Thr Gly Asp Ser Glu Thr Ala Pro Val Pro
690 695 700
Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser
705 710 715 720
Glu Ala Ala Pro Val Pro Pro Thr Asp Asp Ser Lys Glu Ala Gln Met
725 730 735
Pro Ala Val Ile Arg Phe
740
<210>92
<211>467
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the relevant amyloid protein precursor of pancreatic lipase
<222>(1)..(467)
＜223〉on August 29th, 2003 registration number: P54315
<400>92
Met Leu Ile Phe Trp Thr Ile Thr Leu Phe Leu Leu Gly Ala Ala Lys
1 5 10 15
Gly Lys Glu Val Cys Tyr Glu Asp Leu Gly Cys Phe Ser Asp Thr Glu
20 25 30
Pro Trp Gly Gly Thr Ala Ile Arg Pro Leu Lys Ile Leu Pro Trp Ser
35 40 45
Pro Glu Lys Ile Gly Thr Arg Phe Leu Leu Tyr Thr Asn Glu Asn Pro
50 55 60
Asn Asn Phe Gln Ile Leu Leu Leu Ser Asp Pro Ser Thr Ile Glu Ala
65 70 75 80
Ser Asn Phe Gln Met Asp Arg Lys Thr Arg Phe Ile Ile His Gly Phe
85 90 95
Ile Asp Lys Gly Asp Glu Ser Trp Val Thr Asp Met Cys Lys Lys Leu
100 105 110
Phe Glu Val Glu Glu Val Asn Cys Ile Cys Val Asp Trp Lys Lys Gly
115 120 125
Ser Gln Ala Thr Tyr Thr Gln Ala Ala Asn Asn Val Arg Val Val Gly
130 135 140
Ala Gln Val Ala Gln Met Leu Asp Ile Leu Leu Thr Glu Tyr Ser Tyr
145 150 155 160
Pro Pro Ser Lys Val His Leu Ile Gly His Ser Leu Gly Ala His Val
165 170 175
Ala Gly Glu Ala Gly Ser Lys Thr Pro Gly Leu Ser Arg Ile Thr Gly
180 185 190
Leu Asp Pro Val Glu Ala Ser Phe Glu Ser Thr Pro Glu Glu Val Arg
195 200 205
Leu Asp Pro Ser Asp Ala Asp Phe Val Asp Val Ile His Thr Asp Ala
210 215 220
Ala Pro Leu Ile Pro Phe Leu Gly Phe Gly Thr Asn Gln Gln Met Gly
225 230 235 240
His Leu Asp Phe Phe Pro Asn Gly Gly Glu Ser Met Pro Gly Cys Lys
245 250 255
Lys Asn Ala Leu Ser Gln Ile Val Asp Leu Asp Gly Ile Trp Ala Gly
260 265 270
Thr Arg Asp Phe Val Ala Cys Asn His Leu Arg Ser Tyr Lys Tyr Tyr
275 280 285
Leu Glu Ser Ile Leu Asn Pro Asp Gly Phe Ala Ala Tyr Pro Cys Thr
290 295 300
Ser Tyr Lys Ser Phe Glu Ser Asp Lys Cys Phe Pro Cys Pro Asp Gln
305 310 315 320
Gly Cys Pro Gln Met Gly His Tyr Ala Asp Lys Phe Ala Gly Arg Thr
325 330 335
Ser Glu Glu Gln Gln Lys Phe Phe Leu Asn Thr Gly Glu Ala Ser Asn
340 345 350
Phe Ala Arg Trp Arg Tyr Gly Val Ser Ile Thr Leu Ser Gly Arg Thr
355 360 365
Ala Thr Gly Gln Ile Lys Val Ala Leu Phe Gly Asn Lys Gly Asn Thr
370 375 380
His Gln Tyr Ser Ile Phe Arg Gly Ile Leu Lys Pro Gly Ser Thr His
385 390 395 400
Ser Tyr Glu Phe Asp Ala Lys Leu Asp Val Gly Thr Ile Glu Lys Val
405 410 415
Lys Phe Leu Trp Asn Asn Asn Val Ile Asn Pro Thr Leu Pro Lys Val
420 425 430
Gly Ala Thr Lys Ile Thr Val Gln Lys Gly Glu Glu Lys Thr Val Tyr
435 440 445
Asn Phe Cys Ser Glu Asp Thr Val Arg Glu Asp Thr Leu Leu Thr Leu
450 455 460
Thr Pro Cys
465
<210>93
<211>469
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉relevant albumen 2 precursors of pancreatic lipase
<222>(1)..(469)
＜223〉on August 29th, 2003 registration number: P54317
<400>93
Met Leu Pro Pro Trp Thr Leu Gly Leu Leu Leu Leu Ala Thr Val Arg
1 5 10 15
Gly Lys Glu Val Cys Tyr Gly Gln Leu Gly Cys Phe Ser Asp Glu Lys
20 25 30
Pro Trp Ala Gly Thr Leu Gln Arg Pro Val Lys Leu Leu Pro Trp Ser
35 40 45
Pro Glu Asp Ile Asp Thr Arg Phe Leu Leu Tyr Thr Asn Glu Asn Pro
50 55 60
Asn Asn Phe Gln Leu Ile Thr Gly Thr Glu Pro Asp Thr Ile Glu Ala
65 70 75 80
Ser Asn Phe Gln Leu Asp Arg Lys Thr Arg Phe Ile Ile His Gly Phe
85 90 95
Leu Asp Lys Ala Glu Asp Ser Trp Pro Ser Asp Met Cys Lys Lys Met
100 105 110
Phe Glu Val Glu Lys Val Asn Cys Ile Cys Val Asp Trp Arg His Gly
115 120 125
Ser Arg Ala Met Tyr Thr Gln Ala Val Gln Asn Ile Arg Val Val Gly
130 135 140
Ala Glu Thr Ala Phe Leu Ile Gln Ala Leu Ser Thr Gln Leu Gly Tyr
145 150 155 160
Ser Leu Glu Asp Val His Val Ile Gly His Ser Leu Gly Ala His Thr
165 170 175
Ala Ala Glu Ala Gly Arg Arg Leu Gly Gly Arg Val Gly Arg Ile Thr
180 185 190
Gly Leu Asp Pro Ala Gly Pro Cys Phe Gln Asp Glu Pro Glu Glu Val
195 200 205
Arg Leu Asp Pro Ser Asp Ala Val Phe Val Asp Val Ile His Thr Asp
210 215 220
Ser Ser Pro Ile Val Pro Ser Leu Gly Phe Gly Met Ser Gln Lys Val
225 230 235 240
Gly His Leu Asp Phe Phe Pro Asn Gly Gly Lys Glu Met Pro Gly Cys
245 250 255
Lys Lys Asn Val Leu Ser Thr Ile Thr Asp Ile Asp Gly Ile Trp Glu
260 265 270
Gly Ile Gly Gly Phe Val Ser Cys Asn His Leu Arg Ser Phe Glu Tyr
275 280 285
Tyr Ser Ser Ser Val Leu Asn Pro Asp Gly Phe Leu Gly Tyr Pro Cys
290 295 300
Ala Ser Tyr Asp Glu Phe Gln Glu Ser Lys Cys Phe Pro Cys Pro Ala
305 310 315 320
Glu Gly Cys Pro Lys Met Gly His Tyr Ala Asp Gln Phe Lys Gly Lys
325 330 335
Thr Ser Ala Val Glu Gln Thr Phe Phe Leu Asn Thr Gly Glu Ser Gly
340 345 350
Asn Phe Thr Ser Trp Arg Tyr Lys Val Ser Val Thr Leu Ser Gly Lys
355 360 365
Glu Lys Val Asn Gly Tyr Ile Arg Ile Ala Leu Tyr Gly Ser Asn Glu
370 375 380
Asn Ser Lys Gln Tyr Glu Ile Phe Lys Gly Ser Leu Lys Pro Asp Ala
385 390 395 400
Ser His Thr Cys Ala Ile Asp Val Asp Phe Asn Val Gly Lys Ile Gln
405 410 415
Lys Val Lys Phe Leu Trp Asn Lys Arg Gly Ile Asn Leu Ser Glu Pro
420 425 430
Lys Leu Gly Ala Ser Gln Ile Thr Val Gln Ser Gly Glu Asp Gly Thr
435 440 445
Glu Tyr Asn Phe Cys Ser Ser Asp Thr Val Glu Glu Asn Val Leu Gln
450 455 460
Ser Leu Tyr Pro Cys
465
<210>94
<211>465
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉pancreas triglyceride lipase precursor
<222>(1)..(465)
＜223〉on August 29th, 2003 registration number: P16233
<400>94
Met Leu Pro Leu Trp Thr Leu Ser Leu Leu Leu Gly Ala Val Ala Gly
1 5 10 15
Lys Glu Val Cys Tyr Glu Arg Leu Gly Cys Phe Ser Asp Asp Ser Pro
20 25 30
Trp Ser Gly Ile Thr Glu Arg Pro Leu His Ile Leu Pro Trp Ser Pro
35 40 45
Lys Asp Val Asn Thr Arg Phe Leu Leu Tyr Thr Asn Glu Asn Pro Asn
50 55 60
Asn Phe Gln Glu Val Ala Ala Asp Ser Ser Ser Ile Ser Gly Ser Asn
65 70 75 80
Phe Lys Thr Asn Arg Lys Thr Arg Phe Ile Ile His Gly Phe Ile Asp
85 90 95
Lys Gly Glu Glu Asn Trp Leu Ala Asn Val Cys Lys Asn Leu Phe Lys
100 105 110
Val Glu Ser Val Asn Cys Ile Cys Val Asp Trp Lys Gly Gly Ser Arg
115 120 125
Thr Gly Tyr Thr Gln Ala Ser Gln Asn Ile Arg Ile Val Gly Ala Glu
130 135 140
Val Ala Tyr Phe Val Glu Phe Leu Gln Ser Ala Phe Gly Tyr Ser Pro
145 150 155 160
Ser Asn Val His Val Ile Gly His Ser Leu Gly Ala His Ala Ala Gly
165 170 175
Glu Ala Gly Arg Arg Thr Asn Gly Thr Ile Gly Arg Ile Thr Gly Leu
180 185 190
Asp Pro Ala Glu Pro Cys Phe Gln Gly Thr Pro Glu Leu Val Arg Leu
195 200 205
Asp Pro Ser Asp Ala Lys Phe Val Asp Val Ile His Thr Asp Gly Ala
210 215 220
Pro Ile Val Pro Asn Leu Gly Phe Gly Met Ser Gln Val Val Gly His
225 230 235 240
Leu Asp Phe Phe Pro Asn Gly Gly Val Glu Met Pro Gly Cys Lys Lys
245 250 255
Asn Ile Leu Ser Gln Ile Val Asp Ile Asp Gly Ile Trp Glu Gly Thr
260 265 270
Arg Asp Phe Ala Ala Cys Asn His Leu Arg Ser Tyr Lys Tyr Tyr Thr
275 280 285
Asp Ser Ile Val Asn Pro Asp Gly Phe Ala Gly Phe Pro Cys Ala Ser
290 295 300
Tyr Asn Val Phe Thr Ala Asn Lys Cys Phe Pro Cys Pro Ser Gly Gly
305 310 315 320
Cys Pro Gln Met Gly His Tyr Ala Asp Arg Tyr Pro Gly Lys Thr Asn
325 330 335
Asp Val Gly Gln Lys Phe Tyr Leu Asp Thr Gly Asp Ala Ser Asn Phe
340 345 350
Ala Arg Trp Arg Tyr Lys Val Ser Val Thr Leu Ser Gly Lys Lys Val
355 360 365
Thr Gly His Ile Leu Val Ser Leu Phe Gly Asn Lys Gly Asn Ser Lys
370 375 380
Gln Tyr Glu Ile Phe Lys Gly Thr Leu Lys Pro Asp Ser Thr His Ser
385 390 395 400
Asn Glu Phe Asp Ser Asp Val Asp Val Gly Asp Leu Gln Met Val Lys
405 410 415
Phe Ile Trp Tyr Asn Asn Val Ile Asn Pro Thr Leu Pro Arg Val Gly
420 425 430
Ala Ser Lys Ile Ile Val Glu Thr Asn Val Gly Lys Gln Phe Asn Phe
435 440 445
Cys Ser Pro Glu Thr Val Arg Glu Glu Val Leu Leu Thr Leu Thr Pro
450 455 460
Cys
465
<210>95
<211>572
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the dihydropyrimidinase associated protein 2
<222>(1)..(572)
＜223〉on August 29th, 2003 registration number: Q16555
<400>95
Met Ser Tyr Gln Gly Lys Lys Asn Ile Pro Arg Ile Thr Ser Asp Arg
1 5 10 15
Leu Leu Ile Lys Gly Gly Lys Ile Val Asn Asp Asp Gln Ser Phe Tyr
20 25 30
Ala Asp Ile Tyr Met Glu Asp Gly Leu Ile Lys Gln Ile Gly Glu Asn
35 40 45
Leu Ile Val Pro Gly Gly Val Lys Thr Ile Glu Ala His Ser Arg Met
50 55 60
Val Ile Pro Gly Gly Ile Asp Val His Thr Arg Phe Gln Met Pro Asp
65 70 75 80
Gln Gly Met Thr Ser Ala Asp Asp Phe Phe Gln Gly Thr Lys Ala Ala
85 90 95
Leu Ala Gly Gly Thr Thr Met Ile Ile Asp His Val Val Pro Glu Pro
100 105 110
Gly Thr Ser Leu Leu Ala Ala Phe Asp Gln Trp Arg Glu Trp Ala Asp
115 120 125
Ser Lys Ser Cys Cys Asp Tyr Ser Leu His Val Asp Ile Ser Glu Trp
130 135 140
His Lys Gly Ile Gln Glu Glu Met Glu Ala Leu Val Lys Asp His Gly
145 150 155 160
Val Asn Ser Phe Leu Val Tyr Met Ala Phe Lys Asp Arg Phe Gln Leu
165 170 175
Thr Asp Cys Gln Ile Tyr Glu Val Leu Ser Val Ile Arg Asp Ile Gly
180 185 190
Ala Ile Ala Gln Val His Ala Glu Asn Gly Asp Ile Ile Ala Glu Glu
195 200 205
Gln Gln Arg Ile Leu Asp Leu Gly Ile Thr Gly Pro Glu Gly His Val
210 215 220
Leu Ser Arg Pro Glu Glu Val Glu Ala Glu Ala Val Asn Arg Ala Ile
225 230 235 240
Thr Ile Ala Asn Gln Thr Asn Cys Pro Leu Tyr Ile Thr Lys Val Met
245 250 255
Ser Lys Ser Ser Ala Glu Val Ile Ala Gln Ala Arg Lys Lys Gly Thr
260 265 270
Val Val Tyr Gly Glu Pro Ile Thr Ala Ser Leu Gly Thr Asp Gly Ser
275 280 285
His Tyr Trp Ser Lys Asn Trp Ala Lys Ala Ala Ala Phe Val Thr Ser
290 295 300
Pro Pro Leu Ser Pro Asp Pro Thr Thr Pro Asp Phe Leu Asn Ser Leu
305 310 315 320
Leu Ser Cys Gly Asp Leu Gln Val Thr Gly Ser Ala His Cys Thr Phe
325 330 335
Asn Thr Ala Gln Lys Ala Val Gly Lys Asp Asn Phe Thr Leu Ile Pro
340 345 350
Glu Gly Thr Asn Gly Thr Glu Glu Arg Met Ser Val Ile Trp Asp Lys
355 360 365
Ala Val Val Thr Gly Lys Met Asp Glu Asn Gln Phe Val Ala Val Thr
370 375 380
Ser Thr Asn Ala Ala Lys Val Phe Asn Leu Tyr Pro Arg Lys Gly Arg
385 390 395 400
Ile Ala Val Gly Ser Asp Ala Asp Leu Val Ile Trp Asp Pro Asp Ser
405 410 415
Val Lys Thr Ile Ser Ala Lys Thr His Asn Ser Ser Leu Glu Tyr Asn
420 425 430
Ile Phe Glu Gly Met Glu Cys Arg Gly Ser Pro Leu Val Val Ile Ser
435 440 445
Gln Gly Lys Ile Val Leu Glu Asp Gly Thr Leu His Val Thr Glu Gly
450 455 460
Ser Gly Arg Tyr Ile Pro Arg Lys Pro Phe Pro Asp Phe Val Tyr Lys
465 470 475 480
Arg Ile Lys Ala Arg Ser Arg Leu Ala Glu Leu Arg Gly Val Pro Arg
485 490 495
Gly Leu Tyr Asp Gly Pro Val Cys Glu Val Ser Val Thr Pro Lys Thr
500 505 510
Val Thr Pro Ala Ser Ser Ala Lys Thr Ser Pro Ala Lys Gln Gln Ala
515 520 525
Pro Pro Val Arg Asn Leu His Gln Ser Gly Phe Ser Leu Ser Gly Ala
530 535 540
Gln Ile Asp Asp Asn Ile Pro Arg Arg Thr Thr Gln Arg Ile Val Ala
545 550 555 560
Pro Pro Gly Gly Arg Ala Asn Ile Thr Ser Leu Gly
565 570
<210>96
<211>500
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉mitochondria 4-aminobutyric acid ester transamination enzyme precursor
<222>(1)..(500)
＜223〉on August 29th, 2003 registration number: P80404
<400>96
Met Ala Ser Met Leu Leu Ala Gln Arg Leu Ala Cys Ser Phe Gln His
1 5 10 15
Thr Tyr Arg Leu Leu Val Pro Gly Ser Arg His Ile Ser Gln Ala Ala
20 25 30
Ala Lys Val Asp Val Glu Phe Asp Tyr Asp Gly Pro Leu Met Lys Thr
35 40 45
Glu Val Pro Gly Pro Arg Ser Gln Glu Leu Met Lys Gln Leu Asn Ile
50 55 60
Ile Gln Asn Ala Glu Ala Val His Phe Phe Cys Asn Tyr Glu Glu Ser
65 70 75 80
Arg Gly Asn Tyr Leu Val Asp Val Asp Gly Asn Arg Met Leu Asp Leu
85 90 95
Tyr Ser Gln Ile Ser Ser Val Pro Ile Gly Tyr Ser Asp Pro Ala Leu
100 105 110
Val Lys Leu Ile Gln Gln Pro Gln Asn Ala Ser Met Phe Val Asn Arg
115 120 125
Pro Ala Leu Glu Ile Leu Pro Pro Glu Asn Phe Val Glu Lys Leu Arg
130 135 140
Gln Ser Leu Leu Ser Val Ala Pro Lys Gly Met Ser Gln Leu Ile Thr
145 150 155 160
Met Ala Cys Gly Ser Cys Ser Asn Glu Asn Ala Leu Lys Thr Ile Phe
165 170 175
Met Trp Tyr Arg Ser Lys Glu Arg Gly Gln Arg Gly Phe Ser Lys Glu
180 185 190
Glu Leu Glu Thr Cys Met Ile Asn Gln Ala Pro Trp Cys Pro Asp Tyr
195 200 205
Ser Ile Leu Ser Phe Met Gly Ser Phe His Gly Arg Thr Met Gly Cys
210 215 220
Leu Ala Thr Thr His Ser Lys Ala Ile His Lys Ile Asp Ile Pro Ser
225 230 235 240
Phe Asp Trp Pro Ile Ala Pro Phe Pro Arg Leu Lys Tyr Pro Leu Glu
245 250 255
Glu Phe Val Lys Glu Asn Gln Gln Glu Glu Ala Gly Cys Leu Glu Glu
260 265 270
Val Glu Asp Leu Ile Val Lys Tyr Arg Lys Lys Lys Lys Thr Val Ala
275 280 285
Gly Ile Ile Val Glu Pro Ile Gln Ser Glu Gly Gly Asp Asn His Ala
290 295 300
Ser Asp Asp Phe Phe Arg Lys Leu Arg Asp Ile Ala Arg Lys His Cys
305 310 315 320
Cys Ala Phe Leu Val Asp Glu Val Gln Thr Gly Gly Gly Cys Thr Gly
325 330 335
Lys Phe Trp Ala His Glu His Trp Gly Leu Asp Asp Pro Ala Asp Val
340 345 350
Met Thr Phe Ser Lys Lys Met Met Thr Gly Gly Phe Phe Leu Lys Glu
355 360 365
Glu Phe Arg Pro Asn Ala Pro Tyr Arg Ile Phe Asn Thr Trp Leu Gly
370 375 380
Asp Pro Ser Lys Asn Leu Leu Leu Ala Glu Val Ile Asn Ile Ile Lys
385 390 395 400
Arg Glu Asp Leu Leu Asn Asn Ala Ala His Ala Gly Lys Ala Leu Leu
405 410 415
Thr Gly Leu Leu Asp Leu Gln Ala Arg Tyr Pro Gln Phe Ile Ser Arg
420 425 430
Val Arg Gly Arg Gly Thr Phe Cys Ser Phe Asp Thr Pro Asp Asp Ser
435 440 445
Ile Arg Asn Lys Leu Ile Leu Ile Ala Arg Asn Lys Gly Val Val Leu
450 455 460
Gly Gly Cys Gly Asp Lys Ser Ile Arg Phe Arg Pro Thr Leu Val Phe
465 470 475 480
Arg Asp His His Ala His Leu Phe Leu Asn Ile Phe Ser Asp Ile Leu
485 490 495
Ala Asp Phe Lys
500
<210>97
<211>423
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉mitochondria glycine amidinotransferase precursor
<222>(1)..(423)
＜223〉on August 29th, 2003 registration number: P50440
<400>97
Met Leu Arg Val Arg Cys Leu Arg Gly Gly Ser Arg Gly Ala Glu Ala
1 5 10 15
Val His Tyr Ile Gly Ser Arg Leu Gly Arg Thr Leu Thr Gly Trp Val
20 25 30
Gln Arg Thr Phe Gln Ser Thr Gln Ala Ala Thr Ala Ser Ser Arg Asn
35 40 45
Ser Cys Ala Ala Asp Asp Lys Ala Thr Glu Pro Leu Pro Lys Asp Cys
50 55 60
Pro Val Ser Ser Tyr Asn Glu Trp Asp Pro Leu Glu Glu Val Ile Val
65 70 75 80
Gly Arg Ala Glu Asn Ala Cys Val Pro Pro Phe Thr Ile Glu Val Lys
85 90 95
Ala Asn Thr Tyr Glu Lys Tyr Trp Pro Phe Tyr Gln Lys Gln Gly Gly
100 105 110
His Tyr Phe Pro Lys Asp His Leu Lys Lys Ala Val Ala Glu Ile Glu
115 120 125
Glu Met Cys Asn Ile Leu Lys Thr Glu Gly Val Thr Val Arg Arg Pro
130 135 140
Asp Pro Ile Asp Trp Ser Leu Lys Tyr Lys Thr Pro Asp Phe Glu Ser
145 150 155 160
Thr Gly Leu Tyr Ser Ala Met Pro Arg Asp Ile Leu Ile Val Val Gly
165 170 175
Asn Glu Ile Ile Glu Ala Pro Met Ala Trp Arg Ser Arg Phe Phe Glu
180 185 190
Tyr Arg Ala Tyr Arg Ser Ile Ile Lys Asp Tyr Phe His Arg Gly Ala
195 200 205
Lys Trp Thr Thr Ala Pro Lys Pro Thr Met Ala Asp Glu Leu Tyr Asn
210 215 220
Gln Asp Tyr Pro Ile His Ser Val Glu Asp Arg His Lys Leu Ala Ala
225 230 235 240
Gln Gly Lys Phe Val Thr Thr Glu Phe Glu Pro Cys Phe Asp Ala Ala
245 250 255
Asp Phe Ile Arg Ala Gly Arg Asp Ile Phe Ala Gln Arg Ser Gln Val
260 265 270
Thr Asn Tyr Leu Gly Ile Glu Trp Met Arg Arg His Leu Ala Pro Asp
275 280 285
Tyr Arg Val His Ile Ile Ser Phe Lys Asp Pro Asn Pro Met His Ile
290 295 300
Asp Ala Thr Phe Asn Ile Ile Gly Pro Gly Ile Val Leu Ser Asn Pro
305 310 315 320
Asp Arg Pro Cys His Gln Ile Asp Leu Phe Lys Lys Ala Gly Trp Thr
325 330 335
Ile Ile Thr Pro Pro Thr Pro lle Ile Pro Asp Asp His Pro Leu Trp
340 345 350
Met Ser Ser Lys Trp Leu Ser Met Asn Val Leu Met Leu Asp Glu Lys
355 360 365
Arg Val Met Val Asp Ala Asn Glu Val Pro Ile Gln Lys Met Phe Glu
370 375 380
Lys Leu Gly Ile Thr Thr Ile Lys Val Asn Ile Arg Asn Ala Asn Ser
385 390 395 400
Leu Gly Gly Gly Phe His Cys Trp Thr Cys Asp Val Arg Arg Arg Gly
405 410 415
Thr Leu Gln Ser Tyr Leu Asp
420
<210>98
<211>654
<212>PRT
＜213〉people (Homo sapiens)
<220>
<221>GRP 78
<222>(1)..(654)
＜223〉on August 29th, 2003 registration number: P11021
<220>
<221>misc_feature
<222>(302)..(302)
＜223〉Xaa can be any naturally occurring amino acid
<220>
<221>misc_feature
<222>(329)..(329)
＜223〉Xaa can be any naturally occurring amino acid
<220>
<221>misc_feature
<222>(344)..(344)
＜223〉Xaa can be any naturally occurring amino acid
<220>
<221>misc_feature
<222>(461)..(461)
＜223〉Xaa can be any naturally occurring amino acid
<400>98
Met Lys Leu Ser Leu Val Ala Ala Met Leu Leu Leu Leu Leu Ser Ala
1 5 10 15
Ala Arg Ala Lys Glu Glu Asp Met Gly Thr Val Val Ala Ile His Leu
20 25 30
Gly Thr Thr Tyr Pro Cys Val Gly Val Phe Lys Asn Gly Arg Met Glu
35 40 45
Ile Ile Ala Asn Asp Gln Gly Asn Arg Ile Met Pro Ser Tyr Val Ala
50 55 60
Phe Thr Pro Glu Gly Glu Cys Leu Ile Gly Asp Ala Ala Lys Asn Gln
65 70 75 80
Leu Thr Ser Asn Pro Lys Asn Thr Val Phe Asp Ala Lys Arg Leu Ile
85 90 95
Gly Arg Arg Trp His Asp Pro Ser Val Gln Gln Asp Ile Glu Phe Leu
100 105 110
Pro Phe Lys Val Val Glu Lys Asn Thr Lys Ser Tyr Ile Gln Ile Asp
115 120 125
Val Gly Gly Gly Gln Thr Lys Thr Phe Ala Pro Lys Glu Ile Ser Ala
130 135 140
Met Val Leu Thr Lys Met Lys Glu Asn Ala Glu Ala Tyr Leu Gly Lys
145 150 155 160
Val Thr His Ala Val Val Thr Ala Pro Ala Tyr Phe Asn Asp Ala Gln
165 170 175
Cys Gln Ala Thr Lys Asp Ala Gly Thr Ile Ala Asp Leu Asn Val Met
180 185 190
Arg Ile Ile Asn Lys Pro Thr Ala Ala Ala Ile Ala Tyr Gly Leu Asp
195 200 205
Lys Arg Glu Gly Glu Lys Asn Ile Leu Val Phe Asp Leu Gly Gly Gly
210 215 220
Thr Phe Asp Val Ser Leu Leu Thr Ile Asp Asn Gly Val Phe Lys Val
225 230 235 240
Val Ala Thr Asn Gly Asp Thr Tyr Leu Gly Gly Glu Asp Phe Asp Gln
245 250 255
Arg Val Met Glu His Phe Ile Lys Leu Tyr Lys Lys Lys Thr Gly Lys
260 265 270
Asp Val Arg Lys Asp Asn Arg Ala Val Gln Lys Leu Trp Arg Lys Val
275 280 285
Glu Lys Ala Lys Arg Ala Leu Ser Ser Gln His Gln Ala Xaa Val Ile
290 295 300
Glu Ile Glu Ser Phe Tyr Glu Gly Glu Asp Phe Ser Glu Thr Leu Thr
305 310 315 320
Gln Ala Lys Phe Glu Glu Leu Asn Xaa Asp Leu Phe Gln Ser Thr Met
325 330 335
Lys Pro Ser Gln Arg Ser Val Xaa Lys Val Leu Glu Asp Ser Asp Leu
340 345 350
Lys Lys Ser Asp Ile Asp Glu Thr Val Leu Val Gly Gly Phe Thr Gln
355 360 365
Ile Pro Lys Ile Gln Gln Leu Val Lys Glu Phe Phe Asn Gly Lys Glu
370 375 380
Leu Ser Arg Gly Ile Ser Pro Tyr Glu Ala Val Ala Tyr Gly Ala Ala
385 390 395 400
Val Gln Ala Gly Val Leu Ser Gly Asp Gln Asp Thr Gly Asp Leu Val
405 410 415
Leu Leu Asp Ile Cys Pro Leu Thr Leu Gly Ile Glu Thr Val Gly Gly
420 425 430
Val Met Thr Lys Leu Ile Pro Arg Asn Thr Val Val Pro Thr Lys Lys
435 440 445
Ser Gln Ile Phe Ser Thr Ala Phe Asp Asn Gln Pro Xaa Thr Ile Lys
450 455 460
Val Tyr Glu Gly Lys Gln Pro Leu Thr Lys Asp Asn His Leu Leu Gly
465 470 475 480
Thr Phe Asp Leu Thr Gly Ile Pro Pro Ala Pro Cys Gly Val Pro Gln
485 490 495
Ile Glu Val Thr Phe Glu Met Asp Val Ser Asp Ile Leu Gln Val Thr
500 505 510
Ala Lys Asp Lys Gly Thr Arg Tyr Lys Asn Lys Ile Thr Ile Thr Asn
515 520 525
Asp Gln Asn His Leu Thr Pro Glu Asp Ile Glu Arg Met Val Asn Asp
530 535 540
Ala Glu Lys Phe Ala Glu Glu Asp Lys Lys Leu Lys Glu Cys Thr Asp
545 550 555 560
Thr Arg Asn Glu Leu Glu Ser Tyr Ala Tyr Ser Leu Lys Asn Gln Ile
565 570 575
Gly Asp Lys Glu Lys Leu Gly Gly Lys Leu Ser Ser Glu Asp Lys Glu
580 585 590
Thr Met Glu Lys Thr Val Glu Glu Lys Thr Glu Trp Leu Glu Ser His
595 600 605
Gln Asp Ala Asp Thr Glu Asp Phe Lys Ala Lys Lys Lys Glu Leu Glu
610 615 620
Glu Ile Val Gln Pro Ile Ile Ser Lys Leu Tyr Gly Ser Ala Gly Pro
625 630 635 640
Pro Pro Thr Gly Glu Glu Asp Thr Ala Glu Lys Asp Glu Leu
645 650
<210>99
<211>325
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉eukaryotic translation initiation factor 3 subunits-2
<222>(1)..(325)
＜223〉on August 29th, 2003 registration number: Q13347
<400>99
Met Lys Pro Ile Leu Leu Gln Gly His Glu Arg Ser Ile Thr Gln Ile
1 5 10 15
Lys Tyr Asn Arg Glu Gly Asp Leu Leu Phe Thr Val Ala Lys Asp Pro
20 25 30
Ile Val Asn Val Trp Tyr Ser Val Asn Gly Glu Arg Leu Gly Thr Tyr
35 40 45
Met Gly His Thr Gly Ala Val Trp Cys Val Asp Ala Asp Trp Asp Thr
50 55 60
Lys His Val Leu Thr Gly Ser Ala Asp Asn Ser Cys Arg Leu Trp Asp
65 70 75 80
Cys Glu Thr Gly Lys Gln Leu Ala Leu Leu Lys Thr Asn Ser Ala Val
85 90 95
Arg Thr Cys Gly Phe Asp Phe Gly Gly Asn Ile Ile Met Phe Ser Thr
100 105 110
Asp Lys Gln Met Gly Tyr Gln Cys Phe Val Ser Phe Phe Asp Leu Arg
115 120 125
Asp Pro Ser Gln Ile Asp Asn Asn Glu Pro Tyr Met Lys Ile Pro Cys
130 135 140
Asn Asp Ser Lys Ile Thr Ser Ala Val Trp Gly Pro Leu Gly Glu Cys
145 150 155 160
Ile Ile Ala Gly His Glu Ser Gly Glu Leu Asn Gln Tyr Ser Ala Lys
165 170 175
Ser Gly Glu Val Leu Val Asn Val Lys Glu His Ser Arg Gln Ile Asn
180 185 190
Asp Ile Gln Leu Ser Arg Asp Met Thr Met Phe Val Thr Ala Ser Lys
195 200 205
Asp Asn Thr Ala Lys Leu Phe Asp Ser Thr Thr Leu Glu His Gln Lys
210 215 220
Thr Phe Arg Thr Glu Arg Pro Val Asn Ser Ala Ala Leu Ser Pro Asn
225 230 235 240
Tyr Asp His Val Val Leu Gly Gly Gly Gln Glu Ala Met Asp Val Thr
245 250 255
Thr Thr Ser Thr Arg Ile Gly Lys Phe Glu Ala Arg Phe Phe His Leu
260 265 270
Ala Phe Glu Glu Glu Phe Gly Arg Val Lys Gly His Phe Gly Pro Ile
275 280 285
Asn Ser Val Ala Phe His Pro Asp Gly Lys Ser Tyr Ser Ser Gly Gly
290 295 300
Glu Asp Gly Tyr Val Arg Ile His Tyr Phe Asp Pro Gln Tyr Phe Glu
305 310 315 320
Phe Glu Phe Glu Ala
325
<210>100
<211>572
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉the dihydropyrimidinase associated protein 2
<222>(1)..(572)
＜223〉on August 29th, 2003 registration number: Q16555
<400>100
Met Ser Tyr Gln Gly Lys Lys Asn Ile Pro Arg Ile Thr Ser Asp Arg
1 5 10 15
Leu Leu Ile Lys Gly Gly Lys Ile Val Asn Asp Asp Gln Ser Phe Tyr
20 25 30
Ala Asp Ile Tyr Met Glu Asp Gly Leu Ile Lys Gln Ile Gly Glu Asn
35 40 45
Leu Ile Val Pro Gly Gly Val Lys Thr Ile Glu Ala His Ser Arg Met
50 55 60
Val Ile Pro Gly Gly Ile Asp Val His Thr Arg Phe Gln Met Pro Asp
65 70 75 80
Gln Gly Met Thr Ser Ala Asp Asp Phe Phe Gln Gly Thr Lys Ala Ala
85 90 95
Leu Ala Gly Gly Thr Thr Met Ile Ile Asp His Val Val Pro Glu Pro
100 105 110
Gly Thr Ser Leu Leu Ala Ala Phe Asp Gln Trp Arg Glu Trp Ala Asp
115 120 125
Ser Lys Ser Cys Cys Asp Tyr Ser Leu His Val Asp Ile Ser Glu Trp
130 135 140
His Lys Gly Ile Gln Glu Glu Met Glu Ala Leu Val Lys Asp His Gly
145 150 155 160
Val Asn Ser Phe Leu Val Tyr Met Ala Phe Lys Asp Arg Phe Gln Leu
165 170 175
Thr Asp Cys Gln Ile Tyr Glu Val Leu Ser Val Ile Arg Asp Ile Gly
180 185 190
Ala Ile Ala Gln Val His Ala Glu Asn Gly Asp Ile Ile Ala Glu Glu
195 200 205
Gln Gln Arg Ile Leu Asp Leu Gly Ile Thr Gly Pro Glu Gly His Val
210 215 220
Leu Ser Arg Pro Glu Glu Val Glu Ala Glu Ala Val Asn Arg Ala Ile
225 230 235 240
Thr Ile Ala Asn Gln Thr Asn Cys Pro Leu Tyr Ile Thr Lys Val Met
245 250 255
Ser Lys Ser Ser Ala Glu Val Ile Ala Gln Ala Arg Lys Lys Gly Thr
260 265 270
Val Val Tyr Gly Glu Pro Ile Thr Ala Ser Leu Gly Thr Asp Gly Ser
275 280 285
His Tyr Trp Ser Lys Asn Trp Ala Lys Ala Ala Ala Phe Val Thr Ser
290 295 300
Pro Pro Leu Ser Pro Asp Pro Thr Thr Pro Asp Phe Leu Asn Ser Leu
305 310 315 320
Leu Ser Cys Gly Asp Leu Gln Val Thr Gly Ser Ala His Cys Thr Phe
325 330 335
Asn Thr Ala Gln Lys Ala Val Gly Lys Asp Asn Phe Thr Leu Ile Pro
340 345 350
Glu Gly Thr Asn Gly Thr Glu Glu Arg Met Ser Val Ile Trp Asp Lys
355 360 365
Ala Val Val Thr Gly Lys Met Asp Glu Asn Gln Phe Val Ala Val Thr
370 375 380
Ser Thr Asn Ala Ala Lys Val Phe Asn Leu Tyr Pro Arg Lys Gly Arg
385 390 395 400
Ile Ala Val Gly Ser Asp Ala Asp Leu Val Ile Trp Asp Pro Asp Ser
405 410 415
Val Lys Thr Ile Ser Ala Lys Thr His Asn Ser Ser Leu Glu Tyr Asn
420 425 430
Ile Phe Glu Gly Met Glu Cys Arg Gly Ser Pro Leu Val Val Ile Ser
435 440 445
Gln Gly Lys Ile Val Leu Glu Asp Gly Thr Leu His Val Thr Glu Gly
450 455 460
Ser Gly Arg Tyr Ile Pro Arg Lys Pro Phe Pro Asp Phe Val Tyr Lys
465 470 475 480
Arg Ile Lys Ala Arg Ser Arg Leu Ala Glu Leu Arg Gly Val Pro Arg
485 490 495
Gly Leu Tyr Asp Gly Pro Val Cys Glu Val Ser Val Thr Pro Lys Thr
500 505 510
Val Thr Pro Ala Ser Ser Ala Lys Thr Ser Pro Ala Lys Gln Gln Ala
515 520 525
Pro Pro Val Arg Asn Leu His Gln Ser Gly Phe Ser Leu Ser Gly Ala
530 535 540
Gln Ile Asp Asp Asn Ile Pro Arg Arg Thr Thr Gln Arg Ile Val Ala
545 550 555 560
Pro Pro Gly Gly Arg Ala Asn Ile Thr Ser Leu Gly
565 570
<210>101
<211>561
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉phosphoglucomutase (EC 5.4.2.2) (PGM)
<222>(1)..(561)
＜223〉on August 29th, 2003 registration number: P36871
<400>101
Val Lys Ile Val Thr Val Lys Thr Gln Ala Tyr Gln Asp Gln Lys Pro
1 5 10 15
Gly Thr Ser Gly Leu Arg Lys Arg Val Lys Val Phe Gln Ser Ser Ala
20 25 30
Asn Tyr Ala Glu Asn Phe Ile Gln Ser Ile Ile Ser Thr Val Glu Pro
35 40 45
Ala Gln Arg Gln Glu Ala Thr Leu Val Val Gly Gly Asp Gly Arg Phe
50 55 60
Tyr Met Lys Glu Ala Ile Gln Leu Ile Ala Arg Ile Ala Ala Ala Asn
65 70 75 80
Gly Ile Gly Arg Leu Val Ile Gly Gln Asn Gly Ile Leu Ser Thr Pro
85 90 95
Ala Val Ser Cys Ile Ile Arg Lys Ile Lys Ala Ile Gly Gly Ile Ile
100 105 110
Leu Thr Ala Ser His Asn Pro Gly Gly Pro Asn Gly Asp Phe Gly Ile
115 120 125
Lys Phe Asn Ile Ser Asn Gly Gly Pro Ala Pro Glu Ala Ile Thr Asp
130 135 140
Lys Ile Phe Gln Ile Ser Lys Thr Ile Glu Glu Tyr Ala Val Cys Pro
145 150 155 160
Asp Leu Lys Val Asp Leu Gly Val Leu Gly Lys Gln Gln Phe Asp Leu
165 170 175
Glu Asn Lys Phe Lys Pro Phe Thr Val Glu Ile Val Asp Ser Val Glu
180 185 190
Ala Tyr Ala Thr Met Leu Arg Ser Ile Phe Asp Phe Ser Ala Leu Lys
195 200 205
Glu Leu Leu Ser Gly Pro Asn Arg Leu Lys Ile Arg Ile Asp Ala Met
210 215 220
His Gly Val Val Gly Pro Tyr Val Lys Lys Ile Leu Cys Glu Glu Leu
225 230 235 240
Gly Ala Pro Ala Asn Ser Ala Val Asn Cys Val Pro Leu Glu Asp Phe
245 250 255
Gly Gly His His Pro Asp Pro Asn Leu Thr Tyr Ala Ala Asp Leu Val
260 265 270
Glu Thr Met Lys Ser Gly Glu His Asp Phe Gly Ala Ala Phe Asp Gly
275 280 285
Asp Gly Asp Arg Asn Met Ile Leu Gly Lys His Gly Phe Phe Val Asn
290 295 300
Pro Ser Asp Ser Val Ala Val Ile Ala Ala Asn Ile Phe Ser Ile Pro
305 310 315 320
Tyr Phe Gln Gln Thr Gly Val Arg Gly Phe Ala Arg Ser Met Pro Thr
325 330 335
Ser Gly Ala Leu Asp Arg Val Ala Ser Ala Thr Lys Ile Ala Leu Tyr
340 345 350
Glu Thr Pro Thr Gly Trp Lys Phe Phe Gly Asn Leu Met Asp Ala Ser
355 360 365
Lys Leu Ser Leu Cys Gly Glu Glu Ser Phe Gly Thr Gly Ser Asp His
370 375 380
Ile Arg Glu Lys Asp Gly Leu Trp Ala Val Leu Ala Trp Leu Ser Ile
385 390 395 400
Leu Ala Thr Arg Lys Gln Ser Val Glu Asp Ile Leu Lys Asp His Trp
405 410 415
Gln Lys Tyr Gly Arg Asn Phe Phe Thr Arg Tyr Asp Tyr Glu Glu Val
420 425 430
Glu Ala Glu Gly Ala Asn Lys Met Met Lys Asp Leu Glu Ala Leu Met
435 440 445
Phe Asp Arg Ser Phe Val Gly Lys Gln Phe Ser Ala Asn Asp Lys Val
450 455 460
Tyr Thr Val Glu Lys Ala Asp Asn Phe Glu Tyr Ser Asp Pro Val Asp
465 470 475 480
Gly Ser Ile Ser Arg Asn Gln Gly Leu Arg Leu Ile Phe Thr Asp Gly
485 490 495
Ser Arg Ile Val Phe Arg Leu Ser Gly Thr Gly Ser Ala Gly Ala Thr
500 505 510
Ile Arg Leu Tyr Ile Asp Ser Tyr Glu Lys Asp Val Ala Lys Ile Asn
515 520 525
Gln Asp Pro Gln Val Met Leu Ala Pro Leu Ile Ser Ile Ala Leu Lys
530 535 540
Val Ser Gln Leu Gln Glu Arg Thr Gly Arg Thr Ala Pro Thr Val Ile
545 550 555 560
Thr
<210>102
<211>263
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉proteasome subunit Alpha-1 type
<222>(1)..(263)
＜223〉on August 29th, 2003 registration number: P25786
<400>102
Met Phe Arg Asn Gln Tyr Asp Asn Asp Val Thr Val Trp Ser Pro Gln
1 5 10 15
Gly Arg Ile His Gln Ile Glu Tyr Ala Met Glu Ala Val Lys Gln Gly
20 25 30
Ser Ala Thr Val Gly Leu Lys Ser Lys Thr His Ala Val Leu Val Ala
35 40 45
Leu Lys Arg Ala Gln Ser Glu Leu Ala Ala His Gln Lys Lys Ile Leu
50 55 60
His Val Asp Asn His Ile Gly Ile Ser Ile Ala Gly Leu Thr Ala Asp
65 70 75 80
Ala Arg Leu Leu Cys Asn Phe Met Arg Gln Glu Cys Leu Asp Ser Arg
85 90 95
Phe Val Phe Asp Arg Pro Leu Pro Val Ser Arg Leu Val Ser Leu Ile
100 105 110
Gly Ser Lys Thr Gln Ile Pro Thr Gln Arg Tyr Gly Arg Arg Pro Tyr
115 120 125
Gly Val Gly Leu Leu Ile Ala Gly Tyr Asp Asp Met Gly Pro His Ile
130 135 140
Phe Gln Thr Cys Pro Ser Ala Asn Tyr Phe Asp Cys Arg Ala Met Ser
145 150 155 160
Ile Gly Ala Arg Ser Gln Ser Ala Arg Thr Tyr Leu Glu Arg His Met
165 170 175
Ser Glu Phe Met Glu Cys Asn Leu Asn Glu Leu Val Lys His Gly Leu
180 185 190
Arg Ala Leu Arg Glu Thr Leu Pro Ala Glu Gln Asp Leu Thr Thr Lys
195 200 205
Asn Val Ser Ile Gly Ile Val Gly Lys Asp Leu Glu Phe Thr Ile Tyr
210 215 220
Asp Asp Asp Asp Val Ser Pro Phe Leu Glu Gly Leu Glu Glu Arg Pro
225 230 235 240
Gln Arg Lys Ala Gln Pro Ala Gln Pro Ala Asp Glu Pro Ala Glu Lys
245 250 255
Ala Asp Glu Pro Met Glu His
260
<210>103
<211>205
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉heat shock 27kDa albumen
<222>(1)..(205)
＜223〉on August 29th, 2003 registration number: P04792
<400>103
Met Thr Glu Arg Arg Val Pro Phe Ser Leu Leu Arg Gly Pro Ser Trp
1 5 10 15
Asp Pro Phe Arg Asp Trp Tyr Pro His Ser Arg Leu Phe Asp Gln Ala
20 25 30
Phe Gly Leu Pro Arg Leu Pro Glu Glu Trp Ser Gln Trp Leu Gly Gly
35 40 45
Ser Ser Trp Pro Gly Tyr Val Arg Pro Leu Pro Pro Ala Ala Ile Glu
50 55 60
Ser Pro Ala Val Ala Ala Pro Ala Tyr Ser Arg Ala Leu Ser Arg Gln
65 70 75 80
Leu Ser Ser Gly Val Ser Glu Ile Arg His Thr Ala Asp Arg Trp Arg
85 90 95
Val Ser Leu Asp Val Asn His Phe Ala Pro Asp Glu Leu Thr Val Lys
100 105 110
Thr Lys Asp Gly Val Val Glu Ile Thr Gly Lys His Glu Glu Arg Gln
115 120 125
Asp Glu His Gly Tyr Ile Ser Arg Cys Phe Thr Arg Lys Tyr Thr Leu
130 135 140
Pro Pro Gly Val Asp Pro Thr Gln Val Ser Ser Ser Leu Ser Pro Glu
145 150 155 160
Gly Thr Leu Thr Val Glu Ala Pro Met Pro Lys Leu Ala Thr Gln Ser
165 170 175
Asn Glu Ile Thr Ile Pro Val Thr Phe Glu Ser Arg Ala Gln Leu Gly
180 185 190
Gly Pro Glu Ala Ala Lys Ser Asp Glu Thr Ala Ala Lys
195 200 205
<210>104
<211>868
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉Apoptosis 6 interaction proteins (Hp95)
<222>(1)..(868)
＜223〉on August 29th, 2003 registration number: Q8WUM4
<400>104
Met Ala Thr Phe Ile Ser Val Gln Leu Lys Lys Thr Ser Glu Val Asp
1 5 10 15
Leu Ala Lys Pro Leu Val Lys Phe Ile Gln Gln Thr Tyr Pro Ser Gly
20 25 30
Gly Glu Glu Gln Ala Gln Tyr Cys Arg Ala Ala Glu Glu Leu Ser Lys
35 40 45
Leu Arg Arg Ala Ala Val Gly Arg Pro Leu Asp Lys His Glu Gly Ala
50 55 60
Leu Glu Thr Leu Leu Arg Tyr Tyr Asp Gln Ile Cys Ser Ile Glu Pro
65 70 75 80
Lys Phe Pro Phe Ser Glu Asn Gln Ile Cys Leu Thr Phe Thr Trp Lys
85 90 95
Asp Ala Phe Asp Lys Gly Ser Leu Phe Gly Gly Ser Val Lys Leu Ala
100 105 110
Leu Ala Ser Leu Gly Tyr Glu Lys Ser Cys Val Leu Phe Asn Cys Ala
115 120 125
Ala Leu Ala Ser Gln Ile Ala Ala Glu Gln Asn Leu Asp Asn Asp Glu
130 135 140
Gly Leu Lys Ile Ala Ala Lys His Tyr Gln Phe Ala Ser Gly Ala Phe
145 150 155 160
Leu His Ile Lys Glu Thr Val Leu Ser Ala Leu Ser Arg Glu Pro Thr
165 170 175
Val Asp Ile Ser Pro Asp Thr Val Gly Thr Leu Ser Leu Ile Met Leu
180 185 190
Ala Gln Ala Gln Glu Val Phe Phe Leu Lys Ala Thr Arg Asp Lys Met
195 200 205
Lys Asp Ala Ile Ile Ala Lys Leu Ala Asn Gln Ala Ala Asp Tyr Phe
210 215 220
Gly Asp Ala Phe Lys Gln Cys Gln Tyr Lys Asp Thr Leu Pro Lys Glu
225 230 235 240
Val Phe Pro Val Leu Ala Ala Lys His Cys Ile Met Gln Ala Asn Ala
245 250 255
Glu Tyr His Gln Ser Ile Leu Ala Lys Gln Gln Lys Lys Phe Gly Glu
260 265 270
Glu Ile Ala Arg Leu Gln His Ala Ala Glu Leu Ile Lys Thr Val Ala
275 280 285
Ser Arg Tyr Asp Glu Tyr Val Asn Val Lys Asp Phe Ser Asp Lys Ile
290 295 300
Asn Arg Ala Leu Ala Ala Ala Lys Lys Asp Asn Asp Phe Ile Tyr His
305 310 315 320
Asp Arg Val Pro Asp Leu Lys Asp Leu Asp Pro Ile Gly Lys Ala Thr
325 330 335
Leu Val Lys Ser Thr Pro Val Asn Val Pro Ile Ser Gln Lys Phe Thr
340 345 350
Asp Leu Phe Glu Lys Met Val Pro Val Ser Val Gln Gln Ser Leu Ala
355 360 365
Ala Tyr Asn Gln Arg Lys Ala Asp Leu Val Asn Arg Ser Ile Ala Gln
370 375 380
Met Arg Glu Ala Thr Thr Leu Ala Asn Gly Val Leu Ala Ser Leu Asn
385 390 395 400
Leu Pro Ala Ala Ile Glu Asp Val Ser Gly Asp Thr Val Pro Gln Ser
405 410 415
Ile Leu Thr Lys Ser Arg Ser Val Ile Glu Gln Gly Gly Ile Gln Thr
420 425 430
Val Asp Gln Leu Ile Lys Glu Leu Pro Glu Leu Leu Gln Arg Asn Arg
435 440 445
Glu Ile Leu Asp Glu Ser Leu Arg Leu Leu Asp Glu Glu Glu Ala Thr
450 455 460
Asp Asn Asp Leu Arg Ala Lys Phe Lys Glu Arg Trp Gln Arg Thr Pro
465 470 475 480
Ser Asn Glu Leu Tyr Lys Pro Leu Arg Ala Glu Gly Thr Asn Phe Arg
485 490 495
Thr Val Leu Asp Lys Ala Val Gln Ala Asp Gly Gln Val Lys Glu Cys
500 505 510
Tyr Gln Ser His Arg Asp Thr Ile Val Leu Leu Cys Lys Pro Glu Pro
515 520 525
Glu Leu Asn Ala Ala Ile Pro Ser Ala Asn Pro Ala Lys Thr Met Gln
530 535 540
Gly Ser Glu Val Val Asn Val Leu Lys Ser Leu Leu Ser Asn Leu Asp
545 550 555 560
Glu Val Lys Lys Glu Arg Glu Gly Leu Glu Asn Asp Leu Lys Ser Val
565 570 575
Asn Phe Asp Met Thr Ser Lys Phe Leu Thr Ala Leu Ala Gln Asp Gly
580 585 590
Val Ile Asn Glu Glu Ala Leu Ser Val Thr Glu Leu Asp Arg Val Tyr
595 600 605
Gly Gly Leu Thr Thr Lys Val Gln Glu Ser Leu Lys Lys Gln Glu Gly
610 615 620
Leu Leu Lys Asn Ile Gln Val Ser His Gln Glu Phe Ser Lys Met Lys
625 630 635 640
Gln Ser Asn Asn Glu Ala Asn Leu Arg Glu Glu Val Leu Lys Asn Leu
645 650 655
Ala Thr Ala Tyr Asp Asn Phe Val Glu Leu Val Ala Asn Leu Lys Glu
660 665 670
Gly Thr Lys Phe Tyr Asn Glu Leu Thr Glu Ile Leu Val Arg Phe Gln
675 680 685
Asn Lys Cys Ser Asp Ile Val Phe Ala Arg Lys Thr Glu Arg Asp Glu
690 695 700
Leu Leu Lys Asp Leu Gln Gln Ser Ile Ala Arg Glu Pro Ser Ala Pro
705 710 715 720
Ser Ile Pro Thr Pro Ala Tyr Gln Ser Ser Pro Ala Gly Gly His Ala
725 730 735
Pro Thr Pro Pro Thr Pro Ala Pro Arg Thr Met Pro Pro Thr Lys Pro
740 745 750
Gln Pro Pro Ala Arg Pro Pro Pro Pro Val Leu Pro Ala Asn Arg Ala
755 760 765
Pro Ser Ala Thr Ala Pro Ser Pro Val Gly Ala Gly Thr Ala Ala Pro
770 775 780
Ala Pro Ser Gln Thr Pro Gly Ser Ala Pro Pro Pro Gln Ala Gln Gly
785 790 795 800
Pro Pro Tyr Pro Thr Tyr Pro Gly Tyr Pro Gly Tyr Cys Gln Met Pro
805 810 815
Met Pro Met Gly Tyr Asn Pro Tyr Ala Tyr Gly Gln Tyr Asn Met Pro
820 825 830
Tyr Pro Pro Val Tyr His Gln Ser Pro Gly Gln Ala Pro Tyr Pro Gly
835 840 845
Pro Gln Gln Pro Ser Tyr Pro Phe Pro Gln Pro Pro Gln Gln Ser Tyr
850 855 860
Tyr Pro Gln Gln
865
<210>105
<211>280
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉similar 4.5LIM domain 3
<222>(1)..(280)
＜223〉on August 29th, 2003 registration number: Q9BVA2
<400>105
Met Ser Glu Ser Phe Asp Cys Ala Lys Cys Asn Glu Ser Leu Tyr Gly
1 5 10 15
Arg Lys Tyr Ile Gln Thr Asp Ser Gly Pro Tyr Cys Val Pro Cys Tyr
20 25 30
Asp Asn Thr Phe Ala Asn Thr Cys Ala Glu Cys Gln Gln Leu Ile Gly
35 40 45
His Asp Ser Arg Glu Leu Phe Tyr Glu Asp Arg His Phe His Glu Gly
50 55 60
Cys Phe Arg Cys Cys Arg Cys Gln Arg Ser Leu Ala Asp Glu Pro Phe
65 70 75 80
Thr Cys Gln Asp Ser Glu Leu Leu Cys Asn Asp Cys Tyr Cys Ser Ala
85 90 95
Phe Ser Ser Gln Cys Ser Ala Cys Gly Glu Thr Val Met Pro Gly Ser
100 105 110
Arg Lys Leu Glu Tyr Gly Gly Gln Thr Trp His Glu His Cys Phe Leu
115 120 125
Cys Ser Gly Cys Glu Gln Pro Leu Gly Ser Arg Ser Phe Val Pro Asp
130 135 140
Lys Gly Ala His Tyr Cys Val Pro Cys Tyr Glu Asn Lys Phe Ala Pro
145 150 155 160
Arg Cys Ala Arg Cys Ser Lys Thr Leu Thr Gln Gly Gly Val Thr Tyr
165 170 175
Arg Asp Gln Pro Trp His Arg Glu Cys Leu Val Cys Thr Gly Cys Gln
180 185 190
Thr Pro Leu Ala Gly Gln Gln Phe Thr Ser Arg Asp Glu Asp Pro Tyr
195 200 205
Cys Val Ala Cys Phe Gly Glu Leu Phe Ala Pro Lys Cys Ser Ser Cys
210 215 220
Lys Arg Pro Ile Val Gly Leu Gly Gly Gly Lys Tyr Val Ser Phe Glu
225 230 235 240
Asp Arg His Trp His His Asn Cys Phe Ser Cys Ala Arg Cys Ser Thr
245 250 255
Ser Leu Val Gly Gln Gly Phe Val Pro Asp Gly Asp Gln Val Leu Cys
260 265 270
Gln Gly Cys Ser Gln Ala Gly Pro
275 280
<210>106
<211>280
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉skeleton muscle LIM albumen 2 (SLIM 2)
<222>(1)..(280)
＜223〉on August 29th, 2003 registration number: Q13643
<400>106
Met Ser Glu Ser Phe Asp Cys Ala Lys Cys Asn Glu Ser Leu Tyr Gly
1 5 10 15
Arg Lys Tyr Ile Gln Thr Asp Ser Gly Pro Tyr Cys Val Pro Cys Tyr
20 25 30
Asp Asn Thr Phe Ala Asn Thr Cys Ala Glu Cys Gln Gln Leu Ile Gly
35 40 45
His Asp Ser Arg Glu Leu Phe Tyr Glu Asp Arg His Phe His Glu Gly
50 55 60
Cys Phe Arg Cys Cys Arg Cys Gln Arg Ser Leu Ala Asp Glu Pro Phe
65 70 75 80
Thr Arg Gln Asp Ser Glu Leu Leu Cys Asn Asp Cys Tyr Cys Ser Ala
85 90 95
Phe Ser Ser Gln Cys Ser Ala Cys Gly Glu Thr Val Met Pro Gly Ser
100 105 110
Arg Lys Leu Glu Tyr Gly Gly Gln Thr Trp His Glu His Cys Phe Leu
115 120 125
Cys Ile Gly Cys Glu Gln Pro Leu Gly Ser Arg Pro Phe Val Pro Asp
130 135 140
Lys Gly Ala His Tyr Cys Val Pro Cys Tyr Glu Asn Asn Phe Ala Pro
145 150 155 160
Arg Cys Ala Arg Cys Thr Lys Thr Leu Thr Gln Gly Gly Leu Thr Tyr
165 170 175
Arg Asp Leu Pro Trp His Pro Lys Cys Leu Val Cys Thr Gly Cys Gln
180 185 190
Thr Pro Leu Ala Gly Gln Gln Phe Thr Ser Arg Asp Glu Asp Pro Tyr
195 200 205
Cys Val Ala Cys Phe Gly Glu Leu Phe Ala Pro Lys Cys Ser Ser Cys
210 215 220
Lys Arg Pro Ile Val Gly Leu Gly Gly Gly Lys Tyr Val Ser Phe Glu
225 230 235 240
Asp Arg His Trp His His Asn Cys Phe Thr Cys Asp Arg Cys Ser Asn
245 250 255
Ser Leu Val Gly Gln Gly Phe Val Pro Asp Gly Asp Gln Val Leu Cys
260 265 270
Gln Gly Cys Ser Gln Ala Gly Pro
275 280
<210>107
<211>133
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉cytochrome b5
<222>(1)..(133)
＜223〉on August 29th, 2003 registration number: P00167
<400>107
Ala Glu Gln Ser Asp Glu Ala Val Lys Tyr Tyr Thr Leu Glu Glu Ile
1 5 10 15
Gln Lys His Asn His Ser Lys Ser Thr Trp Leu Ile Leu His His Lys
20 25 30
Val Tyr Asp Leu Thr Lys Phe Leu Glu Glu His Pro Gly Gly Glu Glu
35 40 45
Val Leu Arg Glu Gln Ala Gly Gly Asp Ala Thr Glu Asn Phe Glu Asp
50 55 60
Val Gly His Ser Thr Asp Ala Arg Glu Met Ser Lys Thr Phe Ile Ile
65 70 75 80
Gly Glu Leu His Pro Asp Asp Arg Pro Lys Leu Asn Lys Pro Pro Glu
85 90 95
Thr Leu Ile Thr Thr Ile Asp Ser Ser Ser Ser Trp Trp Thr Asn Trp
100 105 110
Val Ile Pro Ala Ile Ser Ala Val Ala Val Ala Leu Met Tyr Arg Leu
115 120 125
Tyr Met Ala Glu Asp
130
<210>108
<211>175
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉pancreatitis associated protein body 1 precursor
<222>(1)..(175)
＜223〉on August 29th, 2003 registration number: Q06141
<400>108
Met Leu Pro Pro Met Ala Leu Pro Ser Val Ser Trp Met Leu Leu Ser
1 5 10 15
Cys Leu Met Leu Leu Ser Gln Val Gln Gly Glu Glu Pro Gln Arg Glu
20 25 30
Leu Pro Ser Ala Arg Ile Arg Cys Pro Lys Gly Ser Lys Ala Tyr Gly
35 40 45
Ser His Cys Tyr Ala Leu Phe Leu Ser Pro Lys Ser Trp Thr Asp Ala
50 55 60
Asp Leu Ala Cys Gln Lys Arg Pro Ser Gly Asn Leu Val Ser Val Leu
65 70 75 80
Ser Gly Ala Glu Gly Ser Phe Val Ser Ser Leu Val Lys Ser Ile Gly
85 90 95
Asn Ser Tyr Ser Tyr Val Trp Ile Gly Leu His Asp Pro Thr Gln Gly
100 105 110
Thr Glu Pro Asn Gly Glu Gly Trp Glu Trp Ser Ser Ser Asp Val Met
115 120 125
Asn Tyr Phe Ala Trp Glu Arg Asn Pro Ser Thr Ile Ser Ser Pro Gly
130 135 140
His Cys Ala Ser Leu Ser Arg Ser Thr Ala Phe Leu Arg Trp Lys Asp
145 150 155 160
Tyr Asn Cys Asn Val Arg Leu Pro Tyr Val Cys Lys Phe Thr Asp
165 170 175
<210>109
<211>1028
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉ATHEROCOLLAGEN lpha-1 (VI) chain precursor
<222>(1)..(1028)
＜223〉on August 29th, 2003 registration number: P12109
<400>109
Met Arg Ala Ala Arg Ala Leu Leu Pro Leu Leu Leu Gln Ala Cys Trp
1 5 10 15
Thr Ala Ala Gln Asp Glu Pro Glu Thr Pro Arg Ala Val Ala Phe Gln
20 25 30
Asp Cys Pro Val Asp Leu Phe Phe Val Leu Asp Thr Ser Glu Ser Val
35 40 45
Ala Leu Arg Leu Lys Pro Tyr Gly Ala Leu Val Asp Lys Val Lys Ser
50 55 60
Phe Thr Lys Arg Phe Ile Asp Asn Leu Arg Asp Arg Tyr Tyr Arg Cys
65 70 75 80
Asp Arg Asn Leu Val Trp Asn Ala Gly Ala Leu His Tyr Ser Asp Glu
85 90 95
Val Glu Ile Ile Gln Gly Leu Thr Arg Met Pro Gly Gly Arg Asp Ala
100 105 110
Leu Lys Ser Ser Val Asp Ala Val Lys Tyr Phe Gly Lys Gly Thr Tyr
115 120 125
Thr Asp Cys Ala Ile Lys Lys Gly Leu Glu Gln Leu Leu Val Gly Gly
130 135 140
Ser His Leu Lys Glu Asn Lys Tyr Leu Ile Val Val Thr Asp Gly His
145 150 155 160
Pro Leu Glu Gly Tyr Lys Glu Pro Cys Gly Gly Leu Glu Asp Ala Val
165 170 175
Asn Glu Ala Lys His Leu Gly Val Lys Val Phe Ser Val Ala Ile Thr
180 185 190
Pro Asp His Leu Glu Pro Arg Leu Ser Ile Ile Ala Thr Asp His Thr
195 200 205
Tyr Arg Arg Asn Phe Thr Ala Ala Asp Trp Gly Gln Ser Arg Asp Ala
210 215 220
Glu Glu Ala Ile Ser Gln Thr Ile Asp Thr Ile Val Asp Met Ile Lys
225 230 235 240
Asn Asn Val Glu Gln Val Cys Cys Ser Phe Glu Cys Gln Pro Ala Arg
245 250 255
Gly Pro Pro Gly Leu Arg Gly Asp Pro Gly Phe Glu Gly Glu Arg Gly
260 265 270
Lys Pro Gly Leu Pro Gly Glu Lys Gly Glu Ala Gly Asp Pro Gly Arg
275 280 285
Pro Gly Asp Leu Gly Pro Val Gly Tyr Gln Gly Met Lys Gly Glu Lys
290 295 300
Gly Ser Arg Gly Glu Lys Gly Ser Arg Gly Pro Lys Gly Tyr Lys Gly
305 310 315 320
Glu Lys Gly Lys Arg Gly Ile Asp Gly Val Asp Gly Val Lys Gly Glu
325 330 335
Met Gly Tyr Pro Gly Leu Pro Gly Cys Lys Gly Ser Pro Gly Phe Asp
340 345 350
Gly Ile Gln Gly Pro Pro Gly Pro Lys Gly Asp Pro Gly Ala Phe Gly
355 360 365
Leu Lys Gly Glu Lys Gly Glu Pro Gly Ala Asp Gly Glu Ala Gly Arg
370 375 380
Pro Gly Ala Arg Gly Pro Ser Gly Asp Glu Gly Pro Ala Gly Glu Pro
385 390 395 400
Gly Pro Pro Gly Glu Lys Gly Glu Ala Gly Asp Glu Gly Asn Pro Gly
405 410 415
Pro Asp Gly Ala Pro Gly Glu Arg Gly Gly Pro Gly Glu Arg Gly Pro
420 425 430
Arg Gly Thr Pro Gly Pro Arg Gly Pro Arg Gly Asp Pro Gly Glu Ala
435 440 445
Gly Pro Gln Gly Asp Gln Gly Arg Glu Gly Pro Val Gly Val Pro Gly
450 455 460
Asp Pro Gly Glu Ala Gly Pro Ile Gly Pro Lys Gly Tyr Arg Gly Asp
465 470 475 480
Glu Gly Pro Pro Gly Ser Glu Gly Ala Arg Gly Ala Pro Gly Pro Ala
485 490 495
Gly Pro Pro Gly Asp Pro Gly Leu Met Gly Glu Arg Gly Glu Asp Gly
500 505 510
Pro Ala Gly Asn Gly Thr Glu Gly Phe Pro Gly Phe Pro Gly Tyr Pro
515 520 525
Gly Asn Arg Gly Ala Pro Gly Ile Asn Gly Thr Lys Gly Tyr Pro Gly
530 535 540
Leu Lys Gly Asp Glu Gly Glu Ala Gly Asp Pro Gly Asp Asp Asn Asn
545 550 555 560
Asp Ile Ala Pro Arg Gly Val Lys Gly Ala Lys Gly Tyr Arg Gly Pro
565 570 575
Glu Gly Pro Gln Gly Pro Pro Gly His Gln Gly Pro Pro Gly Pro Asp
580 585 590
Glu Cys Glu Ile Leu Asp Ile Ile Met Lys Met Cys Ser Cys Cys Glu
595 600 605
Cys Lys Cys Gly Pro Ile Asp Leu Leu Phe Val Leu Asp Ser Ser Glu
610 615 620
Ser Ile Gly Leu Gln Asn Phe Glu Ile Ala Lys Asp Phe Val Val Lys
625 630 635 640
Val Ile Asp Arg Leu Ser Arg Asp Glu Leu Val Lys Phe Glu Pro Gly
645 650 655
Gln Ser Tyr Ala Gly Val Val Gln Tyr Ser His Ser Gln Met Gln Glu
660 665 670
His Val Ser Leu Arg Ser Pro Ser Ile Arg Asn Val Gln Glu Leu Lys
675 680 685
Glu Ala Ile Lys Ser Leu Gln Trp Met Ala Gly Gly Thr Phe Thr Gly
690 695 700
Glu Ala Leu Gln Tyr Thr Arg Asp Gln Leu Leu Pro Pro Ser Pro Asn
705 710 715 720
Asn Arg Ile Ala Leu Val Ile Thr Asp Gly Arg Ser Asp Thr Gln Arg
725 730 735
Asp Thr Thr Pro Leu Asn Val Leu Cys Ser Pro Gly Ile Gln Val Val
740 745 750
Ser Val Gly Ile Lys Asp Val Phe Asp Phe Ile Pro Gly Ser Asp Gln
755 760 765
Leu Asn Val Ile Ser Cys Gln Gly Leu Ala Pro Ser Gln Gly Arg Pro
770 775 780
Gly Leu Ser Leu Val Lys Glu Asn Tyr Ala Glu Leu Leu Glu Asp Ala
785 790 795 800
Phe Leu Lys Asn Val Thr Ala Gln Ile Cys Ile Asp Lys Lys Cys Pro
805 810 815
Asp Tyr Thr Cys Pro Ile Thr Phe Ser Ser Pro Ala Asp Ile Thr Ile
820 825 830
Leu Leu Asp Gly Ser Ala Ser Val Gly Ser His Asn Phe Asp Thr Thr
835 840 845
Lys Arg Phe Ala Lys Arg Leu Ala Glu Arg Phe Leu Thr Ala Gly Arg
850 855 860
Thr Asp Pro Ala His Asp Val Arg Val Ala Val Val Gln Tyr Ser Gly
865 870 875 880
Thr Gly Gln Gln Arg Pro Glu Arg Ala Ser Leu Gln Phe Leu Gln Asn
885 890 895
Tyr Thr Ala Leu Ala Ser Ala Val Asp Ala Met Asp Phe Ile Asn Asp
900 905 910
Ala Thr Asp Val Asn Asp Ala Leu Gly Tyr Val Thr Arg Phe Tyr Arg
915 920 925
Glu Ala Ser Ser Gly Ala Ala Lys Lys Arg Leu Leu Leu Phe Ser Asp
930 935 940
Gly Asn Ser Gln Gly Ala Thr Pro Ala Ala Ile Glu Lys Ala Val Gln
945 950 955 960
Glu Ala Gln Arg Ala Gly Ile Glu Ile Phe Val Val Val Val Gly Arg
965 970 975
Gln Val Asn Glu Pro His Ile Arg Val Leu Val Thr Gly Lys Thr Ala
980 985 990
Glu Tyr Asp Val Pro Tyr Gly Glu Ser His Leu Phe Arg Val Pro Ser
995 1000 1005
Tyr Gln Ala Leu Leu Arg Gly Val Phe His Gln Thr Val Ser Arg
1010 1015 1020
Lys Val Ala Leu Gly
1025
<210>110
<211>338
<212>PRT
＜213〉people (Homo sapiens)
<220>
＜221〉basement membrane glycan precursor
<222>(1)..(338)
＜223〉on August 29th, 2003 registration number: P51884
<400>110
Met Ser Leu Ser Ala Phe Thr Leu Phe Leu Ala Leu Ile Gly Gly Thr
1 5 10 15
Ser Gly Gln Tyr Tyr Asp Tyr Asp Phe Pro Leu Ser Ile Tyr Gly Gln
20 25 30
Ser Ser Pro Asn Cys Ala Pro Glu Cys Asn Cys Pro Glu Ser Tyr Pro
35 40 45
Ser Ala Met Tyr Cys Asp Glu Leu Lys Leu Lys Ser Val Pro Met Val
50 55 60
Pro Pro Gly Ile Lys Tyr Leu Tyr Leu Arg Asn Asn Gln Ile Asp His
65 70 75 80
Ile Asp Glu Lys Ala Phe Glu Asn Val Thr Asp Leu Gln Trp Leu Ile
85 90 95
Leu Asp His Asn Leu Leu Glu Asn Ser Lys Ile Lys Gly Arg Val Phe
100 105 110
Ser Lys Leu Lys Gln Leu Lys Lys Leu His Ile Asn His Asn Asn Leu
115 120 125
Thr Glu Ser Val Gly Pro Leu Pro Lys Ser Leu Glu Asp Leu Gln Leu
130 135 140
Thr His Asn Lys Ile Thr Lys Leu Gly Ser Phe Glu Gly Leu Val Asn
145 150 155 160
Leu Thr Phe Ile His Leu Gln His Asn Arg Leu Lys Glu Asp Ala Val
165 170 175
Ser Ala Ala Phe Lys Gly Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser
180 185 190
Phe Asn Gln Ile Ala Arg Leu Pro Ser Gly Leu Pro Val Ser Leu Leu
195 200 205
Thr Leu Tyr Leu Asp Asn Asn Lys Ile Ser Asn Ile Pro Asp Glu Tyr
210 215 220
Phe Lys Arg Phe Asn Ala Leu Gln Tyr Leu Arg Leu Ser His Asn Glu
225 230 235 240
Leu Ala Asp Ser Gly Ile Pro Gly Asn Ser Phe Asn Val Ser Ser Leu
245 250 255
Val Glu Leu Asp Leu Ser Tyr Asn Lys Leu Lys Asn Ile Pro Thr Val
260 265 270
Asn Glu Asn Leu Glu Asn Tyr Tyr Leu Glu Val Asn Gln Leu Glu Lys
275 280 285
Phe Asp Ile Lys Ser Phe Cys Lys Ile Leu Gly Pro Leu Ser Tyr Ser
290 295 300
Lys Ile Lys His Leu Arg Leu Asp Gly Asn Arg Ile Ser Glu Thr Ser
305 310 315 320
Leu Pro Pro Asp Met Tyr Glu Cys Leu Arg Val Ala Asn Glu Val Thr
325 330 335
Leu Asn
Claims (53)
1, a kind of mark that is used to diagnose cancer of pancreas, it comprises at least a polypeptide of listing in table 2 and table 3 that is selected from.
2, mark according to claim 1, the group that wherein at least a polypeptide is therefrom selected is made up of one group of listed polypeptide of table 2.
3, a kind of table 2 and listed polypeptide of table 3 of being selected from, as being used for cancer of pancreas and/or to the mark of the diagnosis of cancer of pancreas neurological susceptibility or the component of mark.
4, a kind of in-vitro diagnosis cancer of pancreas and/or the method for cancer of pancreas neurological susceptibility be may further comprise the steps:
A) obtain biological specimen; And
B) detect and/or measure the mark that claim 1 or 2 described expression increase.
5, in-vitro method according to claim 4, mark wherein comprises at least two peptide species.
6, according to claim 4 or 5 described in-vitro methods, wherein the biological specimen of indication derives from serum, blood plasma, pancreatic secretion and pancreatic tissue cell.
7, a kind of in-vitro diagnosis cancer of pancreas and/or the method for cancer of pancreas neurological susceptibility be may further comprise the steps:
A) obtain biological specimen; And
B) detect and/or measure the increase of the nucleic acid of at least a coding claim 1 or 2 described marks.
8, in-vitro method according to claim 7, wherein the nucleic acid molecules of indication is RNA or DNA.
9, in-vitro method according to claim 8, wherein the DNA of indication is cDNA.
10,, wherein, the nucleic acid of at least a indication is compared doubting the expression and the expression of identical nucleic acid in healthy individual of suffering from cancer of pancreas and/or the susceptible cancer of pancreas individuality according to any one described in-vitro method among the claim 7-9.
11, according to any one described in-vitro method among the claim 4-6, wherein, with being marked at of at least a indication doubt to suffer from cancer of pancreas and/or the susceptible cancer of pancreas individuality expression with compare with a kind of expression that is marked in the healthy individual.
12, in-vitro method according to claim 11, wherein the increase of the marker expression level of indication is a cancer of pancreas or to the sign of cancer of pancreas neurological susceptibility.
13, a kind of screening technique that is used to identify and/or obtain and list in the interactional compound of polypeptide of table 2 and/or table 3, the polypeptide of indication increases for expressing in cancer of pancreas, and this method may further comprise the steps:
A) polypeptide that makes indication and one or more compounds contact can making under this compound and the interactional condition of the polypeptide of indication; And
B) interaction between the polypeptide of one or more compounds of detection indication and indication.
14, the screening technique of the compound of a kind of inhibitor that is used to identify and/or obtain to belong to table 2 and/or the listed polypeptide of table 3 or antagonist, the polypeptide of indication increases for expressing in cancer of pancreas, and this method may further comprise the steps:
A) polypeptide that makes indication and the compound of identifying by the screening technique of claim 13 and/or obtaining the compound that can make indication with the interactional condition of the polypeptide of saying under contact;
B) activity of mensuration indication polypeptide;
C) according to the definition of (a), be determined at the activity of the indication polypeptide of expressing among the host, this polypeptide does not contact with the compound of indication; And
D) will be at (b) and the active level that records (c) contact, wherein the specific activity that in (b), records in (c), record low, show that this compound is inhibitor or antagonist.
15, a kind of screening technique that is used to identify and/or obtain to belong to the compound of table 2 and/or listed polypeptide expression inhibitor of table 3 or antagonist, the polypeptide of indication increases for expressing in cancer of pancreas, and this method may further comprise the steps:
A) host who expresses the indication polypeptide is contacted with compound;
B) the polypeptide expression level and/or the activity of mensuration indication;
C) according to the definition of (a), measure expression and/or the activity of polypeptide in the host of indication, this host does not contact with the compound of indication; And
D) the described polypeptide expression level that will record at (b) with (c) is quantitatively got in touch, and wherein the expression that records in (b) is lower than what record in (c), shows that then this compound is the polypeptide expression inhibitor of indication.
16, the compound of identifying and/or obtaining by any one described screening technique among the claim 13-15.
17, a kind of pharmaceutical composition, it contains the described compound of claim 16.
18, a kind of method for preparing the described pharmaceutical composition of claim 17 comprises by prescription the described compound of claim 16 is prepared with pharmaceutically useful carrier or thinning agent.
19, the purposes of the described compound of claim 16 in the medicament of preparation treatment and prevention of pancreatic cancer.
20, the purposes of the described compound of claim 16 in the diagnosis composition for preparing the tendency of diagnosing cancer of pancreas or easily suffering from cancer of pancreas.
21, according to claim 19 or 20 described purposes, wherein the compound of indication comprises antibody, antibody derivatives, antibody fragment, peptide or antisense construct thing.
22, be used for diagnosing the table 2 of in-vitro method of cancer of pancreas and/or the antibody of the listed albumen of table 3, or its Fab.
23, a kind of kit of diagnosing cancer of pancreas, it comprises the described antibody of one or more claims 22, or its Fab.
24, a kind of kit of diagnosing cancer of pancreas, it comprises the nucleic acid of the mark of one or more coding claims 1 or 2.
25, a kind of kit that is used for screening compounds, this compound activates or suppresses to list in any polypeptide of table 2 and/or table 3, perhaps stimulates or suppress the polypeptide expression of any indication.
26, a kind of mark that is used to diagnose cancer of pancreas, it comprises at least a listed polypeptide of table 6 that is selected from.
27, mark according to claim 26, wherein at least a polypeptide of indication does not comprise Seq ID No.25 and 50-55.
28, according to any one described mark among the claim 26-27, also comprise the listed polypeptide of at least a table 5 in addition.
29, a kind ofly be used to diagnose cancer of pancreas and/or to the in-vitro method of the neurological susceptibility of cancer of pancreas, it may further comprise the steps:
A) obtain biological specimen; And
B) detect and/or measure the increase of the listed polypeptide of at least a table 6.
30, in-vitro method according to claim 29 also comprises the step that detects and/or measure the minimizing of the listed polypeptide of at least a table 5 in addition.
31, according to claim 29 or 30 described in-vitro methods, wherein at least a polypeptide of indication does not comprise Seq ID No.25 and 50-55.
32, according to any one described in-vitro method of claim 29-31, wherein the biological specimen of indication derives from serum, blood plasma, pancreatic secretion and pancreatic tissue cell.
33, a kind ofly be used to diagnose cancer of pancreas and/or to the in-vitro method of cancer of pancreas neurological susceptibility, it may further comprise the steps:
A) obtain biological specimen; And
B) detect and/or measure the increase of the nucleic acid of any one described mark among at least a coding claim 26-28.
34, in-vitro method according to claim 33, wherein the nucleic acid molecules of indication is RNA or DNA.
35, in-vitro method according to claim 34, wherein the DNA of indication is cDNA.
36, according to any one described in-vitro method of claim 33-35, wherein, the nucleic acid of at least a indication is suffered from cancer of pancreas and/or the expression in healthy individual compares to expression in the individuality of cancer of pancreas susceptible and identical nucleic acid doubting.
37,, wherein, being marked at of indication doubted the expression and the expression of same tag in healthy individual of suffering from cancer of pancreas and/or the susceptible cancer of pancreas individuality compare according to the described in-vitro method of claim 33-36.
38, according to the described in-vitro method of claim 37, wherein the increase of the marker expression level of indication is the sign of cancer of pancreas or cancer of pancreas neurological susceptibility.
39, a kind of screening technique that is used to identify and/or obtain and be selected from the interactional compound of polypeptide of listing in table 6, this polypeptide expression increase for expressing in cancer of pancreas, and this method may further comprise the steps:
A) polypeptide that makes indication and one or more compounds contact can making under this compound and the interactional condition of the polypeptide of indication; And
B) interaction between the polypeptide of one or more compounds of detection indication and indication.
40, a kind of screening technique that is used to identify and/or obtains to belong to the compound of the inhibitor of the listed polypeptide of table 6 or antagonist, the polypeptide expression of indication increases for expressing in cancer of pancreas, and this method may further comprise the steps:
A) polypeptide that makes indication and the compound of identifying by the screening technique of claim 39 and/or obtaining can make this compound with the interactional condition of the polypeptide of saying under contact;
B) activity of mensuration indication polypeptide;
C) according to the definition of (a), be determined at the activity of the indication polypeptide of expressing among the host, this polypeptide does not contact with the compound of indication; And
D) will be at (b) and the active level that records (c) contact, wherein the specific activity that in (b), records in (c), record low, show that then this compound is inhibitor or antagonist.
41, a kind of screening technique that is used to identify and/or obtain to belong to the compound that is selected from the listed polypeptide expression inhibitor of table 6, the polypeptide expression of indication increase for expressing in cancer of pancreas, and this method may further comprise the steps:
A) host who expresses the indication polypeptide is contacted with certain compound;
B) measure indication polypeptide expression level and/or activity;
C) according to the definition of (a), measure indication polypeptide expression levels and/or activity in the host, this host does not contact with the compound of indication; And
D) the described polypeptide expression level that will record at (b) with (c) is quantitatively got in touch, and wherein the expression that records in (b) is lower than what record in (c), shows that this compound is an indication polypeptide expression inhibitor.
42, a kind of compound of identifying or obtaining by any one described screening technique among the claim 39-41.
43, a kind of pharmaceutical composition, it comprises the described compound of claim 42.
44, a kind of method for preparing the described pharmaceutical composition of claim 43 comprises by prescription the described compound of claim 42 is prepared with carrier or thinning agent that can be medicinal.
45, the purposes of the described compound of claim 42 in the medicament of preparation treatment or prevention of pancreatic cancer.
46, the purposes of the described compound of claim 42 in preparing the diagnosis composition of diagnosing cancer of pancreas or easily suffering from the cancer of pancreas tendency.
47, according to claim 45 or 46 described purposes, wherein the compound of indication comprises antibody, antibody derivatives, antibody fragment, peptide or antisense construct thing.
48, can be used for diagnosing the table 5 in the in-vitro method of cancer of pancreas and/or antibody or its Fab of the listed albumen of table 6.
49, a kind of kit of diagnosing cancer of pancreas, it comprises the described antibody of one or more claims 48, or its Fab.
50, a kind of kit of diagnosing cancer of pancreas, it comprises the nucleic acid of the described mark of one or more coding claim 26-28.
51, a kind of kit that is used for screening compounds, this compound activates or suppresses to list in any polypeptide of table 5 and/or table 6, perhaps stimulates or suppress the polypeptide expression of any indication.
52, the described kit of claim 51, wherein the polypeptide of indication is the listed polypeptide of table 6.
53, as indicated above basically, especially in albumen, compound, kit, method and the purposes described in the embodiment above.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02028058.2 | 2002-12-17 | ||
| EP02028058 | 2002-12-17 | ||
| EP03025237.3 | 2003-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1726395A true CN1726395A (en) | 2006-01-25 |
Family
ID=35925169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200380106539 Pending CN1726395A (en) | 2002-12-17 | 2003-12-11 | Specific markers for pancreatic cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1726395A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102272156A (en) * | 2008-12-02 | 2011-12-07 | 玛丽皇后和威斯特-弗尔德学院 | Treatment of autoimmune disease by regulating annexin-1 |
| CN102565418A (en) * | 2011-12-25 | 2012-07-11 | 复旦大学附属中山医院 | Early-stage diagnosis marker for aorta disease and application thereof |
| CN103415624A (en) * | 2010-08-13 | 2013-11-27 | 私募蛋白质体公司 | Pancreatic cancer biomarkers and uses thereof |
| US9127051B2 (en) | 2010-06-09 | 2015-09-08 | Queen Mary & Westfield College, University Of London | Annexin 1 antibody |
| CN105637367A (en) * | 2013-08-13 | 2016-06-01 | 电泳有限公司 | Materials and methods relating to pancreatic cancer |
| CN106461665A (en) * | 2014-05-12 | 2017-02-22 | 延世大学校产学协力团 | Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer |
| CN111316102A (en) * | 2017-09-05 | 2020-06-19 | 温口特 | Method for diagnosing pancreatic cancer using methionyl-tRNA synthetase and pancreatic cancer diagnostic kit using same |
| US10752677B2 (en) | 2011-12-14 | 2020-08-25 | Queen Mary & Westfield College, University Of London | Methods of treating obsessive compulsive disorder (OCD) or anxiety using an antibody that binds to annexin-1 |
| CN113447659A (en) * | 2021-07-01 | 2021-09-28 | 浙江大学医学院附属儿童医院 | Kit for detecting anti-proteasome subunit alpha 1-IgG antibody |
| CN114316015A (en) * | 2021-12-03 | 2022-04-12 | 河北大学 | Insect-resistant protein hRI and coding gene and application thereof |
| CN115074365A (en) * | 2022-06-28 | 2022-09-20 | 中国医学科学院北京协和医院 | sgRNA targeting GATM gene and application thereof |
-
2003
- 2003-12-11 CN CN 200380106539 patent/CN1726395A/en active Pending
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8980255B2 (en) | 2008-12-02 | 2015-03-17 | Queen Mary & Westfield College | Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1) |
| CN102272156A (en) * | 2008-12-02 | 2011-12-07 | 玛丽皇后和威斯特-弗尔德学院 | Treatment of autoimmune disease by regulating annexin-1 |
| USRE47982E1 (en) | 2010-06-09 | 2020-05-12 | Queen Mary & Westfield College, University Of London | Annexin 1 antibody |
| US9127051B2 (en) | 2010-06-09 | 2015-09-08 | Queen Mary & Westfield College, University Of London | Annexin 1 antibody |
| CN103415624A (en) * | 2010-08-13 | 2013-11-27 | 私募蛋白质体公司 | Pancreatic cancer biomarkers and uses thereof |
| CN106198980A (en) * | 2010-08-13 | 2016-12-07 | 私募蛋白质体公司 | Cancer of pancreas biomarker and application thereof |
| CN103415624B (en) * | 2010-08-13 | 2017-03-01 | 私募蛋白质体公司 | Cancer of pancreas biomarker and application thereof |
| CN106198980B (en) * | 2010-08-13 | 2018-09-07 | 私募蛋白质体公司 | Cancer of pancreas biomarker and application thereof |
| US10752677B2 (en) | 2011-12-14 | 2020-08-25 | Queen Mary & Westfield College, University Of London | Methods of treating obsessive compulsive disorder (OCD) or anxiety using an antibody that binds to annexin-1 |
| CN102565418A (en) * | 2011-12-25 | 2012-07-11 | 复旦大学附属中山医院 | Early-stage diagnosis marker for aorta disease and application thereof |
| CN105637367A (en) * | 2013-08-13 | 2016-06-01 | 电泳有限公司 | Materials and methods relating to pancreatic cancer |
| CN106461665B (en) * | 2014-05-12 | 2019-01-25 | 江泰控股株式会社 | The kit of the antibody of the antibody and Carbohydrate Antigen 19-9 albumen including complement factor B albumen for diagnosis of pancreatic cancer |
| US10656154B2 (en) | 2014-05-12 | 2020-05-19 | Jw Holdings Corporation | Methods for detecting an amount of complement factor B protein and carbohydrate antigen 19-9 protein, and methods for diagnosing and treating pancreatic cancer using the same |
| CN106461665A (en) * | 2014-05-12 | 2017-02-22 | 延世大学校产学协力团 | Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer |
| CN111316102A (en) * | 2017-09-05 | 2020-06-19 | 温口特 | Method for diagnosing pancreatic cancer using methionyl-tRNA synthetase and pancreatic cancer diagnostic kit using same |
| CN113447659A (en) * | 2021-07-01 | 2021-09-28 | 浙江大学医学院附属儿童医院 | Kit for detecting anti-proteasome subunit alpha 1-IgG antibody |
| CN113447659B (en) * | 2021-07-01 | 2022-05-17 | 浙江大学 | Kit for detecting anti-proteasome subunit alpha 1-IgG antibody |
| CN114316015A (en) * | 2021-12-03 | 2022-04-12 | 河北大学 | Insect-resistant protein hRI and coding gene and application thereof |
| CN114316015B (en) * | 2021-12-03 | 2024-06-14 | 河北大学 | Insect-resistant protein hRI, and encoding gene and application thereof |
| CN115074365A (en) * | 2022-06-28 | 2022-09-20 | 中国医学科学院北京协和医院 | sgRNA targeting GATM gene and application thereof |
| CN115074365B (en) * | 2022-06-28 | 2023-02-28 | 中国医学科学院北京协和医院 | sgRNA targeting GATM gene and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1238367C (en) | Isolated nucleic acid molecules which encodt T cell inducible factors (TIFs), proteins encoded, and uses thereof | |
| CN1968601A (en) | Liver disease-related methods and systems | |
| CN1957256A (en) | Methods and compositions for the detection of cervical disease | |
| CN1839205A (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
| CN1745299A (en) | Method of diagnosis, treatment and useful agents for conditions characterized by modulation in the level of activin beta c | |
| CN1492879A (en) | Protein tau | |
| CN101044247A (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer | |
| CN1726395A (en) | Specific markers for pancreatic cancer | |
| CN101057144A (en) | Methods and compositions for evaluating breast cancer prognosis | |
| CN1789411A (en) | Isolated nucleic acid molecules which encode T cell inducible factors (TIF), the proteins encoded, and uses thereof | |
| CN1842603A (en) | Method of selecting wt1 vaccine adaptive patient | |
| CN1527720A (en) | Global analysis of protein activities using proteome chips | |
| CN1636058A (en) | Novel alanine transaminase enzyme and methods of use | |
| CN1592793A (en) | Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas | |
| CN1276254C (en) | Cardiovascular safety assay | |
| CN1877336A (en) | Method for the identification of epitopes related to immunogenicity in biopharmaceuticals | |
| CN1961073A (en) | Truncated DANCE, DANCE complex and method of using these | |
| CN1492875A (en) | TTK in diagnosis and as a therapeutic target in cancer | |
| CN101046475A (en) | Method for measuring kinase activity and kit for measuring | |
| CN1673368A (en) | HCV regulated proteins | |
| CN1609616A (en) | Specific markers for diabetes | |
| CN101061239A (en) | Method for diagnosing non-small cell lung cancers by tRNA-dihydrouridine synthase activity of URLC8 | |
| CN1619312A (en) | Specific markers for metabolic syndrome | |
| CN1845936A (en) | Ra antigenic peptides | |
| CN1856708A (en) | Human diabetes-mediating proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |